Regulation of haem oxygenase-1 nitrosative stress in cardiac cells. by Naughton, P.
REFERENCE ONLY
UNIVERSITY OF LONDON THESIS
Degree  Year  Name of Author  \jAu ^ wtOn> /  ^  *
COPYRIGHT
This is a thesis accepted for a  Higher Degree  of the  University of London.  It is  an 
unpublished typescript and the copyright is held by the author.  All persons consulting 
the thesis must read and abide by the Copyright Declaration below.
COPYRIGHT DECLARATION
I recognise that the copyright of the above-described thesis rests with the author and 
that no quotation from it or information derived from  it may be published without the 
prior written consent of the author.
Theses may not be lent to individuals, but the Senate House Library may lend a copy 
to  approved  libraries  within  the  United  Kingdom,  for  consultation  solely  on  the 
premises  of  those  libraries.  Application  should  be  made  to:  Inter-Library  Loans, 
Senate House Library, Senate House, Malet Street, London WC1E 7HU.
REPRODUCTION
University  of  London  theses  may  not  be  reproduced  without  explicit  written 
permission from  the  Senate  House  Library.  Enquiries  should  be  addressed to the 
Theses Section of the Library.  Regulations concerning  reproduction vary according 
to the date of acceptance of the thesis and are listed below as guidelines.
A.  Before  1962.  Permission granted only upon the prior written consent of the
author.  (The Senate House Library will provide addresses where possible).
B.  1962- 1974.  In many cases the author has agreed to permit copying upon
completion of a Copyright Declaration.
C.  1975 - 1988.  Most theses may be copied  upon  completion of a  Copyright
Declaration.
D.  1989 onwards.  Most theses may be copied.
This thesis comes within category D.
This copy has been deposited in the Library of  -----^  u   ----------------------
This copy has  been  deposited  in  the Senate  House  Library,  Senate House,
LOANS
Malet Street, London WC1E 7HU.
C:\Documents and Settings\lproctor\LocaI Settings\Temporary Internet Files\OLK8\Copyright - thesis (2).docM
UCL
REGULATION OF HAEM OXYGENASE-1  BY 
NITROSATIVE STRESS IN CARDIAC CELLS
PATRICK NAUGHTON
THESIS SUBMITTED FOR THE DEGREE OF 
DOCTORATE OF PHILOSOPHY 
IN THE UNIVERSITY OF LONDON 
2005
FROM THE VASCULAR BIOLOGY UNIT, DEPARTMENT OF 
SURGICAL RESEARCH, NORTHWICK PARK INSTITUTE FOR 
MEDICAL RESEARCH, HARROW, MIDDLESEX, HA1 3UJ.UMI Number: U592173
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted.  Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U592173
Published by ProQuest LLC 2013.  Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved.  This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml  48106-1346“The body possesses the high art of wrecking and also of restoring. ” 
Paracelsus (1493-1541)ACKNOWLEDGEMENTS
I would like to acknowledge a number of people who  have made this Thesis 
possible.  Firstly,  my  supervisor  and  Head  of the  Vascular  Biology  Unit,  Dr. 
Roberto  Motterlini,  and  Prof.  Colin  J.  Green  Director of the  Northwick  Park 
Institute for Medical Research, for allowing me to undertake this research work 
and providing me with continuous support and encouragement throughout the 
project.
I  would  also  like  to  thank  current  members  of  the  Department  of  Surgical 
Research  at the  Northwick  Park  Institute for Medical  Research,  namely:  Dr. 
James Clark for his technical assistance in the laboratory and advice and help 
in writing this Thesis; Aaron Southgate for his assistance with the formatting; 
Dr.  Roberta Foresti for her helpful advice and  instruction with the cell  culture 
and  biochemical  procedures;  and  Hadil  Abuarqob,  Sandip  K.  Bains,  Jehad 
Hammad, Martha Hoque, Montaser Musameh, Yasin Owais, Ashraf Sandouka 
and  Philip  Sawle,  for  their  assistance  and  camaraderie  in  and  out  of  the 
laboratory.ABSTRACT
The reactive nitrogen species (RNS) nitric oxide (NO), nitroxyl anion (N0‘) and
\
nitrosonium  cation  (NO+),  modulate  a  myriad  of  biological  processes.  The 
microsomal haem oxygenases (HO-1,  HO-2 and  HO-3) oxidatively catabolise 
haem to bilirubin, carbon monoxide (CO) and ferrous iron (Fe2+). Sensitivity of 
the inducible isoform (HO-1) to a variety of inducers has identified HO-1  as an 
effective  endogenous  cytoprotectant  against  oxidative  stress.  Although 
nitrosative  stimuli  can  enhance  HO-1  expression,  little  is  known  about  the 
biochemistry  and  mechanisms  of  this  response.  This  Thesis  examines  a 
number  of  aspects  related  to  HO-1  and  nitrosative  stimuli  in  cardiac  cells, 
including:  1.  induction  by  NO';  2.  the  biochemistry  of  NO'/NO-mediated 
induction of HO-1; 3.  identification of a possible mechanism for the activation 
of HO-1  by  NO congeners;  4.  the antinitrosative  potential  of bilirubin;  and  5. 
the potential of glyceryl trinitrate (GTN), a clinically used NO donor, to activate 
the  haem  oxygenase  pathway.  These  different  aspects  of  HO-1  were 
addressed using biochemical, molecular biology and cell culture techniques. The 
results  indicate  that  NO',  in  analogy with  other  RNS,  is  a  potent  inducer of 
haem oxygenase activity and HO-1  mRNA and protein expression. A proposed 
mechanism  for  this  response  is  modulation  of  thiol  groups  within  redox- 
sensitive transcription  factors.  An  antinitrosative  and  HO-1  inducing  capacity 
was  identified for bilirubin  and  GTN,  respectively.  Collectively,  these findings 
suggest that the haem oxygenase pathway can act both as a sensor to,  and 
target of, redox based mechanisms involving RNS, and extend our knowledge 
on the biological function of HO-1  in response to nitrosative stress.LIST OF ABBREVIATIONS
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xviiINTRODUCTION
1  INTRODUCTION
1.1  Historical perspective on nitric oxide
In  1847 the Italian scientist Ascanio Sobrero discovered nitroglycerin (NG).  It 
wasn’t until 1863 that Alfred Nobel, the person whose name is associated with 
the Nobel Prize,  patented his detonator and harnessed the potential of using 
the stabilised form  of NG as  dynamite,  the  invention which  gave him world 
wide  success  1.  However,  when  in  1890  Nobel  was  recommended  by  his 
doctor to  take  NG to  alleviate  his  symptoms  of angina,  he  stated:  “It  is the 
irony  of  fate  that  I  should  be  ordered  by  my  doctor  to  take  nitroglycerine 
internally”  2.  The  reason  for this  medicinal  usage  of  NG  stemed  from  work 
carried out during the  preceding 50 years.  In  the  mid  to  late  19th   century a 
number of European scientists discovered that nitrite (NCV) and nitrate (NO3 ) 
containing compounds,  e.g.  amyl  nitrite  and  glyceryl  trinitrate  (GTN),  had  a 
pharmacological potential as ‘nitrovasodilators’.  To this day nitrovasodilators 
are still used as therapeutic agents for cardiovascular disease 1.
For most of the 20th century scientists tried in vain to elucidate the mechanism 
by  which  the  medicinal  effects  of  vasodilators  are  mediated.  However,  a 
breakthrough came in the 1970s when a series of experiments revealed that 
various vasodilators, including NG and nitric oxide (NO) gas, had the capacity 
to relax vascular smooth muscle 3.  In each case relaxation coincided with an 
increase  in  the  activity  of  cyclic  guanidine  monophosphate  (cGMP),  the 
molecule whose synthesis  is catalysed  by soluble guanylate cyclase  (sGC), 
which led to the suggestion that cGMP activation could occur via the formationINTRODUCTION
of NO3,4  With the discovery of endothelium-derived relaxing factor (EDRF) in 
the endothelial cells of arterial smooth muscle by Robert Furchgott and John 
Zawadzki in 1980, the mechanism o^action of NO gradually began to emerge 
5.  In  the  late  1980s  two  independent  groups  discovered  that  the  effects 
mediated by EDRF was simulated by NO gas and that both were identical6,7. 
It  is  now  known  that  enzymatic  metabolism  of  the  vasodilators  within  the 
target tissue generates  NO,  which  in turn  mediates the  drugs vasodilatatory 
action8. Consequently, the perspective of NO changed in the late 20th century 
from a potentially toxic molecule into a signalling factor, thus generating a new 
era of scientific research.
The  important status  of NO is  illustrated  in a  number of ways:  1.  there  has 
been an exponential growth in the number of publications related to NO since 
the 1980s; 2. a scientific journal, “Nitric Oxide”, is devoted specifically towards 
NO  research;  3.  NO  was  declared  “Molecule  of  the  Year”  by  Science 
magazine  in  1992  9;  and  4.  in  1998  the  Nobel  Prize  for  physiology  was 
awarded  to  Robert  Furchgott,  Louis  Ignarro  and  Ferid  Murad  for  their 
pioneering  work  into  NO.  However,  the  contribution  of  Salvador  Moncada, 
another  important  figure  involved  in  the  discovery  of  NO,  was  overlooked 
much  to  the  disappointment  of  others  10.  From  a  breakdown  product  of 
vasodilators to a versatile signalling molecule, NO has generated an explosion 
of research to examine its role in  a  myriad  of physiological and pathological 
processes  and  highlighted  its  potential  medical  application  and  therapeutic 
manipulation.
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1.2  Nomenclature and biochemistry of nitric oxide
The  combination  of  one  atom  of  molecular  oxygen  (02)  with  one  atom  of
\
nitrogen  (N2)  gives  rise  to  the  chemical  nitrogen  monoxide  (NO),  more 
commonly  known  as  nitric  oxide.  The  chemical  symbol  for the  molecule  is 
written with a superscript dot,  (NO*), to indicate the presence of an unpaired 
electron,  i.e.  NO’ is a radical 11.  Nitric oxide should not be confused with the 
anaesthetic nitrous oxide  (N20),  also  known  as ‘laughing  gas’. Although the 
abbreviations NO and NO* are used synonymously in the literature to refer to 
the  same  entity,  the  former  takes  precedence.  This  standardisation  in  the 
nomenclature of NO research was agreed upon by the International Union of 
Pharmacology (IUP)  1 2   Similarly,  in this Thesis,  the abbreviation  NO will  be 
used unless otherwise indicated.
Nitric oxide has a number of physio-chemical properties which make it unique 
and  set  it  apart  from  other  molecules.  Due  to  its  radical  nature,  NO  is 
generally perceived as highly reactive, but the number of target molecules that 
react with NO is limited to a few examples, e.g. 02, thiol- and metal-containing 
proteins and 0 2 ' 1 3 ,14  Despite being a small simple molecule NO is produced 
by a group of complex enzymes, the nitric oxide synthases (NOSs, discussed 
further in Section 1.5)15, at a concentration of 1-2 pM 1 6,17  As it is a gas,  NO 
can freely diffuse though cell  membranes;  this feature  along with  its  radical 
nature  gives  the  molecule  a  short  half-life  (between  6  and  30  seconds)  11. 
However,  when  NO  forms  an  adduct with  cellular  S-nitrosothiols  (R-SNO) 
species,  e.g.  S-nitroso-serum  albumin,  the  half-life  can  be  extended  to  60 
minutes  18.  Other fates for NO include:  binding with  haemoglobin  (Hb)  1 9  orINTRODUCTION
myoglobin (Mb)20; activation of the enzyme sGC (discussed further in Section
1.7)  21;  interaction  with  glutathione  (GSH)  to  form  S-nitrosoglutathione 
(GSNO) 22;  and  slowly reacting vyith  02  to form  nitrogen  dioxide  (N02)  1 1   or 
rapidly  with  superoxide  anion  (02 ')  to  generate  peroxynitrite  (ONOO‘)  23. 
Although the quantity of NO targets is few their diverse range illustrates that 
the physiological effects of NO are controlled not just by its concentration but 
also  its  rates  of  interaction  with  other  molecules  and  their  respective 
concentrations 1 3
Another interesting aspect of NO is its diverse chemistry which gives rise to 
different metabolites, know collectively as reactive nitrogen species (RNS, see 
Table  1.1  for examples),  each  having different oxidation states 17.  The  RNS 
have  been  implicated  in  a variety of environmental  and  occupational  health 
effects,  e.g.  road  traffic and  air pollution,  food  and  water contamination,  as 
well as N20 poisoning 24. Among the more common biological species are the 
nitrosonium cation (NO+) and the nitroxyl anion (NO'), each of which has their 
own  distinct  properties  and  reactivities  1 3 ,2 5   This  raises  the  possibility  that 
other NO  redox subtypes  (or NO congeners),  i.e.  NO+   and  NO',  may exert 
biological effects akin to, or instead of, NO 11.
4INTRODUCTION
Table 1.1  Examples of RNS and their oxidation states
Name Symbol Oxidation State
Nitroxyl anion NO' +  1
Nitrous oxide ^N20 +  1
Nitric oxide NO + 2
Nitrite no2 - + 3
Nitrosonium cation NO+ + 3
Peroxynitrite ONOO' + 3
Nitrogen dioxide N02‘ + 4
Nitrate NO3 + 5
Formation of the oxidised form of NO, NO+, is feasible, but only on a transient 
basis,  at pH 7 as its strong electrophilic nature limits  its  reactivity with  other 
nucleophiles, the exception being water (H20) to generate nitrous acid (HN02)
11.  At pH 7 a key role for NO+  is in the process of nitrosation,  i.e. transfer of 
NO+   usually  from  a  carrier  compound  (e.g.  sodium  nitroprusside  (SNP, 
Na2[Fe(CN)5(NO+)],  S-nitroso-A/-acetylpenicillamine  (SNAP)  and  GSNO)  to 
nucleophilic centres,  e.g.  thiol groups  (R-SH),  to generate  R-SNO  (where  R 
can be one of a large range of chemical entities)2 6   Endogenous formation of 
R-SNO, via reaction of NO with R-SH in the presence of an electron acceptor 
or  as  a  nitrosyl  complex  formed  by  NO  and  ferric  iron  (Fe3+ )  centres,  is 
feasible 25-2 7 < 2 8  in addition, further transfer of NO+  from a R-SNO to a second 
R-SH  or other nucleophiles,  a  process  known  as transnitrosation,  can  occur 
until a critical nitrosation event takes place 2 5   Another possible reaction is S- 
thiolation,  which  involves  addition  of a  thiolate  anion  (R-S‘)  to  the  R-SNO 
group, giving rise to a disulfide and NO'2 9 ,3 0
The fact that  R-SH  groups  are  often  found  at  receptor sites  in  control  and 
signalling  pathways  has  implicated  nitrosation,  transnitrosation  and
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S-thiolation as  important mediators in the control of cell signalling pathways, 
gene expression and  health  and disease 26,31,32.  Despite recent confirmation 
of their existence in vivo R-SNO have long been suggested to exert a number 
of biological functions,  e.g. vasodilation and activation  of sGC 33,34;  act as a 
source of NO and  its congeners 29;  inhibit platelet function  26;  and  serve  as 
neuromodulators  35,36  Thus,  a  biological  role  for  the  NO+   species  can  be 
proposed, but this is exerted via NO+  carriers, i.e. R-SNO.
1.3  Nitroxyl anion: chemistry, sources and physiological aspects
Nitroxyl  is the traditional  name given to  its protonated  (HNO,  nitroxyl  ion  or 
nitrosyl  hydride)  and  unprotonated  (NO')  species*,  both  of which  have  their 
own distinct chemistry and are highly reactive molecules 3 7   Unlike NO+,  NO', 
the one electron reduction product of NO, can exist freely in solution at pH 7 
38.  As  NO* is a short lived species (~5 milliseconds)  identifying  its  presence 
can  be difficult as  it rapidly decomposes by dimerization and dehydration to 
yield N20 2 5   Despite the previous observation NO* is formed transiently when 
NO reacts with  reductants,  e.g.  hydroxylamine 29,  and as an  intermediate  in 
NO type reactions 25  The first direct observation of NO' in aqueous solution 
suggested it was a weak acid (pKa = 4.7)37; however, a recent publication by 
Shafirovich  and  Lymar suggests a weaker acidity for NO* (pKa  ~11.4) 39.  In 
analogy with 02, NO* is isoelectronic,  i.e. it can exist in singlet (1N0‘) or triplet
*  The  chemical  notation  for  nitroxyl  (NO'/HNO)  is  often  used  interchangeably,  but  in  this 
Thesis  the  term  N 0‘  will  be  used  with  the  understanding  that  the  molecule  can  exist  as  a 
protonated species as well.
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(3N0‘) electronic spin states, with zero or two unpaired electrons, respectively. 
In aqueous solution the ground state for NO' is 1NO', while the excited state is 
3NO', with the former being the more reactive of the two 25,40  However,  1NO' 
does  not  react with  0 2   to  produce  ONOO',  rather  3NO'  does  2S ,  although 
ONOO' formation was observed when  NO' was formed from the reduction of 
NO by ferrocytochrome c 41,  thus illustrating the complexity surrounding  NO' 
chemistry.
Chemical sources of NO' include:  1. sodium trioxodinitrate (Angeli’s salt; AS, 
Na2N20 3 );  2.  benzenesulfohydroxamic  acid  (Piloty’s  acid;  PA,
CeH5S02NH0H);  and  3.  methanesulfohydroxamic  acid  (MSHA)  38.  Potential 
endogenous sources of NO' include:  1.  oxidation of L-arginine by  NOS 42,43, 
although this mechanism is still contentious 44'46; 2. decomposition of R-SNO 
in  the  presence  of thiols 30;  3.  reduction  of NO  by ferrocytochrome  c 41;  4. 
metabolic oxidation of cyanamide (NH2CN),  an alcohol deterrent agent used 
to inhibit aldehyde dehydrogenase (A1DH,  EC 1.2.1.3)47; and 5. oxidation of 
NO' to NO by the ubiquitous electron acceptor superoxide dismutase (SOD), 
as illustrated in Equation 1.1 4 8
NO" + SOD[Cu(ll)] o N O  + SOD[Cu(l)]
Equation 1.1 Reversible conversion of nitroxyl anion to nitric oxide
A number of reports have shown that NO* can elicit similar pharmacological 
effects to NO,  and  in some cases  be more effective.  Examples  of beneficial 
effects include: vasodilation in aorta and arterial smooth muscle 42,49; inhibition 
of platelet activation and stimulation of neutrophil migration 50'52; attenuation of
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post-ischaemic myocardial injury in vivo, in a manner analogous to NO 53; the 
ability  to  increase  myocardial  performance  without  altering  heart  rate  in 
contrast to NO, thus suggesting a^potential clinical application of NO'54;  and 
modulation  of  A/-methyl-D-aspartate  (NMDA)  receptors  in  a  neuroprotective 
manner unlike NO 55,56. Adverse effects mediated by NO' include: cytotoxicity 
and DNA damage in the presence of strong oxidants, e.g. hydrogen peroxide 
(H2O2) 57; also,  NO' is more cytotoxic than NO, dinitrogen trioxide (N203) and 
ONOO'5 8   The latter characteristics of NO' may be harnessed for therapeutic 
applications, e.g. targeting cancer cells, but also indicates that the anion may 
play a role in the etiology of various pathological conditions.  In  analogy with 
NO  59,6°,  the  aforementioned  effects  of  NO'  can  be  mediated  by  cGMP 
dependent  and  independent  (e.g.  calcitonin  gene-related  peptide  (CGRP)) 
5 4 ,6 1   mechanisms.  In  the  case  of  cGMP  dependent  reactions  it  is  now 
accepted that intracellular oxidation of NO' to NO occurs.  In fact, a number of 
routes have been proposed, including oxidation by SOD 48,62,  copper ions 63, 
quinones 64  O2, flavins and methaemoglobin (Hb+) 62.
Mechanisms for detecting the presence of NO' include: trapping with thiols 6 5  
and ferric (Fe3+) haem centres such as tetracyanonickleate anion [Ni(CN)4 ]2', 
metmyoglobin  (Mb+)  and  Hb+   66;  while  electron  paramagnetic  resonance 
(EPR)  can  distinguish  NO' from  NO  as the former,  in  analogy with  NO+,  is 
diamagnetic,  whereas  NO  is  paramagnetic 6 7 ,6 8   The adverse  effects  of NO" 
can  be  attenuated  using  cobalamins  6 9   and  thiols  (e.g.  L-cysteine)  65  The 
latter reaction exploits the scavenging potential of thiols as well as the affinity 
of NO' for sulphydryl groups4 7
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1.4  Nitric oxide biosynthesis
With  the  discovery  that  NO  was  the  labile  factor  responsible  for vascular
\
smooth  muscle relaxation 6,T,  interest in the way NO is produced  intensified. 
Key discoveries  related to this  area  included:  1.  research  into  the  basis for 
N02' and N03' synthesis in vivo 70,71; 2. identification of L-arginine,  but not D- 
arginine,  as  the  principal  source  for  mammalian  NO  synthesis  72;  3. 
recognition  that  NO,  L-citrulline  and  /V“-hydroxy-L-arginine  (NHA)  are 
intermediates  in  the  conversion  of  L-arginine  to  N02'  and  N03',  in 
macrophages 73-75 and endothelial cells 76;  and 4.  discovery of the enzymes 
responsible for the synthesis of NO from L-arginine (i.e. the NOSs) in various 
mammalian tissues 77. As a result, the enzymatic conversion of L-arginine to 
NO and L-citrulline by NOS in the presence of 0 2  is known as the L-arginine- 
NO pathway (see Figure 1.1)78.
H3n  guu
1  NADPH 0.5 NADPH
H3N  COO 
N(0'Hydroxyarginine
H3N" TJOO
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©
+  NO
i«-Arginine Citrulline  Nitric Oxide
Figure 1.1 The L-arginine-NO pathway.
Adapted from 7 9
The  semi-essential  amino  acid  L-arginine  is  synthesised  in  vivo  within  the 
cytosolic and mitochondrial compartments of cells in the intestine, kidneys and 
liver from a number of sources, e.g. L-citrulline, L-glutamine and L-proline, viaINTRODUCTION
a  series  of  enzymatic  reactions.  The  most  important  aspect  of  L-arginine 
metabolism  is  its  catabolism,  as  this  amino  acid  plays  a  central  role  in 
generating  cell-signalling  molecules,  e.g.  NO,  glutamate,  polyamines, 
agmatine and  precursors for the synthesis of proteins,  urea  and  creatine 8 0  
The  principal  regulators  of  L-arginine  homeostasis  are  the  NOSs  and 
arginases, which form urea and L-ornithine 81.  In the context of NO synthesis 
the  importance  of  L-arginine  is  illustrated  by  the  existence  of  a  means  to 
recycle  L-citrulline  to  L-arginine  via  the  citrulline/NO  (or  arginine/citrulline) 
cycle.  The  latter  reaction  is  catalysed  by  the  enzymes  argininosuccinate 
synthase (ASS)  and  argininosuccinate  lyase  (ASL),  with  L-argininosuccinate 
as an intermediate80.
1.5  The nitric oxide synthases
Having established the existence of the L-arginine-NO pathway, the next step 
was  to  identify  the  constituents  of  this  pathway  and  its  mechanism(s)  of 
regulation. This began with the rapid characterisation, purification and cloning 
of the NOSs (E.C.  1.14.13.39), a group of highly regulated, but medium-sized 
(130-160 kDa) enzymes, which participate in a myriad of biological functions. 
The  term  ‘synthases’  is  used  instead  of ‘synthetases’  as  the  NOSs  do  not 
employ ATP during their reactions 82.  To date, four distinct isoforms of NOS 
have  been  identified  in  different cells types:  1.  endothelial  NOS  (eNOS);  2. 
inducible  NOS (iNOS);  3.  neuronal  NOS  (nNOS);  and  4.  mitochondrial  NOS
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(mtNOS)\  These  isoforms  are  often  classified  according  to  their  means  of 
expression, either constitutive (eNOS, nNOS and mtNOS) or inducible (iNOS) 
and  their  calcium  (Ca2+)-dependence  (eNOS,  nNOS  and  mtNOS)  or  - 
independence (iNOS), although such groupings are not clearcut8 3
1.5.1  Neuronal nitric oxide synthase
The first isoform to be purified and cloned was neuronal nitric oxide synthase 
(nNOS)  from  rat  brain  84,85.  This  isoform  has  also  been  observed  in  non­
neuronal tissues, e.g. skeletal muscle, and mapped to human chromosome 12 
8 6   It  is  constitutively  expressed  in  the  cytosolic  fraction  (molecular  weight 
(MW),  150-160  kDa)  as  a  dimer in  its  native  state  and  is  highly conserved 
(93%)  among  species  87  Activation  relies  upon  increased  Ca2 +   forming  a 
complex with the Ca2 +  binding protein calmodulin (CaM)88.
1.5.2  Inducible nitric oxide synthase
The  second  isoform,  inducible  NOS  (iNOS),  was first  discovered  in  murine 
macrophages  following  their  exposure  to  an  ‘inducing’  agent,  e.g. 
lipopolysaccharides  or cytokines 8 9   This  dimeric  enzyme  (MW of  130  kDa) 
has  been  purified,  cloned  and  ascribed  to  chromosome  17  in  humans  90. 
Activity has been detected in the cytosolic fraction of immune and nonimmune 
cell  types  of  various  species,  while  interspecies  amino  acid  sequence
*  The  IUP  recommends  that  a  standardised  terminology  for  the  NOSs  be  based  upon  their 
cellular origin  and  location  of their  respective  cDNAs  12,  a  similar  nomenclature will  apply  in 
this Thesis.
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similarity is > 80% 8 6   The strong affinity between iNOS and CaM,  even after 
boiling in SDS and PAGE, accounts for the Ca2+ -independence of this isoform
91 \
1.5.3  Endothelial nitric oxide synthase
The second constitutive isoform,  endothelial  NOS  (eNOS),  has been  purified 
and  cloned  in  bovine  endothelial  cells  92.  Analogous  to  the  other  isoforms 
eNOS is dimeric, but it has a MW of 135 kDa, is assigned to chromosome 7, 
and displays a very high (> 94%) degree of interspecies amino acid sequence 
similarity 8 6   This isoform is present in numerous cells types predominantly (> 
90%) in the particulate fraction, due to the presence of a N-myristoylation and 
palmitylation sequence in the eNOS gene (see Figure 1.3), although cytosolic 
expression  has  been  detected  7 7   Akin  to  nNOS,  eNOS  requires  binding  of 
increased Ca2 +  to CaM for its regulation and expression;  however,  similarity 
between  these  isoforms  is  only  57%,  revealing  that  both  are  distinct  gene 
products 8 2   As this isoform predominates in endothelial cells lining the lumen 
of  blood  vessels  its  expression  can  be  regulated  in  a  Ca2+ -independent 
manner  as  a  result  of  haemodynamic  forces,  e.g.  fluid  shear  stress  (the 
dragging  frictional  force  created  by  blood  flow)  and  mechanical  stretch  (a 
cyclic strain  stress  created  by  blood  pressure)  9 3 _ 9 5 .  Of these  stimuli  shear 
stress induced activation of eNOS has assumed great importance as a means 
for sustained  NO production independent of intracellular Ca2 +  concentrations 
([Ca2 + ]j)  96  Alterations  in  intracellular  pH  as  well  as  activation  of 
phosphoatidylinositol 3-kinase (PI3K) and the subsequent phosphorylation of 
its  downstream  target  Akt  (also  know  as  protein  kinase  B),  which  in  turn
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phosphorylates  eNOS  on  Ser1177,  have  been  proposed  as  mechanisms  by 
which shear stress promotes an increase in eNOS activity 97'9 9
1.5.4  Mitochondrial nitric oxide synthase
Recently,  a  fourth  dimeric  NOS  isoform,  mitochondrial  NOS  (mtNOS),  has 
been  identified,  purified  and  characterized  from  the  inner  mitochondrial 
membrane of rat liver1 00-101. This enzyme shares similarities with other NOSs, 
e.g. it has a MW of 125-130 kDa, akin to iNOS, while its membranous location 
and Ca2 + -dependence is similar to eNOS  101. As mitochondria  play a central 
role  in  a  number  of  physiological  processes,  e.g.  02   consumption,  energy 
metabolism  and  Ca2 +   buffering,  it  has  been  suggested  that  mtNOS  may 
regulate such functions 102.
1.6  Nitric oxide synthases: structure and mechanism of action
Although there are four isoforms of NOS  details regarding the structure and 
mechanism  of action  of  NOSs  have  been  derived  from  eNOS,  iNOS  and 
nNOS.  A  number  of  common  structural  features  exist  suggesting  the 
possibility  of  a  common  ancestral  origin  for  the  NOS  gene  8 3   All  NOSs 
contain a recognition site for their substrate, L-arginine, and possess a tightly 
bound  haem  (ferro-(Fe2+)protoporphyrin  IX)  prosthetic group which functions 
in arginine turnover79  Their dimeric composition comprises two domains (see 
Figure 1.2 and Figure 1.3), a N-terminal oxygenase domain and a C-terminal 
reductase  domain,  which  are  linked  by a  CaM  recognition  site.  The  former 
domain contains the binding sites for L-arginine,  haem and the cofactor (6R)- 
5,6,7,8-tetrahydrobiopterin  (BH4),  while  the  latter  domain  contains  binding
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sites  for  NADPH  and  other  essential  cofactors,  i.e.  flavoproteins  (flavin 
adenine  dinucleotide  (FAD)  and  flavin  mononucleotide  (FMN))  82.  Also, 
different regulatory sites (see Figure  1.3) exist in certain  NOS  isoforms.  For 
example,  nNOS  has  a  PDZ  (PSD-95  Discs-large/ZO-1)  1 0 3   and  a  protein 
inhibitor of  NOS  (PIN)  1 0 4   domains  which  target  this  isoform  to  signalling 
regions and exert a negative influence upon its dimeric structure, respectively. 
In  eNOS  the  N-myristoylation  and  palmitoylation  sequences  localise  this 
isoform to the plasmalemmal caveolae8 3
Caveolae  are  dynamic  non-clathrin-coated  invaginations  present on  the  cell 
surface  membrane  of  many  cell  types,  including  endothelial  cells  and 
myocytes.  They have  been  implicated  in  a variety of cellular functions,  e.g. 
signal  transduction,  endocytosis,  transcytosis,  receptor-mediated  uptake  of 
small molecules (also know as potocytosis) and  regulation of [Ca2+ ]i105-106. a 
number of physiochemical features define caveolae, namely, an abundance of 
cholesterol,  sphingomyelin  and  glycosphingolipids  on  their  cytoplasmic 
surface  and  the  presence  of a  Triton-insoluble  protein  coat  called  caveolin 
107,108  far f0ur different caveolin isoforms have been identified (caveolin-1 a 
and  -1 p,  caveolin-2  and  caveolin-3).  Caveolin-1  and  -2  are  ubiquitously 
expressed whereas caveolin-3 predominates in  muscle;  however,  caveolin-1 
and -3 are the most studied 1 0 8   Given the variety of critical functions ascribed 
to caveolae a number of signalling molecules, e.g. G proteins, protein kinases, 
growth  factor  and  hormonal  receptors  as  well  as  eNOS  and  nNOS,  are 
compartmentalized within them via the scaffolding protein caveolin 108-1 0 9
The  targeting  of  NOS  to  caveolin  exhibits  an  isoform  specificity,
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namely,  eNOS  and  nNOS  interact  directly  with  caveolin  via  a  ‘caveolin 
scaffolding domain’ in caveolin and a ‘caveolin binding domain’  in eNOS and 
nNOS 1 1 0 ‘113, whereas iNOS, given'is tight binding of calmodulin, is unlikely to 
be targeted to caveolae or regulated by caveolin 114. In endothelial cells eNOS 
is associated with caveolin-1,  but with caveolin-3 in myocytes 115. As a result 
of  these  interactions  caveolin  exerts  an  inhibitory  influence  over  eNOS 
release; however, this inhibition can be overcome by agonist stimulation, e.g. 
increased  blood  flow  or  binding  of  Ca2 + -calmodulin  to  eNOS,  leading  to 
competitive displacement of caveolin and thus synthesis of NO by the active 
enzyme 111-112. When basal levels of Ca2 +  are reattained calmodulin detaches 
from  eNOS  allowing  caveolin  to  rebind  and  deactivate  the  enzyme,  thus 
illustrating the reciprocal regulatory cycle exerted by calmodulin (an activator) 
and caveolin (an inhibitor)1 16. In addition, Flam et al. observed that NOS, and 
the  enzymes  involved  in  arginine  regeneration,  ASS  and  ASL,  colocalise 
within  plasmalemmal  caveolae  117,  thus  illustrating  the  potential  for  rapid 
activation  and  deactivation  of  NO  synthesis.  Modulation  of  caveolin 
expression  can  play  a  role  in  a  number  of  NO-related  pathologies.  For 
example,  Feron  et  al.  demonstrated  that  an  abundance  of  caveolin-3 
decreased  NO  production  leading  to  an  impairment  of  the  muscarinic 
cholinergic  negative  chronotropic  effect  in  isolated  cardiac  myocytes  118. 
Conversely,  downregulation  of caveolin  could  play  a  role  in  cardiac failure. 
Furthermore,  exposure  of  endothelial  cells  to  high  levels  of  cholesterol 
increases  caveolin  mRNA  leading  to  stabilisation  of  the  caveolin/eNOS 
complex and thus decreased NO bioavailability 1 1 6
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Figure 1.2 Structure of nitric oxide synthase dimer.
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Figure 1.3 Regulatory sites within the nitric oxide synthase genes.
Myr = N-myristoylation; Palm = palmitoylation sequence;
PDZ =  PSD-95  Discs-large/ZO-1;  PIN = protein inhibitor of nNOS 
(residues 161-245); and Zn = zinc. Adapted from 8 3
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Initially NOS was assumed to be a haemoprotein as its amino acid sequence
bore a close homology with CYP-450 reductase (CPR) 85;  however, they are
\
distinct entities since  NOS  requires the cofactor BH4  for dimerization,  haem 
transition, efficient electron transfer and NO production 59  In addition,  NOS is 
analogous to fatty acid monooxygenase (P-450B m 3) from Bacillus megaterium, 
as they are the only known self-sufficient P-450 type enzymes,  i.e. they have 
their  flavoprotein  reductase  and  haem  domains  as  part  of  the  same 
polypeptide, thus illustrating the evolutionary conservation of the flavoprotein 
reductase in bacteria and mammals 119/l20.
Despite their diverse locations, expression and  regulation the mechanism  by 
which NOSs catalyse the five-electron oxidation of L-arginine (the substrate) 
to NO and L-citrulline (the products), a reaction that is common to all isoforms, 
has assumed great importance given the key biological role played by NO 5 9  
Although the exact mechanism is not fully understood the reaction,  illustrated 
in  Figure  1.4,  is  a  highly  regulated  and  complex  process  comprising  two 
mono-oxygenation  steps,  with  NHA  as  an  intermediate,  and  shows  an 
absolute requirement for reducing equivalents (NADPH), 02,  cofactors (FAD, 
FMN and BH4), and in certain cases Ca2 +  and CaM (i.e. eNOS and nNOS), for 
successful completion 1 5
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Figure 1.4 Mechanism of nitric oxide synthesis from L-arginine.
The shaded atoms show the origin of the constituent atoms of NO. 
Adapted from 82.
In the first mono-oxygenation step one equivalent of NADPH  and O2 is used 
to hydroxylate one of the guanidino nitrogens of L-arginine, in the presence of 
BH4,  to  generate  NHA  121122.  in  the  absence  of  sufficient  BH4   the  latter 
reaction proceeds but produces reactive oxygen species (ROS), e.g. 02‘ and 
H2O2,  and  less  NO instead 83.  The second  mono-oxygenation  step oxidises 
NHA to  A^-oxo-L-arginine,  followed  by  loss  of  H+   to  generate  an  unstable 
amino  acid  radical  which  fragments  to  yield  NO  and  the  amino  acid 
carbodimine which reacts with H20 to produce L-citrulline 1 2 3
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In response to an increase in Ca2 +  or immunogenic stimuli CaM binds to the
enzyme,  this  has  the  dual  effect of increasing  the  rate  and  efficiency  with
\
which electrons are transferred both within and  between  NOS domains (see 
Figure  1.2)  “   Electrons,  which  are  supplied  by  NADPH,  are  transferred 
through  the  reductase  domain  to  sequentially  reduce  FAD  and  FMN  and 
conveyed  into  the  oxygenase  domain.  In  the  latter  domain,  the  electrons 
interact with  both  haem iron and  BH4  at the enzymes active site to catalyse 
the reaction 87. Binding of L-arginine promotes the reduction of NOS causing a 
conformational change of the prosthetic haem from a low spin six-coordinate 
(Fe3 + )  to  a  high  spin  five-coordinate  (Fe2+ )  state,  thus  increasing  the  redox 
potential of the ligand  1 2 4   Although  BH4  is present in all isoforms of NOS its 
function  is somewhat unusual  and controversial  1 2 5   The suggested roles for 
BH4  include:  1. a direct catalytic redox role in both monooxygenase cycles; 2. 
allosteric binding stabilises the enzyme; and 3.  protection against inactivation 
and  autoactivation  8 7   Another  important  function  ascribed  to  BH4   in  NOS 
catalysis is its critical role in the control of one- and two-electron mechanisms 
of NOS 1 2 6   However, in the presence of low concentrations, or the absence of 
BH4   or  L-arginine,  NOS  catalyses  the  uncoupled  oxidation  of  NADPH  to 
liberate 02‘ and H202  1 27  This uncoupled reaction exhibits isoform specificity 
namely,  eNOS  coupling  is  controlled  by  BH4   scavenging  0 2‘  128,  whereas 
nNOS  coupling  is  regulated  via  L-arginine  decreasing  the  rate  of  NADPH 
oxidation 129-1 3 0
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1.6.1  Regulation of nitric oxide production
Generally the  intensity and  rate of NO production varies according  to  need. 
For  example,  the  activities  of  eNOS  and  nNOS  are  tightly  regulated  by 
fluctuations in Ca2 + /CaM to produce brief (seconds to minutes) but potent cell 
signalling effects,  whereas iNOS,  once expressed in response to  an  inducer 
(e.g. endotoxin and cytokines),  is constitutively active for prolonged (hours to 
days) periods 81.  In disease states NO may be under (e.g.  hypertension and 
atherosclerosis) or over (e.g. septic shock, inflammation and stroke) produced 
131.  To  effectively  control  imbalances  in  NO  a  number  of  strategies  are 
available.  Lack of NO can be overcome by pharmacological  NO donors e.g. 
organic nitrates and  nitrite esters such as GTN  8   Control of excess  NO has 
received the most attention, as a result there are a  myriad of NOS  inhibitors 
described and in use as pharmacological tools. Among the most widely used 
are the  amino  acid  analogues  of L-arginine  (see  Figure  1.5  for examples), 
which  compete for the active site of NOS to impose a  rapid,  but reversible, 
inhibition of activity.
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Figure 1.5 Examples of L-arginine analogues.
L-NMMA  =  NG-nitro-L-arginine  methyl  ester;  L-NIO  =  N5- 
iminoethyl-L-ornithine;  L-ADMA  =  NG-dimethyl-L-arginine;  and  L- 
NNA = N“-nitro-L-arginine. Adapted from82.
Other  inhibitors  are  based  upon  aromatic  heterocyclics  (e.g.  1-(2-
trifluoromethylphenyl)  imidazole  (TRIM))  and  nonamino  acid  (e.g. 
aminoguanidine)  structures  8 3   A  major  drawback  with  many  of  the 
aforementioned  types  of  inhibitors  include:  their  lack  of  isoform  specificity; 
promotion  of  conformational  changes  in  NOS;  poor  tissue  uptake;  and 
attachment  to  other  essential  enzymes  1 3 2   There  are  a  number  of  post- 
translational  mechanisms  by which  NO  production  can  be  regulated,  these 
include:  Ca2 +   chelation  with  EDTA  or  EGTA;  flavoprotein  inhibitors,  e.g. 
diphenyleneiodonium; CaM antagonists, e.g. trifluroperazine; and BH4 -binding 
site inhibitors (e.g. 4-amino-BH4) or BH4  synthesis inhibitors e.g. methotrexate
81,83
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Feedback  inhibition  by  the  product  upon  the  enzyme  is  a  common 
phenomenon, similarly with  NO inhibiting the NOSs via binding to their haem 
irons  7 9   Also,  the  intermediate  NHA  is  a  potent  endogenous  inhibitor  of 
arginase (L-arginine-urea hydrolase), a binuclear manganese metalloenzyme 
which  catalyses  the  hydrolysis  of  L-arginine  to  urea  and  L-ornithine. 
Therefore,  interest in arginases has risen due to their ability to modulate the 
availability of substrate,  i.e.  L-arginine 80,81.  The asymmetric methylarginines 
(L-NMMA  and  asymmetric  dimethylarginine  (ADMA))  arise  from  the 
methylation of L-arginine residues in proteins by the enzyme protein arginine 
methyltransferase  (PRMT)  1 3 3   As  endogenous  guanidino  substituted 
analogues of L-arginine both L-NMMA and ADMA inhibit NOSs and  regulate 
the  availability  of  L-arginine.  The  latter  effect  is  achieved  by  the  enzyme 
dimethylarginine dimethylaminohydrolase (DDAH)  metabolising  L-NMMA and 
ADMA to citrulline, thus maintaining NO production 1 3 3
The  ubiquitously  expressed  stress-activated  gene  heat  shock  protein  90 
(HSP90) serves as a molecular chaperone involved in the folding, activation, 
stability,  maturation,  transport  and  targeting  of  important signalling  proteins 
e.g. steroid hormone receptors, G protein py subunits,  protein kinases (c-Src 
and  Raf-1)  and  NOSs  1 3 4 -1 3 5   The  binding  of  HSP90  to  eNOS  and  nNOS 
enhances  the  activation  of  both  isoforms  136'1 3 7   in  response  to  stimuli 
(estrogen, fluid shear stress, histamine and vascular endothelial growth factor 
(VEFG)) HSP90 promotes an allosteric modulation of eNOS via recruitment of 
other  proteins,  e.g.  Akt,  to  the  caveolin-eNOS  complex.  This  leads  to 
phosphorylation of serine  1117  (human)/1179 (bovine)  on  eNOS  by Akt and
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thus  facilitating  the  CaM-induced  dissociation  of  eNOS  from  the  inhibitory
influence of caveolin  1 37-1 38  in  addition,  HSP90  my act as  a  scaffold for the
\
recruitment  of  other  eNOS-associated  proteins,  e.g.  kinases  and 
phosphatases,  as well as prevent eNOS uncoupling,  i.e.  its production of 02‘ 
instead of NO 139-140. The effects of HSP90 upon nNOS include increasing the 
isoforms affinity for CaM 1 4 1  and facilitating the sustained opening of the haem 
binding cleft,  and thus  incorporation  of haem  into  nNOS,  especially  so  in  in 
vivo situations where free  haem is  limited  136.  The crucial  regulatory role of 
HSP90  over  the  activation  of  eNOS  and  nNOS  was  confirmed  using  the 
specific inhibitor of HSP90, the ansamycin antibiotic geldanamycin (GA)1 3 9
Other modulators of NO production are the cytokines which can regulate NOS 
in  a  positive  (interferon  gamma  (IFN-y)  and  interleukin  1   beta  (IL1-p))  and 
negative (e.g. transforming growth factor beta (TGF-p)) manner81.  Hormones 
such  as  estrogen  enhance  eNOS  and  nNOS  mRNA  15,  whereas 
glucocorticoids inhibit iNOS mRNA142. Interaction with proteins, e.g. caveolins 
for  eNOS,  proteins  containing  PDZ  domains  for  nNOS  and  Rho  family 
GTPases  for  iNOS,  regulates  the  activity  and  cellular  distribution  of  the 
isoforms  143.  Collectively,  the examples  given  illustrate a  number of diverse, 
though sometimes  ineffective,  mechanisms  to control  NO  production.  Given 
the ubiquitous nature of NO and its association with a number of pathologies 
identifying  specific  and  selective  therapeutic  modulators  of  NO  is  an  area 
worthy of further investigation.
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1.7  Cyclic guanosine monophosphate and guanylate cyclases
The cyclic nucleotides,  cyclic guahosine monophosphate  (cGMP)  and  cyclic 
adenosine  monophosphate  (cAMP),  have  been  shown  to  act  as  important 
intracellular second  messengers  1 4 4   Since  its  discovery  in  the  1960s,  the 
biological  roles  of cGMP  remained  elusive  due  to  cAMP  superseding  it  in 
importance 145.  However, the identification of the enzymes responsible for its 
synthesis  (guanylate  cyclase;  GC)  and  hydrolysis  (cyclic  nucleotide 
phosphodiesterase), along with the discovery of NO,  led to a greater interest 
in the function of cGMP 3   The two  mammalian  GCs,  particulate (pGC)  and 
soluble  (sGC),  catalyse  the  conversion  of guanosine  triphosphate  (GTP)  to 
cGMP  146,  while  enzymatic  activity  has  been  observed  in  a  wide  range  of 
mammalian cells and tissues 1 4 7
Particulate GCs are membrane bound enzymes containing different subtypes 
(GC-A,  GC-B  and  GC-C)  that  partition  to  the  nuclear  and  microsomal 
fractions.  They  are  found  in  mammals  and  bacteria  and  their  principal 
functions  are the  regulation  of fluid  volume  and  movement  1 4 6   Structurally, 
this  group  contains  an  extracellular  ligand  binding  region,  a  single 
transmembrane domain, a protein kinase like domain and a catalytic domain 
1 4 6   A variety of agents,  e.g.  heat-stable  endotoxin from E.  coli,  atriopeptins, 
atrial natriuretic peptide (ANP),  intracellular Ca2 +  binding proteins and hemin, 
have been shown to regulate this isoform 1 4 5
Soluble GC (sGC),  the  principal  physiological target for NO,  is found  in the 
cytosolic fraction of all mammalian cells as a heterodimeric protein comprising
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two subunits,  designated a1-a2 and p1-p2, which are derived from separate 
genes 1 4 8   The a and p subunits comprise three functional domains:  1. a haem 
with  ferrous  iron  (Fe2+ )  at  its  centre;  2.  a  catalytic  domain;  and  3.  a 
dimerization  domain  (see structure in  Figure  1.6). A catalytically active sGC 
heterodimer is formed when corresponding monomers,  e.g.  a1  and  pi,  fuse 
via their respective  dimerization  domains  1 48-1 4 9   a second  metal,  copper,  is 
also present in sGC, although its exact function remains elusive it may act as 
a  cofactor  for  enzymatic  activity  1 5 0   Activation  of  sGC  can  occur  with 
protoporphyrin IX (the iron-free precursor of haem),  NO,  azide, CO and OH‘, 
while methylene blue, Mb and Hb are potent inhibitors 151.
Akin to other cell types, activation of cytosolic sGC by NO in cardiomyocytes 
promotes  the  formation  of  the  second  messenger  cGMP  from  GTP  3'4. 
Therefore,  cGMP  can  serve  as  a downstream  effector of sGC  and  thereby 
one of the main routes through which NO mediates its signalling effects in the 
heart  1 5 2   Like  NO,  cGMP  can  affect  a  variety  of  signalling  pathways  153. 
Potential  myocardial  functions  reported  for  cGMP  include:  modulation  of 
sarcolemmal  Ca2+   influx,  reduction  of  myofilament  Ca2 +   sensitivity,  altered 
sarcoplasmic reticulum (SR) function, changes in action potential,  modulation 
of cell  volume  and  reduction  in  02   consumption  1 5 4   The  principal  myocytic 
targets for cGMP include:  cGMP-dependent protein  kinases  (cGKs type  I  (a 
and p) and II, also known as protein kinase G (PKG)); inhibitory or stimulatory 
phosphodiesterases (PDEs), e.g. iPDE or PDE type 3 and sPDE or PDE type 
2,  respectively;  and  cGMP-gated  ion  channels  (also  known  as  cyclic 
nucleotide-gated  (CNG)  cation  channels)1 5 5 '1 5 9
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These  mediate  phosphorylation  of  proteins  that  regulate  intracellular  Ca2 +  
levels,  cyclic nucleotide catabolism  and  cation  influx  across  the  membrane, 
respectively 158-1 6 0   Despite the fact that cardiac cGMP levels change on the 
millisecond time scale to reflect the rapid changes characteristic of excitation- 
contraction (EC) coupling 161, the mechanisms by which sGC/cGMP regulates 
different  cardiomyocyte  functions,  e.g.  contraction  (inotropy),  relaxation 
(lusitropy) and  heart rate (chronotropy),  are becoming  more distinct 162.  The 
involvement of cGMP  in  inotropic function  was first  noted  in  1977  and  has 
since been confirmed in various mammalian myocytes using NO donors (e.g. 
SIN-1  and SNAP) and inhibitors of cGMP PDE (e.g.  milrinone), sGC (e.g.  LY 
83583) or PKG (e.g. KT 5823)1 5 4
The  biphasic  (positive  or  negative)  nature  of  NO  in  cardiomyocytes  is 
mediated by changes in the concentration of sGC/cGMP 163'164.  For example, 
low (nanomolar) concentrations of cGMP evoke a positive inotropic response 
via inhibition of PDE type 3 and a concomitant increase in the cAMP content 
of cardiomyocytes, which potentiates the stimulatory effect of cAMP upon the 
L-type  Ca2 +   channel  (/ca)  to  promote  Ca2 +   influx  and  myocyte  contraction
1 6 0 .1 6 5   The  latter  reaction  occurs  via  phosphorylation  by  protein  kinase  A 
(PKA)  of  intracellular voltage-operated  Ca2 +   channels,  e.g.  phospholamban 
(PLN) and inositol trisphosphate (IP3) receptors, in the SR of cardiomyocytes
162.166  (mjCrom0|ar)  cGMP  concentrations  have the  opposite  outcome, 
i.e.  activation  of  PDE  type  2,  lower  intracellular  cAMP  and  Ca2 +  
concentrations,  leading to a negative inotropic effect 167-1 6 8   The latter effect, 
inhibition of the /C a, may also occur via cGMP activating PKG which promotes
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either  direct  phosphorylation  of  the  channel,  phosphorylation  of  an 
intermediate protein opposing the action of PKA or Ca2 +  export1 6 9
A positive lusitropic effect can be induced by PKG and  PKA phosphorylation 
of troponin I (Tnl) within cardiac myofilaments thus decreasing their sensitivity 
to  Ca2 +   1 4 0   In  response  to  beta  (p)-adrenergic  stimulation  eNOS-derived 
cGMP may affect myocyte chronotropy in a negative manner via inhibition of 
/C a  through PDE type 2 degradation of cAMP 1 1 8 '1 4 0 '1 7 0   a positive chronotropic 
effect has  been  observed  in  patients  infused  with  the  NO  donor SNP  after 
heart transplantation  165.  The  importance  of endogenous  sGC/cGMP  in  the 
control of heart rate is illustrated by the fact that mice lacking the eNOS gene 
exhibit significant bradycardia (slow heart rate, < 60 beats per minute)171. The 
cooperation of cGMP originating from pacemaker cells of the sinoatrial  node 
should not be overlooked regards the chronotropic effects of sGC within target 
cardiomyocytes 172.  Finally, it has been noted that the expression pattern and 
activity of sGC changes with different stages of cardiomyocyte development, 
i.e. higher expression in the neonatal period with a decline after birth followed 
by a reversion to higher levels with age or in septic hearts 1 7 3 '1 75  The basis for 
these changes may be  related to a switch  in  sGC expression  to  myocardial 
endothelial  cells  as  well  as  the  content  of  myocardial  Mb,  an  endogenous 
scavenger of NO, as adult myocardium has a greater content of Mb compared 
with neonatal myocardium 1 73-174.
Thus,  in  response  to  increased  NO  production  sGC/cGMP  can  modulate  a 
number of cardiomyocyte functions  in  a  dynamic  manner.  One  should  also 
bear  in  mind  that  NO  can  exert  its  signalling  effects  independent  of
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sGC/cGMP  production,  e.g.  post-translational  modification of proteins via  S- 
nitrosothiol  bond  formation,  interaction  with  haem  proteins,  Ca2 + -dependent 
K+ -channels  and  non-haem  iron  1 3 -1 7 '60-1 7 6 -1 7 7   |n  addition,  sGC  can  also  be 
stimulated,  but to  a  weaker extent,  by  carbon  monoxide  (CO;  see  Section
1.7.1  for  more  details),  originating  from  the  cytoprotective  enzyme  haem 
oxygenase 1 7 8 '181.
cG M P
Figure 1.6 Structure of soluble guanylate cyclase.
Adapted from 1 4 9
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1.7.1  Activation of soluble guanylate cyclase
Investigations  of  sGC  regulation  revealed  that  haem  dependent  (NO  and 
related agents) and independent (protoporphyrin IX) mechanisms of activation 
proceeded via similar routes, i.e. formation of a Fe2 +  complex (see examples 
in Figure 1.7)1 8 2 .
NO
Fe
protoporphyrin-IX
heme
410 nm
Figure 1.7 Activators of soluble guanylate cyclase.
Adapted from 1 5 1 .
When NO binds to the six-coordinate position of the haem group it causes a 
number of physiochemical changes in sGC. Among these are disruption of the 
five-coordinate Fe2 +  axial histidine (His  105) bond  (absorption  maximum 430 
nm) and formation of a five-coordinate NO(nitrosyl)-Fe2 +  complex (absorption 
maximum  398  nm) 21.  Second,  there is an  increase  in  both  enzyme activity
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(> 200-fold) and affinity for the substrate GTP brought about by the presence 
of  the  essential  divalent  cation  magnesium  (Mg2+)  183.  Formation  of  the 
NO(nitrosyl)-Fe2 +   complex  is  near  diffusion  controlled,  while  dissociation 
occurs  quite  rapidly,  5  sec at 37°C,  thus  enabling  rapid  deactivation  of the 
enzyme in a biological scenario 15 1 . Another gaseous molecule, CO, has been 
shown to activate sGC,  but activation occurs in a different manner to NO 178. 
Although  CO also binds to the  Fe2 +  haem,  the five-coordinate  axial  His  105 
bond  remains  intact,  albeit  slightly  bent due  to  the  low vibration  frequency 
arising from CO, thus creating a Fe2+ -CO complex 184. This complex causes a 
shift in the absorbance maximum from 430 nm (native sGC) to 424 nm which 
is suggestive of a six-coordinate carboxy derivative. Secondly, the association 
and dissociation rate constant of the Fe2 + -CO complex at pH 7.5 at 23°C has 
been calculated as 1.2 ± 0.1  * 105  M'1  sec'1  and 28 ± 2 sec'1, respectively 178. 
The latter value strongly suggests the transient formation of a five-coordinate 
carboxyhaem  intermediate  thus  accounting  for the  low,  4-fold,  activation  of 
sGC by CO 21. Therefore, activation of sGC by NO and CO exhibit somewhat 
similar mechanisms but differ with respect to their intensity of increasing the 
catalytic  capacity  of  the  enzyme.  Protoporphyrin  IX  (PPIX),  the  iron-free 
precursor  of  haem,  strongly  activates  sGC  in  a  manner  similar  to  NO 
(absorbance maximum 410 nm)1 8 5   In all these examples the prosthetic haem 
group is essential,  as  removal of the group abolishes activation,  but can  be 
restored by NO-haemoprotein complexes 186.
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1.7.2  Modulation of soluble guanylate cyclase
\
Nitric oxide  mediates  a  diverse  range  of biological  effects  via  its  interaction 
with  a  number of  cellular targets,  e.g.  transition  metal  ions,  non-haem  Fe- 
proteins,  ADP-ribosyltransferase,  protein  thiols,  Fe-S  enzymes,  0 2,  02'  and 
transcription factors 1 3  31-176-187.  Given that sGC is the primary target of NO it 
would seem logical to focus on the former in order to modulate the beneficial 
and  adverse  aspects  of  NO.  Currently  there  are  a  number  of  direct  and 
indirect  acting  pharmacological  modulators  available.  Examples  of  direct 
acting  activators  include  NO donor compounds,  e.g.  GTN,  nitroprusside,  R- 
SNO  and  the  NONOates  (discussed further in  Section  1.10),  thus  enabling 
precise modulation of sGC via metabolism to or release of NO. Isoliquiritigenin 
is another example of a direct acting sGC activator. Its mechanism of action is 
unclear but is thought to be multifactorial1 4 9
The  benzylindazole  derivative  3-(5’-hydroxymethyl-2’-furyl)-1-benzylindazole, 
YC-1,  is a novel sGC stimulator which acts by a NO-independent mechanism 
1 8 8   This  agent  has  the  capacity  to  inhibit  platelet  aggregation,  enhance 
vascular smooth  muscle  relaxation and  potentiates the activation  of sGC by 
NO,  CO and  PPIX by >  40,  >  4000 and  360  percent,  respectively 1 8 9   Two 
possible  mechanisms  for  YC-1  are:  1.  allosteric  modification  of  the  sGC 
molecule;  and 2.  reduction of the dissociation rates for CO and  NO  1 8 9   The 
former mechanism requires the presence of an intact haem prosthetic group 
on the enzyme,  even though YC-1  doesn’t bind to haem,  as evidenced  by a 
lack of change  in  the  Soret absorption  when  YC-1  was  bound  to  native  or
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haem-depleted sGC either on  its own or in the presence of CO and  NO 1 8 9  
The data obtained with YC-1, in particular allosteric modification, suggest that 
an endogenous ‘YC-1  like’ modulator may sensitise sGC to modulation by NO 
and even more so by CO 151. Although the identity of the endogenous ‘YC-1 
like’ modulator is as yet unknown Colpaert et al. recently highlighted the ability 
of biliverdin and bilirubin to potentiate the CO-mediated  relaxation of porcine 
gastric fundus by a sGC-dependent mechanism 1 9 0   Even though there is still 
no  categorical  data  identifying  the  endogenous  ‘YC-1  like’  modulator,  the 
results  with  the  bile  pigments  (see  Chapter 6)  deserves  further exploration 
with the ultimate aim of manipulating the potential of sGC endogenously.
A  recent  publication  by  Stasch  et  al.  identified  a  regulatory  site  through 
Cys238  and  Cys243,  within  the  a1  subunit  of  sGC  that  was  sensitive  to 
catalytic  and  haem  ligand  modulation  via  a  new  type  of  direct  acting 
stimulator, BAY 41-2272 191. BAY 41-2272 shares a number of similarities with 
YC-1,  these  include:  1.  NO-independent,  but haem-dependent,  activation  of 
sGC; 2. analogous structure; 3. lack of change in the Soret band in either non­
stimulated or stimulated sGC; 4.  antiplatelet and vasodilatory potentials;  and 
5.  enhanced  responsiveness  of  sGC  is  achieved  without  the  need  for 
biotransformation  191.  These features of YC-1  and  BAY 41-2272  represent a 
novel  and  potentially  useful  class  of  NO  modulators  as  long  term  use  of 
organic  nitrates,  e.g.  GTN,  can  lead  to  tolerance  as  a  result  of  impaired 
metabolism 192.
Examples of sGC inhibitors include methylene blue and 6-anilinoquinoline-5,8- 
quinone (LY83583). Their mechanism  of  action  is  not  directed  specifically
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towards  sGC,  but  proceeds via  formation  of 0 2‘ which  inactivates  NO,  and 
direct inhibition of NOS activity 149. N-methylhydroxylamine is an example of a 
selective  sGC  inhibitor.  A  drawback  with  this  agent  is  the  necessity  to 
administer  milimolar  quantities  of  the  substance,  thus  questioning  its 
selectivity  1 4 9   The  compound,  1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one 
(ODQ), is an example of a highly selective inhibitor of sGC that has been used 
as  a  tool  to  distinguish  between  cGMP-dependent  and  cGMP-independent 
NO signalling  in the  brain  and  platelets  1 9 3 -1 9 4   Although  the  mechanisms  of 
ODQ are unclear, it is believed to compete with NO for the haem of sGC and 
once  bound  causes  a  reduction  in  the  Vmax  as  well  as  a  shift  in  the 
absorbance maximum from 430 nm to 398 nm, thus irreversibly oxidising the 
haem from Fe2 +  to Fe3+, therefore limiting the use of ODQ to in vitro studies of 
sGC 195. From the examples given it is clear that further research in the field of 
sGC modulation  is worthwhile in order to identify,  refine and  understand the 
mechanism  of  novel  compounds  which  could  be  used  as  potential 
pharmacological modulators of NO.
1.8  Physiological and pathophysiological aspects of nitric oxide
For many decades NO was considered purely as yet another toxic molecule, 
possible  carcinogen  and  an  environmental  pollutant;  however,  after  the 
discovery  of  its  production  in  the  vasculature  and  other  tissues,  the 
importance of NO in  mediating a variety of physiological functions started to 
gain  credence  196.  Nitric  oxide  participates  in  a  wide  range  of  biological 
functions in different systems, the most important being the nervous, vascular, 
immune  and  reproductive  systems  5 9   In  the  subsequent  sub-sections,  the
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beneficial  and  adverse consequences of NO will  be  discussed  in  relation to 
the aforementioned systems.
1.8.1  Nitric oxide in the nervous system
In 1982, Takeo Deguchi showed that L-arginine was the endogenous activator 
of sGC  in  the  brain  1 9 7   Later on,  the  identification  of the  nNOS  isoform  in 
neurons  and  nerve  endings  throughout the  central  and  peripheral  nervous 
system  (CNS  and  PNS,  respectively),  firmly  established  that  NO  was 
produced  within  the  nervous  system  1 9 8   Also,  a  link  between  NO  and  the 
excitatory amino acid glutamate was established as stimulation of A/-methyl-D- 
aspartate  (NMDA)  receptors  with  glutamate  results  in  an  increase  in  Ca2 +  
which activates nNOS to produce NO, thus elevating cGMP levels, while NOS 
inhibitors attenuated cGMP production 1 9 9   Excess NMDA receptor activation 
via  glutamate  can  result  in  a  variety  of  neurodegenerative  disorders,  e.g. 
cerebral  ischaemia,  epilepsy  and  Alzheimer’s  disease,  which  arise  from 
enhanced  NO  production 2 0 0   The  information  derived from  the  work linking 
glutamate, NMDA and NO, has been used as a model for various neurological 
pathologies  and also as a means to generate therapeutic treatments,  in the 
form of NMDA antagonists201.
The principal site of nNOS production in the brain and peripheral tissues is in 
neurons 202.  It has been shown that nNOS neurons co-localise with a discrete 
set of neurons called diaphorase neurons, which incidentally make up 2% of 
the  cerebral  cortex  203.  A  unique  feature  of  diaphorase  neurons  is  their 
resistance  to  toxic  insults  in  various  models  of  neurotoxic  disease,  e.g.
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Alzheimer’s and Huntington’s disease 1 9 6   The fact that neurons synthesising 
NO in response to increased glutamate activity could withstand the  resulting 
neurotoxic  effects  was  a  paradox.  A  possible  explanation  for  these 
observations  was  the  suggestion  that  NOS/diaphorase  neurons  release  a 
powerful burst of NO into the surrounding environment,  thus  killing  adjacent 
neurons 204. One of the functions assigned to NO within the nervous system is 
that of a neurotransmitter 2 0 5   The evidence to support this hypothesis came 
from studies of neurotransmission in  non-adrenergic non-cholinergic (NANC) 
nerves  which  serve  as  a  means  of innervation  for the  autonomic  nervous 
system in the gastrointestinal tract,  urogenital,  respiratory and cardiovascular 
systems 206. These studies revealed that:  1. a ‘NO-like’ substance is released 
from  stimulated  NANC  nerves;  2.  in  the  presence  of  NANC  inhibitors  NO 
derived from NO donors mimicked NANC relaxation; 3. NO could be produced 
outside of the brain in the autonomic nervous system; and 4. inhibition of NOS 
activity in  neurons  innervating the anococcygeus  muscle,  the gut and  blood 
vessels in the cerebral arteries and penis, led to a modulation of NANC nerve 
stimulation, thus supporting the neurotransmitter capacity of NO 205.
In the nervous system, NO fulfils the criteria for a neurotransmitter in a variety 
of ways:  1.  the  presence  of the  synthetic  enzyme  NOS  within  the  relevant 
neurons;  2.  release  from  the  nerve  terminals  occurs  following  Ca2 +  
stimulation;  3.  the  effect  induced  by  NO  is  similar  to  that  invoked  by 
physiologic  nerve  stimulation;  and  4.  inhibition  of  NO  synthesis  results  in 
inactivation of the nerve stimulation 2 05  Nevertheless, NO does not have any 
characteristics that resemble the conventional chemical neuromodulators 207.
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Firstly,  it  is  a  gas  rather  than  a  peptide  and  unlike  other  types  of 
neurotransmitters  it  is  not  stored Jn  synaptic  vesicles  but  is  produced  on 
demand.  Secondly,  as  a  gas  it  diffuses  freely  out  of cells  rather than  via 
exocytosis.  In addition,  NO has few receptors on postsynaptic cells, the best 
known ‘receptor’  being the iron  in sGC,  although  it has also  been shown  to 
stimulate  adenosine  diphosphate  (ADP)  ribosylation  of  glyceraldehyde-3- 
phosphatedehydrogenase (GAPDH) 205.  Despite such dissimilarities between 
the classical neurotransmitters and NO, the signalling capabilities of NO in the 
brain cannot be discounted,  while the gaseous nature of NO creates  a  new 
class of neural messenger207. Lastly, NO has been suggested to play a role in 
learning and memory by acting as a retrograde messenger in different types 
of  neuronal  plasticity  such  as  long-term  potentiation  (LTP)  and  long-term 
depression (LTD) 202'208t although this aspect remains to be proven.
1.8.2  Nitric oxide in the vascular system
Within  the  vascular  system  NO  plays  a  key  role  in  the  maintenance  of 
vascular tone,  i.e.  blood pressure,  and preservation of an intact endothelium 
to  prevent  thrombus  formation  2 0 9   Surrounding  the  inner  walls  of  blood 
vessels,  on top of the  underlying smooth  muscle layer,  are endothelial cells 
which comprise the endothelium.  The  endothelial  cells  have  receptors for a 
variety of neurotransmitters, e.g. acetylcholine (ACh), and in response to this 
stimulus  they  release  a  diffusible  substance  that  acts  on  the  underlying 
smooth  muscle  to  stimulate  relaxation  and  ultimately  a  lowering  of  blood 
pressure 2 10  While working  with  rabbit thoracic aorta  Robert Furchgott and 
John  Zawadzki  observed,  by  chance,  that  the  vasodilatory  response  was
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absent from blood vessels denuded of their endothelium but was maintained 
in vessels with an intact endothelium 5   The diffusible substance, which was 
very labile and nonprostanoid in nature, was first named EDRF 211, but further 
experiments revealed that EDRF was in fact NO6,?. In vitro and in vivo studies 
have  confirmed  that  continuous  release  of  NO  from  endothelial  cells  is 
essential  to  maintain  vascular  tone  212-2 1 3   As  a  result,  NO  has  been 
suggested as  an  important pharmacological therapy for vascular disease  in 
analogy with angiotensin and noradrenaline 1 9 6
Within the vasculature the highest quantity of NO is derived from arteries, the 
purpose being to maintain a dilator tone between resistance (small diameter 
arteries)  and  the  microvascular network 2 1 4   Continuous  secretion  of  NO  by 
the vascular endothelium helps to maintain  basal levels (~1-2  pM) of NO 59; 
however,  a  number  of  physiological  factors  can  augment  this  production. 
Examples  include:  platelet  products,  e.g.  ADP  and  serotonin,  thrombin, 
changes in oxygen tension,  neuronal stimuli,  pulsatile flow and shear stress. 
Of these stimuli shear stress and pulsatile flow are the main determinants of 
NO release 59  Maintenance of an intact endothelium for the release of NO is 
vital  as  numerous  animal  and  human  studies  show  that  augmented  NO 
production  may  be  a  causative  factor  in  the  pathogenesis  of  a  number  of 
cardiovascular related  diseases,  e.g.  hypertension,  arteriosclerosis,  diabetes 
mellitus and septic shock21 5
Abnormalities  in  endothelium  function  can  lead  to  impaired  NO-mediated 
regulation of vascular tone, which is a causative factor in the development of 
essential hypertension in humans2 16  Animal models of hypertension, e.g. the
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spontaneously  hypertensive  (SH)  and  deoxycorticosterone  (DOCA)-salt 
hypertensive rats,  have supported this theory, while induction of a  prolonged 
hypertensive state in rabbits using L-NMMA could be attenuated by excess L- 
arginine  212-215.  Also,  mice which  are  homozygous  (-/-)  for the  eNOS  gene 
exhibit hypertensive characteristics 17 1 . A dysfunctional endothelium causes a 
disruption in NO release and function, which can lead to the development of a 
chronic  inflammatory  response  within  arteries  as  manifested  by 
arteriosclerosis  217.  Animal  and  human  models  of arteriosclerosis  show that 
certain risk factors,  e.g.  hypercholesterolemia and free radical mediated  lipid 
peroxidation,  promote fatty streaks and lesion development, the hallmarks of 
the disease, thus decreasing NO release and penetration to the lower smooth 
muscle 2 15  Akin to arteriosclerosis,  long term  diabetes can  lead  to vascular 
complications at the  endothelium and  smooth  muscle  layers 218,  as  a  result 
NO release and function is altered.
Diabetes  promotes  these  changes  in  NO via  a  number  of  mechanisms:  1. 
decreased availability or impaired transport or metabolism of the substrate L- 
arginine;  2.  cellular stores  of NADPH  are consumed  by the  enzyme  aldose 
reductase when  it converts glucose to sorbitol  (this reaction  is known as the 
polyol  pathway),  as  a  result reducing  equivalents for  NOS  are  depleted;  3. 
alterations  in  the  responsiveness  of endothelial  cells towards  agonists,  e.g. 
ACh,  and  reduced  expression  and  structural  modification  of  endothelial 
receptors, e.g. G proteins, via activation of diacylglycerol-protein kinase C; 4. 
increased  production  of  vasoconstrictors,  e.g.  endothelin-1,  attenuates  the 
biological action of NO; and 5. enhanced nonenzymatic binding of glucose to
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lipids or to free amino acids on  proteins generates advanced  glycation  end- 
products  (AGEs)  which  inhibit  the  action  of  NO.  The  aforementioned 
examples can  serve  as  sources  of  ROS,  the  causative factors  of oxidative 
stress, which if left unchecked via endogenous antioxidants (e.g. GSH, SOD, 
catalase)  can  lead  to  endothelial  dysfunction  characterised  by  impaired 
release/inactivation  of  NO  and  vasoconstriction  219-220.  The  latter  changes 
predispose  diabetic  patients  to  an  increased  risk  of vascular complications 
namely  coronary  heart  disease  (CHD)  manifested  by  accelerated 
development  of  atherosclerosis,  hypertension,  dyslipidemia  and  a 
hypercoagulable  state.  Other cardiovascular pathologies  include  congestive 
heart failure and sudden cardiac death221.
When  excess  NO  is  released  by the endothelium,  e.g.  septic shock arising 
from endotoxin exposure or underlying disease,  there  is a rapid fall  in  blood 
pressure  leading  to  hypotension  and  myocardial  depression  209  A  link 
between NO and septic shock is illustrated by the fact that endotoxins cause a 
rapid and immediate increase in eNOS and iNOS expression, while N02 ‘ and 
N03 ' are particularly high in septic patients. Also, mice genetically deficient in 
iNOS have a greater resistance to endotoxin induced septic shock 222 223. The 
ability  of  NO  to  modulate  platelet function  has  been  well  documented  and 
shown  to  be  important  to  prevent  thrombus  formation  and  maintain 
endothelium  integrity  2 1 °.  NO  can  inhibit  ADP  induced  aggregation  and 
promote disaggregation of preaggregated  platelets via  increased  cAMP  and 
cGMP  concentrations  in  platelets  51-224-225  The  cAMP  is  derived  from 
prostacyclin  and  cGMP  originates  from  three  sources:  1.  NO  itself;  2.
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synergism  between  NO  and  prostacyclin;  and  3.  NO  produced  within  the 
platelets themselves,  as  human  platelets  can  produce  NO via  activation  of 
their  own  NOS  upon  stimulation  226227  Also,  leukocyte  aggregation  and 
adhesion can be prevented by NO2 2 8
In addition to NO,  the endothelium releases other vasoactive autacoids,  e.g. 
prostaglandins such as prostacyclin (prostaglandin l2 ) PGI2), and endothelium- 
derived  hyperpolarising  factor (EDHF) 2 2 9   Initially discovered  in  1976,  PGI2  
exerts its principal effects, vasodilation and inhibition of platelet aggregation, 
via binding to specific plasma membrane receptors present on some,  but not 
all,  smooth  muscle,  blood  elements  and  endothelial  cells.  This  leads  to 
activation  of  adenylate  cyclase  which  in  turn  promotes  an  increase  in  the 
second  messenger  cAMP  in  target  cells  2 29  A  diverse  range  of  stimuli 
(physical,  chemical,  hormonal  and  immunological)  initiate  the  local  de  novo 
synthesis and release of PGI2  from the endothelium 210-230  Synthesis of PGI2, 
which  is  swift  (<  60  sec)  in  onset  and  transient  (~5  min),  occurs  via  the 
sequential  activation  of the  enzymes  cyclooxygenase  (COX,  also  know  as 
prostaglandin  H  (PGH)  synthase)  and  PGI2   synthase  to  metabolise  their 
respective  substrates,  arachidonic  acid  (AA,  which  is  released  from 
membrane phospholipids by phospholipase A2  (PLA2)) and the endoperoxide 
prostaglandin  H2   (PGH2)  210-2 3 0   Next,  PGI2   is  quickly  hydrolysed  non- 
enzymatically  to  6-keto-PGFia  followed  by  enzymatic  conversion  to  the 
inactive  metabolites  2,3-dinor-6-keto-PGFia and  6,15-diketo-2,3-dinor-PGF1 a  
2 3 1   The  latter are excreted  in  urine and their measurement can  serve as  an 
index  of  PGI2   generation  2 1 °.  The  liberation  of  PGI2   can  be  regulated  at
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various points, e.g. glucocorticoids inhibit PLA2, aspirin-like drugs and protein 
kinase  C  (PKC)  respectively,  inhibit  and  modulate  COX  and  high 
concentrations of lipid peroxides impedes PGI2  synthase 210’229  in addition to 
its vasodilator and haemostatic functions  PGI2  can  prevent the development 
of  atherosclerotic  plaques  via  inhibiting  the  release  of  growth  factors  that 
cause abluminal occlusion, as well as enhancing and attenuating cholesterol 
ester  metabolism  and  accumulation  by  smooth  muscle  cells  and 
macrophages, respectively2 1 0
Along with NO and PGI2  endothelial cells release a third diffusible vasodilator, 
endothelium-derived hyperpolarising factor (EDHF), that induces relaxation by 
hyperpolarising vascular smooth muscle cells. Although release of EDHF,  NO 
and  PGI2  are  mediated in  response to increased  [Ca2 + ]j and  haemodynamic 
changes 2 3 2  the identity and mechanism of action of EDHF are less clear-cut. 
However,  a  number of candidates  have  been  forwarded,  among  these  are 
potassium  (K+)  ions  233,  isoprostanes,  which  are  COX-independent 
metabolites of AA,  234,  epoxyeicosatrienoic acids (EETs) generated by CYP- 
450  epoxygenase  235  and  endogenous  cannabanoids  236.  EDHF  mediates 
hyperpolarisation  of the  plasma  membrane  of vascular smooth  muscle  via 
opening  of K+  channels,  the  net effect  being to  decrease  [Ca2 + ]i  and  impair 
activation of phospholipase C 236. Akin to the ambiguous nature of EDHF, the 
aforementioned  mechanism  of  action  has  since  been  challenged  by  more 
recent experimental data 2 37  Among the proposed mechanisms are release of 
K+  from endothelial cells with hyperpolarisation transmitted to smooth muscle 
cells via gap junctions. Alternatively, an efflux of K+  ions from endothelial cells,
41INTRODUCTION
via small  and  intermediate  conductance  Ca2 + -dependent  K+   (KC a)  channels, 
could induce hyperpolarisation through activation of inwardly rectifying K+  (K|R ) 
channels and/or the Na+ -K+ -ATPase on vascular smooth muscle cells 237.
The  endothelium  derived  autacoids  do  not function  in  isolation,  but  interact 
together to regulate vascular function and one another.  For example,  NO and 
PGb, which  respectively activate the second messengers cGMP and cAMP, 
can synergise to inhibit platelet function,  this effect can  be enhanced by the 
inhibition of cGMP breakdown by cAMP in platelets, as well as in other target 
cells,  e.g.  smooth muscle and endothelial cells.  Conversely,  cGMP does not 
possess the ability to regulate cAMP in a similar manner 2 3 8   The association 
between  NO  and  PGI2  is  further  illustrated  by  the  fact  that  absence  or 
inhibition of one of these autacoids diminishes vasodilation by -10%, whereas 
a combination of the two restored the vasodilatory response 238. Given that the 
precursor enzymes of NO and  PGI2  synthesis,  NOS and  COX,  respectively, 
are regulated by Ca2 +  Bolz and  Pohl demonstrated that PGI2  could  regulate 
NO  release.  Using  human  umbilical  vein  endothelial  cells  (HUVEC)  they 
observed that agonist stimulation of endothelial Ca2 +  release using bradykinin 
led  to  enhanced  NO  synthesis  and  cGMP  production  in  the  presence  of a 
PGI2  inhibitor,  i.e.  indomethacin,  but  supplementation  with  forskolin,  an 
adenylyl  cyclase  stimulator,  or  PGI2,  attenuated  [Ca2+ ]i  concentrations  and 
consequently NO production. Thus, PGI2, by altering cellular cAMP, can exert 
a negative effect upon its own as well as NO synthesis via a Ca2+ -dependent 
feedback  mechanism.  Conversely,  endogenous  NO  does  not  mediate  a 
similar influence over [Ca2+ ]s  or PGI2  production 239. Although NO may not be
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able  to  modulate  PGI2  it  has  been  shown  to  attenuate  EDHF  release  in 
coronary  arteries.  Therefore,  EDHF  could  compensate  for  diminished  NO 
release  in  damaged  arteries.  However,  this  effect  of  EDHF  may  be 
suppressed by elevated levels of oxidised LDL 238.  Nevertheless, the fact that 
three different vasodilators, each with different mechanisms of synthesis and 
action, are released by the endothelium illustrates the potential for adaptation 
to different (patho)physiological scenarios  and the possibility of manipulation 
via pharmacological means.
1.8.3  Nitric oxide synthases and nitric oxide in the heart
It is well recognised that NOS and its product NO play significant roles in the 
cardiovascular  system  240,241.  It  has  now  been  established  that  all  three 
isoforms  of NOS  (eNOS,  nNOS  and  iNOS) are  expressed  in  the  heart and 
exert  different  physiological  roles  depending  upon  their subcellular  location 
and  expression  242.  Numerous  studies  at the  molecular,  cellular and  organ 
level  have  verified  that  NO  can  enhance  or  impair  a  variety  of  cardiac 
parameters, namely: myocardial coronary vascular tone; myocyte chronotropy 
(heart  rate),  inotropy  (contraction)  and  lusitropy  (relaxation);  and  energy 
production  and  consumption  1 5 4 -2 4 3   in  addition,  NO  can  regulate  cardiac 
thrombogenicity,  proliferation  and  antiinflammatory  responses,  as  well  as 
angiogenesis 1 4 0  224. The  mechanism by which these different cardiac effects 
of NO occur are via activation of either cGMP-dependent (discussed further in 
Section 1.7) or -independent signal transduction pathways 32'1 5 4  244.
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In normal human myocardium eNOS and nNOS are constitutively expressed, 
whereas  iNOS  is  synthesised  under  pathogenic  conditions  in  response  to 
inflammatory  stimuli,  resulting  in  high  levels  of  myocardial  NO  production 
2 45 ,2 4 6   In the case of eNOS, this  isoform  has been  identified  in a  number of 
cardiac  cells  types,  e.g.  endothelium  of  the  endocardium  and  coronary 
vasculature (both capillaries and venules), atrial and ventricular myocytes, as 
well  as  specialised  cardiac  conduction  tissue,  i.e.  the  sinoatrial  and 
atrioventricular nodes (SAN  and AVN,  respectively) 24 5   Subcellular locations 
within  myocytes  for  eNOS  include:  plasmalemmal  caveolae  (via  its 
association  with  muscle  specific  isoform  caveolin-3);  the  sarcoplasmic 
reticulum (SR); T-tubule membranes; and mitochondria 115-118'177. As a result, 
eNOS  can  control  Ca2 +   flux  and  thereby  participate  in  the  regulation  of 
myocardial force and rhythm contraction 247,  in addition to controlling  energy 
(O2)  consumption  248.  Akin  to  other  cell  types  myocytic  eNOS  can  be 
regulated, either positively or negatively,  by Ca2+ -dependent or -independent 
mechanisms 118'138-249
Although the number of studies relating to the role of eNOS in the heart and 
cardiomyocytes is constantly expanding the information derived is sometimes 
contradictory,  i.e.  NO  exerts  a  bimodal  (either  stimulatory  or  inhibitory) 
response,  due  to  the  different  models,  sources  (either  endogenous  or 
exogenous) and concentrations of NO used. Nevertheless, eNOS is known to 
regulate myocardial and cardiomyocyte functions under basal, stimulated and 
diseased  scenarios  1 4 0   Under basal  condition  low concentrations  of eNOS 
mediate  paracrine,  e.g.  inhibition  of  platelet  aggregation,  promotion  of
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vascular  smooth  muscle  relaxation  and  inhibition  of  proliferation;  and
\
autocrine  (within  myocytes),  e.g.  increased  diastolic  relaxation  (a  positive 
lusitropic effect) and contraction (a positive inotropic effect) and decreased 0 2  
consumption and heart rate (a chronotropic effect), outcomes; whereas higher 
concentrations have the opposite outcome 1 6 9   With regards the chronotropic 
effects of NOS  upon  pacemaker cells within the SAN  and AVN  both  eNOS 
and nNOS have been implicated as potential comodulators of these cells, i.e. 
nNOS  acts  presynaptically  in  cardiac  ganglia,  while  eNOS  acts 
postsynaptically  in  cardiomyocytes  where  it  modulates  the  response  to 
muscarinic cholinergic stimulation 1 40-170-1 72-250  An absence or reduced eNOS 
synthesis  has  been  implicated  as  a causative factor  in  the  development  of 
atrial  thrombosis  (clots)  and  cardiac pathologies characterised  by  increased 
chronotropy, e.g. atrial fibrillation and stroke 251,252.
Under stimulated  settings,  such  as during  exercise,  there  is  an  increase  in 
beating frequency  (force-frequency relationship),  cardiac  muscle  stretch and 
release of catecholamine  signalling  through  p-adrenergic  receptors  (p1  and 
p2) all of which combine to increase cardiac inotropism 140  To accommodate 
these  changes  eNOS  and  nNOS  promote  increased  0 2   consumption, 
coronary vasodilation,  myocardial contractility (to protect against arrhythmia), 
inhibition of p-adrenergic-induced inotropy (the latter effect can be enhanced 
by p3-adrenoceptors  activation  of eNOS)  and sensitivity of the  myocytes to 
Ca2 +   1 40-242-2 53  in  individuals  with  underlying  cardiopathologies  or  vascular 
related  diseases,  e.g.  diabetes  and  hypertension,  the  aforementioned
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responses to cardio-stressful exercises may be somewhat compromised.
\
In the diseased heart not only is there dysregulation in the type, quantity and 
expression  of  NOS  and  NO  produced  but  there  are  also  changes  in  the 
availability  of  substrates,  cofactors,  targets  and  activity  of  NO,  and  these 
parameters  vary  at  different  stages  of  disease  development  1 4 0   However, 
animal  and  human  models  of heart failure  have  noted  spatial  and  temporal 
changes  in  the  regulation  of  the  expression  of  eNOS  and  nNOS  towards 
enhanced iNOS within cardiomyocytes and other cardiac cell types 2 54  In the 
case of eNOS, its activity is reduced due to decreased release from peripheral 
and coronary vasculature sources,  endothelial dysfunction  1 4 0   As a result of 
which the p-adrenoceptors (p1  and p2), which are colocalised with eNOS (via 
caveolin-3)  within  caveolae,  exert  an  enhanced  inotropic  response  as  the 
inhibitory effect of NO is attenuated 1 15-255;  in addition, control  of contractility 
and relaxation is diminished. Despite these changes increased NO originating 
from nNOS within the SAN, infiltrating macrophages which produce iNOS, and 
p3-adrenoceptors,  which  are  coupled  to  eNOS  production,  may,  during  the 
initial  stages  of  heart  disease,  exert  a  negative  inotropic  response  1 4 0  
However, sustained loss of eNOS,  increased oxidative damage and cell loss 
(via apoptosis) can compound the situation in a defective myocardium.
Initial  studies  of  nNOS  suggested  that,  unlike  skeletal  muscle  fibres, 
cardiomyocytes did  not express significant amounts  of this isoform  161-250-256. 
Thus, eNOS was assumed to be the only constitutive isoform of NOS involved 
in  autocrine  regulation  of Ca2 +   homeostasis  and  myocardial  contraction  154. 
However,  nNOS  has  since  been  identified in the atria, along epicardial
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coronary  arteries  and  within  cholinergic,  nonadrenergic  and  noncholinergic 
nerve terminals  of specialised  cardiac conduction  tissue,  e.g.  the  SAN  and 
AVN 169. The release of NO from nNOS within these different cell types can be 
down  regulated through  phosphorylation  by  protein  kinases,  e.g.  Ca2 + /CaIn­
dependent,  cAMP-dependent,  cGMP-dependent  and  PKC;  while 
dephosphorylation by calcineurin and increasing the binding of CaM to nNOS, 
supported  by  the  abundant  cytosolic  protein  HSP  90,  enhances  catalytic 
activity to produce more NO 1 36-257-2 5 8
Within  myocytes,  nNOS has been targeted to the  SR  259,  where  it reacts to 
changes  in  intracellular  Ca2 +   concentration  by  modulating  sarcolemmal  /ca  
involved  in  Ca2 +   distribution,  thus  modulating  excitation-contraction  (EC) 
coupling within the heart 260,261. The targeting of nNOS to the SR is mediated 
by  its  N-terminal  PDZ  domain which  can  link with  other muscle  associated 
proteins,  e.g.  a1-syntrophin  and  dystrophin,  thereby  integrating  nNOS  in 
synaptic  signalling  within  cardiomyocytes  103.  The  latter  integration  is 
facilitated by binding of nNOS with the muscle specific variant of caveolin, i.e. 
caveoilin-3,  a  component  of  specialized  invaginations  of  the  sarcolemma, 
called caveolae 262.  Unlike brain nNOS cardiac SR  nNOS is larger (155 and 
160  kDa,  respectively)  2 5 9   and  may  be  a  new  splice  or  posttranslationally 
modified variant of nNOS designated as the mu-isoform (nNOSp) 263. The SR 
of  cardiomyocytes  play  an  important  role  as  intracellular  sequesters  and 
releasers of Ca2 +  which  is  involved  in the contraction/relaxation  cycle of the 
beating  heart  25 9   Given  its  prominent  role  in  Ca2 +   homeostasis  it  is  not 
surprising that a source of NO,  i.e.  nNOS,  is found in close association with
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the SR 259.  Potential targets for NO within  the  SR  include the  /C a,  the  Ca2 *
\
release  channel  (or  ryanodine  receptor  (RyR))  and  the  Ca2+ -ATPase
259,260.264,265  proposec|  mechanisms  by which  NO  can  inhibit these  proteins, 
and  thus  regulate  cardiomyocyte  contractility,  include  modification  of  their 
critical thiol groups or through GSNO2 6 6
Given  its prominent neuronal distribution  it is  not surprising  that nNOS  may 
also regulate cardiac function both at the level of baroreceptor afferents within 
the  NTS  of  the  brainstem  267,268  and  within  the  myocardium  itself,  as  this
isoform  has  been  localised  in  cardiac  ganglion  cells  and  nerve  fibres
innervating  the  SAN  172,261.  In  addition,  nNOS  colocalises  with  the  enzyme 
choline  acetyltransferase,  which  catalyses  the  synthesis  of  ACh,  in
intracardiac  neurons  1 7 °.  Under  normal  conditions  stimulation  of  the  right 
vagus nerve leads to ACh release from nerve terminals into the synaptic cleft 
in  response  to  depolarisation  induced  by  Ca2 +   influx.  The  liberated  ACh 
diffuses  across  the  synaptic  cleft  and  binds  to  muscarinic  M2  receptors, 
coupled to inhibitory heterotrimeric G proteins,  on the SAN  pacemaker cells. 
This causes a spontaneous depolarisation  of these cells during diastole and 
the rhythmic generation of an action potential that regulates heart rate 1 7 0   The 
latter comprises three parts:  1. the upstroke which  is mediated by the /C a;  2. 
the hyperpolarisation activated, or pacemaker, current (lf), which comprises a 
mixture of sodium and potassium currents to maintain the pacemaker activity; 
and 3.  repolarisation by potassium currents (lK )  1 7 0   Due to its central role in 
the  regulation  of heart  rate  modulation  of the  SAN  by  nNOS  has  been  the 
subject of many investigations.  Using low doses of NO donors in vitro and in
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vivo  experiments  have  shown  that nNOS  can  exert a  positive  chronotropic
\
effect  within  the  SAN  via  stimulation  of  the  lf  as  a  result  of  a  signal 
transduction cascade involving inhibition of PDE-3 by cGMP, which promotes 
increased cAMP/PKA-dependent enhancement of the lf and intracellular Ca2 +  
mobilisation  172.  A dissimilar effect,  prolongation  of the sinus  node  recovery 
time,  was  observed  when  high  doses  of  NO,  NO  and  sGC  inhibitors  were 
included  in the  assay protocol,  thus illustrating  the  biphasic ability of NO to 
directly regulate the SAN and thereby increase or decrease heart rate 1 7 2  269. 
Herring et al.  have suggested that nNOS may also act presynaptically within 
right  vagal  neurons  by  promoting  the  release  of ACh  which  subsequently 
stimulates M2 receptors on the SAN pacemaker cells 170.
In parallel with its role as an important physiological mediator of basal cardiac 
function  NO also participates in cardiopathologies.  For example,  NO  inhibits 
the  positive  inotropic  response  to  p-adrenergic  stimulation  in  humans  with 
dilated  cardiomyopathy  more  so  compared  with  patients  with  normal 
ventricular  function  248  Cai  et  al.  have  shown  a  link  between  the  most 
common  cause  of  cardiac  arrhythmia,  i.e.  atrial  fibrillation,  and  reduced 
expression of eNOS and  NO bioavailability 252. As a result of these changes 
expression  of  the  prothrombotic  stimulant  plasminogen  activator  inhibitor-1 
(PAI-1)  is  upregulated  in  parallel with  an  absence  of  NO,  which  is  a  potent 
antithrombotic agent, thus increasing the potential for clot formation within the 
left atrial endocardium 252  Myocardial  expression of eNOS  (diminished) and 
iNOS  (enhanced)  have  been  implicated  as causative factors  in  heart failure 
2 54  As  a  result,  contractility  is  reduced,  O2  consumption  is  increased  and
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expression of genes involved in Ca2 +  homeostasis are upregulated 270.  It has 
been  suggested  that  a  compensatory  switch  in  NOS  expression,  i.e.  from 
eNOS to nNOS, takes place in heart failure to maintain autocrine myocardial 
contractility 154.  In  fact,  Damy  et al.  observed  that nNOS  and  its  regulatory 
protein HSP90 were significantly enhanced in an in vivo model of myocardial 
infarction (Ml) in aging rats271.
It is  now  known  that the  myocardium  can  express  the  inducible  isoform  of 
NOS, iNOS, in response to LPS and cytokine stimulation 272'273. Although the 
exact  physiological  role  and  pathophysiological  consequences  of  this 
induction  is  unclear  at  present  reports  from  studies  of animal  and  human 
myocytes  have  observed  increased  iNOS  expression  following  a  cardiac 
allograft, as well as in different types of cardiac pathologies, e.g. heart failure, 
myocardial contractile dysfunction and ischaemic preconditioning 245* 274-275.  it 
has  been  noted  that  iNOS  activity  in  cardiomyocytes  is  enhanced  by 
increased  intracellular cAMP or activation  of PKC  isoforms,  which  suggests 
that augmented intracardial or systemic levels of catecholamines and peptide 
autacoids,  e.g.  angiotensin  II,  all  of which  are  an  indication  of heart failure, 
could  promote  and  sustain  iNOS  expression  in  this  pathology  2 4 5   The 
generation of iNOS,  and the subsequent RNS,  can affect not only the heart 
via  the  induction  of  cardiomyocyte  apoptosis,  but  can  also  give  rise  to 
increased  systemic  microvascular  permeability  245.  Thus,  therapeutic 
reduction of the aforementioned stimuli could lessen iNOS expression and the 
adverse  effects  associated  with  heart  failure,  i.e.  cardiac  hypertrophy, 
ventricular dilatation, increased apoptosis and interstitial fibrosis 2 76'278  There
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is also the possibility of endogenous regulation of NO/iNOS as Godecke et al.
\
observed that under normal  circumstances myoglobin  (Mb)  can  serve as  an 
endogenous ‘sink’ for excess NO and thus protect the heart against nitrosative 
stress  and  subsequent  heart failure  2 7 9   Given  its  role  as  an  important  0 2  
carrier in heart and skeletal muscle, myoglobin can act as an effective trap for 
different  types  of  RNS,  e.g.  NO  and  NO',  as  oxygenated  Mb  (Mb02)  can 
scavenge  and  degrade  NO  leading  to  metmyoglobin  (Mb+)  which  itself can 
react with NO' 20-66-280-281. The Mb+  is metabolised back to Mb, which can bind 
with  more 02,  by the enzyme  Mb+  reductase, thus continuing the. cycle of 02  
delivery,  RNS scavenging, and thereby protecting important myocytic targets, 
e.g.  cytochromes,  from  the  adverse  effects  of  RNS  and  maintaining  an 
ambient coronary blood flow and contractility 282. The  expression  of iNOS  is 
not  always  detrimental  as  it  may  be  employed  in  the  resolution  of  an 
intracardial  inflammatory  response,  to  attenuate  low  oxygen  tension  (i.e. 
hypoxia),  protection  against  ischaemia-reperfusion  (IR)  injury,  as  well  as 
maintaining  cardiac  homeostasis  2 8 3 '2 86  Also,  it  is  not  restricted  to just the 
cardiomyocytes  as  other  cardiac  cells,  e.g.  the  endothelium  and  smooth 
muscle  of  the  microvasculature,  the  endocardial  endothelium  and  tissue 
macrophages,  release this isoform 245. Therefore, the cellular constituents of 
the heart can act in unison to generate iNOS and  RNS within focused areas 
as  part  of the  normal  innate  immune  response  to  pathogens  287,  whereas 
widespread  and  uncontrolled  iNOS  activation  can  lead  to  more  generalized 
myocardial dysfunction 2 8 3
The  above  examples  illustrate  that  all  three  isoforms  of  NOS  and  NO  are
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present  within  different  spatial  and  temporal  of  the  heart  and  myocytes.
\
Production of NO at these locations serves to  regulate and  maintain  normal 
homeostatic function, but excess enzymatic activity or diminished product can 
be indicative of an  underlying cardiopathology or a causative factor of such. 
Despite the current knowledge on this subject there  is still  a  great need for 
further research to understand the complex role of NOSs and NO in the heart 
and exploiting the therapeutic potential of this unique gas as the incidence of 
CHD is becoming more prevalent worldwide2 8 8
1.8.4  Nitric oxide in the immune system
A link between  NO and the immune system was first made by Tannenbaum 
and  colleagues when  they  demonstrated  in  animal  and  human  models that 
NO2'  and  NO3'  could  be  formed  via  endogenous  metabolism  and  during 
inflammatory  conditions  71-280-291.  independent  work  by  Michael  A.  Marietta 
and  John  B.  Hibbs  Jr.  revealed  that  macrophages  were  the  principal 
immunological source of NO2' and  N0 3 ‘ 70,72.  The  identification of L-arginine 
as the source of NO2' and N0 3 ', along with the discovery of the iNOS gene in 
immunostimulated macrophages, strengthened the case for an immunological 
function  for  NO  and  confirmed  earlier  hypothesises  suggesting  that  NO 
mediates the phagocytic and cytotoxic aspects of macrophages 72-74'2 9 2  293.
Another source of RNS  in  macrophages,  apart from  NOS,  is the  peroxidase 
enzyme  myeloperoxidase  (MPO).  This  abundant  haemoprotein  (MW  ~150 
kDa)  is  stored  in  primary  azurophilic  granules  and  released  during  the 
respiratory  burst  by  activated  neutrophils,  monocytes  and  macrophages
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294 ,2 9 5   Parallel with  MPO,  secretion of 02‘ and its product H202i  respectively 
derived from  the  NADPH  oxidase  complex and  nonenzymatic  or enzymatic 
(via  SOD)  dismutation,  enhance  respiratory  burst  activity  296  A  number  of 
endogenous  molecules,  e.g.  0 2 ',  H202,  chloride  (Cl'),  NO  and  N02 '  (the 
oxidation  product of  NO),  can  serve  as  substrates,  either  individually or  in 
combination,  for  MPO,  thus  generating  a  variety  of  reactive  oxidants,  e.g. 
hypochlorous  acid  (HOCI),  and  nitrating  species  such  as  nitryl  chloride 
(N02CI) and nitrogen dioxide (N02) 2 9 5 > 2 9 7   As a result of these reactions the 
native  ferric  enzyme,  MPO-Fe3+,  can  generate  multiple  intermediates,  e.g. 
Compound-1,  -II  and  -III,  to  regenerate  MPO-Fe3 +   in  a  classical  peroxidase 
cycle that varies in reaction rate depending upon the local pH 298. As a result 
of these varied reactions and products MPO has been implicated as a cause 
of, or contributor to, oxidative modification of lysine, tryptophan, tyrosine and 
cysteine  targets  within  low  density  lipoprotein  (LDL),  proteins  and 
antioxidants, all of which are causative factors in atherogenesis,  both in vitro 
and in vivo 299'300.
In  the  case  of nitrating  agents the  powerful  oxidising  species  N02,  derived 
from the  MP0-H202-N02' system 301,  converts  LDL  into  a  high-uptake form 
(N02 -LDL)  which  is  actively  scavenged  by  macrophages  via  their  CD36 
receptor,  thus  generating  lipid-laden  or  ‘foam’  cells  characteristic  of 
atherosclerotic lesions 298-302.  in the arterial wall  NO and 0 2', originating from 
endotheial cells and NADPH and xanthine oxidases,  respectively, can readily 
combine  to  form  ONOO',  a  RNS  capable  of  modifying  LDL  2 9 9   The 
endogenous  antioxidants  vitamin  C  (ascorbate)  and  E  (a-tocopherol)  have
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been proposed as a potential means to attenuate the adverse effects induced
\
by MPO-mediated LDL modification originating from reactive oxygen, chlorine 
and nitrogen species 300-303-3 0 4
Production of, and sensitivity to,  NO is not limited to macrophages as eNOS 
and nNOS are present in immune system (e.g. dendritic and mast cells) and 
immune responsive (e.g. fibroblasts and hepatocytes) cells 305  Immunological 
functions  assigned  to  NO  include:  participation  in  the  pathogenesis  and 
control  of  infectious  diseases;  tumour  development;  and  autoimmune  and 
inflammatory  reactions  3 0 6   These  diverse  effects  are  mediated  primarily  by 
iNOS-derived  NO and  RNS via:  1.  modulating the development,  proliferation 
and apoptosis of immune cells; 2. regulating the production and expression of 
cytokines,  immune  mediators;  and  3.  adhesion  molecules  along  with  the 
synthesis  and  deposition  of  extracellular  matrix  components  307-308.  Nitric 
oxide  can  promote  the  survival  of  an  infectious  agent  through  cytotoxic 
mechanisms  and  the  provision  of  blood-borne  nutrients  concomitant  with 
subversion of the hosts immune response 305-309  Conversely, NO may subvert 
disease  progression  directly  through  mutation  of  DNA  or  indirectly  through 
induction of iNOS, which depletes L-arginine, and promotion of neutrophil cell 
killing  1 7 * 80-305.  However,  excessive  activation  of  the  latter  mechanism  can 
occur  in  chronic  inflammatory  diseases,  e.g.  rheumatoid  arthritis  (RA),  as 
nitrotyrosine has been detected in the serum and synovial fluid of RA patients
310
The  first  role  identified  for  NO  in  the  immune  system  was  modulation  of 
tumour growth  and  cell  death  73.  Since  then  opposing  functions,  both  pro-INTRODUCTION
(increasing tumour angiogenesis, immunsuppression and inhibiting leukocyte 
infiltration)  and  anti-tumour  (cytotoxic,  cytostatic  and  antimetastatic)  actions 
have been  purported for NO 311312.  The  original  perception  of iNOS-derived 
NO in autoimmunity was a negative one as it activates macrophages which in 
turn causes tissue damage 306. However, experimental models of autoimmune 
disease,  e.g.  experimental  autoimmune  arthritis  (EAA)  and  experimental 
autoimmune  nephritis  (EAN),  portrayed  NO  in  a  positive  light  with  regards 
negative feedback  regulation  of T-helper  (TH1)  cells,  thus  guarding  against 
immunopathological  consequences 3 0 5   The  antiinflammatory aspects  of  NO 
are  manifested  by  inhibition  of  leukocyte  and  platelet  function  51,228,  while 
inhibition  of  iNOS  expression  can  promote  transplant  accommodation  and 
graft survival305.
The antiinflammatory mechanisms employed by RNS can be focused directly 
upon  critical  target  such  as  DNA,  proteins  and  lipids  or  indirectly  via 
modulation  of the  immune  response  or other  host cell  functions  313.  In  the 
case  of  DNA,  NO  can  promote  deamination  314,  ONOO'  induces  DNA 
mutations 313, while N02 ‘ can reversibly bind to the iron-sulphur (Fe-S) group 
of ribonucleotide reductase, the rate limiting enzyme in  DNA replication, thus 
inhibiting  DNA synthesis 315  A variety of proteins,  e.g.  reactive thiols,  haem 
and  Fe-S  groups,  tyrosyl  radicals,  phenolic  and  aromatic  acid  residues  or 
amines, can be targeted by RNS.  Nitric oxide can inactivate thiol and tyrosyl 
groups  within  nucleic  adenoribonucleotidase,  a  key  enzyme  in  translation 
processes 13. In addition, formation of iron-nitrosyl complexes and inactivation 
of  the  Fe-S  prosthetic  group  within  aconitase  (which  converts  citrate  to
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isocitrate,  in  the  tricarboxylic  acid  (or  Krebs)  cycle),  as  well  as  complex  I 
(NADH  dehydrogenase)  and  complex  II  (succinate  dehydrogenase)  of  the 
electron transport chain,  by ONOO' and NO leads to metabolic inhibition and 
promotes  depletion  of  iron,  an  essential  element  for  microbial  survival 
3 1 3 ,3 1 5 ,3 1 6 . the overa|| effect being cytostasis. Haemoproteins such as catalase, 
which  mitigates the adverse effect of H202,  cytochrome c oxidase  (complex 
IV),  the terminal  component of the respiratory chain,  and cytochrome  P450, 
are additional inhibitory targets of NO.
Thiol  proteins  are  among  the  most  prominent  targets  of  NO  and  S- 
nitrosylation  (transfer  of  NO+)  result  in  transnitrosation  (reaction  with  other 
thiol  groups)  thus  enhancing  or  inhibiting  their  activity  32.  An  example  of 
inhibition  is  the  auto-ADP-ribosylation  of  the  glycolytic  enzyme 
glyceraldehyde-3-phosphate dehydrogenase  (GAPDH)  by  NO,  the  outcome 
being loss of enzymatic activity and impairment of glycolysis 317.  Nitration of 
tyrosine residues,  not just by ONOO'3 1 8  but also by the enzyme  MPO in the 
presence  of N02'  and  H2 02  with  N02   as  the  product 2 ",  can  alter tyrosine 
phosphorylation  thus  disrupting  protein  function  and  turnover.  Furthermore, 
ONOO' and N02  can instigate lipid peroxidation which can lead to damage of 
the lipid-rich coat of microbes 3 1 3   Lastly,  NO can:  1.  promote vasodilation; 2. 
modulate the expression and function of endothelial cell adhesion  molecules 
(ECAMs)  via  inhibition  of  the  transcription  factor  NF-KB  (possibly  by 
stimulation of lKB an inhibitor of the latter) and the enzyme activity of PKC, as 
their expression  affects  recruitment of other inflammatory-related  cells,  e.g. 
neutrophils,  macrophages  and  platelets;  3.  regulate  cytokine  production,  as
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well  as  T-helper cell  proliferation  and  differentiation;  and  4.  alter  epithelial 
permeability  306-313-319  Whether  NO  will  exert  a  pro  or  antiinflammatory 
response  will  depend  upon  its  quantity,  the  presence  of  ROS  and  other 
potential  targets  in  the  surrounding  environment,  in  addition  to  the  level  of 
antioxidants which counteract toxic metabolites derived from RNS interactions
14
1.8.5  Nitric oxide in the reproductive system
A role for NO in  the  male  reproductive system  stems from the  detection  of 
iNOS and eNOS in the neurons of the corpus cavernosum and the adventitial 
layer  of  penile  arteries,  respectively  3 20  Animal  and  human  studies  which 
employed  NOS  inhibitors,  electrical  field  stimulation  or  NO  donors,  verified 
that NO  mediates  penile  erection  320,321.  These  reproductive  aspects  of  NO 
have  been  harnessed  for therapeutic  purposes  in  the  treatment  of erectile 
dysfunction  (ED)  with  the  type  V  phosphodiesterase  (PDE-5)  inhibitor, 
sildenafil, more commonly known as Viagra® 322.  Development of ED is often 
associated  with  underlying  cardiovascular  disease,  e.g.  ischaemic  heart 
disease,  as  both  share  similar  risk factors,  i.e.  hypertension,  smoking  and 
diabetes 3 2 3   A comparison of the relaxant responsiveness of isolated strips of 
corpus  cavernosum, from  diabetic  and  non-diabetic  men  with  impotence, 
towards nerve stimulation and ACh, noted a correlation between impaired NO 
responsiveness and underlying diabetes 324.
Preeclampsia,  which  has  a  prevalence  of 6-8%  of all  pregnancies  over 20 
weeks,  accounts  for  more  than  75%  of  pregnancy  induced-hypertensive
57INTRODUCTION
disorders and is one of the main causes of foetal and maternal morbidity and 
mortality,  but  is  resolved completely  post partum  325-326.  Although  the  exact 
cause of preeclampsia is unknown the trigger for the disease is believed to be 
placental  in  origin,  as  a  result of which  the  mother responds  with  a  strong 
systemic  inflammatory  response  characterised  by  vascular  dysfunction  327. 
Risk factors for preeclampsia  include:  first pregnancy;  asthma;  a  change  in 
partner; a genetic disposition; and living at high altitude 325  Normal pregnancy 
is associated with  a  number of vascular adaptations,  i.e.  a  50%  increase  in 
blood volume and cardiac output which leads to a fall in blood pressure due to 
peripheral vasodilation; the opposite occurs in preeclampsia 32 8
Preeclampsia  is  characterised  by  a  triad  of symptoms:  1.  hypertension,  2. 
proteinuria and 3. oedema.3 2 5   Other characteristics of preeclampsia include: 
increased vascular resistance (the latter arises from increased foetalplacental 
hypoxia  due  to  either  decreased  oxygen  availability  or  transfer);  poor 
perfusion; elevated circulating lipid peroxides because of oxidative stress; and 
an  enhanced  immune  response  which  can  result  in  a  dysfunctional 
endothelium  that  promotes  adhesion  of  platelets  and  leukocytes  to  the 
placental  villi  or  intervillous  spaces  3 2 9   Nitric  oxide  is  important  during 
pregnancy  as  the  activity  of the  NO  system  (eNOS,  iNOS  and  L-arginine 
pathway) is shifted to a new higher equilibrium during  normal pregnancy and 
maintained  throughout  gestation  to  inhibit  uterine  contractility  and  declines 
towards term to initiate labour 329. Nitric oxide production, as measured by NO 
metabolites  (N02‘ and  N03‘) and cGMP,  are either significantly increased  in
325 3 2 9  330 preeclampsia and eclampsia, compared with normal pregnancy  ;  or
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decreased  326,331.  When  NO  synthesis  is  increased  it  helps  to  promote 
vasodilation  within  the  foetal  capillaries,  this  results  in  better  perfusion, 
reduced  lipid  peroxidation  and  prevention  of  platelet  aggregation  and 
leukocyte adhesion 33 0
From the examples given above, it is clear that NO plays an important role in 
a  diverse  range  of  physiological  functions.  At  the  same  time  the  effects 
mediated  by  NO  are  not  always  beneficial  but  can  be  detrimental  and 
cytotoxic in the extreme, thus illustrating the two faced nature of NO 332.
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1.9  Oxidative  and  nitrosative  stress:  sources,  biochemistry  and 
relevance to cellular function and injury
Molecular oxygen  (02)  and  nitrogen  (N2)  constitute  over 98%  of the  air we 
breath.  Even  though  both  are  essential  for  plant  and  animal  life  reactions 
involving 02  are more commonplace, due to its higher atmospheric quantity14. 
Although 0 2  is an  essential energy source,  its redox derivatives can  lead to 
alterations of cellular function, e.g.  lipid peroxidation and modification of DNA 
and proteins, and have been implicated in the development of many diseases 
14,333-335  y^ese redox derivatives, which exist as radicals or non-radicals,  are 
known collectively as ROS (see Table  1.2 for examples) 14.  Reactive oxygen 
species  are  constantly  formed  in  vivo  as  ‘accidents  of  chemistry’  or 
deliberately. Examples of accidentally formed ROS include: 0 2 ‘, H20 2  and the 
hydroxyl  radical  (OH*),  while  the  generation  of 0 2'  by  activated  phagocytes 
during cellular killing  is an example of deliberate formation 333  In their ‘free’ 
form  transition  metal  ions,  e.g.  iron  (Fe2+ )  and  copper  (Cu2+),  can  act  as 
powerful  promoters  of  ROS  formation  336  When  the  levels  of  ROS  are  in 
excess of the capacity of endogenous cell protectants (see examples in Table 
1.3)  an  increase  in  cellular  damage  and  dysfunction  can  occur  due  to 
oxidative stress, while the causative agents are termed oxidants 333.
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Table 1.2 Examples of reactive oxygen and nitrogen species
Reactive oxygen species (ROS)
Radicals Non-radicals
Superoxide anion (02 ‘) Hydrogen peroxide (H202)
Hydroxyl (OH‘) Hypochlorous acid (HOCL)
Peroxyl (L02‘) Ozone (03)
Alkoxyl (L0‘) Singlet oxygen (1 02)
Hydroperoxyl (H02‘) Lipid peroxides
Reactive nitrogen species (RNS)
Nitric oxide (NO) Nitrous acid (HN02)
Nitrogen dioxide (N02)
Dinitrogen trioxide (N203) 
Dinitrogen tertroxide (N20 4) 
Peroxynitrite (ONOO')
Alkyl peroxynitrites (LOONO)
Although  the  chemical  and  biological  aspects  of  02   and  ROS  have  been 
studied for almost 50 years, the same cannot be said of N2.  Nevertheless,  N2  
has a rich chemistry as this element has the ability to occupy a wide range of 
oxidation states from - 3 to + 5 37. Biologically important oxides of N2  lie in the 
+ 1  to + 5 range, examples include (NO', + 1; NO, + 2; NO+, + 3; and ONOO', 
+  3),  other  examples  are  shown  in  Table  1.2  337.  The  discovery  that  the 
simplest N2  and O2  based molecule,  NO,  is produced in  vivo and  has many 
important  physiological  functions  (see  Section  1.8)  and  a  diverse  redox 
chemistry, opened up a new field of biological interest on a par with 02  related 
biology 17,25.
61INTRODUCTION
Maximal  basal  levels  of  NO,  derived  from  NOS,  are  ~1-2  |jM,  while  levels 
above 2 |jM are associated with the formation of redox derivatives, which may 
be radical or non-radical in nature, and are known collectively as RNS 1 7   The 
reactions mediated by NO can occur directly, e.g. with O2,  O2' and the haem 
of sGC,  or indirectly,  e.g.  nitration (addition of NO2),  oxidation,  hydroxylation 
and  nitros(yl)ation  (addition  of  NO+)  of  different  molecular  targets  2 9   The 
indirect effects of NO are mediated by RNS, which in excess can give rise to 
nitrosative  stress,  a  common  factor  in  many  pathologies,  while  the  causal 
species are referred to as nitrosants 244 3 3 8
The  reactions  in  which  RNS  and  ROS  participate  are  not  confined  to 
biomolecules  or  specific  molecular  targets  as  both  types  of  reactants  can 
interact with each other to generate even more reactive species. Among the 
best characterized of these examples is the rapid reaction (6.7 (± 0.9) x 109  M'
1   s'1 )  of  NO with  O2' to form  ONOO'  Reaction  1  3 18  The  concentration  of 
ONOO'  is  controlled  by  the  activities  of  both  NOS  and  SOD  as  a  10-fold 
increase in both NO and 0 2’ leads to a 100-fold increase in ONOO' production 
2 3   Another potential in vivo source of ONOO' is through reaction of NO' with
0 2  Reaction  2  339  Under  physiological  conditions,  ONOO'  is  a  strong 
oxidising species with  a short half-life (t!4 = ~1  sec) and will decompose via 
peroxynitrous acid (ONOOH) to form NO3’ through isomerisation Reaction 3
340
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NO + 0 2 ‘"  -> ONOO- Reaction 1
NO- + 0 2   ONOO- Reaction 2
ONOO" +H+*> ONOOH  N03- + H+ Reaction 3
Due to its very reactive nature ONOO’ can engage in oxidation, nitration and 
nitrosation  type  reactions,  which  are  the  causative  factors  for  many 
pathologies, e.g. cardiovascular and neurological diseases as well as cancer 
17, 341,342  A  positive  aspect  to  ONOO’ formation  is  its  role  in  mediating  cell 
cytotoxicity  towards  pathogens  within  macrophages  and  neutrophils  in 
response  to  increased  iNOS  activity  1 7   As  ONOO'  can  cause  nitration  of 
aromatic amino acids,  e.g. tyrosine,  quantification of 3-nitrotyrosine could  be 
used as a biomarker of RNS damage 310
In  order to  combat the  adverse  effects  of  ROS  and  RNS  the  body  has  a 
repertoire  of  naturally  occurring  defence  mechanisms  in  the  form  of: 
antioxidants;  repair enzymes to  remove  damaged  proteins,  lipids  and  DNA; 
storage proteins;  and scavengers 334.  These  cellular protective systems can 
be  distributed  within  (intracellular)  or outside  (extracellular)  cells  or  occupy 
both  compartments  (see  Table  1.3  for examples).  A second  line  of cellular 
defence is the  enzyme  haem oxygenase,  discussed further in  Sections  1.12 
and  1.13.  Along with  these  natural  defence  mechanisms,  ‘synthetic’  agents 
and a diet rich in fruit and vegetables have been suggested as an exogenous 
defence against radical based diseases 334. In summary, ROS and RNS share 
a number of similarities: they both generate radical and non-radical derivatives 
from  their  respective  precursors,  O2  and N2, on a continuous basis in v/Vo;
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their  formation  can  be  beneficial,  i.e.  killing  pathogens,  or  adverse  when 
excess  quantities  overwhelm  endogenous  attenuating  mechanisms;  they 
share similar molecular targets; and both have been shown to play a role in 
various  pathologies  either  on  their  own  or  through  interaction  with  one 
another.
Table 1.3 Types and location of naturally occurring cell protectants
Type Location
Antioxidants Intracellular Extracellular
Superoxide dismutase (SOD) + -
Catalase + -
Glutathione peroxidase + -
Reduced glutathione (GSH)* + +
Storage Proteins
Ferritin - +
Transferrin - +
Lactoferrin - +
Caeruloplasmin - +
Haemopexin - +
Haptoglobin - +
Albumin - +
Scavengers
a-tocopherol (TH) + +
Ascorbic acid (Vitamin C) + +
Urate - +
Ascorbate - +
Bilirubin (BR) - +
Repair Enzymes + -
*  Reduced  glutathione  (GSH)  is  present  mainly  intracellularly  at  millimolar 
(0.1-10  mM)  concentrations,  but  trace  amounts  exist  extracellularly  (>  2 
pmol/L);  however, fluids lining the lower respiratory tract have a much higher 
concentration (> 100 pmol/L) 343 344.
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1.10  Nitric oxide donors
\
For  over  130  years  the  organic  nitrates  and  nitrites  (know  collectively  as 
nitrovasodilators),  e.g.  amyl  nitrite  and  GTN,  have  been  used  as 
pharmacological  agents  for  the  relief  of  cardiovascular  complications  1. 
Despite  their  extensive  usage  it  is  only  in  the  last  30  years  that  their 
mechanism  of action  has  been  unravelled,  i.e.  metabolic  conversion  to  NO 
within the tissues 3,  although the factor(s) responsible for this  effect are still 
unclear  345* 3 46  in  addition,  prolonged  usage  of  these  agents  can  have  a 
number  of  negative  impacts,  i.e.  adverse  haemodynamic  effects,  drug 
tolerance,  lack  of  sensitivity  and  limited  bioavailability  8  The  more 
conventional term  ‘NO donors’  is  used  to  describe compounds that release 
active  NO  and  its  congeners,  i.e.  NO+   and  NO’,  in  a  controlled  manner 
through enzymatic, chemical, electrochemical or photochemical pathways 347. 
Advantages  of  NO  donors  over  nitrovasodilators  include:  1.  predictable 
amounts and release rates of the RNS; 2. instantaneous effect, i.e. they do no 
need to undergo biotransformation; and 3. lack of tolerance development 347.
In  order to  study the wide  range  of physiological  mechanisms  mediated  by 
NO,  there are two choices open to the investigator:  1.  inhibition of the  NOS 
pathway  to  prevent  endogenous  NO  production;  or  2.  administration  of 
authentic NO gas,  in solution or via inhalation, as an exogenous NO source. 
However,  option  1   has  the  disadvantage  of  lack  of  specificity,  while  the 
second  choice  has  further  downsides,  i.e.  lack  of  solubility  of  NO  gas  in 
aqueous  media  and  applicability  to  different experimental  settings,  plus the 
short  half-life  of  NO  adds  to  the  difficulty  of exogenous  administration  and
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limits  the  use  of the  gas.  These  drawbacks  have  been  overcome  with  the 
commercial availability of NO donors 3 4 8   The NO donors are classified into six 
categories  based  upon  the  molecule  to  which  the  NO  releasing  moiety  is 
attached,  with further subclasses within  each  (see Table  1.4 for examples). 
Disadvantages  associated  with  using these  different types  of NO  donors  is 
that they exhibit inter and intra class instability in the presence of light, thiols, 
oxygen and heat 347  Nonetheless, research is ongoing towards the production 
of NO donors, from all categories, which are more stable, give greater control 
of NO release and are more tissue specific 348.
Table 1.4 Classes and subclasses of commercial nitric oxide donors
Class of NO Donor Subclasses
C-NO Donors Nitro, nitroso, guanidine and oximes
N-NO Donors N-nitrosamines,  N-hydroxy-N-nitrosamines, 
N-nitrosoamides and diazeniumdiolates
D-NO Donors Organic nitrates and organic nitrites
S-NO Donors Thionitrates and thionitrites
Heterocyclic NO Donors Sydonimines,  oxadiazoles  (furoxans)  and 
oxatriazoles
Transition metal NO complexes Nitrogen  is  bound  to  the  metal  instead  of 
oxygen, e.g. sodium nitroprusside (SNP)
1.10.1  Diazeniumdiolates
The  experiments  detailed  in  this  Thesis  utilise  diazeniumdiolates,  which 
belong  to  the  N-NO  donor  class  (see  Figure  1.8  for  examples). 
Diazeniumdiolates are chemicals containing the structure X-[N(0)N0]', where 
X  is  a  carrier  molecule  and  [N(0)N0]'  the  anionic  functional  group  349. 
Nucleophiles,  e.g.  primary  amines,  secondary  amines,  polyamines,  oxygen 
(oxide) or sulphur (sulphite), can serve as carrier molecules, which allows for
66INTRODUCTION
compounds  with  specific  NO  releasing  characteristics  347350.  Previously 
referred to as “NONOates”, “Drago complexes” and “NOC” compounds, these 
terms have been abandoned in favour of the term “diazeniumdiolates”, which 
is based on the structural and functional nomenclature of the functional group
349
Figure 1.8 Structure of the diazeniumdiolates used in this Thesis.
A Sodium trioxodinitrate or Angeli’s salt (AS);  B diethylamine NO
(DeaNO); and C diethlyenetetraamine NO (DetaNO).
Although  other  classes  of  NO  donors  exist,  the  diazeniumdiolates  have  a 
number  of  physiochemical  features  to  merit  their  use  in  NO  research:  1. 
stability as solids at low temperatures; 2.  known rates of NO generation,  i.e. 
they  decompose  spontaneously,  and  dissociate  according  to  first-order 
kinetics at constant pH to produce 2 moles of NO per mole of donor (Equation 
1.2) thus, obviating the need for redox activation; 3. are insensitive to thiols or 
other  redox-active  agents;  4.  half-lives  range  from  2  sec  to  20  h  at 
physiological pH and temperature  (37°C);  and  5.  different types of RNS can 
be produced, e.g. NO", NO+, NO, N02  or ONOO" 349.
H
.0
\ 0 -
0“
A B C
X - [N(0)N0]'  p H 7 : 4 —>  X~ + 2 NO
Equation 1.2 Decomposition pathway of diazeniumdiolates
67INTRODUCTION
An  interesting  characteristic of diazeniumdiolates  is that  pH  can  affect their 
rate of decomposition,  i.e.  increased "rate constants with  decreasing  pH  and 
vice versa 3 50  This feature enables the user to prepare stable alkaline stock 
solutions,  e.g.  1-10  mM  NaOH  (pH  12),  which  become  active  to 
spontaneously generate a bioactive RNS at physiological  pH or upon mixing 
with  physiological  buffer  or  media  3 47  Examples  of  commonly  used 
diazeniumdiolates, together with their respective acronyms and  half-lives are 
shown in Table 1.5.
Table 1.5 Commonly used diazeniumdiolates
Chemical Name Acronym Half-life (t1 /2) at 37°C, pH 7.4
Sodium trioxodinitrate 
(Angeli’s salt) AS 2.3 Minutes
Diethylamine NONOate DeaNO 2 Minutes
Diethlyenetetraamine
NONOate DetaNO 20 Hours
Propylaminopropylamine
NONOate
PAPANO 15 Minutes
Proline NO PROLINO 1.8 Seconds
Methylamine  hexamethylene 
methylamine NO
MAHMANO 1   Minute
1.10.2  Chemistry and sources of sodium trioxodinitrate (Angeli’s salt)
Sodium trioxodinitrate  (Na2N20 3 ,  or Angeli’s salt (AS)),  see  Figure  1.8 A for 
structure, spontaneously decomposes at neutral pH to liberate NO' and  N02' 
2 5   Although AS is included in the category of diazeniumdiolates it differs from 
other members  of this  group  as it releases NO'  instead of NO 349.  Since its 
discovery  by  the  Italian  scientist  A.  Angeli  in  1902  investigations  into  the 
chemistry  of  AS,  in  particular  its  decomposition  reaction,  37,38  and  the 
physiological  significance  of  its  product  NO'  2 5 > 5 8 i3 5 1 )   have  generated
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considerable interest as this agent is the most widely used synthetic source of 
NO' to study the effect of the anion in'biological systems. Angeli’s salt can be 
synthesised through reacting hydroxylamine (NH2OH) with an organic nitrate, 
e.g. ethyl, isopropyl and butyl nitrates, or purchased from commercial sources 
3 8   Studies  of  AS  decomposition  and  reactivity  have  revealed  different 
answers  depending  upon  the  model  (gas  or aqueous  phases),  composition 
(presence  of  0 2l  thiols,  metals  and  oxidants),  pH  and  temperature  of  the 
surrounding environment 25,37.
Kinetic studies reveal that decomposition of AS is pH-dependent.  In aqueous 
solution  at  pH  below  4  the  monoanion  (N20 3 2')  decomposes  to  yield  NO 
(Equation 1.3 A)3 7   This reaction can be inhibited by N02'. At pH above 4 two 
reactions take place: 1. the unstable conjugate acid of NO', nitroxyl ion (HNO), 
undergoes  dimerization  and  dehydration  via  formation  of  hyponitrous  acid 
(H2N202)  to  give  N20 and water (H20)  (Equation  1.3  B)  40;  2.  spontaneous 
decomposition  of hydrogen trioxodinitrate  monoanion  (HN20 3’)  liberates  NO' 
and N02 ' (Equation 1.3 C). The latter reaction can be inhibited by N02', which 
illustrates the reversible nature of the reaction 339. Thus, the decomposition of 
AS  is  independent of pH  between  pH 4.4-8.1  and  proceeds via a first-order 
reaction involving dissociation of the monoanion,  but different rate constants 
(k) and half-life (V/2) values apply depending upon  the reaction temperature, 
i.e. k = 6.8 x  1 0 -4 s'1  at 25°C, X'A = 17 min; k = 4.1  x icr3 s ’ at 37°C, t% = 2.3
25 min
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N20 32- + 2H+  -> 2NO + H20 A
HNO + HNO -> N20 + H20 B
HN20 3' o N0“+N02 '+H+ C
Equation  1.3  Decomposition  sequence  of  Angeli’s  salt  in  aqueous 
solution
Although a N=N bond makes up the solid state of AS, Figure 1.8 A, cleavage 
occurs via  heterolysis  of a singly bonded  N-N  structure,  i.e.  tautomerisation 
between  double  and  single  bonded  species  occurs  3 8   Originally,  NO'  was 
assumed to be a weak acid (pKa = 4.7)37, however, recent reports indicated it 
has a weaker acidity (pKa ~7-11.4) 39,351. A number of suggestions have been 
put  forward  for  the  electronic  spin  state  of  the  NO'  released  from  AS  in 
different models (gas or aqueous phases). Similar to 0 2,  NO' is isoelectronic, 
i.e. it can exist in singlet (1NO') and triplet (3NO') states. Hughes suggests that 
thermal decomposition of AS  in the presence  of 0 2  yields  1NO'  (the  ground 
state)  as  only  3NO'  (the  excited  state)  reacts  with  02   to  yield  ONOO'  2 5  
Recent articles by Bartberger et al. and Miranda and coworkers using NO' in 
the  gas  phase  and  in  aerobic conditions,  respectively  propose  3NO'  as  the 
ground state 58,351.
Despite its short lived nature NO' originating from AS is known to react with a 
number of endogenous targets resulting  in different outcomes.  For example, 
NO' interacts with 0 2  to generate potent oxidising species which can promote 
double strand DNA breaks and base mutations 352-353. Binding of NO* with iron
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centres of haemoproteins such as hemin  (the oxidised form of haem)  yields 
nitrosyl complexes that act as potent Stimuli for the induction of cytoprotective 
enzymes, e.g. haem oxygenase 3 5 4   Akin to NO, critical thiol groups can serve 
as  prominent  targets  for  NO'  as  illustrated  by  the  latter’s  ability  to 
downregulate  the  activity  of  the  NMDA  receptor  via  S-nitrosylation  of  a 
specific  cysteine  residue  (Cys  399),  as  a  result  NO'  could  provide
neuroprotection  from  excitotoxic  insults  5 5,355  Other  important  regulatory
molecules that could be influenced by NO' through S-nitrosylation include: the 
RyR 356; /ca  260; Ca2+ -dependent K+  channels (K+Ca)60; caspase enzymes 357; 
transcription factors, e.g. NF-KB 31; and indirect S-nitrosylation of haemoglobin 
possibly via the liberation of NO from the interaction of NO' with R-SNO and 
thiols,  the  NO  can  then  S-nitrosylate  the  Cys  p93  residue  of  haemoglobin 
30,358.  Lastly,  NO'  has  been  shown  to  exert a  beneficial  effect  in  models  of 
cardiac dysfunction 5 4  and IR injury4 6
Although  other sources  of  NO'  exist,  e.g.  Piloty’s  acid  (PA),  discrepancies 
exist as to the product released, i.e. NO5 0  or NO'38, by this agent. The reason 
for  these  different  observations  stems  from  the  fact  that  at  pH  7  PA
decomposes  very  slowly to  give  NO,  while  at pH  8  and  above NO'  is  the
active product.  Thus AS  is  more  robust as a  NO' donor at physiological  pH 
than PA, while the latter is a good NO' generator at pH > 8 38. In summary, the 
chemistry of AS and its product NO' is quite complex and diverse depending 
upon the environment and  models  used.  This feature  adds to the variety of 
beneficial  and  adverse  effects  of  this  agent,  and  at  the  same  time  merits 
further investigation to harness the potential of this unique compound.
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1.11  The structure of haem
\
Haem  (ferro-(Fe2+)protoporphyrin  IX) is a nonpolypeptide unit which acts as 
the prosthetic group for a variety of important biological molecules, see Table 
1.6 for examples  350.  Haemoglobin  (Hb),  which  is  comprised  of four globin 
molecules each with a central haem prosthetic group, acts as an O2 carrier for 
red  blood  cells  (RBC),  thus  representing  the  principal  biological  source  of 
haem 360.
Table 1.6 Biologically important haemoproteins and their function
Molecule Function
Myoglobin Oxygen carrier in muscle
sGC Endogenous receptor for NO
Cytochromes (b, c, c1, a and a3) Cellular respiration and electron transfer
Cytochrome b5
Dehydrogenation of fatty acids in 
microsomes and reduction of 
methaemoglobin to haemoglobin in RBC
Cytochrome P-450 (CYP-450) Drug metabolising enzymes
Catalase and peroxidase Hydrogen peroxide scavengers
Tryptophan pyrrolase Regulates L-tryptophan metabolism
Nitric oxide synthase (NOS) Production of NO
Haem  (Figure  1.9)  consists  of  an  organic  protoporphyrin  structure,  four 
pyrroles each of which are linked by unsaturated methene (meso) bridges (a, 
p, y and 5) to form a tetrapyrrole  ring,  surrounding a central  iron  (Fe) atom 
linked to four nitrogens (N2). Attached to the tetrapyrrole ring are four methyl 
(CH3), two vinyl (CH=CH2) and two propionate (CH2CH2COOH) side chains. 
Fifteen different isomers can be formed by rearranging the location of these 
side  chains;  however,  only  one  of these,  protoporphyrin  IX,  is  present  in 
biological  systems  360.  In  addition  to  its  bonding  with  N2,  Fe  is  capable  of 
forming  two  additional  bonds  either  above  or  below the  haem  plane  (alsoINTRODUCTION
referred to as the fifth and  sixth  coordinate positions).  As the  Fe  atom  can 
exist in two different oxidation states XFe2 +  or Fe3+) the corresponding forms of 
haem  are  ferro-(Fe2+)protoporphyrin  IX and  ferri-(Fe3+)protoporphyrin  IX  (or 
hemin, the oxidised form of haem). In RBC only ferro-(Fe2+)haemoglobin can 
bind 02 360
CH
CH.
II a
=  N
CH
8 HC CH  p
HOOC* CH CH2 •COOH
Figure 1.9 Structure of haem (ferro-(Fe2+)protoporphyrin IX).
Adapted from 359
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1.11.1  The haem biosynthesis pathway
In  the  1950s,  Shemin  and  coworkers  identified  that  glycine  and  succinyl 
coenzymes A (CoA) were the primary substrates in the biosynthesis of haem. 
Since then the pathway of haem synthesis, as well as the enzymes and their 
respective  genes,  have  been  characterized.  The  haem  synthesis  pathway 
(Figure  1.10)  in  mammals  consists of eight enzymatic steps  divided  equally 
between the mitochondria and the cytosol3 5 9
MITOCHONDRION  CYTOPLASM
SUCONYI.-C0A
!  coo'
<Q M -A -S Y N T K A S e
CHj-
C«J-
CH,-
CHj
2COj  JH-
CH, -CHj
Figure 1.10 Pathway of haem synthesis.
Side chain abbreviations:  Pr = Propionate (CH2CH2COOH); Vi = 
Vinyl  (CH=CH2);  CH3   =  Methyl;  and  Ac  =  Acetic  acid 
(CH2COOH). Adapted from3 5 9
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The  first  step  of  the  pathway  occurs  in  mitochondria  and  involves  the
\
condensation of glycine and succinyl CoA to form 5-aminolevulinic acid (ALA), 
concomitant with the release of CoA and carbon dioxide (C02). This reaction 
is  catalysed  by  cytosolic  ALA  synthase  (ALA-S)  and  requires  pyridoxal- 
5’-phosphate  (PLP)  as  a  cofactor.  The  next  four  steps  take  place  in  the 
cytosol,  beginning  with  the  condensation  of two  molecules  of ALA  via  the 
cytosolic  enzyme  ALA  dehydratase  (ALA-D).  This  results  in  the  release  of 
water (H20)  and  the  production of the  monopyrrole  porphobilinogen  (PBG). 
Next, polymerisation of four PBG molecules by the cytosolic PBG deaminase 
generates  hydroxymethylbilane  (HMB)  preuroporphyrinogen  concurrent with 
the elimination  of the four methane (NH3)  molecules,  one for each  methene 
bridge  of the  tetrapyrrole  ring.  The  structure  of  HMB  resembles  that  of  a 
tetrapyrrole  ring,  but  is  unstable  as  it  is  open  on  one  side.  Therefore,  the 
cytosolic enzyme uroporphyrinogen (URO) III synthase catalyses the ‘closure’ 
of the ring, generating URO III, concomitant with the release of H20. The final 
cytosolic step, decarboxylation of the four acetic acid (CH2COOH) side chains 
of  URO  III  to  methyl  (CH3)  groups  forms  coproporphyrinogen  III  and  is 
catalysed  by  the  cytosolic  enzyme  URO  III  decarboxylase.  This  reaction 
requires four hydrogens (H+) and liberates four C02  molecules 359-361.
The remaining biosynthesis steps occur in the mitochondria. The first of these, 
oxidative decarboxylation of coproporphyrinogen III to protoporphyrinogen  III, 
is  catalysed  by  the  intermembrane  space  enzyme  coproporphyrinogen  III 
oxidase. This reaction requires 02  to convert two propionate (CH2CH2COOH) 
side chains to vinyl (CH=CH2) groups, concomitant with the elimination of two
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H+  and  CO2  molecules.  In the penultimate reaction  protoporphyrinogen III  is 
oxidised  to  protoporphyrin  IX  by  the  mitochondrial  enzyme
protoporphyrinogen  III  in  parallel  with  the  loss  of  six  H+.  The  final  step, 
insertion  of  Fe2 +   into  protoporphyrin  IX and  release  of two  H+   ions  to  give 
haem, is catalysed by the mitochondrial enzyme ferrochelatase 3 5 9  361.
1.11.2  Regulation of haem biosynthesis
Haem synthesis occurs predominantly in erythroid tissue, i.e. the spleen, but 
non-erythroid tissues, e.g. liver, muscle, adrenal glands, gonads and neuronal 
tissue, also produce haem 359  Identification and cloning of all the mammalian 
enzymes  involved  in  the  pathway  of  haem  synthesis  has  enabled  control 
points to be targeted as a mechanism to manipulate haem production 361. The 
principal location for regulation of haem synthesis is the enzyme ALA-S; thus, 
it  has  been  referred  to  as  the  rate-limiting  step  in  the  haem  biosynthesis 
pathway 359  The enzymes PBG deaminase, coproporphyrinogen oxidase and 
ferrochelatase  have  also  been  proposed  as  possible  targets  for regulation, 
however, most of the evidence relating to regulation of haem biosynthesis is in 
favour of ALA-S  361.  The  latter enzyme  exists  as  two  isoforms  encoded  by 
separate  genes:  the  ubiquitous  (ALA-S1  or  ALAS-N)  and  the  erythroid 
(ALA-S2 or ALAS-E) specific 361.
Different  mechanisms  of  ALA-S  regulation  prevail  in  liver  and  erythroid 
tissues.  In non-erythroid tissues it is generally understood that the excess of 
haem  suppresses ALA-S 1   transcription  and  vice versa 359.  However,  recent 
evidence suggests that excess haem exerts feedback inhibition by decreasing
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the  half-life  of ALA-S1  mRNA,  thus  blocking  the  movement  of the  ALA-S1
\
precursor  proteins  into  mitochondria,  whereas  when  haem  is  limited  these 
mechanisms  are subverted,  leading  to ALA-S1  activation.  In  erythroid  cells, 
regulation of haem production is not necessarily via haem itself but rather iron, 
as the reaction is counter regulated by haem361.
1.12  The haem oxygenase pathway
Unlike  the  process  of  haem  synthesis,  which  involves  a  series  of complex 
enzymatic reactions,  the  process of haem degradation  is far simpler.  Haem 
catabolism,  also  referred  to  as  the  haem  oxygenase  pathway,  see  Figure 
1.11,  is  carried  out  by the  enzyme  haem  oxygenase  (HO-1  and  HO-2;  EC 
1.14.99.3) which is located within the endoplasmic reticulum 362. This reaction 
produces  equimolar quantities of carbon  monoxide  (CO),  ferrous  iron  (Fe2 + ) 
(which is sequestered by the iron storage protein ferritin) and the intermediate 
biliverdin, which is subsequently reduced to bilirubin via the cytosolic enzyme 
biliverdin reductase (BVR;  E.C.  1.3.1.24) 363. As the process requires 02  and 
a  reducing  agent,  reduced  nicotinamide  adenine  dinucleotide  phosphate- 
cytochrome P-450 reductase (NADPH-CPR), it is known as coupled-oxidation. 
However,  coupled-oxidation  of  haem  can  also  proceed  via  non-enzymatic 
routes,  but the  haem oxygenase  pathway is the  most efficient and the only 
one to produce bile pigments and CO exclusively3 64
Depending  upon  the  tissue,  organ  and  cell  type  examined,  as  well  as  the 
underlying  homeostatic state,  i.e.  normal  or disease conditions,  three  major 
sources  of  haem  exist:  1.  intracellular  haemoproteins  (e.g.  those  listed  in
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Table  1.6);  2.  haem  derived  from  haemoglobin  in  blood;  and  3.  de  novo
\
synthesis via the  haem  biosynthesis pathway described  earlier.  As  haem  is 
potentially  toxic  in  the  free  (unbound)  state  and  must  be  synthesised  and 
degraded  within  the  same  cell,  an  exception  being  senescent  erythrocytes 
phagocytosed  by  macrophages,  the  respective  enzymes,  ALA-S  and  haem 
oxygenase  (constitutive  HO-2  and  inducible  HO-1;  discussed  further  in 
Section  1.13),  act  in  tandem  to  regulate  the  essential  iron  containing 
prosthetic group  haem  as well  as  maintain  the  balance  between  basal  and 
adverse  physiological  levels  365*370  Furthermore,  the  products  of the  haem 
oxygenases,  bilirubin and  CO, can serve as a constant (via  HO-2) source of 
endogenous  cytoprotective  molecules,  and  more  so  in  situations  of cellular 
stress  where  HO-1  is  activated  by  different  stimuli  371'373  in  addition, 
haemoproteins, e.g. CYP-450, and the gaseous molecule NO can affect haem 
availability  and  turnover  by  HO-1.  For  example,  CYP-450  and  HO-1  are 
induced  by  similar  electrophilic  agents,  e.g.  drugs,  chemicals,  carcinogens 
and cellular toxins. As a result, induction of HO-1  is paralleled by a decrease 
in microsomal CYP-450 which can safeguard against subsequent toxicity 364. 
The combination of hemin and NO can significantly augment haem oxygenase 
activity  resulting  in  elevated  bilirubin  production  and  haem  uptake  374;  the 
mechanisms  behind  this  observation  will  be  explored  further  in  this  Thesis. 
Lastly,  reversible  inhibition  of  substrate  binding  of  Bachl,  a  DNA-binding 
protein  that senses  intracellular haem  content,  to  the  HO-1  active  site  can 
lessen  haem  metabolism when  haem  is  limited,  but exposes  the  active site 
when  it  ‘senses’  that  haem  is  plentiful  375;  thus  conserving  haem  for 
haemoproteins  during  periods  of  limited  haem  availability  as  well  as
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restricting the potential toxicity of excess bilirubin and CO release 376-377.
The principal extracellular sources of haem for the haem oxygenase pathway 
include  Hb  and  myoglobin,  while  those  other molecules  listed  in  Table  1.6 
represent the main intracellular reservoir. In its unbound or “free” state, haem 
can be quite toxic to the body and therefore must be recycled, eliminated from 
the body or contained 3 6 1  •365.  The vast majority of haem  is  recycled through 
oxidation  via  the  haem  oxygenase  pathway  364.  Other  minor  pathways  for 
haem  degradation  exist  in  mammalian  systems  these  include:  1.  a 
NADPH-dependent  system  in  heart mitochondria;  2.  protein  degradation  by 
xanthine oxidase and H2O2 plus NADPH-CPR; and 3. degradation of haem by 
2-allyl-2-isopropylacetamide.  The latter pathway does  not produce CO, while 
the  two  other  pathways  do  not  generate  biliverdin  or  CO,  rather  pyrrolic 
complexes 372-378. Although haem metabolism produces > 85% of endogenous 
CO the remaining fraction is derived from other metabolic pathways, including 
the  CYP-450-dependent  oxidation  of  particular  xenobiotics  (e.g. 
dihalomethanes,  methylene  chloride)  and  lipid  substrates  379  and  iron- 
dependent lipid peroxidation 38°.
Ferritin
Heme Biliverdin
Biliverdin
Reductase
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Figure 1.11  Pathway of haem degradation.
Adapted from 381.
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Although  the discovery of the components,  products  and  mechanism  of the
\
haem oxygenase pathway has been elucidated during the past 30 years, the 
actual  reaction  has  been  manifested  clinically  for  centuries  in  human  skin 
during the process of cellular reconstitution following bruising. This is because 
the various steps in the haem oxygenase pathway are colour coded 382. When 
skin becomes  bruised,  a characteristic black/purple colour,  which represents 
haem from  damaged  RBC,  appears.  As the tissue heals  in  response to the 
damage,  a  green  hue,  which  denotes  the  presence  of biliverdin,  develops. 
This  is  followed  by  a  yellowing  of  the  underlying  cells,  which  represents 
bilirubin. While CO is represented by the increased flow of oxygenated  (red) 
blood into the healed area 381.
The reason(s) why humans should generate the final  products bilirubin,  CO 
and  Fe2+,  all  of which  are  potentially  more  toxic than  the  original  substrate 
haem, puzzled scientists for some time 3 83  However, various research groups 
have  identified  a  number  of  important  physiological  functions  for the  haem 
oxygenase pathway in the control of cellular homeostasis 373. For example:  1. 
iron can act as a regulator of gene expression and also be reutilised for the 
production  of  new  haemoprotein  molecules  384;  2.  CO  has  similar 
characteristics  to  another  gaseous  molecule,  NO,  with  respect  to  signal 
transduction  and  regulation  of cellular function  180'377;  and  3.  biliverdin  and 
bilirubin  have  been  proposed  as  major  cytoprotectants  385386.  in  the 
subsequent sections the  haem oxygenase pathway will be discussed further 
in terms of its biochemical mechanism, the haem oxygenase enzymes and the 
biological function of its products.
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1.12.1  Biochemical mechanisms and regulation of the haem oxygenase
\
pathway
Microsomal haem oxygenase catalyses the first and  rate  limiting step  in the 
oxidative cleavage of the a-meso carbon  bridge of the haemoprotein  haem, 
which  is  in  the ferric  (Fe3+ )  oxidation  state,  to  yield  equimolar quantities  of 
biliverdin, CO and Fe2+, in the presence of O2 and the reductase NADPH-CPR 
3 6 4   The  metabolism  of biliverdin  to  bilirubin  is  discussed  further  in  Section 
1.14. Advancements in biochemistry procedures and detection equipment has 
enabled hypothetical mechanisms of haem catabolism to be postulated, which 
despite  some  ambiguities  in  their details,  reflect common  features  38 7   The 
overall  reaction  (see  Figure  1.12)  involves  a  complex  sequence  of 
transformations over three stages with the formation of two intermediates, a- 
meso-hydroxyhaem and verdohaem, and requires three molecules of 02  and 
at least seven electrons from  NADPH-CPR 388  Although  NADH can also be 
used  as  a  cofactor  in  the  haem  oxygenase  pathway  NADPH  is  a  more 
effective electron  donor 389.  Potential  cellular sources of NADPH  include:  1. 
the oxidative  degradation  of glucose 6-phosphate to  ribose  5-phosphate  by 
the  dehydrogeases  glucose  6-phosphate  dehydrogenase  (G6PDH)  and  6- 
phosphogluconate  dehydrogenase  (6PGDH)  via  the  pentose  phosphate 
pathway (hexose monophosphate shunt); 2. oxidation of L-malate to pyruvate 
by  the  ‘malic  enzyme’  NADP-linked  malate  dehydrogenase  (NADP-MDH) 
during lipogenesis; 3. oxidative decarboxylation of isocitrate to 2-oxoglutarate 
by  NADP-linked  isocitrate  dehydrogenase  (NADP-ICDH)  in  the  citric  acid 
(Krebs) cycle;  and 4. the enzyme H+ -transhydrogenase (H+ -Thase) catalyses
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the  transfer  of  hydride  ion  between  NADH  and  NADP*  coupled  with  the
\
translocation of protons from the cytosol to mitochondria. Reactions 1-3 occur 
in the cytosol while reaction 4 occurs in the inner mitochondrial membrane390
Me Me OH
Me Me
NADPH
Me
iX-wmMtydroxyhaem
CO
Me Me
Oo .0+
Me Me
2.6 NADPH
NH  HN
HN
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BiHverdui IX tt
Figure 1.12 Structural pathway of haem catabolism.
Me  =  Methyl  (CH3);  Pr =  Propionate  (CH2CH2COOH);  and V = 
Vinyl (CH=CH2). Adapted from 387
In the first stage haem oxygenase forms a complex with its substrate haem to 
generate  Fe3+   a-meso-hydroxyhaem.  The  Fe3 +   is  reduced  to  Fe2 +   then  02  
binds to the latter to form a metastable oxy-form complex (H0-Fe2 + -02). This
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is followed  by formation  of an  iron-bound  hydroperoxide  intermediate which 
targets  the  a-meso  carbon,  thus  converting  HO-Fe2+ -02  to  a  Fe3+   a-meso- 
hydroxyhaem-HO complex 388,391.  The purpose of NADPH-CPR is to interact 
with  the  enzyme-substrate  complex  and  transfer  reducing  equivalents  to 
convert  and  maintain  iron  in  the  reduced  (Fe2+)  state  and  activate  O2  for 
attack at  the  a  position,  as  only  Fe2 +   can  bind  O2  364  A  unique  feature  of 
haem  oxygenase  is  that  it  uses  haem  as  both  its  substrate  and  prosthetic 
group,  yet  the  enzyme  is  not  a  haemoprotein;  however,  when  haem 
oxygenase binds haem  in  a  1:1  ratio as a  H0-Fe2 + -02  complex,  a  transitory 
‘haemoprotein’  with  its  distinctive  absorption  maximum  at 405  nm  is formed
392
The second stage transforms  Fe3 * a-meso-hydroxyhaem  to  Fe2 + -verdohaem 
and at the same time CO is released from the a-meso bridge.  Two possible 
mechanisms have been proposed for this procedure: one mechanism requires 
O2  and  one  electron,  i.e.  Fe3 +   a-meso-hydroxyhaem  is  oxidised  to  Fe3 +  
verdohaem  by  0 2   followed  by  reduction  to  Fe2 + -verdohaem  after  CO  is 
released 391. The second mechanism, which has similar energy requirements, 
could  proceed  via  two  parallel  routes:  1.  reduction  of  the  Fe3+   a-meso- 
hydroxyhaem-HO  complex  to  its  Fe2 +   form,  followed  by  oxygenation;  or  2. 
oxygenation  of  the  Fe3 +   a-meso-hydroxyhaem-HO  complex,  followed  by 
one-electron reduction 388
The  final  stage  of  haem  degradation  involves  conversion  of verdohaem  to 
biliverdin and free Fe2+. Although the exact mechanism is unclear the fact that
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the O2 incorporated into biliverdin originates from two different O2  molecules 
rules out the possibility of a hydrolytic reaction and points towards the need 
for reducing equivalents and 02  3 93  A proposed sequence for this reaction is 
binding  of O2 to the  Fe2+ -verdohaem-HO complex,  which  is the  rate  limiting 
step  in  this  phase,  to  generate an  oxy-verdohaem-HO complex followed  by 
conversion  to  unknown  intermediates  and  lastly  two  electron  reduction  to 
produce  the  Fe3 + -biliverdin-HO complex 3 88  The  latter product still  remains 
attached to haem oxygenase,  but is released as biliverdin and  Fe2 +  with the 
help of NADPH-CPR,  thus completing the metabolism of haem and allowing 
the  catabolic  cycle  to  start  again  391.  However,  in  the  absence  of  the 
reductase, iron is not reduced and the Fe3 + -biliverdin complex is not a suitable 
substrate for BVR 394.
Investigations  into  the  mechanism  of the  aforementioned  reactions  reveals 
that  steric  orientation  of  the  haem  molecule  within  the  enzyme  haem 
oxygenase  accounts  for the  regiospecific oxidation  of the  a-meso  position, 
which is similar to the mechanism of other haemoproteins, e.g. myoglobin and 
haemoglobin,  although oxidation can also occur at the other meso-positions, 
i.e.  p, y and 5 3 9 5 _ 3 9 7   These observations are supported  by the recent X-ray 
crystallographic  structure  of  rat  and  human  HO-1  with  and  without  haem, 
respectively, as the protein sterically obstructs access to the p-, y- and 5-meso 
carbons of haem in the closed conformation 398-399. Another factor suggested 
to  control  ligand  and  regiospecific  metabolism  is  the  presence  of  histidine 
(His)  residues  (His  25  and  His  132)  in  the  enzyme,  as  mutations  in  either 
leads to decreased catalytic activity 40°-402. However, X-ray crystallography did
84INTRODUCTION
not identify any  His,  or other polar residues,  within  the active site  region  of 
human  HO-1,  thus  adding to the  complexity  surrounding  the  mechanism  of 
haem metabolism 403
The metabolism of haem can be regulated at the first committed step,  i.e. a- 
meso-hydroxylation,  to  produce  only  biliverdin  and  no  CO  via  a-meso 
substitutions  391.  A  second  site  of regulation  is  at  the  Fe2 + -verdohaem-HO 
complex,  as  binding  of Fe2 +  haem ligands,  e.g.  azide,  cyanide and  CO,  can 
inhibit further progress of the reaction 3 8 8   Biliverdin can inhibit the activity of 
haem oxygenase through blocking access of the substrate to the catalytic site 
of the  enzyme  404.  Although  NADPH-CPR  has  the  capacity  to  oxidatively 
degrade haem,  the  products are propentdyopents rather than  bile  pigments, 
but simultaneous  incubation  with  haem  oxygenase  is  necessary to  produce 
biliverdin-IXa 405.
Metabolism of haem to iron and  bile pigments is not limited to  mammals,  as 
the pathogenic bacteria C. diphtheriae uses Hmu O, a protein homologous to 
haem  oxygenase,  to  acquire  iron  from  haem  when  the  quantity  of  free 
extracellular iron is low 406‘408. Also, cyanobacteria, algae and plants all have 
haem oxygenase enzymes which enables them to convert haem to biliverdin- 
IXa,  the  precursor  of  phytobilins  (e.g.  phycobilins  and  phytochromobilins) 
4°9,410  |n  su m m ary |  the X-ray crystal structure of human  and  rat HO-1  have 
provided a more detailed insight into the process of haem metabolism. Further 
investigations are  required to fully clarify the identity of intermediaries in the 
pathway as well  as  make comparisons with other organisms that utilise the
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haem  oxygenase  pathway,  so  that  a  better  understanding  of  the  reaction
\
mechanisms can be acquired 4 0 3
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1.13  Haem oxygenase and its isoforms
Due to the instability of biliverdin and bilirubin compared with haem, together 
with  an  inability  to  obtain  pure  samples  of  these  bile  pigments,  haem 
oxygenase is the most studied component of haem metabolism 411 .  The first 
documented existence of haem oxygenase was made by Wise and coworkers 
in  1964 with an in  vitro assay showing haem was degraded to biliverdin 412. 
Further  work  by  Tenhunen  and  colleagues  led  to  the  identification, 
characterisation  and  localisation  of  haem  oxygenase  as  the  enzyme 
responsible  for  haem  catabolism  363-4 1 3   The  reaction  catalysed  by  haem 
oxygenase was originally assumed to be a mixed function oxidase rather like 
the drug metabolising enzymes cytochrome P450 (CYP-450) as both required 
NADPH and 0 2 ) but could be inhibited by CO 389  However, closer inspection 
of  both  systems  revealed  sharp  contrasts.  Specifically,  the  wavelength  at 
which monochromatic light could reverse the inhibition by CO is 450 nm and 
464-468 nm for CYP-450 and haem oxygenase, respectively. Also, these two 
enzymes  share  different  inducers,  haem  oxygenase  activity  is  present  in 
macrophages,  but  CYP-450  activity  is  absent  in  such  cells  3 8 9   These 
differences led to the haem oxygenase enzyme being classified as a distinct 
microsomal entity that does not require CYP-450 for its activity414.
The  haem  oxygenase  enzyme  is found  exclusively bound  to  membranes  of 
the  endoplasmic  reticulum  (ER),  predominantly  within  the  smooth 
endoplasmic reticulum (SER) fraction 362. Various mammalian tissues express 
haem oxygenase but the highest levels are found in spleen,  brain and testes 
383.  Interest in haem oxygenase increased following the observation that the
87INTRODUCTION
inducible isoform, haem oxygenase-1  (HO-1) (or heat shock/stress protein 32;
\
HSP32)  was  up-regulated  by various  forms  of oxidative  stress  415-417  Two 
other  isoforms  of  haem  oxygenase,  HO-2  and  HO-3,  have  since  been 
discovered and like HO-1  they are rather diverse and highly conserved 415-418. 
Both  HO-1  and  HO-2  have  been  fully  characterized  and  shown  to  be 
phosphoproteins  that  utilise  the  same  cofactors  and  substrate  (haem)  to 
produce bilirubin, CO and Fe2+; however, they differ with regards their genetic 
make  up,  chromosomal  location,  regulation,  molecular  and  biochemical 
characteristics and cellular distribution 371.
It is the sensitivity of HO-1 towards a variety of inducing agents, such as those 
listed in Table  1.7,  which  sets  it apart not only from  other haem  oxygenase 
isoforms  but also other biological enzymes 381.  HO-1  (MW 32  kDa) was first 
identified as a distinct enzyme in spleen and liver microsomes 392'419  but it is 
also expressed in many other cells types in response to different inducers 3 6 4  
Although HO-1 from rat is a HSP, human HO-1  is not inducible by heat shock, 
except in a hepatoma cell line Hep3B,  despite the presence of a heat shock 
element (HSE) in its promoter region 4 2 0
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Table 1.7 Examples of haem oxygenase-1 inducers
Inducer Reference Number
Haem
421
Heavy metals, e.g. arsenite
422
Cellular stress, e.g. hypoxia, hyperoxia
423,424
UV irradiation
425
GSH depletion
426
Nitric oxide
427
Heat shock
416
Bacterial toxins, e.g. endotoxin
428
Oxidative/nitrosative stress
373,429
Ischaemia-reperfusion (IR) injury
430
Plant-derived phenolics, e.g. curcumin, caffeic acid 
phenethyl ester (CAPE)
431,432
Disease states, e.g. anaemia, cancer
433
The  second  isoform,  HO-2  (MW  36  kDa),  was  first  identified  in  rat  liver 
microsomes 415  In  contrast to  HO-1  this  isoform  is  constitutively expressed 
and  has  few,  if  any  inducers,  although  developmental  factors,  adrenal 
glucocorticoids,  opiates and  possibly  NO,  have been suggested  as possible 
candidates 371.  Secondly,  HO-2  is  not a  HSP 434 and  despite  its continuous 
expression  the  brain  435 and  testes  4 3 6   represent the  major sites  of activity. 
The  most recently discovered  isoform of haem oxygenase  is  HO-3 (MW 33 
kDa)  418.  This  isoform  is  similar  to  HO-2  in  that  it  is  also  constitutively
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expressed, but differs compared to HO-1 with respect to structure. Also, HO-3
\
is a weak metaboliser of haem and so far its physiological role has not been 
fully clarified 383  Therefore, this isoform will not be discussed any further.
1.13.1  Structure and regulation of the haem oxygenase gene
Advances in molecular genetic techniques have revealed that the amino acid 
and nucleotide sequences of HO-1  and HO-2 are translation products of two 
gene  loci,  i.e.  they  are  isoforms,  and  not  derived  from  one  another  by 
posttranslational  modifications  437-4 3 8   Polymerase  chain  reaction  (PCR)  and 
fluorescence  in  situ  hybridisation  (FISH)  techniques  have  assigned  human 
HO-1  and HO-2 to chromosome regions 22q12 and 16p13.3, respectively 4 39 
Structurally,  the  isoforms  of  haem  oxygenase  have  five  exons,  four introns 
and  numerous  binding  sites  for  transcription  factors  within  their  N-terminal 
coding  regions  (see  Figure  1.13),  while  a  hydrophobic  carboxy  terminus 
anchors  them  to  the  ER  364.  Also,  the  haem  oxygenase  protein  is 
posttranslationally  integrated  into  the  SER  as  a  functional  protein,  thus 
obviating the need for prior processing by a precursor molecule 4 40
The isoforms vary in their content of amino acids and nucleotides (HO-2 316 
amino  acids  and  12563  nucleotides  vs.  HO-1  289  amino  acids  and  6830 
nucleotides) 438-441. The  HO-1  gene is a product of a single transcript of -1.8 
kb, whereas HO-2 is the product of two or more transcripts, -1.3 and -2.1  kb 
4 3 5   The coding sequence for HO-1  begins in exon 1, whereas exon 1   of HO-2 
is  a  5’-untranslated  region  (UTR)  with  exon  2  containing  the  start  codon. 
Analysis  of the  amino  acid  sequences  of  both  isoforms  showed  that  HO-2
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contains three  cysteine  residues,  while  HO-1  has  none 437.  There  is  a  high 
degree  of similarity in  the  primary amino  acid  and  nucleotide  sequences  of 
HO-1  (85-95%)  and  HO-2  (>  90%)  among  different  mammalian  species 
suggesting  a  common  ancestral  gene;  however,  homology  between  the 
different haem oxygenase isoforms is limited to about 40% 442.
- 12,000 -MOO 4,000 -t-MOO ■>•4,000
exons
is
585  atm*
■   AIM 
S   SIM
U2  nfkb
Q   K S   i u ;k r
m   <  S O I   u s e :
Mvm
AIV2
STAi'-J
l/SF
Figure 1.13 Structure of the haem oxygenase-1 gene.
The white  boxes  represent exons the  black boxes  between the 
exons are introns. The promoter (P), proximal enhancer (PE) and 
two distal enhancers (DE1  and DE2) regions contain the known 
binding  site  for  transcription  factors  (patterned  boxes).  C/EBP 
CCAT  enhancer binding  protein;  AP-1  activator protein-1;  SP-1 
stress  protein-1;  CDRE  cadmium  response  element;  IL-GRE 
glucocorticoid  response  element;  HSE  heat  shock  element; 
MTRE metal response element; PRE proximal response element; 
NF-kB nuclear factor-kappa  B; AP-2 activator protein-2;  STAT-3 
signal  transduction  and  activator  of  transcription;  and  USF 
upstream stimulatory factor. Adapted from 4 4 3
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Despite the lack of homology between the two isoforms of haem oxygenase, 
a highly conserved (96%) sequence of 24 amino acids is present within exon 
3  of HO-1  and  exon  4 of HO-2 4 44  This  hydrophobic region,  known  as the 
haem pocket, contains the consensus sequence Leu-Leu-Val-Ala-His-Ala-Tyr- 
Th-Arg or haem signature,  and  has been implicated in orientating the  haem 
molecule  so  that  the  a-methane  bridge  is  broken  437-438  Conserved  His 
residues  (His  25  and  132  of  HO-1  and  His  151  of  HO-2)  within  the  haem 
pocket  have  been  identified  in  both  isoforms  and  shown  to  regulate  haem 
catalysis 400- 401-445
Like other types of enzyme catalysed reactions the quantity of intermediate or 
final products can exert feedback inhibition upon the catalytic enzyme.  In the 
case  of  the  haem  oxygenase  reaction  biliverdin  is  the  only  pathway 
component or cellular constituent able to  inhibit haem  oxygenase  activity in 
vivo through  occupying  the  haem  binding  site  404.  An  increase  in  biliverdin 
occurs  via  feedback  inhibition  of  the  serine/threonine  kinase,  BVR,  by  its 
product  bilirubin  446.  Availability  of  the  substrate  haem  can  influence  the 
activity of haem  oxygenase  447,  as well  as  other metabolic pathways  448  In 
situations  where  there  is  excess  haem  oxygenase  activity  synthetic 
derivatives of haem, i.e. metalloporphyrins, can act as competitive inhibitors of 
the enzyme 449. This form of haem oxygenase inhibition is frequently used in 
the suppression  of jaundice 45°.  However,  certain  metalloporphyrins,  e.g.  tin 
proto-  and  meso-porphyrin,  are  photosensitisers,  which  can  generate 
cytotoxic  oxygen  species,  such  as  singlet  oxygen  (1 02).  Other  drawbacks 
include:  1. inhibition and stimulation of sGC and NOS activity,  respectively; 2.
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lack of discrimination between the HO-1  and HO-2 isoforms; and 3. long term
\
treatment with  zinc or tin  protoporphyrin  (ZnPP or SnPP,  respectively)  can 
induce HO-1 451.
As  HO-1  has  many  more  inducers  compared  with  HO-2,  studies  of  HO-1 
transcription and translation have provided most of the information pertaining 
to the regulation of haem oxygenase gene expression.  Nevertheless,  recent 
evidence suggests a role for HO-2 with regards gene regulation in the cell452. 
Metals were among the first type of HO-1  inducers 422,  since then the list has 
expanded  to  cover  a  wide  range  of  agents  (see  Table  1.7  for  examples). 
Cloning and sequencing of the HO-1  and HO-2 gene has identified a number 
of regulatory transcription factor-binding sites,  or regulatory elements (Figure 
1.13), some of which are repeated within the promoter region of both isoforms 
4 3 8 ,4 4 1 ,4 5 3   though  HO-1  and  HO-2  may  share  similar  regulatory  elements 
(see Table  1.8 for examples),  those within  the  HO-2  isoform  are  refractory 
towards stimulation.  Consequently,  HO-1  is  more  responsive to  a variety of 
inducers  3 64  However,  glucocorticoids  can  promote  HO-2  induction  but 
suppress HO-1  expression 454-455.
Presently,  the  exact molecular mechanism(s)  by which  an  inducer elicits  an 
increase in HO-1  gene expression is not fully understood; however, studies of 
the HO-1  gene in various species has revealed that the stimuli, which bind to 
cell surface receptors, act through a signal transduction process known as the 
mitogen-activated protein kinases (MAPKs) pathway, thus initiating a cascade 
of events leading to the release of transcription factors, e.g. AP-1  and -2, NF- 
kB,  hypoxia-inducible factor 1   (HIF-1)  and  nuclear factor-erythroid 2 related
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factor  (Nrf2)  412456.  The  transcription  factors  propagate  the  signal  to  the
\
nucleus  where  they  bind  to  their respective  binding  elements  in  the  HO-1 
gene, which ultimately leads to upregulation of HO-1  mRNA to counteract the 
negative stimuli 457
Table 1.8 Examples of haem oxygenase regulatory elements
Regulatory Elements Reference Number
Heat shock element (HSE) 416
Haem-binding regulatory motif (HRM) 474
Glucocorticoid response element (GRE) 475
Stress response element (StRE) 412
Hypoxia responsive element (HRE) 476
GCN4 binding site 416
Activator protein-1  (AP-1) binding element 457
Metal responsive element (MRE) 416
Nuclear factor-kappa B (NF-kB) response element 477
Sp1  binding site 416
TATA-like box sequence 416
Antioxidant response element (ARE) 465
The  MAPKs  signal  transduction  pathway  is  part of a  family  of evolutionary 
conserved  serine-threonine  (Ser-Thr)  protein  kinases  that  play  a  prominent 
role in coupling an array of extracellular signals, e.g. growth factors, cytokines, 
irradiation,  osmolarity and  fluid shear stress,  to  intracellular targets such  as 
nuclear  transcription  factors,  cytosolic  kinases,  PI_A2,  membrane-bound 
tyrosine  kinase  receptors  (e.g.  EGF  receptor)  and cytoskeletal  components.
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As a result,  a variety of biological responses including: gene expression, cell
\
proliferation,  differentiation and cell death,  can  be elicited 45 6 -459.  So far four 
different  subfamilies  of  MAPKs  have  been  identified:  1.  the  extracellular 
signal-regulated  kinases  1   and  2  (ERK1/2);  2.  c-Jun  amino(NH2)-terminal 
kinases 1, 2 and 3 (JNK 1/2/3); 3. the p38 (a homologue of the yeast HOG1 
kinase) enzymes (p38a,  p38p, p38y and p385); and 4.  ERK5 458  In response 
to  upstream  interactions  with  small  GTP-binding  proteins  (GTPases)  of the 
Ras  or  Rho  family,  or  phosphorylation  (addition  of  a  phosphate  group)  by 
MAP  kinase  kinase  kinase kinases (MAP(4)K),  a sequential phosphorylation 
cascade,  beginning  with  MAP(3)K  followed  by  the  dual-specific  kinase 
MAP(2)K terminates with activation of one of the four MAPK subfamilies. The 
latter response  is  achieved  via  phosphorylation  of a  threonine  and  tyrosine 
(ThrXTyr)  tripeptide  motif,  where X can  be different amino  acids,  within  the 
activation  loop  of  the  MAPKs.  Once  activated  the  MAPKs  initiate  proline- 
directed phosphorylation of the Ser-Thr-proline (Ser-Thr-Pro) sequence within 
their downstream target substrates 4 6 °. The activity of MAPKs are governed by 
the  balance  between  upstream  kinase  phosphorylation  (to  activate)  and 
protein  phosphatases  dephosphorylation  (to inactivate)  of the threonine  and 
tyrosine  residues.  Examples  of  inactivators  include,  dual  specificity 
(threonine/tyrosine)  phosphatases  (DSPs,  also  called  MAPK  phosphatases 
(MKPs)),  tyrosine-specific  phosphatases  and  serine/threonine-specific 
phosphatases 461.
The  most  studied  MAPKs,  i.e.  ERK,  JNK  and  p38,  have  been  classified 
according to their method of regulation,  i.e.  ERK expression is enhanced  by
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signals  associated  with  growth  and  proliferation,  while  JNK  and  p38  are 
regulated by cellular stress signals and as such are known collectively as the 
stress-activated protein kinases (SAPKs) 460.  The fact that HO-1  and MAPKs 
are activated by stressful stimuli, via tyrosine phosphorylation, suggests a link 
between  these  two  pathways  412.  For example,  Kietzmann  and  colleagues 
showed that arsenite, a potent inducer of MAPKs and HO-1, promoted HO-1 
protein and mRNA induction in primary cultures of rat hepatocytes via the JNK 
pathway 462, whereas Elbirt et al., using a chick hepatoma cell line, suggested 
that  ERK  and  p38,  but  not  JNK,  MAPK  pathways  were  responsible  for 
arsenite-dependent  upregulation  of  HO-1  457;  while  Alam  and  coworkers 
identified  p38,  but  not  ERK  or JNK,  as  the  route  through  which  cadmium 
activates Nrf2 thereby inducing HO-1  gene expression in mammary epithelial 
cells 463.  In  contrast,  Yu  and  collaborators  observed  that the  MAPKs  could 
differentially  regulate  Nrf2,  i.e.  JNK  activates  but  p38  deactivates  Nrf2  464, 
which in turn can bind to the antioxidant response element (ARE) leading to 
induction of several cytoprotective genes among them HO-1  465-466  in primary 
rat  cardiomyocytes,  p38,  but  not  ERK,  was  shown  to  induce  HO-1  during 
hypoxia  467;  however,  Ryter  et  al.  noted  that  both  ERK  and  p38  MAPK 
pathways  negatively  regulated  HO-1  in  vascular  endothelial  and  smooth 
muscle cells exposed to hypoxia 468. A number of reports have documented 
an association  between CO and the MAPK pathways.  In  particular,  CO may 
exert its cytoprotective influences, i.e. as an antiinflammatory, antiproliferative 
and  antiapoptotic agent,  via  a  sGC-independent mechanism  using  p38  and 
ERK as mediators of these effects 4 6 9 '472. Recently, TaillS et al. showed that in 
vitro  and  in  vivo  induction  of  HO-1  could  exert  an  antiproliferative  effect
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upon  airway  smooth  muscle  (ASM)  through  a  bilirubin-mediated  redox
\
modulation  of  phosphorylation  of  ERK1/2  473.  Collectively,  these  examples 
illustrate  the  ability  of  the  MAPKs  to  serve  as  an  effective  link  between 
extracellular chemical signals and intracellular protective responses mediated 
by  HO-1.  In  addition,  the  type  of  MAPK  that  is  activated,  as  well  as  the 
eventual outcome, will vary with the stimulus provided,  cell type and species 
examined.
1.13.2 Physiological role of the haem oxygenase pathway
The degradation of haem by haem oxygenase is the principal mechanism for 
in vivo production of bile  pigments (biliverdin and bilirubin), CO and  Fe2 +  3 6 4  
Why a  catabolic pathway for the elimination  of a toxic agent,  haem,  should 
produce even  more  lethal  products:  CO a poisonous gas;  bile pigments can 
cause jaundice and possible brain damage at excessive levels; and iron may 
exacerbate  oxidative  stress  and  haematological  pathologies,  puzzled 
biologists  for  many  decades  382-478-479  in  this  subsection  these  enigmatic 
features of the haem oxygenase enzyme, in particular HO-1, will be discussed 
with respect to cellular stress, the immune, vascular and nervous systems.
Since its discovery, the negative perception of the haem oxygenase pathway 
has been challenged  by strong evidence to support a role for endogenously 
generated  bile  pigments  and  CO  as  important  physiological  mediators  of 
cellular  and  tissue  homeostasis  4 8 °.  In  response  to  alterations  in  cellular 
homeostasis  due  to  oxidative  (e.g.  UV irradiation,  H202 )  metals)  422,425  and 
nitrosative (e.g. NO, ONOO') 481,48 2 stress two events take place. Firstly, there
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is a decline in the quantity of the most abundant cellular antioxidant, GSH, as
\
a  result  of  increased  ROS  and  RNS  generation  14;  and  2.  specific  stress 
proteins,  in particular HO-1, are expressed 373417. Combating oxidative stress 
is  not  limited  to  the  HO-1  isoform  as  HO-2  can  protect  neurons  against 
oxidative stress through the production of bilirubin 4 83  The mechanism(s) by 
which  HO-1  mediates cytoprotection is not clear;  however,  bilirubin,  CO and 
ferritin are seen as potential candidates381.
Although  ‘free’  iron  derived  from  the  haem  oxygenase  pathway  can  be 
deleterious,  the  parallel  induction  of  the  iron  sequestering  protein,  ferritin, 
scavengers  iron,  thus  preventing  its  adverse  effects  484  The  importance  of 
HO-1  in the regulation of cellular iron has been illustrated in both animal and 
human  models.  Mice with a targeted deletion  of the  HO-1  gene,  HO-1*'' null 
mice,  exhibit  alterations  in  iron  metabolism  characterized  by  severe  iron 
deficiency,  pathological  iron-loading,  as  well  as  a  reduced  responsiveness 
towards  oxidative  challenge,  both  in  vitro  and  in  vivo 369-429  More  recently, 
Yachie et al.  reported the first case of HO-1  deficiency in a six year old  boy 
3 7 0   Like  the  animal  model,  the  patient  exhibited  similar  biochemical  and 
pathological  features,  e.g.  growth  retardation,  anaemia  and  increased 
sensitivity to oxidative injury. A comparison of apoptosis levels in HO-T;‘ mice 
and  those  expressing  HO-1  revealed  that  HO-1  was  cytoprotective  via 
modulation  of  intracellular  iron  levels  4 85  In  some  circumstances,  e.g.  UV 
irradiation or enhanced  HO-1  activity,  iron released via the haem oxygenase 
pathway  can  exert  a  negative  influence  due  to  overloading  the  capacity  of 
other iron  homeostasis  proteins,  e.g.  ferritin  and  transferrin  (an  iron  binding
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protein), which can lead to deleterious effects through redox-cycling of the iron
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4 86  These examples emphasise the key role played by HO-1  with regards to 
in vivo and in vitro iron homeostasis.
The  importance  of  HO-1  within  the  immune  system  is  illustrated  in  the 
following  examples.  In  rats,  prior enhancement  of haem  oxygenase  activity 
and  HO-1  protein  expression,  using  haem,  resulted  in  greater  protection 
towards a subsequent acute  inflammatory challenge,  compared with animals 
given the haem oxygenase inhibitor tin-protoporphyrin (SnPP),  prior to and at 
the time of administration  of the immunological activator 487.  Preservation of 
organs  for transplants  as  well  as  manipulation  of  the  hosts  immunological 
response  are  important  determinants  to  prevent  rejection  and  enable 
successful  accommodation  by  the  recipient.  Two  recent  publications  have 
highlighted the possibility of HO-1  attenuating organ  rejection.  In  a  model of 
xenografting,  mouse  to  rat  transplants  which  were  accommodated  by 
immunosuppressive drugs,  it was noted that the degree of HO-1  expression 
correlated with the extent of survival and accommodation, as mice which had 
altered HO-1  gene expression rejected the transplants sooner 488. A common 
feature  of  heart transplant  rejection  is  accelerated  arteriosclerosis  due  to  a 
chronic  immune  response  478.  An  in  vitro  and  in  vivo  study  of  accelerated 
arteriosclerosis by Hancock and colleagues revealed that prior expression of a 
range  of antioxidant  and  apoptotic  genes,  including  HO-1,  was  associated 
with an absence of arteriosclerosis induced by alloantibodies, thus protecting 
allografts  against  chronic  rejection  489.  The  mechanism(s)  by  which  HO-1 
mediates  its  immunomodulatory  function  has  not  been  fully  elucidated.
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However,  prevention  of  oxidative  stress  mediated  expression  of  adhesion
\
molecules  on  endothelial  cells,  thus  inhibiting  the  production  of 
proinflammatory  mediators (e.g.  complement components,  IgM  and  TNF-a), 
together with the antioxidative and anticomplement effects of bilirubin and the 
vasodilatory  and  antiinflammatory  effects  of  CO,  represents  a  powerful 
stratagem in the prevention of an adverse inflammatory response 470-487-490
Vascular  diseases,  e.g.  arteriosclerosis,  hypertension,  hypoxia  and 
reperfusion injury, are a common cause of morbidity and mortality world wide. 
A characteristic feature of such diseases are oxidative and nitrosative stress 
induced injury u. Even though antioxidants have been proposed as a possible 
therapy,  they are  not always  effective 491.  However,  HO-1  and  HO-2  genes 
have been described as possible endogenous protectors against a variety of 
vascular diseases 492. Carbon monoxide originating from HO-1 within vascular 
smooth muscle and HO-2 expressed by endothelial cells has been suggested 
as the  mechanism  by which  haem  oxygenase  regulates vascular tone  both 
physiologically  and  pathophysiologically  493‘4 95  Recently,  the  application  of 
gene  transfer  of  HO-1  has  demonstrated  its  usefulness  in  promoting 
angiogenesis,  long-term  myocardial  protection  and  safeguarding  against 
hyperoxia-induced  lung  injury 424-496-497.  Sammut et al.  observed  that aortas 
expressing  high  levels  of  HO-1  were  more  resistant  to  the  vasoconstrictor 
effect of phenylephrine  (PE),  possibly due to elevation  of cGMP  by CO 4 9 8  
Using an in vivo model of acute hypertension Motterlini et al. reported that CO 
derived from enhanced HO-1  expression was effective towards suppression of 
the hypertensive response 4 99  Reperfusion injury is a common cause of organ
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transplant failure and post operative injury, but a number of publications have
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highlighted  the  potential  of  HO-1  and  its  products,  bilirubin  and  CO,  as 
possible protectants 430'500 501.
The  nervous  system  is  another  area  that  shows  a  high  level  of  haem 
oxygenase activity, with HO-2 being the more prominent isoform 502. A unique 
characteristic of haem oxygenase expression in the nervous system is that it 
is found colocalised with NOS enzymes or in areas lacking the latter enzymes 
5 0 3 ,5 0 4   Bilibin and CO derived from both isoforms have been highlighted as 
protective  agents  in  models  of oxidative  stress  injury  in  neurons,  glial  and 
astrocytes 483-505-507. Neuronal expression of HO-2 has been shown to account 
for neurotransmission in the peripheral and autonomic nervous system as well 
as the  developmental  and  growth  response  of  neurons  to  adrenal  steroids 
3 7 1 ,4 5 4 ,5 0 7   \/y/jthjn  the  baroreceptor  region  of the  brain,  the  nucleus  tractus 
solitarius  (NTS),  both  endogenous  and  exogenous  CO  can  lower  blood 
pressure, while inhibition of haem oxygenase leads to vasoconstriction 377.
The  aforementioned  physiological  effects  of  haem  oxygenase  illustrate  the 
significance of its metabolites and widespread distribution of both isoforms in 
different  organs  and  systems.  Further  mechanistic  studies  of  HO-1  should 
help  to  elucidate  the  mechanism(s)  of  cytoprotection,  while  new  scientific 
procedures, e.g. gene regulation and transfer as well as selective induction of 
the HO-1  gene by pharmacological means, could both be used to harness the 
therapeutic potential of the haem oxygenase pathway 457.
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1.14  Bile pigments
•v
The bile pigments, biliverdin and bilirubin, are continuously formed in vivo by 
their respective ubiquitous enzymes haem oxygenase and BVR, as a result of 
oxidative  cleavage  of the  a-meso  bridge  of ferric  (Fe3+)  haem  (see  Figure 
1.14) 364.  Both  prokaryotic and eukaryotic species have the ability to oxidise 
haem and generate bile pigments. The overall reaction is manifested in nature 
and  biology as  a  specific colour sequence,  red  green  -> yellow.  Ferrous 
(Fe2 + ) haem, which has a crimson colour, gives rise to the blue-green colour 
range of the biliverdins which are used by birds, to camouflage their eggs, and 
as precursors for essential photosynthetic bilins by algae, bacteria and plants, 
while  the  yellow-golden  colouring  of jaundice  is  due  to  excess  bilirubin  411. 
Disruption  of the  a-meso  bridge  in  haem  by  microsomal  haem  oxygenase 
generates  the  corresponding  isomer  of  biliverdin,  i.e.  IXa,  although  other 
isomers, i.e.  IXp,  IXy and IX5, are possible (see Figure 1.15). The IX denotes 
the order of ring substituents and Greek letters identify the meso bridge that is 
cleaved 411.  The biliverdin-IX isomers are rapidly converted by cytosolic BVR 
(discussed further in Section  1.14.1) to the corresponding isomer of bilirubin. 
In  adult  bile,  bilirubin-IXa  (or  simply  bilirubin)  is  the  most  common  (95%) 
isomer,  while  5%  are  non-a isomers  5 0 8   Bilirubin  is often  represented  as a 
linear  two-dimensional  tetrapyrrole  structure  (Figure  1.16,  upper  diagram), 
although a more accurate representation is that of a three-dimensional ridge- 
tile  shape  (Figure  1.16,  lower diagram)  which  is  more  stable  and  has  the 
ability to flex,  bend and  invert to a  mirror image  ridge-tile without loss of its 
intramolecular  hydrogen  bonds  5 09  The  presence  of  propionic  acid
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(CH2CH2CO2H)  groups  at  positions  8  and  12  accounts  for  the  high
\
hydrophobicity and lipophilic nature of bilirubin and explains why it cannot be 
excreted  intact,  but must undergo metabolism  in the  liver before  elimination 
via the bile 509'510  This is in stark contrast to the other isomers,  i.e.  IXp,  IXy 
and  IX5,  which are  more polar and less lipophilic,  as they do not engage  in 
intramolecular hydrogen bonding, but are excreted intact by the liver411.
Although the pathways and mechanism of haem biosynthesis and catabolism 
have  been well  studied,  due to the  stability of haem  and  the  importance  of 
haem homeostasis, the same cannot be said about bile pigments as bilirubin, 
biliverdin and BVR are unstable, difficult to work with and obtain in a pure form 
411.  Despite these drawbacks a number of physiochemical and  physiological 
properties  have  been  identified  for  the  enzyme  BVR  and  mammalian  bile 
pigments.
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Figure 1.16 Structural representations of bilirubin.
Upper  diagram  of  two-dimensional  structure,  lower  diagram 
illustrating the more stable three-dimensional ridge-tile shape and 
intramolecular hydrogen bonds. Adapted from 509.INTRODUCTION
1.14.1  Biliverdin reductase
\
As shown in Figure 1.15 haem oxygenase can open up the haem molecule at 
either of its four meso bridge carbons to generate the respective isomers  of 
biliverdin. These isomers are subsequently metabolised to the corresponding 
isomer  of  bilirubin  by  the  cytosolic  enzyme  BVR  385.  Purification  and 
characterisation  of  a  highly  stable  form  of  rat  (MW  -34  kDa)  and  human 
(MW -41-42  kDa)  BVR  show that this  enzyme  has  quite  unique  properties 
513,514.  For example,  the  enzyme  is  encoded  by a  single  copy  gene  and  is 
postranslationally  modified;  it  is  thiol  (SH)-dependent;  BVR  is  a  kinase 
enzyme that can be autophosphorylated and reversibly phosphorylated on its 
serine/threonine  residues,  which  is  essential for enzymatic activity;  it  is  the 
only enzyme to have a dual pH (pH 6.6-6.9 and pH 8.5) and cofactor (NADH 
or NADPH) requirement, with pH 8.5 and NADPH being the optimal conditions 
for activity 446'513.
The complete amino acid  sequences of four different isomers,  two  BVR-IXp 
(BVR-B)  reductases  (isoforms  I  and  II,  MW  -21  kDa)  and  two  BVR-IXa 
(BRV-A)  reductases  (isoforms  III  and  IV,  MW -34  kDa),  have  been  cloned 
and  characterized  in  human  liver  cytosolic  fractions  and  mapped  to 
chromosomes and 19 and 7, respectively 515‘519. The BVR-IXa reductases are 
limited  to  the  regiospecific  reduction  of  the  a  -meso  (C10)  hydrogen  on 
biliverdin-IXa to produce bilirubin-IXa, whereas  BVR-IXp reductases catalyse 
the reduction of the non-a isomers of biliverdin to the corresponding bilirubin 
isomers, as well as a variety of flavins and ferric ions516 ,5 2 0
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Recently  the  crystal  structure  of  BVR-IXa  and  BVR-IXp  have  been 
characterized  in  rats  and  humans,  respectively,  and  revealed  a  number of 
structural and mechanistic details about these two isoforms 5 2 1  * 522.  Firstly, the 
rat BVR-IXa comprises two tightly packed domains, whereas human BRV-IXp 
is a single monomer 521,522. Second, the substrate binding site is large enough 
to accommodate  substrate and cofactor (NADH  or NADPH)  simultaneously, 
but separate  mechanisms  are  employed for each  cofactor 521.  Although  the 
mechanism of catalysis used by BVR is unclear, the discovery of a ‘conserved 
EYP  motif  (Glu  96-Tyr  97-Pro  98),  which  corresponds  to  other  critically 
important structural motifs, at the proposed active site of BVR-IXa is important 
521.  Also,  electrostatic  interactions  aid  enzyme-substrate  binding  and 
recognition,  e.g.  the  presence  of two  negatively  charged  residues  enables 
BVR-IXp to have a wider repertoire of substrates,  but prevents metabolism of 
biliverdin IXa as it has propionate side chains. Therefore, the latter is the only 
substrate for BVR-IXa 520-522.
1.14.2  Physiological  and  pathophysiological  aspects  of  biliverdin  and 
bilirubin
The  reason  why  energy  should  be  expended  to  metabolise  biliverdin  to 
bilirubin has been an enigma for many years 5 2 3   In fact, biliverdin is non-toxic 
and easily excretable whereas bilirubin can be neurotoxic and is unexcretable 
unless  it  is  metabolised  by  a  third  enzyme  system,  uridine  diphosphate 
glucuronyl  transferase  (UDPGT)  524.  However,  it  has  been  suggested  that 
biliverdin  is the only in  vivo agent capable of regulating the activity of haem
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oxygenase 4 04 and it also has potential antioxidant 3 8 5  and immunoprotective
\
525  capacities.  Although  the  exact  physiological  role  of  biliverdin  may  be 
unclear,  what  is  apparent  is  that  the  synthesis  of  its  product,  bilirubin,  is 
essential.  For  example,  the  percentage  of biliverdin  isomers  varies  among 
adult and foetal liver:  in adults 95-97% is IXa, 3-5% is IXp, with little or none 
of 1X5 and IXy;  in the foetus 87% is IXp, 6% is IXa and 1X5, while 0.5% is IXy 
5 08  The physiological relevance for the higher quantity of biliverdin-IXp in the 
foetus and biliverdin-IXa in adults is not clear entirely,  but may be due to:  1. 
immaturity  of the  conjugating  enzymes  in  the foetus  required  to  dispose  of 
bilirubin-IXa,  as the other isomers of bilirubin are hydrophilic and  excretable 
without  the  need  for  conjugation;  2.  the  switch  from  foetal  to  adult 
haemoglobin; also 3.  bilirubin-IXa may be more effective than the IXp isomer 
at combating oxidative stress due to the higher oxygen pressure of pulmonary 
respiration after birth compared with placental respiration 508,515.
The oxidative metabolism of haemoproteins by the enzyme haem oxygenase 
generates approximately 250 mg/day of bilirubin in healthy humans 509  Due to 
its poor water solubility bilirubin is  bound to the transport protein  albumin  in 
the systemic circulation. Normal plasma levels range from ~5 to 17 pM, while 
levels greater than 300 pM are associated with disease states, especially of a 
neurological nature, due to the lipophilicity of unbound ‘free’ bilirubin 526.  Even 
before  the  discovery  that  bilirubin  was  derived  solely  from  the  haem 
oxygenase  pathway  its  toxic  aspects  were  well  known,  e.g.  it  can  cause 
neurotoxicity,  uncouple oxidative phosphorylation,  inhibit NADH oxidase and 
interfere  with  mitochondrial  structure  and  function  527,52 8  This  negative
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perception of bilirubin  remained  until  a series of publications  during  the  late
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1980s and early 1990s hypothesised a beneficial role for bilirubin. In an article 
by  Antony  F.  McDonagh,  ‘Is  bilirubin  good  for  you?’  523,  the  author  puts 
forward two answers to this question,  saying bilirubin  is “definitely not”  good 
due to the pathologies arising from disorders of bilirubin metabolism, but “may 
be”  good  on  the  basis  of  evidence  showing  its  protective  function  as  a 
naturally occurring antioxidant against radical induced injury.
The beneficial aspects of bilirubin were first proposed by Roland Stocker and 
colleagues  following  the  observation  that  free  and  albumin-bound  bilirubin 
were effective scavengers of peroxyl radicals, a cause of lipid peroxidation 5 2 9  
Furthermore, bilirubin is more effective than another endogenous antioxidant, 
i.e.  a-tocopherol  or vitamin  E,  at attenuating  lipid  peroxidation  526  The fact 
that bilirubin is one of the most powerful in vitro and in vivo antioxidants has 
led  to  its  utilisation  as  a  defence  against  oxidative  injury  of  lipids  and 
lipoproteins,  which  are  early  event  in  atherosclerosis  and  subsequent 
development of coronary artery disease (CAD) 428-530-531. Also the presence of 
bilirubin on albumin  protects the latter from damage inflicted  by OH* radicals
532
The  novel  concept  that  bilirubin  is  an  endogenous  antioxidant  has  gained 
widespread  acceptance,  but  other  beneficial  aspects  as  a  cytoprotectant, 
antimutagen  and  anticomplement  agent,  have  been  muted  480  The 
cytoprotective  nature  of  bilirubin  has  been  documented  in  rat  liver  and 
hepatocytes,  bovine  vascular  smooth  muscle  cells,  human  erythrocytes, 
human monocytes and human blood  plasma  following  exposure  to
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oxidants  5 33'537.  in  premature  infants,  their  antioxidant  capacity  is  often
\
reduced  due  to  immaturity  of  the  necessary  enzymes;  as  a  result, 
susceptibility to oxygen free radical based disease is increased 538  Similarly, 
such  infants  often  have  elevated  levels  of  bilirubin  (hyperbilirubinemia), 
therefore  bilirubin  may exert a protective function  against free radical  injury, 
thus compensating for the lack of antioxidant enzymes 539-540.
Although hyperbilirubinemia can be detrimental a number of publications have 
queried whether such a state could be a marker for, or possibly attenuate, the 
development of CAD 541,542.  Evidence to support this theory has shown both 
positive  and  inverse  correlations  between  serum  bilirubin  levels  and  the 
development of CAD in humans and animals 543‘547.  Furthermore,  risk factors 
associated with the development of CAD, e.g.  smoking,  high  LDL-cholesterol 
and  obesity,  lead  to  lower  plasma  levels  of  bilirubin,  thus  attenuating  the 
protective  effect  of  bilirubin  5 48 5 49  Prospective  cohort  studies  in  adult  and 
young  males  and  females  revealed  that  higher  serum  bilirubin  levels, 
particularly in men, were associated with a lower incidence of cardiovascular 
and  cancer  mortality  549_552.  in  a  study  of  IR  injury  Clark  et  al.  noted  that 
upregulation  of cardiac  HO-1  using  hemin  (75  pM/kg  i.p.) 24  h  beforehand, 
significantly ameliorated  myocardial  dysfunction  due to an  increased  rate  of 
bilirubin  formation,  while  exogenously  administered  bilirubin  (100  nM) 
mediated a similar cardioprotective effect 4 30  Using a rat model of IR injury of 
the liver, Yamaguchi and colleagues reported that bilirubin was protective as 
an in vivo antioxidant in response to oxidative stress 553.
Due  to  its  high  lipophilicity the  neurotoxic  nature  of free  bilirubin  has  been
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known for almost a century 376.  Despite this adverse image experiments have
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concluded  that  bilirubin  derived  from  haem  oxygenase  exerts  a 
neuroprotective  function  and  also  compensates  for  the  poor  antioxidant 
capacity of the brain 483-554. in Alzheimer’s, a disease characterized by chronic 
oxidative  stress,  increased  bilirubin  formation  as  a  consequence  of  HO-1 
induction could modulate the severity of the condition 555  A number of recent 
reports have indicated that the brain may be able to protect itself from bilirubin 
toxicity  though  the  oxidation  of  bilirubin  556-557.  Although  the  enzyme 
responsible for bilirubin oxidation has not been fully characterized a number of 
details  are  known,  e.g.  enzyme  activity is cytochrome  c dependent;  activity 
increases  with  age;  the  expression  is  subject  to  genetic  variability;  and  is 
lowest among neurons compared with glial cells 5 5 7  558.
Due  to  its  lipophilic  nature  free  bilirubin  can  traverse  cell  membranes  and 
cross the blood brain barrier, where it can induce toxic effects 559. To prevent 
such  reactions  occurring,  bilirubin  is  bound  to  albumin  in  the  systemic 
circulation. The albumin-bilirubin complex is transported to the liver to undergo 
further metabolism by a series of intricate and poorly understood reactions so 
that bilirubin  is  excreted  in  bile.  The  process  of bilirubin  metabolism  begins 
with  the  passage  of the  albumin-bilirubin  complex through  fenestrae  of the 
endothelial cells lining the hepatic sinusoids into the space of Disse 5 1 0   At this 
location  bilirubin  dissociates from  albumin  at the  surface  of the  hepatocyte 
and  is taken  up  by  protein  mediated  transporters  located  in  the  sinusoidal 
membrane  5 24  Within  the  hepatocyte  bilirubin  is  bound  to  ligandin,  a 
glutathione-S-transferase  (GST)  isomer that has  a  high  affinity for bilirubin,
112INTRODUCTION
and carried to the ER where it is translocated into the ER lumen via a protein 
mediated transport pathway5 1 0
In the  ER,  a family of microsomal  membrane  bound  enzymes called  uridine 
diphosphate (UDP)-glucuronosyltransferases (UGTs) catalyse the conjugation 
of bilirubin to UDP-glucuronic acid (UDPGA) 560  The latter process, which is 
also known as glucuronidation, esterifies bilirubin’s two CH2CH2C02H groups 
to  generate  bilirubin  mono-  and  di-glucuronides,  thus  making  the  molecule 
more  water  soluble.  The  water  soluble  glucuronides  are  returned  to  the 
cytosol via transporters  located  in the  ER membrane and excreted from the 
hepatocyte  into  the  bile  via  an  ATP-dependent  anion  transporter,  termed 
canalicular  multispecific  organic  anion  transporter  (cMOAT)  in  rats  and 
multidrug resistance protein 2 (MRP2) in humans, which is located in the bile 
canalicular  membrane  524-560  The  bile  then  passes  from  the  liver  to  the 
gastrointestinal  tract  (GIT)  and  within  the  colon  the  glucuronides  are 
enzymatically converted to  urobilinogens,  and other products,  and  ultimately 
excreted in the faeces 561.
A number of pathological conditions or hereditary disorders of hepatic bilirubin 
metabolism  can  disrupt  the  above  pathway  leading  to  hyperbilirubinemia. 
Hyperbilirubinemia  can  be  classified  as  ‘unconjugated’  or  ‘conjugated’  to 
indicate  its  respective  causes,  free  (unconjugated)  bilirubin,  defective 
canalicular  excretion  of  glucuronides  or  obstruction  of  bile  flow  56a562. 
Physiological  hyperbilirubinemia  is a common  non-life threatening feature  in 
jaundiced neonates and those with Gilbert’s syndrome.  However,  most cases 
are transitory or can be alleviated using phototherapy and metalloporphyrins,
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e.g. tin (Sn) and zinc (Zn) metalloporphyrin, which act as competitive inhibitors
\
of  haem  oxygenase  450563564i  in  severe  cases  of  hyperbilirubinemia, 
kernicterus and bilirubin encephalopathies can develop and ultimately lead to 
irreversible neurotoxicity, developmental abnormalities and death 527.
The  toxic  effects  of bilirubin  can  also  be  manifested when:  1.  the  buffering 
capacity of albumin is exceeded; 2. when drugs compete with  bilirubin for, or 
displace  it  from,  albumin  binding  sites;  and  3.  due  to  the  transitory  and 
reversible nature of the binding of bilirubin with albumin at body temperature 
563.565.566  |n action, the characteristic yellow/orange hue of jaundiced babies 
and Gilbert’s  syndrome subjects,  as well as the yellow staining  of the  basal 
ganglia  in  post-mortem  victims  of  kernicterus,  are  due  primarily  to  the 
formation of colloid (micropolymer crystals of bilirubin) in extravascular sites, 
although  flocculants  (macroaggregrates  of  colloids)  can  also  develop  5 6 7  
Despite having a partial deficiency of liver UGTs which results in chronic, but 
non-fatal,  hyperbilirubinemia  those with  Gilbert’s  syndrome  have  a  reduced 
risk  of  ischaemic  heart  disease  (IHD).  The  basis  for  this  observation  was 
suggested  to  be  due  more  so  to  elevated  concentrations  of free  bilirubin, 
which  protects  LDL  cholesterol  (a  common  target  in  the  process  of 
atherogenesis)  against  the  deleterious  effects  of  oxidative  stress,  than 
increased  high  density  lipoprotein  (HDL)  cholesterol  levels  546.  These 
observations  are  comparable  to  those  in  other  human  and  animal  studies 
where hyperbilirubinemia was correlated with protection against postischemic 
myocardial  dysfunction  430  and  reduced  oxidative  stress,  thereby  mitigating 
the development of IHD 544-545-5 47
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The  availability  of  animal  models  for  hyperbilirubinemia  has  enabled  the
\
elucidation of the molecular mechanisms responsible for this disease as well 
as providing a  means to test new therapeutic agents 560.  Crigler-Najjar (CN) 
syndrome, which is an example of unconjugated hyperbilirubinemia, can be of 
three types: Type  1   or severe CN syndrome is characterized by very high (> 
340  pM)  serum  bilirubin;  Type  2  or  moderate  CN  syndrome  has  serum 
bilirubin levels of 85-340 pM; and Type 3 or mild CN syndrome, also known as 
Gilbert’s  syndrome,  has  serum  bilirubin  of  <  84  pM  5 24  CN  syndrome  is 
caused by mutations in the UGTs, but the Gunn rat, which is a mutant strain 
of Wistar rats, serves as a model for Type 1  CN syndrome 568.
Dubin-Johnson  (DJ)  and  Rotor's  syndromes  are  examples  of  conjugated 
hyperbilirubinemias 562.  Of the two,  DJ syndrome has been the most studied 
as  it  is  caused  by  mutations  in  the  MRP2  gene  leading  to  mild  or chronic 
conjugated  hyperbilirubinemia  as  a  result  of  the  secretion  of  conjugated 
bilirubin,  and  organic anions,  into the bile canaliculus,  even though  bile acid 
excretion into bile is normal569.  Two animal models of DJ syndrome,  both of 
which exhibit autosomal  recessive defects in  hepatobiliary excretion  of non­
bile  acids  and  organic  anions,  exist.  They  are  the  GY/TR-  rat,  which  is  a 
homozygous  mutant  of  Wistar  rats,  and  the  Eisai  (or  spontaneous) 
hyperbilirubinemic rat (E(S)HBR), which is a mutant strain of inbred Sprague 
Dawley rats 569.
In summary, the specific cleavage of the haem molecule at the a  -meso bridge 
by haem oxygenase and formation of the bile pigments biliverdin and bilirubin 
is  not  without  significance  or  energetically  wasteful.  These  bile
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pigments,  particularly  bilirubin,  have  since  been  shown  to  possess  quite
\
unique and previously unrecognised beneficial attributes,  i.e.  as antioxidants 
and cytoprotectants.  Further research into the mechanism(s) of these effects 
along with  the development of pharmacological  BVR  active site inhibitors is 
needed to gain a better understanding of the properties of bile pigments and 
modulate their formation for therapeutic purposes.
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1.15  Carbon  monoxide:  history,  metabolism  and  physiological
\
applications
Another  product  of the  haem  oxygenase  reaction  is  the  gaseous  molecule 
carbon  monoxide  (CO)  372.  The toxic,  “silent killer”,  nature  of CO  has  been 
recognised for centuries.  The basis for this conception stems from a number 
of factors: 1. CO is a colourless, odourless, tasteless, non-corrosive gas which 
is insoluble in water and has a similar density to air;  2.  it is produced by the 
incomplete combustion of fossil fuels and is widely studied due to its presence 
in  cigarette  smoke  and  as  a  means  of suicide;  and  3.  global  atmospheric 
levels  are  estimated  to  be  0.19  parts  per  million  (ppm),  90%  of  which  is 
derived from natural sources e.g. the oceans and  microorganisms,  the other 
10%  from  human  activity.  Thus,  avoiding  daily  exposure  to  CO  is  an 
impossible task 57°. The first demonstration that human blood carries a small 
but measurable  amount of CO occurred  over 50 years ago 571.  Subsequent 
studies by Sjostrand and Cobum revealed that CO is constantly formed in vivo 
from the  haem  in  haemoglobin and that certain  pathological conditions,  e.g. 
anaemia  and  polycythaemia,  could  augment  CO  formation  572’576  The 
discovery by Tenhunen et al.  that the microsomal enzyme  haem oxygenase 
was  responsible  for  catalysing  the  aforementioned  reaction  stimulated  a 
deeper interest in the function of endogenous CO production 3 6 3  413.
Under normal circumstances, endogenous CO originating from haemoprotein 
metabolism  is  transported  to  the  lungs  via  binding  to  RBC,  producing 
carboxyhaemoglobin  (COHb).  Within  the  lungs  COHb  equilibrates  with  the 
inhaled  oxygen  and  is  eliminated  from  the  body via  the  breath,  although  a
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small proportion (< 1%) is retained 577.  In a pathological situation, excess CO
\
produces a myriad of toxic effects, the earliest symptom being an increase in 
the level of COHb (10-20%) which interferes with oxygen delivery and use by 
the RBC, as the binding affinity of Hb for CO is ~240 times greater than for 02  
578, while levels of 40-60% are associated with death due to CO binding with 
other  haemoproteins,  e.g.  CYP-450  and  myoglobin  377.  As  CO  is  excreted 
primarily via the lungs, and is derived from haem oxygenase in a 1:1  ratio with 
bilirubin, measurement of CO in the blood (as COHb) and breath can be used 
as an  indicator of haem  degradation  and  bilirubin formation  579  Akin  to the 
outward  manifestations  of bilirubin toxicity,  i.e.  yellowing  of the skin,  excess 
COHb  in  the  blood  gives  a  rosy  hue to the complexion  of the victim  571.  In 
adults, CO is formed at a rate of 0.4 ml/h (16.4 pmol/h) 577.  Normally the rate 
of CO  production  (VCo)  is  relatively  constant  in  males  over time;  however, 
newborns exhibit a higher VCo compared to adults, while in females the VCo 
varies due to the menstrual cycle.  Under pathological conditions the VCo can 
increase in an adult male from 18 to 160 pmol/h 580.  The majority (> 86%) of 
endogenous CO  is  derived from the enzymatic  metabolism of haem  via the 
haem  oxygenase  pathway,  the  remaining  (<  14%)  is  acquired  from  non- 
enzymatic  sources  which  include:  1.  lipid  peroxidation;  2.  photooxidation  of 
natural  or  synthetic  photosensitisers,  e.g.  riboflavin,  bilirubin  and  some 
metalloporphyrins; and 3. intestinal bacteria 571581.
A great deal of information is known about the mechanisms and pathological 
effects  of  CO  poisoning  377-582-583  Similar  to  the  other  products  of  haem 
metabolism, CO was long considered a mere waste product until 1991, when
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Marks  et  at.  published  a  paper  entitled:  “Does  carbon  monoxide  have  a
physiological  function?”  584.  In  their article  the  authors  suggested  that  CO,
\
derived from endogenous haem catabolism,  may play a similar role to NO in 
the regulation of cell function and communication, as both gases have similar 
chemical  and  biological  properties,  i.e.  both  diatomic  molecules  with  a 
complex biochemistry.  The  basis for the latter suggestion was influenced  by 
evidence showing that the other derivatives of haem metabolism, i.e. biliverdin 
and  bilirubin,  were  beneficial 3 8 5   The  idea that CO,  regarded  primarily as a 
toxic agent,  could  have  a  widespread  physiological  function  was  dismissed 
initially.  However,  the  evidence  in  support  of  this  hypothesis  has  grown 
strongly, but questions still remain 585. Since 1991  the number of publications 
confirming a physiological role for CO continues to rise 383  No longer viewed 
as  a  superfluous  by-product of haem  catabolism,  CO  is  now considered  to 
play a central role in many aspects of human health and disease,  e.g.  in the 
vasculature, CNS, reproductive and immune systems 578.
Exogenous CO has been shown to maintain vascular tone in large and small 
arteries  and  directly  relax  vascular smooth  muscle  in  a  reversible  manner 
494,495,586,587  ^  threshold  concentration  of  1   pM  CO was  sufficient to  induce 
these  effects  and  was  not  dependent  upon  the  presence  of  an  intact 
endothelium, unlike the situation of vasorelaxation induced by NO 5,588  In the 
liver, where all the haem oxygenase isoforms are expressed, inhibition of their 
activity  (but  not  NOS  activity)  increased  hepatic vascular resistance,  which 
was  reversed  by  1   pM  exogenous  CO  589.  Moreover,  the  constitutive 
expression of HO-2 or the induction of HO-1  in endothelial cells points to the
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possibility of CO regulating blood pressure in vivo, during normal and stressful
conditions  493-499.  The  vasorelaxation  capability of CO  is  not common  to  all
\
vascular  tissues  as  cerebral  arteries  seem  to  be  refractive  to  CO,  but 
responsive to only NO; the differential response to these two gases in cerebral 
arteries  is  not entirely clear at present 5 78  Situations that lead to  increased 
HO-1  expression,  e.g.  IR  injury and  hypoxia,  are  associated with  increased 
CO production, which would ultimately increase blood flow and oxygenation of 
the affected tissues 495'554-590-5 92  j^e effects of CO on blood pressure may be 
directly through  the  promotion  of vasodilation  or indirectly via  acting  on  the 
nucleus  tractus  solitarius  in  the  brain,  which  leads  to  an  alteration  of 
glutamatergic transmission  and thus a lowering  of blood  pressure 593.  It has 
been  suggested  that  CO  acts  in  conjunction  with  bilirubin,  or  on  its  own 
through  inhibition  of  platelet  aggregation  via  cGMP,  to  prevent  the 
development  of  atherosclerosis,  as  the  expression  of  HO-1  is  induced  by 
many proatherogenic stimuli,  e.g. oxidised LDL, hypoxia and proinflammatory 
cytokines 428594.
The discovery of a neuronal  role for NO led to the suggestion that CO  may 
function  as  a  neurotransmitter,  intercellular  messenger  and  modulator  of 
neuroendocrine  function  207-505-506'595  The  discovery  of  haem  oxygenase 
isoforms,  particularly HO-2, throughout the CNS and  PNS has added weight 
to the hypothesis that CO is an important gaseous neural messenger, while in 
certain  cases  CO  formation  may  substitute  for  decreased  or  absent  NOS 
activity 502-504 596. in the digestive system, mice lacking the HO-2 gene have an 
impaired  NANC relaxation  response in their mysenteric plexus,  a phenotype
120INTRODUCTION
that was  also  observed  in  mice  lacking  NOS  507  In  another study,  it  was
reported  that  CO  and  NO  act  as  coneurotransmitters  in  the  modulation  of
\
neuronal activity in the enteric nervous system 597. These examples illustrate 
the neurotransmitter capacity of CO and support the possibility that CO and 
NO  act  as  coneurotransmitters  in  the  same  neurons.  Certain 
neurodegenerative  disorders,  e.g.  Alzheimer’s  and  Parkinson’s  disease  (AD 
and PD,  respectively), show increased expression of HO-1  protein in regions 
with  senile  plaques  and  neurofibrillary  tangles,  while  amyloid  precursor 
protein,  which  is  postulated to  be a  major cause  in  the neurotoxicity of AD, 
leads  to  inhibition  of  haem  oxygenase  598.  The  precise  function  and 
mechanism  of action  of haem  oxygenase,  and  therefore  CO,  in  these  and 
other  neurodegenerative  disorders  is  unclear  at  present.  Another  possible 
neurological function for CO is in the area of learning and memory as there is 
evidence to support a role for the molecule in long-term potentiation 5 99 600.
Carbon  monoxide  also  seems  to  play  a  role  in  different  aspects  of 
reproduction. During pregnancy, CO maintains normal vascular tone to protect 
against  preeclampsia  and  relaxes  smooth  muscle  in  the  uterus  578  In  the 
placenta,  CO  has  been  suggested  to  control  functional  and  developmental 
maturity as haem oxygenase isoforms are widely distributed in the placenta at 
different  periods  of  gestation  578,601.  The  reproductive  effects  of  CO  are 
conveyed through the  regulation of the endocrine system.  For example,  CO 
inhibits  the  release  of  corticotrophin-releasing  hormone  (CRH),  arginine 
vasopressin  and  oxytocin,  but promotes the  release  of luteinising  hormone- 
releasing  hormone,  all  of which  are  involved  in  the  hypothalamus-pituitary-
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adrenal axis control of pregnancy 602. Within the male reproductive track, CO
originating from specific neuronal populations within the vas deferens may act
\
as a neurotransmitter in the regulation of ejaculation as mice with a targeted 
deletion  of HO-2  exhibit ejaculatory abnormalities  6 0 3   Secondly,  cholinergic 
nerves which  innervate the corpus cavemosum  (CC)  and  spongiosum  (CS) 
contain  haem  oxygenase  isoforms,  which  suggests  a  role  for CO  in  penile 
erection 604.
Another important role for CO is modulation of immune responsive cells, e.g. 
inhibition  of  platelet  activation  and  neutrophil  migration  via  increasing  the 
concentration of cGMP 594 605. These characteristics have been suggested as 
a  mechanism  by  which  CO  promotes  survival  of  transplanted  organs  as 
expression of HO-1  has been shown to protect against chronic rejection 4 8 9  
Furthermore, a direct link between CO formation and suppression of xenograft 
rejection  in  mouse-to-rat  cardiac  and  liver  transplant  models  was 
demonstrated by Soares and coworkers, as inhibition of HO-1  induction with 
SnPP  promoted  an  acute  rejection  response,  whereas  exogenous  CO 
restored  long-term  xenograft survival  4 8 8  4 9 °.  A number of  publications  have 
highlighted  the  antiinflammatory  ability  of  HO-1  derived  CO  to  suppress 
endothelial cell apoptosis via activation of the p38 MAPK signal transduction 
pathway 469-470.
The discovery that CO can bind to the iron within the haem  moiety of sGC, 
thus activating the enzymatic conversion of GTP to cGMP,  suggests that CO 
mediates  its  biological  effects via  a  cGMP  pathway 606  This  mechanism  of 
activating sGC is similar to that elicited  by NO but differs with respect to the
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bonds  formed  and  intensity  of  upregulation  of  the  enzyme  21-178184
Furthermore,  the benzylindazole derivative YC-1  can enhance the activation
\
of  sGC  by  CO  >  4000%  1 8 8 -1 8 9   suggesting  an  endogenous  ‘YC-1  like’ 
molecule may enable a higher degree of activation of sGC by CO akin to NO 
151.  Akin  to  NO,  the  gaseous  molecule  CO  can  exert  its  effects  through  a 
variety  of  sGC-independent  mechanisms.  For  example,  CO  can  enhance 
vasorelaxation  by  directly  activating  Ca2 + -dependent  K+   (Kca)  channels, 
possibly via  a  histidine  residue  on the  extracellular side of the  channel,  but 
without elevating  intracellular Ca2 +   concentration  588'607-608  The  KC a   channel 
complexes comprise  noncovalently linked  a  and  p  subunits which affect the 
electrophysiological and pharmacological properties of the pore. More detailed 
studies  have  revealed  that the  a  subunit is  the  preferred target for CO,  but 
supplementation  with  NO,  which  preferentially  activates  the  p  subunit, 
significantly attenuated the CO-mediated excitatory effect upon the a subunit, 
possibly  via  modulation  of  a  histidine  residue  within  the  latter  subunit. 
However, CO was unable to exert a similar influence on the responsiveness of 
the  p  subunit towards  NO 609.  Selective modulation  of the p38  MAPK signal 
transduction  pathway,  which  in  turn  leads  to  downregulation  of 
proinflammatory cytokines (e.g. TNFa and IL-1 p), may represent an important 
target of CO action 469-471-610.  in contrast to NO which has an affinity for both 
Fe2 +  and  Fe3+  haems,  CO only binds with reduced (Fe2+) haemoproteins 1 8 0  
Although CO may activate sGC and cyclooxygenase (COX), a haemoprotein 
that is involved in prostaglandin synthesis, it has an inhibitory effect upon CYP 
450, catalase, iNOS,  Hb,  Mb, cytochrome c oxidase and NADPH:oxidase 61 1 '
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614. Given the variety of potential targets for CO it is no surprise this gaseous
molecule,  in  analogy  with  NO,  can  exert  an  influence  upon  a  number  of
\
important  homeostatic  functions  namely,  vasoregulation,  inflammation, 
apoptosis, cellular respiration, oxygen transport and drug detoxification.
Although many studies of CO function have employed metalloporphyrins (e.g. 
SnPP)  as  inhibitors  of haem  oxygenase  the  use  of such  agents  has  been 
questioned due to possible inhibition of sGC and  modulation of NOS activity 
451.  Nevertheless,  the  physiological  effects  of CO can  no  longer be viewed 
from  a  purely  toxic  perspective  as  the  molecule  plays  a  vital  role  in  many 
important aspects  of human  health  and  disease.  The weight  of evidence  in 
favour of a physiological role for the haem oxygenase/CO pathway is strong 
and increasing, while at the same time there is a growing understanding of the 
mechanism(s) by which CO exerts its effects. The possibility of harnessing the 
beneficial aspects of CO for therapeutic purposes was brought a step closer 
with  the  discovery  that  carbon  monoxide-releasing  molecules  (CO-RMs) 
liberate CO to elicit direct biological activities 615.  Much knowledge about CO 
has still to be attained and as Barinaga commented  in Science  in  1993,  "... 
this gas is likely to provide fuel to run plenty of labs” 616
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1.16  Iron:  metabolism,  mechanism  of  regulation  and  physiological 
function
Haemoglobin  (Hb) from  RBC represents the principal  endogenous source of 
iron,  one  of the  most  abundant transition  metals  479  When  RBC  die,  after 
about 120 days in the circulation, their Hb is liberated and catabolised further 
to  release  its  four  globin  chains  each  of  which  contains  a  haem 
(Fe-protoporphyrin  IX)  molecule  with  ferric  iron  (Fe3+ )  at  its  centre.  Within 
splenic macrophages the  globin  molecules  are  metabolised  to amino  acids, 
while  haem  is degraded via the  haem oxygenase  pathway to  Fe2+,  CO and 
biliverdin 479  Both free (unbound to protein) iron and haem can be deleterious 
due to their ability to  cause  oxidative  injury and  stimulate  inflammation,  but 
NO and  haem  oxygenase can counteract these adverse effects  365-368-617  |n 
addition,  specific  binding  proteins,  e.g.  haemopexin  (Hx)  for  haem  and 
transferrin (Tf) for iron, can form complexes to make iron inert and deliver it to 
other cells for further metabolism  and  recycling,  thus ensuring  there  is very 
little iron lost through excretion 365-479 618619.
Due to the toxic nature of iron, its metabolism is finely regulated in terms of its 
transport,  processing  and  storage via transcriptional  and  post-transcriptional 
control of the proteins involved at each stage. Among the major players in this 
act are: the plasma carrier protein Tf; transferrin receptors (TfRs); the cellular 
storage  protein  ferritin;  and  lastly,  iron-regulatory  proteins  (IRPs)  of  which 
there are two types (IRP1  and IRP2) 620  When iron levels are low,  IRPs bind 
to the iron response elements (IREs), which are mRNA stem-loops, present in 
the 3’  or 5’  untranslated  region  (UTR) of ferritin  (which  has  1   IRE  in  the  5’
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UTR)  and  TfRs  (which  has  5  IREs  in  the  3’  UTR).  This  has  the  effect  of 
decreasing ferritin  mRNA translation,  but enhancing the stability of the TfRs 
mRNA and  increasing  the availability of intracellular iron  through  uptake  by 
the  TfRs.  The  opposite  occurs  when  iron  is  plentiful  621.  The  human  iron- 
binding  protein  (IBP)  Tf  (MW  80  KDa),  or  apotransferrin  (apoTf)  in  its 
unsaturated  state,  is  a  monomer  glycoprotein  that  has  a  low  capacity,  it 
becomes  maximally  active  with  Fe3 +   iron  atoms  (this  confirmation  is  called 
diferric transferrin),  but high affinity (dissociation constant (Kd)  =  10'23 M) for 
iron 620. The importance of Tf in iron homeostasis is illustrated by the fact that 
absence  of the  gene,  which  is  located  on  human  chromosome  3,  causes 
serve  hypochromic  microcytic  anaemias  (hereditary  atransferrinemia) 
associated with iron overloading 361.
The acquisition of iron from Tf by cells,  especially erythroid cells,  is a finely 
regulated  procedure  (see  Figure  1.17).  The  process  begins  with  binding  of 
diferric Tf to TfRs on the cell surface to form a Tf-TfR complex. Internalisation 
of the complex, via receptor-mediated endocytosis within clathrin coated pits, 
forms an intracellular endosome within which an acidic environment promotes 
the dissociation of iron from Tf to form an apoTf-TfR complex.  Exocytosis of 
the  latter leads to  reattachment of the  TfR to the cell  surface  and  liberates 
apotransferrin  to  collect  more  Fe3+,  thus  maintaining  the  cycle.  The 
natural-associated  macrophage  protein  2  (Nramp2;  also  known  as  divalent 
cation transporter 1   (DCT1)) assists in the transport of iron, which must be in 
the Fe2 +  form as Nramp2 can  not bind  Fe3+, from the endosome 361 •62°  This 
iron  enters  an  enigmatic compartment  known  as  the  intracellular  labile  iron
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pool.  From here it can  be:  1.  incorporated into  low or high molecular weight 
iron  complexes;  2.  modulate the  activity of the  IRPs;  or 3.  taken  up  by the 
intracellular iron storage protein ferritin 361.
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Figure 1.17 Cellular iron uptake by receptor-mediated endocytosis.
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The versatility and reactivity of iron stems from its ability to reversibly change 
its  oxidation  state  from  reduced  (Fe2+)  to  oxidised  (Fe3+)  and  vary  the 
oxidation  potential  and  electron  spin  configuration  of  different  ligands  384. 
Thus,  iron functions as a  protein cofactor of many essential  haemoproteins, 
e.g.  cytochromes,  haemoglobin  and  NOS,  and  participates  in  important 
biological  processes,  e.g.  cellular  respiration,  enzyme  catalysis,  drug 
metabolism and DNA synthesis 384-622. But the same qualities that endow iron 
with positive multifactorial roles also enable it to mediate multiple deleterious 
reactions.  For example,  Fe3 * is  insoluble at neutral pH  and cannot bind with 
0 2 , Fe2 +  can cleave DNA via the Fenton reaction, while both redox states can 
participate in the formation of oxygen radicals (Equation  1.4,  Reactions  1-3) 
and  cause  lipid  peroxidation  618-623-625.  Also,  deficiencies  (anaemia)  and 
excesses (haemochromatosis) of cellular iron exist621626
Fe3 +  + 0 2   — >Fe2++ 0 2   Reaction 1
Fe2 +  +H2 0 2  — ^  Fe3 +  + 0H  +OH  Reaction 2
02 *  + H2 0 2  — >  0 2  + OH  + OH  Reaction 3
Equation 1.4 Examples of iron-mediated oxygen radical formation
The  Fenton  reaction (Reaction 2), which produces the hydroxyl 
radical  (OH*),  can  be  combined with  Reaction  1   in  the  Haber- 
Weiss reaction (Reaction 3).
The cytotoxic potential of free iron is kept to a minimal by the actions of haem 
oxygenase and ferritin 484-627-628. This cytoprotective feature can be modulated 
by nitric oxide,  haem  and  oxidative stress  617-629-630  Akin to the other haem
128INTRODUCTION
oxygenase pathway products,  bilirubin and CO, the physiological role of iron 
has also generated considerable interest. The principal function of Fe2 +  is its 
reuse in new haemoproteins. Animal studies of iron metabolism reveal that a 
high proportion of mice which are genetically deficient in HO-1  protein 
(HO-1"7 ') die in utero, those that survive exhibit a number of pathologies,  e.g. 
severe anaemia, due to low serum iron, and increased sensitivity to oxidative 
stress 369429. The significance of these animal studies was reinforced with the 
first report of human HO-1  deficiency in a boy aged six 370  The boy exhibited 
similar  features  to  the  mice,  i.e.  anaemia,  growth  retardation,  tissue  iron 
deposition, and increased sensitivity to oxidative stress, and died prematurely.
Exposure of fibroblasts to stress inducers,  e.g.  staurosporine,  etoposide and 
serum  deprivation,  was  tolerable  by  wild  type  cells,  but  caused  apoptotic 
death  in  HO-1'7 '  cells.  However,  transfection  of  the  HO-1  gene  or  iron 
chelation  therapy  protected  cells,  this  led  the  authors  to  conclude  that 
regulation  of  intracellular  iron  efflux  was  the  mechanism  by  which  HO-1 
protects cells 485. Although haem oxygenase cannot pump iron from cells the 
coexpression of a specific iron ATPase pump that is inducible in tissues with 
high  levels  of HO-1  protein  activity suggests that both factors  cooperate to 
exert  cytoprotection  504  These  examples  illustrate  that  production  and 
regulation of cellular iron  is another important cytoprotective aspect of haem 
oxygenase.
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1.17  Haem oxygenase and nitric oxide in cardiomyocytes
The oxidative enzymes NOS (eNOS, iNOS and nNOS) and haem oxygenase 
(HO-1  and HO-2) share a number of similarities as well as differences  180 504. 
For  instance,  they  both  utilise  NADPH  as  an  electron  donor  to  generate 
bioactive  gaseous  end  products,  NO  (from  NOS)  and  CO  (from  haem 
oxygenase),  which  can  modulate  similar cellular targets  to various  degrees 
32,372,609  gQth  constitutive  and  inducible  biosynthetic  enzymes  exist in  each 
case  83,364,  however,  the  effects  of their inducible  forms  are  dissimilar,  i.e. 
iNOS  generates cytotoxic  NO to  kill  other cells  631,  whereas  HO-1  exerts  a 
cytoprotective influence via its products bilirubin and CO 428 and its ability to 
eliminate  iron  from  cells  485  Their  cellular  and  subcellular  locations  often 
coincide,  e.g.  in  the  nervous,  reproductive,  digestive  and  vascular systems 
372,595,597,604,632,633^   0f serve as a substitute for the other in locations where one 
is absent or weakly expressed 503- 634- 635.  |n addition, recent publications have 
highlighted an  intimate  link between  HO-1  and  NO in the context of cellular 
homeostasis and regulation of each others expression 373-636; while Otterbein 
et al.  have suggested that HO-1  may serve as a therapeutic funnel through 
which the beneficial aspects of NO/NOS are mediated 637.
The  haem  oxygenase  enzymes,  along with  their products  bilirubin  and  CO, 
have  been  detected  in  different cardiac cell types,  including  cardiac muscle 
cells (cardiomyocytes), where they exert positive effects 536-634-638. Specifically, 
HO-1  is targeted to the  intercalated disc area and sarcoplasmic reticulum of 
the cardiomyocytes 639, while HO-2 is present in the sarcolemma region where 
is  serves  as  a  constant  source  of  bilirubin  and  CO  63S .  The  physiological
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importance  of  the  haem  oxygenase  system,  in  particular  HO-1,  has  been
documented  in recent reports of cardiac pathologies,  e.g.  hypoxia,  l/R injury
\
and myocardial infarction  181 ■ 590-640.  studies of HO-1  in  cardiomyocytes have 
used  similar  models  to  illustrate  the  protective  influence  of  HO-1  and  its 
products  bilirubin  and  CO.  For  example,  Lakkisto  et  al.  suggested  that 
induction  of HO-1  shortly after a  myocardial  infarction  may  be  an  important 
adaptive  mechanism 639.  Loss or damage to cardiomyocytes  in  response to 
ROS and  RNS can,  if left unchecked,  be the catalyst for a variety of cardiac 
pathologies 641-643  in addition to its cytoprotective influence in other cell types 
HO-1  has  been  shown  to  be  beneficial  in  cardiomyocytes.  In  response  to 
metalloporphyrins,  e.g.  cobalt  and  iron  tetrakis-(4-benzoic  acid)  porphyrin 
(CoTBAP  and  FeTBAP,  respectively),  HO-1  inhibited  doxorubicin  (DOX)- 
induced  apoptosis  and  promoted  ROS  scavenging  in  cardiomyocytes  644. 
Using  cultured  neonatal  rat  cardiomyocytes  Luss  and  coworkers 
demonstrated  that  inhibition  of  proteasomes,  intracellular  multisubunit 
complexes  that  regulate  the  degradation  of regulatory  as well  as  damaged 
proteins,  with  the  proteasome  inhibitor  carbobenzoxyl-leucinyl-leucinyl- 
leucinal  (MG132)  led  to  activation  of  p38  MARK  concomitant  with  HO-1 
induction, and thereby protection against hyperthermic and oxidative injury645 
Enhanced  expression  of  HO-1  in  vivo  was  correlated  with  protection  of 
cardiomyocytes against l/R  injury and  improved recovery of cardiac function 
646.  Exposure  of cardiomyocytes  to  acute  and  chronic episodes  of  hypoxia 
leads to increased expression of HO-1  mRNA,  protein and augmented haem 
oxygenase  activity  and  bilirubin  levels,  all  of  which  are  associated  with  a 
greater  degree  of  cardioprotection  and  responsiveness  towards
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hypoxia-induced  stress  467-647  Conversely,  mice  lacking  the  HO-1  gene
exhibited a  greater degree  of cardiomyocyte  apoptosis  and  developed  right
\
ventricular  dilatation,  compared  with  their wild  type  counterparts,  following 
exposure to chronic hypoxia in vivo 648.
Given their ubiquitous  nature all three isoforms  of  NOSs  (eNOS,  iNOS  and 
nNOS)  have  been  identified  in  cardiomyocytes  where  they  serve  as  a 
constant source of NO 242 649. Normally NO functions as a paracrine molecule, 
i.e.  it is made in one cell and diffuses outwards towards its cellular targets in 
other neighbouring cells 650;  however,  cardiomyocytes are unique in that the 
source (NOS) and key targets (e.g. sGC,  K+  channels, iron centres and thiols) 
of NO reside within the same cell. Therefore, NO can function as a paracrine, 
autocrine and intracrine molecule in the regulation of different cardiomyocyte 
functions 154.  For example,  eNOS has been  identified in sarcolemma and T- 
tubule  membranes  115118  where  it  exerts  direct effects  over cardiomyocyte 
contraction, relaxation and heart rate 1 40. Neuronal NOS, which is localised to 
the SR, can assist in the regulation of these physiological aspects of myocytes 
as  it  participates  in  Ca2+   handling  via  inhibition  of the  RyR  within  the  SR 
membrane 259-261-264-651.  The  high output and  Ca2+ -independent  NOS  (iNOS) 
which  is  expressed  by  myocytes  during  inflammatory  responses  (e.g. 
cytokines,  sepsis,  heart failure)  serves  as  a  continuous  source  of  NO  that 
negatively modulates myocyte function274
Under  pathological  conditions  (e.g.  l/R  injury,  heart  failure  and  heart 
transplantation)  NO/NOS  may  exert  beneficial  and  adverse  effects  in 
myocytes  154  An  increase  in the expression and  activity of eNOS and  iNOS
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has been observed in the early (up to 30 min) stage of ischaemia (or hypoxia) 
272,652  p u rp o Se  of this upregulation is to maintain coronary blood flow and 
myocyte function,  lessen  the  concentration  of deleterious  ROS,  as well  as 
inhibit the build up of and infiltration (via increased vascular permeability) by 
inflammatory  cells  154-284 653  Upregulation  of  HO-1  expression  and  CO 
release,  in  response  to  increased  NO,  can  serve  as  another  adaptive 
response in myocytes 286-590-654.  However, reperfusion can rapidly reverse the 
above  responses  due  to  the  build  up  of  ROS,  which  inactivates  NO,  and 
deficiency of substrate and cofactor availability 154  Haem oxygenase may also 
serve as a positive regulatory of myocyte NO production 452 636-655 656 and vice 
versa 657.  In addition,  expression of HO-1  and  its  products  may compensate 
for lack of NO production 4".
The above  examples  illustrate that both  NOS/NO and the  haem  oxygenase 
system  exert  important  roles  within  cardiomyocytes.  It  is  well  known  that 
oxidants can be potent catalyst for this enhancement of HO-1  417, in addition, 
the  importance  of  RNS  as  mediators  of  HO-1  is  gaining  credence  373. 
Nevertheless, little is know at present about the interaction between these two 
important regulatory systems within cardiomyocytes, therefore, this Thesis will 
endeavour to examine this association.
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1.17.1  Hypothesis and aims
The ability of HO-1  to counteract oxidative stress is well established 381, while
\
a  number  of  recent  reports  have  documented  a  link  between  RNS  and 
activation of the haem oxygenase pathway 373636  This Thesis will  utilise cell 
culture,  molecular  biology  and  biochemical  techniques  to  elucidate  the 
biochemistry and  mechanisms  responsible for HO-1  induction  by  nitrosative 
stimuli. The hypothesis for this work is:
Increased  haem  oxygenase activity and  induction  of HO-1  protein  and 
gene expression  in  response to  reactive  nitrogen  species,  particularly 
NO*, attenuates nitrosative stress in cardiac ceils.
To verify this theory a number of objectives were set:
(i)  Establish  that  Angeli’s  salt  (AS),  a  NO*  generator,  activates  the 
haem oxygenase pathway.
(ii)  Dissect the mechanism of AS-mediated HO-1 induction.
(iii)  Investigate the  mechanism and  identify possible  molecular targets 
which  lead  to  increased  haem  oxygenase  activity  and  HO-1 
expression in response to cellular stress.
(iv)  Utilise bilirubin, an end product of the haem oxygenase pathway, as 
an effective means to counteract nitrosative stress.
(v)  Examine  the  potential  of  a  clinically  used  NO  donor,  GTN,  to 
promote activation of the haem oxygenase pathway.
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2  MATERIALS AND METHODS
\
2.1  Materials and equipment
Hemin (ferriprotoporphyrin IX chloride), bilirubin and biliverdin were purchased 
from  Porphyrin  Products  Inc.  (Logan,  Utah,  USA).  The  NO  donors 
DeaNONOate  (DeaNO)  and  DetaNONOate  (DetaNO)  as  well  as  the  NO' 
liberator, Angeli’s salt (AS), along with the NO trapping agent carboxy phenyl- 
tetramethyl imidazolineoxyl-oxide (potassium salt) (C-PTIO), were all obtained 
from Alexis Biochemicals (Nottingham,  UK). All other reagents were acquired 
from Sigma (Dorset, UK) unless otherwise stated.
Solutions were pHed using a pH  meter (Fisher Scientific UK,  Loughborough, 
UK)  and  a  Russell  combination  pH  electrode  (Thermal  Russell  Ltd.,  Fife, 
Scotland).  Samples  were  weighed  on  electronic  balances  (Sartorius  AG, 
Goettingen, Germany). A NO meter (ISO-NO Mark II), sensor (ISO-NOP) and 
NO  chamber  (NOCHM)  were  purchased  from  World  Precision  Instruments 
(Sarasota, FL, USA). Consumables were acquired from Fisher Scientific UK.
2.2  Cell culture
2.2.1  Preparation and maintenance of the cardiomyocytes
Rat  H9c2  cardiomyocytes  were  obtained  from  American  Type  Culture 
Collection  (ATCC,  Manassas,  Virginia,  USA).  The  H9c2s  are  a  subclone  of 
the original cell line derived from embryonic BD1X rat myocardium tissue and 
exhibit  many  of the  properties  of skeletal  muscle.  The  morphology  is  of  a 
myoblastic variety  in  which  cells fuse to form  multinucleated  myotubes  and
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respond to ACh stimulation.  Cardiomyocytes were  handled  aseptically at all 
times  and  cultured  in  fresh  complete  Dulbecco’s  modified  Eagle’s  media 
(DMEM) which was supplemented with 10% foetal bovine serum (FBS), 4 mM 
L-glutamine,  all  from  Sigma,  and  100  U/ml  of  penicillin-streptomycin 
(Invitrogen Life Technologies Ltd.,  Paisley,  Scotland).  Upon  receipt of a  1   ml 
vial of H9c2 cardiomyocytes, cells were quickly thawed in a water bath (37°C) 
by gentle agitation.  The contents were transferred carefully to  a  75 cm2 cell 
culture flask (Sarstedt Ltd., Leicester, UK) containing 9 ml of complete media, 
followed by gentle swirling to disperse the cells.  The flask was incubated  at 
37°C in an incubator in a 95% 0 2 /5 % CO2 environment. The following day, the 
media  containing  the  cytoprotective  agent  was  removed  and  replaced  with 
fresh complete media. Subsequent media changes took place every two days.
In this Thesis an established cell  line (H9c2) was used  instead of a primary 
cell line because of its convenience and unlike the latter the H9c2s were more 
stable and less labour intensive to maintain. Although the product description 
highlights  that  H9c2s  are  similar  to  skeletal  muscle  the  cells  maintain  a 
myoblastic  morphology  akin  to  myocytes.  To  prevent  any  possibility  of  a 
switch in phenotype, i.e. to skeletal muscle, cells were utilised in experiments 
up to passage 26, as a greater passage number may lead to inconsistency of 
results.  Furthermore,  repeated  use of this cell line within the above  passage 
limit provided consistent and repeatable results.  In addition, the mechanisms 
examined  in  this  Thesis  were  replicated  in  other cell  lines,  e.g.  endothelial 
cells,  smooth  muscle,  keratinocytes  and  macrophages,  by  our  group 
suggesting  a  generalised  response towards the  agents  administered.  Thus,
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the H9c2 cells were utilised to ascertain the effect, and potential mechanism, 
of RNS upon the haem oxygenase system in cardiac cells.
2.2.2  Subculturing the cardiomyocytes
In order to maintain the cell line and prevent loss of the myoblastic cells the 
cardiomyocytes were  subcultured  every 3-4 days when  they  reached  about 
70%-80% confluency. The old media was discarded and replaced with  10 ml 
of warm sterile phosphate buffered saline (PBS) (10X), without Ca2+  and Mg2 +  
(Invitrogen  LifeTechnologies Ltd.). After a brief wash the latter was removed 
and  replaced  with  4  ml  of  warm  0.25%  (w/v)  trypsin-0.02%  (w/v) 
ethylenediaminetetraacetic  acid  (EDTA)  solution  (Sigma).  The  flasks  were 
placed  in the  incubator for a few minutes to allow the trypsin  to detach the 
cardiomyocytes from the base of the flask and each other. The contents of the 
flasks were transferred carefully to individual  15 ml tubes containing  6  ml  of 
warm (37°C) fresh complete DMEM. After centrifuging (1000 x g) for 5 min at 
room  temperature  in  a  bench-top  centrifuge  (MSE  Harrier  15/80,  Sanyo 
Gallenkamp Pic.,  Leicestershire,  UK) the supernatant was discarded and the 
pellets resuspended gently in sufficient DMEM to prepare a new set of flasks, 
final volume 10 ml, in a 1   to 4 ratio. The flasks were returned to the incubator 
to allow the cells to grow.  Cells were subcultured until  passage  number 26, 
after which time a  new vial was subcultured.  In some cases cardiomyocytes 
were seeded  into 24 well  plates  (Sarstedt Ltd.)  in a  ratio of three plates  per 
flask. The procedure is similar to that just described with minor variations. The 
pellets were  gently  resuspended  in  fresh  complete  DMEM  (6  ml).  The  cell 
suspension (4 ml) was dissolved in a sufficient volume of DMEM so that the
137MATERIALS AND METHODS
final volume in each well was 1   ml. Cells were ready in 2-3 days, thus media 
changes were not necessary.
\
2.2.3  Preparation of agents and treatment of cardiomyocytes
Stock  solutions  (50  mM)  of  AS  (a  source  of  NO'),  DeaNO  and  DetaNO 
(sources  of  NO)  were  prepared  in  0.01  M  NaOH  according  to  the 
manufacturer’s  instructions.  A  100  mM  stock  solution  of  A/-acetylcysteine 
(NAC) was prepared with 5% (v/v) 2 M NaOH. Stock solutions (50 mM) of the 
NO scavengers,  2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-oxyl  3- 
oxide  (potassium  salt)  (C-PTIO)  and  hydroxocobalamin  (HCB)  Vitamin  Bi2 a  
acetate  salt,  were  dissolved  in  ethanol  and  dH20,  respectively.  A  stock 
solution of copper sulphate (CuS04)  (1 0 mM) was prepared with sterile  PBS 
(10X). All of the agents were prepared fresh in opaque Eppendorfs, or a 15 ml 
tube wrapped in foil for CuSO^ and placed on ice until required.  Hemin (ferri- 
(Fe3+ )protoporphyrin  IX)  (Frontier  Scientific  Europe,  Camforth,  Lancashire, 
UK) was prepared as a 2 mM stock using 0.5% (v/v) NaOH (2 M), phosphate 
buffer (2 mM MgCI2 and  1 0 0 mM KH2P0 4 , pH 7.4) and dH20.
The agents were incubated with confluent cardiomyocytes in 75 cm2 flasks or 
24 well  plates,  final  volumes  1 0  ml  and  1  ml,  respectively,  within  different 
vehicles. The vehicles used were fresh complete DMEM and Dulbecco’s PBS 
(DPBS),  modified  with  Ca2 +   and  Mg2 +   (Sigma).  Decomposed  AS  was 
prepared by placing the agent at 37°C for 1   h in one or both vehicles. Where 
DMEM  was  the  vehicle,  both  freshly  prepared  and  decomposed  AS  were 
applied to the cells for the  required  duration. When  DPBS was  used as the
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vehicle,  fresh  and  decomposed AS were preincubated with  the  cells for  15 
min,  removed  and  replaced  with  fresh  complete  media  for  the  remaining 
duration.  A variety of concentrations and durations  (0-24  h) were  used with 
each  experiment.  Negative controls, which  consisted  of vehicle alone,  were 
included in each experiment.
2.2.4  Cell metabolism assay
In  order  to  examine  the  metabolic  effect  of  the  agents  applied  to  the 
cardiomyocytes  a  cell  metabolism  assay  using  the  reduction-oxidation 
(REDOX)  indicator Alamar blue  (Serotec,  Oxford,  UK) was  performed.  This 
reagent  contains  various  stabilising  agents  along  with  the  non-fluorescent 
tetrazolium  blue-based  dye  resazurin,  which  upon  oxidative  metabolism  by 
metabolically active cells yields the reduced product resorufin. The latter has a 
pink/red colour and the extent of colour change in the growth  media can  be 
measured fluorometrically or colourometrically, the former method being more 
sensitive 658-659.  Alamar  blue  has  been  used to  assess  cytotoxicity,  viability 
and  antimicrobial  efficacy in  both  animal,  bacterial  and  plant cells  65866°-663. 
Previous  studies  in  eukaryotic  cells  have  revealed  that  Alamar  blue  can 
undergo  reduction  within  living  cells  via  cytosolic,  microsomal  and 
mitochondrial  enzymes,  e.g.  alcohol  and  aldehyde  oxioreductases, 
NAD(P)H:quinine oxidoreductase, flavin reductase and NADH dehydrogenase 
and cytochromes,  as  a  result the  quantifiable  reduction  product resorufin  is 
released into the medium  658-664  Given that Alamar blue has a positive redox 
potential  (+  0.38  V)  it  can  be  reduced  by viable  cells without the  need  for 
energy expenditure,  therefore,  in  mitochondria the reagent acts between the
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final reduction of 0 2 and cytochrome  c oxidase by substituting for  0 2  as an 
electron acceptor without affecting tt\e activity of the respiratory chain as the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl  tetrazolium  bromide  (MTT)  assay 
does 661.  In addition, the indicator is not affected by antioxidant or free radical 
scavenging enzymes in the media and is stable in reduced media under C02 
incubation 660  It has been suggested that FBS might interfere with the Alamar 
blue readings when  it is coincubated with a treatment or during prolonged (> 
24 h) incubation in the medium.  However, this can be overcome by applying 
the Alamar blue after the compound incubation period in fresh media and for 
no  longer  than  6   h  658  In  addition,  Rasmussen  et  al.  have  observed  no 
interference with  Alamar blue  reduction  in the  presence  of DMEM  665  As a 
decrease  in  Alamar  blue  fluorescence  or  absorbance  is  an  indication  of 
diminished  metabolic  activity,  and  vice  versa,  the  assay  can  serve  as  a 
sensitive  means  to  monitor  intracellular  cytoplasmic,  mitochondrial  and 
nuclear changes,  all  of which  are sensitive to imbalances of the  intracellular 
redox state.
Cardiomyocytes, which were seeded into 24 well plates according to Section 
2.2.2,  were  incubated  with  the  required  agent(s)  in  fresh  complete  DMEM 
(total volume  1   ml  per well).  After mixing  by gentle swirling,  the plates were 
placed in the incubator for the duration required. At the end of the incubation 
period  the  media  was  removed  and  replaced  with  1  ml  of fresh  complete 
media containing 10% (v/v) Alamar blue. The plates were then returned to the 
incubator for 4-5  h  until  a colour change  appeared. Addition and  removal of 
media were performed carefully so as not to dislodge any cells from the base
140MATERIALS AND METHODS
of  the  wells.  After  4-5  h,  200  pi  of  each  sample  was  transferred  to  its
respective well of a microtitre plate and the absorbance was read at 570 nm
\
and 600 nm against a blank set of wells containing DMEM  plus 10% Alamar 
blue, in a microplate reader (Versamax,  Molecular Devices Ltd., Wokingham, 
UK).  The  difference  between  the  absorbance  at  600  nm  and  570  nm  was 
expressed as a percentage of the control group.
2.3  Biochemical procedures
2.3.1  Collection of cardiomyocytes
For this procedure, all reagents and collecting tubes (15 ml) were kept on ice. 
At the end of an experiment the media was discarded and cells were washed 
with 10 ml of ice-cold non-sterile PBS (10X). After a brief wash the latter was 
discarded and replaced with 5 ml of ice-cold non-sterile PBS (1X) (non-sterile 
PBS 10 X diluted 1:10 with dHaO). Cells were gently scraped from the base of 
the flasks with a plastic scraper (policeman) (Thomas Scientific, Swedesboro, 
New  Jersey,  USA),  followed  by  careful  transfer  to  pre-labelled  collecting 
tubes.  A further  5  ml  of  PBS  (1X)  was  added  to  each  flask to  collect  any 
residual  cells  and  then  transferred  to  its  respective  tube.  The  tubes  were 
centrifuged (1000 x g) for 5 min at room temperature to pellet the ceils. The 
supernatants  were  discarded  and  the  tubes  inverted  on  tissue  paper  to 
remove  any  excess  of  liquid.  The  cell  pellets  requiring  haem  oxygenase 
activity  analysis  (Section  2.3.4)  were  resuspended  in  550  \i\  of phosphate 
buffer (2 mM MgCI2 and  1 0 0  mM KH2P04, pH 7.4). Samples for HO-1  protein 
analysis  (Section  2.4.2)  were  resuspended  in  150  y\  of  PBS  (pH  7.4), 
containing  1%  (v/v) Triton  X-100,  to  lyse  the  cells.  In  both  cases,  samples
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were  dissolved  fully  using  a  bench-top  vortexor  and  stored  at  -70°C  until 
required for analysis.
\
2.3.2  Protein determination in cells and tissues
The  DC  Protein  Assay  kit  (Bio-Rad  Laboratories  Ltd.,  Hemel  Hempstead, 
Hertfordshire,  UK) was  used to determine  protein  concentration.  A standard 
curve was prepared using serial dilutions  (0  to  2 .8  mg/ml) of a bovine serum 
albumin (BSA) standard (Bio-Rad  Laboratories Ltd.),  prepared in triplicate,  in 
phosphate buffer (pH 7.4).  The absorbance readings at an optical density of 
750  nm  (OD750)  were  plotted  against  their  respective  protein  standard 
concentrations  (see  Figure 2.1  for a  representative  plot).  The  procedure for 
protein determination in cell and tissue samples was performed as follows. A 
100 pi aliquot of the cell suspension and a blank of phosphate buffer or PBS 
Triton  X-100  was  added  to  10  ml  polystyrene  tubes  (Sarstedt  Ltd.).  When 
tissue samples  were  used,  the aliquot was  diluted  1 :1 0  in  phosphate  buffer 
(pH 7.4). To each tube, 500 pi of A’ (20 pi of Reagent S per ml of Reagent A) 
was  added,  then  vortexed  briefly without frothing.  Next,  4  ml  of  Reagent  B 
was added to each tube,  mixed well then left at room temperature for 2 0  min 
before  reading  the  OD750  against  the  blank  using  a  UVikon  81 OP 
spectrophotometer (Tegimenta AG,  Switzerland).  A  numerical value  (mg/ml) 
for the protein concentration  in the unknowns was derived  by multiplying the 
respective O D 750 by the slope of the standard curve (Equation 2 .1).
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Figure 2.1 Representative standard curve for protein determination.
Serial dilutions of bovine serum albumin (BSA) (0-2.8 mg/ml) were 
prepared  according  to  Section  2.3.2.  The  O D 7 5 0   was  plotted 
against its respective protein concentration.
OD7 50 x Slope of standard curve
Equation 2.1 Calculation of protein concentration
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2.3.3  Preparation of liver cytosol and liver microsomes
A male Sprague Dawley rat (250-300 g) was used as a source of liver cytosol. 
Following sacrifice by anaesthetization with phenobarbital Lethobarb® sodium 
BP (500 |jl. i-P ) and cervical dislocation, a 50 ml syringe was used to perfuse 
cold  (4°C)  buffer  (1.15%  (w/v)  KCI)  through  the  liver  lobes  to  remove  any 
residual blood,  while  clotted  tissue was discarded.  The  organ was weighed, 
finely  chopped  with  a  scissors  and  homogenised  in  2-3  volumes  of 
homogenising  buffer (20  mM  Tris-HCI,  pH  7.4,  containing  1.15%  (w/v)  KCI), 
followed  by partition  among  a  set of polyallomer centrifuge  tubes  (Beckman 
Coulter Ltd.,  High Wycombe,  UK). After centrifuging (5,000 x g) for 20 min at 
4°C  in  a  refrigerated  ultracentrifuge  (Optima  LE  80,  Beckman  Instruments, 
Palo Alto,  California,  USA)  the  supernatant was  retained  and  recentrifuged 
(105,000 x g) for 90 min at 4°C.  Following each centrifugation, the turbid lipid 
layer was removed with a Pasteur pipette. The supernatant was collected, and 
protein and haem oxygenase activity were measured as described in Sections 
2.3.2 and 2.3.4, respectively, then aliquoted and stored at -70°C.
The preparation of liver microsomes is similar to that for liver cytosol with the 
following variations.  The rat was pre-treated with hemin  (50  mg/kg,  i.p.) 24 h 
beforehand  to  induce  HO.  The  lobes  were  perfused  with  cold  (4°C)  saline 
(0.9% (w/v) NaCI) and homogenised in 5 volumes of sucrose solution (0.25 M 
sucrose,  0.05  M  Tris-HCI,  pH  7.4)  then  centrifuged.  After  the  last 
centrifugation step, the resulting microsomal pellet was resuspended gently in 
1   ml of phosphate  buffer (pH  7.4)  and  protein  and  haem oxygenase activity 
were determined according to Sections 2.3.2 and 2.3.4, respectively, followed
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by storage at -70°C.
2.3.4  Determination of haem oxygenase activity
Stock  solutions  of  the  assay  reagents,  i.e.  glucose-6-phoshate  (G6P)  (20 
mM),  glucose-6-phoshate  dehydrogenase  (G6PDH)  (50  U/ml)  and  NADPH 
(40 mM), were prepared with  phosphate buffer (pH  7.4) and stored  at -70°C 
until required. The NADPH was wrapped in foil as it is light sensitive. Hemin (2 
mM) was prepared freshly for each assay as described in Section 2.2.3.  Rat 
liver cytosol and liver microsomes were prepared according to Section 2.3.3.
The samples,  collected  according  to  Section  2.3.1,  were  disrupted  by three 
rounds  of freeze-thawing  (-70°  to  37°C),  followed  by  sonication  for  15  sec, 
then  placed  on  ice.  A  100  pi  aliquot was  retained  for protein  determination 
according to Section 2.3.2. To a set of glass tubes, which were maintained on 
ice,  the  cell  suspension  (400  pi)  was  added  to  the  reaction  mixture  (final 
volume,  900  pi) containing:  phosphate  buffer (pH  7.4),  20  pM  hemin,  2  mM 
G6P,  0.5  U/ml  G6PDH,  3  mg  of  rat  liver cytosol,  as  a  source  of  biliverdin 
reductase (BVR), and 0.8 mM NADPH. The negative and positive controls (rat 
liver microsomes)  contained  proportionate volumes  of phosphate  buffer (pH 
7.4)  instead  of  the  cell  suspension.  The  tubes  were  vortexed  well  and 
incubated  in  the  dark  for  1   h  at  37°C.  The  activity  of  the  cytosolic  and 
microsomal fractions was verified  by replacing  hemin  with  biliverdin  (1  mM), 
while the samples were incubated in the dark for 30 min at 37°C. The reaction 
was  terminated  by  addition  of  chloroform  (1  ml),  followed  by  thorough 
vortexing and centrifuging (200 x g) 2-3 times for 5 min at room temperature
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using a bench-top centrifuge until three distinct layers were formed.  Using  a 
quartz cuvette  and  the  UVikon  81 OP  spectrophotometer the  absorbance  (at 
464  nm  and  530  nm)  of  the  lower  organic  layer,  which  contains  bilirubin 
(extinction  coefficient  (e)  for bilirubin  in chloroform,  40  mM‘1 cm'1),  was  read 
against a  blank  of chloroform.  Haem  oxygenase  activity was  expressed  as 
picomoles of bilirubin formed/mg protein/h using Equation 2.2.
pmoles bilirubin  ( AOD (OD464 - OD530)  /  ^
— — .  .  -  — -  =  ---------— 7^  —  /mg protein  x 106
mg protein in 60 min  v  40  /   )
Equation 2.2 Calculation of haem oxygenase activity
2.4  Molecular biology procedures
2.4.1  Preparation of nuclear extracts*
In the  cytosol  the  redox-sensitive transcription factor Nrf2  lies  dormant as a 
result of its association with Keapl  6 66  In response to electrophiles, or agents 
that modify thiol  groups,  e.g.  nitrosants,  the  repression  of Nrf2  by  Keapl  is 
lost and the former migrates to the nucleus where it activates the transcription 
of defensive genes, e.g. HO-1 465  In order to determine the responsiveness of 
Nrf2 towards nitrosants nuclear extracts were prepared as follows. Cells were 
washed twice with  PBS (1X) then  harvested in  1   ml of PBS (1X) followed by 
centrifugation (800 x g) for 3 min at 4°C. The resulting pellet was resuspended 
carefully in 200 pi of cold  Buffer A (10 mM  Hepes (pH 7.9),  10 mM  KCI,  0.1 
mM  EDTA,  0.1  mM  EGTA,  final  volume  950  pi,  followed  by  10  pi  of 0.1  M
1   All nuclear extracts were kindly prepared by Martha Hoque, Dept, of Surgical Research, NPIMR.
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dithiothreitol  (DTT)  and  40  pi  of  complete  protease  inhibitor  cocktail  (PIC) 
(Roche,  Mannheim, Germany)). Next, the pellet was placed on ice for 15 min 
to allow the cells to swell then 15 pi of 10% Nonidet P-40 was added followed 
by a 10 sec vortex-mix and centrifuging (800 x g) of the resulting homogenate 
for 3 min at 4°C.  The supernatant was discarded and the nuclear pellet was 
resuspended in 30 pi of cold  Buffer B (20 mM  Hepes (pH 7.9), 0.4 M NaCI,  1  
mM EDTA,  1   mM EGTA, final volume 950 pi, followed by 10 pi of 0.1  M DTT 
and 40  pi  of complete  PIC).  The  pellet was  placed  on  ice  for  15  min  and 
vortex-mixed for 10-15 sec every 2 min. After a final centrifugation (10000 x  g) 
for 5  min  at 4°C the  supernatant,  which  contains  the  nuclear proteins,  was 
retained  and  stored  at  -70°C  until  further  analysis  of  the  Nrf2  protein  by 
Western blot (Section 2.4.2) was performed.
2.4.2  Western blot protein analysis
Total  protein  of  each  sample  was  calculated  as  per  Section  2.3.2.  An 
appropriate  volume  of  each  unknown  sample  was  combined  with  loading 
buffer  (Laemmli  buffer  (Bio-Rad  Laboratories  Ltd.)  containing  5%  (v/v) 
p-mercaptoethanol), total volume 30 pi, so that the final concentration loaded 
onto each  lane was equal to 30-50  pg.  The  HO-1  positive control  (Bioquote 
Ltd., York,  UK) was diluted to 1   pg/ml in loading buffer. Samples were pulsed 
for 20-30  sec  on  a  bench-top  microcentrifuge  (MSE  Microcentaur,  Sanyo 
Gallenkamp  Pic.,  Leicestershire,  UK) followed  by  denaturing  of the  proteins 
for  10  min  at  100°C  on  a  heating  block  (Techne  DB2A,  Techne  GmBH, 
Germany). The molecular weight marker (MWM) (Invitrogen LifeTechnologies 
Ltd.)  was  not  heated  but  placed  on  ice  until  required.  After  heating,  the
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samples were re-pulsed and  15-30 pi of samples,  MWM  and  positive control 
was loaded carefully using  gel  loading  tips  (Fischer,  UK)  into  the wells  of a 
12% Tris-glycine Ready gel (Bio-Rad Laboratories Ltd.).  Electrophoresis was 
carried out at room temperature in a tank containing running buffer (0.025 M 
Tris,  0.192  M  glycine,  0.1%  (v/v)  SDS)  (Fischer,  UK)  using  the
Mini-PROTEAN®  II  system  and  Power-Pac  300  power  supply  (Bio-Rad 
Laboratories Ltd.) at a constant voltage of 110 V until the  loading  buffer had 
migrated to, but not beyond, the base of the gel.
The  subsequent  procedures  were  carried  out  using  the  Mini  Trans-Blot® 
electrophoretic transfer cell  (Bio-Rad  Laboratories  Ltd.)  and gloved  hands to 
avoid contamination of membranes.  While the gel was  running  appropriately 
sized  sheets  of  nitrocellulose  membrane  45  pm  pore  size  (Amersham 
Biosciences  UK  Ltd.,  Little  Chalfont,  Buckinghamshire, UK)  and  3MM
Whatman™  blotting  paper were  cut and  presoaked  in  dH20 and cold  (4°C)
transfer  buffer  (0.025  M  Tris,  0.192  M  glycine,  0.1%  (v/v)  SDS,  20%  (v/v)
methanol) for 10 and 5 min, respectively. After electrophoresis was completed 
a ‘gel sandwich’  (see  Figure 2.2 for assembly) was  prepared  upon the clear 
(positive electrode) side of a gel cassette within a shallow vessel flooded with 
transfer  buffer.  After  removing  any  air  bubbles  the  cassette  was  closed 
securely via  the  latch  and  placed  into  the  electrode  module  with  the  black 
(negative electrode) side facing the black (cathode) panel of the module. This 
orientation  ensures the  proteins  migrate from  the  gel  onto the  nitrocellulose 
membrane  and  not  into  the  transfer buffer while  transferring.  Extra  transfer 
buffer  was  added  and  overnight  transfer  was  carried  out  at  4°C  with  a
148MATERIALS AND METHODS
constant  voltage  of  30  V  using  a  1000/500  transfer  unit  from  Bio-Rad 
Laboratories Ltd.
Figure 2.2 Arrangement of gel sandwich assembly.
Next, equal protein transfer in each lane of the  nitrocellulose membrane was 
verified  by reversible  protein  staining with  Ponceau  S  (3%  (v/v)  acetic acid, 
0.2%  (w/v)  Ponceau  S),  then  washed  off  thoroughly  with  dH20.  All 
subsequent  procedures  were  performed  at  room  temperature  on  an  orbital 
shaker  (Denley  Instruments  Ltd.,  Sussex,  UK)  at  low  speed.  Non-specific 
binding (NSB) of the antibodies was prevented by incubating the membrane in 
blocking  solution  (5%  (w/v)  non-fat  dried  milk  in  PBS  (0.01  M  phosphate 
buffer, pH 7.4, containing 0.2% Tween-20) for 2 h at room temperature. This 
was  followed  by  a  single  5  min  wash  with  10  ml  of  PBS  (pH  7.4).  All 
subsequent washes were  for 5  min  with  10  ml  of the  named  solution.  The 
membrane was incubated for 2 h with anti-HO-1  (Bioquote Ltd., York,  UK) or 
anti-Nrf2  (Santa  Cruz  Biotechnology,  Santa  Cruz,  CA,  USA)  primary 
antibodies, diluted 1:1000 or 1:500, respectively, in Tris buffered saline (TBS) 
(0.05  M  Tris-HCI,  0.0037  M  KCI,  0.7137  M  NaOH,  pH  7.4).  Next,  the
Nitrocellulose Whatman paper
Positive electrode Negative electrode
Gel
Foam pads
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membrane was washed three times,  once with  PBS-T (PBS  0.01  M,  pH 7.4,
containing 0.05% (v/v) Tween 20), then twice with TBS (pH 7.4).
\
Proteins were visualised using an  ExtrAvidin® alkaline  phosphatase  staining 
kit (Sigma).  The biotinylated  anti-rabbit  IgG  antibody,  diluted  1:1000 in  TBS 
(pH  7.4),  was  incubated  with  the  membrane  for  1   h.  The  membrane  was 
washed  three  times  with  TBS  (pH  7.4)  and  the  ExtrAvidin®  alkaline 
phosphatase conjugate,  diluted  1:1000 in TBS  (pH 7.4),  applied for 1   h.  The 
three washes with TBS (pH 7.4) were repeated. After the last wash a freshly 
prepared  substrate  solution  (9.8  ml  of 0.1  M  Tris  buffer,  pH  8.2,  containing 
200  pi  of  1%  (w/v)  Napthol-AS-BI  phosphate  in  N-N-N-dimethyl  formamide 
and a 10 mg Fast Red DT salt tablet) was incubated with the membrane until 
red/pink  bands,  which  indicates  the  location  of  the  antigen-antibody 
complexes of the protein on the nitrocellulose membrane, was observed.  In all 
Western  blot  experiments  only  one  blot  (replicate)  was  prepared.  After 
maximal  colour  change  was  attained,  any  excess  substrate  solution  was 
washed off with  dH20 and the  membrane stored  in foil,  until  scanned  into a 
PC.
2.4.3  Isolation and determination of total haem oxygenase-1  mRNA
In order to  maintain  the  integrity  of the  ribonucleic  acid  (RNA)  and  prevent 
contamination  or  degradation  by  RNases  (enzymes  that  degrade  RNA)  a 
number  of  precautions  were  taken:  gloves  were  worn  at  all  times;  all 
glassware  was  sterilised  by  baking  for  6  h  at  200°C  beforehand;  and  the 
equipment and  solutions  were  washed  and  prepared  with  dH20  which  was
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pre-treated  with  diethyl  pyrocarbonate  (DEPC).  The  latter was  prepared  by 
adding  DEPC (0.5  ml/litre) to dH20,  within  pre-baked  glass  bottles,  shaking 
vigorously to mix, followed by baking at 40°C for 24 h. The water was purged 
of any remaining DPEC by autoclaving at 121°C for 25 min.
The  method  for  HO-1  mRNA  isolation  was  based  upon  that  described  by 
Chomczynski and Sacchi 667.  Samples were collected  by washing the flasks 
twice  with  sterile  PBS  (10X)  followed  by  the  addition  of  1   ml  of guanidine 
thiocyanate  (GT)  lysis  buffer  (4  M  guanidine  thiocyanate,  25  mM  sodium 
citrate,  0.5%  sarkosyl  (pH  7.0),  containing  7.2  pi  (v/v)  of  0.1  M  2- 
mercaptoethanol).  The flasks were  gently swirled  to  cover all  the  cells  and 
placed at an angle for 5 min to pool the viscous lysate, followed by transfer to 
15  ml  tubes.  The  following  extraction  agents  were  added  to  each  tube 
sequentially: 0.2 ml of 2 M sodium acetate (pH 7.4); 2.5 ml of phenol (pH 4.3); 
and  0.4  ml  of  chloroforrrdsoamylalcohol  (in  a  ratio  of  49:1  v/v).  This  was 
followed by thorough vortexing,  15 min on ice, then centrifuging (10,000 x g) 
for 20 min at 4°C in  a bench-top centrifuge (Avanti 30 Centrifuge,  Beckman 
Instruments). The upper aqueous layer was transferred to a new 15 ml tube 
and the addition of GT lysis buffer, extraction agents, vortexing and standing 
on ice were repeated.
The  tube  contents  were  divided  equally  among  1.5  ml  Eppendorfs  then 
recentrifuged.  The  upper  aqueous  layer  was  retained  and  divided  equally 
among 1.5 ml Eppendorfs. An equal volume (~600-700 pi) of cold 2-propanol 
was added to each. After inverting three times the samples were placed at - 
20°C for at least 1   h or overnight. Next, the samples were centrifuged (10,000
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x g) for 30 min at 4°C. The supernatants were discarded and GT lysis buffer 
(300 pi) was used to resuspend and pool the pellets from each sample into a 
single  Eppendorf.  Cold  2-propanol  (300  pi)  was  added  to  each  Eppendorf, 
then  mixed  by inversion  three times  and  left at -20°C for  1   h.  The  samples 
were  centrifuged  (10,000  x  g)  for  30  min  at  4°C.  The  supernatants  were 
discarded and the pellet was washed with 75% ethanol (500  pi). After a brief 
vortexing to dislodge the pellet samples were centrifuged  (10,000 x g) for 15 
min at 4°C. The supernatant was discarded and the Eppendorfs inverted to air 
dry the pellet on the  bench top for 30 min.  The  pellets,  containing the  RNA, 
were dissolved in DPEC water (20 pi).
The  RNA  concentration  was  determined  spectrophotometrically with  3  pi  of 
each sample diluted in 97 pi of DEPC water. The absorbance was read at 260 
nm  and  280  nm  against  a  blank  of  DPEC  water  using  a  UV-visual 
spectrophotometer  (Helios  a,  Unicam  Ltd.,  Cambridge,  UK).  The  total  RNA 
concentration of the entire sample was derived from Equation 2.3. The quality 
of the extracted RNA was based on the ratio of the readings at OD260/OD280. A 
ratio of 1.6-1.8 indicates good quality while anything less that 1.6 signifies that 
the sample contains DNA instead of RNA.
OD260 x 4 = RNA(fig / jul)
Equation 2.3 Calculation of total RNA concentration
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2.4.4  Reverse  transcriptase-polymerase  chain  reaction  (RT-PCR) 
analysis of HO-1  mRNA§
Having  isolated  and  calculated  the  total  RNA  concentration  as  described 
above  sufficient  DPEC  water  was  added  to  each  sample  so  that  a  final 
concentration  of  50  ng  RNA  was  obtained.  The  reverse  transcriptase- 
polymerase chain  reaction  (RT-PCR)  consists of two  parts,  1.  denaturing  of 
the enzyme RT,  and 2.  amplification of the cDNA products.  The  RT reaction 
was  carried  out  in  a  50  pi  reaction  volume  using  Ready-To-Go™  RT-PCR 
Beads (Amersham Biosciences UK Ltd., UK) in 0.2 ml thin-walled tubes. Each 
bead  contains  all  the  necessary  reagents,  i.e.  Moloney  murine  leukaemia 
virus  (M-MuLV)  RT  in  1.5  mM  MgCI2,  Taq  DNA  polymerase  and  RNase 
inhibitor, except primers and template, to generate PCR amplification products 
from an RNA template. To each reaction tube 35 pi of DPEC water was added 
and  left for 5-10  min  to  dissolve the  beads.  Next,  5  pi  of first strand  primer 
(pd(N)6  random hexamer primers) and 2 pi of sample was added to each tube 
and mixed  by gentle pipetting. A 50 pi aliquot of mineral oil was added onto 
the  latter  mixture,  then  the  tubes  were  placed  in  a  UNO  II  thermal  cycler 
(Biometra  Ltd.,  Maidstone,  Kent,  UK)  and  underwent  RT  denaturation  for a 
duration of 20 min (15 min at 42°C and 5 min at 95°C).
The RT reaction was amplified by PCR, for this 8 pi of primer mixture (2 pi of 
the following primers:  HO-1  sense, HO-1  antisense, p-actin sense and {3-actin
§  All RT-PCR assays were kindly performed by Martha Hoque, Dept, of Surgical Research, NPIMR.
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antisense (see Table 2.1 for sequences) in J52 |jl of DPEC water) was added 
under the  mineral  oil.  The  second  cycle  parameters  consisted  of a  30  sec 
denaturing step at 94°C,  a 30 sec annealing step at 60°C and a  1   h 30 min 
extension step at 68°C. A total of 26 cycles were used  per amplification and 
the annealing temperature for HO-1  and p-actin was 65°C. In the mean time a 
1.5% agarose gel (1.5 g of agarose in 100 ml of 0.5% TBE buffer (10 mM Tris- 
HCI,  1   mM  EDTA),  containing  0.5  pg/ml  of  ethidium  bromide  (EB),  was 
prepared. The gel was poured into a gel casting mould and pre-run for 10 min 
at 120 V in a tank containing 0.5% TBE buffer.
After completion of the  PCR the samples were placed  on  ice while prepared 
for running on the gel. To a fresh set of Eppendorfs 3 pi of loading buffer and 
10 pi of sample (taken from below the mineral oil layer) was added and mixed 
by gentle pipetting. A molecular weight marker (MWM) (5 pi of 100 base pair 
(bp) PCR ladder, 5 pi of DPEC water and 3 pi of loading buffer) was prepared 
in  parallel.  Aliquots  (13  pi)  of samples and  MWM were carefully loaded  into 
their respective wells, their loading order recorded,  and the gel  run at 120 V 
for about 1-1.5 h. The PCR products were visualised using a UV dual-intensity 
transilluminator  TM  20  (UVP,  Genetic  Research  Instrumentation  Ltd., 
Dunmow,  Essex,  UK) and photographed using a Polaroid DS 34 camera with 
a DS H-8 hood (Polaroid UK Ltd.,  St Albans,  Hertfordshire,  UK) and Polaroid 
film (Type 667) with a No.  15, deep yellow filter.  In all  PCR experiments only 
one assay (replicate) was performed.
154MATERIALS AND METHODS
Table 2.1  RT-PCR primer sequences for>10-1 and p-actin
Primer  Sequence 5* -  3’  Product  Primer
size (bp)  length
HO-1
Sense  ctt tca gaa ggg tca ggt gtc ca  23
246
Antisense  ctg aga ggt cac cca ggt agc gg  23
p-actin
Sense  c g tg  ggc cgc c c t agg cac ca  21
309
Antisense  cg g tt ggc c t t  agg c tt cag agg gg  25
2.4.5  Northern blot analysis of haem oxygenase-1  mRNA
A 1.3% (w/v) denaturing agarose gel was prepared using 1.4 g of agarose-LE 
(Ambion  Inc.,  Austin,  Texas,  USA)  per  100  ml,  10X  MOPS  buffer 
(3-(N-morpholino)  propane  sulfonic acid)  and  DPEC  water.  The  10X  MOPS 
buffer (pH 5.5-7.0) was made as a stock solution using, 0.2 M MOPS, pH 6.0; 
50 mM sodium acetate; and 10 mM EDTA. The gel mixture was heated for 6 
min,  or until  all  the  agents were fully dissolved,  on  low-medium  power in  a 
microwave.  After  a  short  cooling  period  at  room  temperature  2.2  M 
formaldehyde was added  and  mixed  by gentle swirling.  The gel was  poured 
into a casting tray on a flat surface and left to set. The set gel was placed into 
an  electrophoresis  apparatus  and  pre-run at 120 V for  10  min  in  1X MOPS 
buffer  (0.02  M  MOPS,  pH  6.0;  5  mM  sodium  acetate;  and  1   mM  EDTA) 
containing 5% (v/v) EB.
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A  10-20  M d  concentration  of  extracted  total  RNA  was  added  to  10  jjI  of 
denaturing  buffer  (1X  MOPS,  50%  (v/v)  deionised  formamide,  2.2  M 
formaldehyde),  vortexed  briefly,  then  heated  in  a water bath  at 60°C for  10 
min to denature the RNA, followed by rapid cooling on ice. To each sample, 2 
pi  of loading  dye  (5%  glycerol,  10%  bromophenol  blue,  saturated  solution) 
and  1   pi  of  EB  (diluted  1:2  with  DPEC  water)  was  added,  then  mixed  by 
pulsing  (30  sec)  in  a  Microcentaur  centrifuge  (Sanyo  Gallenkamp  Pic.). 
Samples (10-20 pg RNA/lane) were loaded onto the 1.3% gel and run at 120 
V in  1X MOPS  buffer until the  loading dye had  migrated  a distance of 5 cm 
from the wells,  i.e. a duration of 2-2.5 h. A positive control, derived from cells 
exposed  to  hemin  (50  pM)  in  DMEM for 3  h  followed  by fresh  media  for a 
further 3 h, was run in parallel with the treated samples. The migration pattern 
was observed using a UV dual-intensity transilluminator TM 20 and recorded 
with  a  Polaroid  DS  34  camera  with  a  DS  H-8  hood  and  Type  667  film 
(Polaroid  UK Ltd.). After rinsing with  DPEC water,  the gel was washed once 
with 1  X rinse solution (75 mM NaOH,  100 mM NaCI) for 45 min followed by a 
second wash second with Tris-HCI  (100  mM,  pH  7.5) for 1   h,  on the orbital 
shaker.  The  gel  was  blotted  overnight  by  upward  capillary  action  onto  a 
positively  charged  nylon  membrane  (GeneScreen™,  NEN®  Research 
Products,  Du  Pont  de  Nemours  &  Co.  Inc.,  Boston,  MA,  USA)  in  a  tank 
containing 1  X phosphate buffer (25 mM Na2HP0 4 , 25 mM NaH2P0 4 , pH 6.5), 
using the assembly shown in Figure 2.3.
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Figure 2.3 Assembly of Northern blot for blotting process.
Following overnight blotting, the membrane was baked in an oven for 2  h at 
80°C. The membrane was incubated for 1   h at 65°C in 15-20 ml of Rapid-Hyb 
buffer (Amersham Biosciences UK Ltd.,  UK), while rotating in a rotisserie (SI 
20H  Hybridisation  Oven/Shaker,  Stuart  Scientific  Co.  Ltd.,  Redhill,  Surrey, 
UK).  All  subsequent  procedures  where  carried  out  at  65°C  using  the 
rotisserie,  unless stated otherwise.  A rat HO-1  cDNA probe (kindly provided 
by  Professor  Shibahara,  Tohoku  University,  Japan)  was  labelled  with 
Redivue™  [a32P]-dCTP  (Amersham  Biosciences  UK  Ltd.,  UK)  using  a
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commercial  Nick Translation  kit  (Boehringer  Ingelheim  Ltd.,  UK.,  Bracknell, 
Berkshire,  UK).  Unincorporated  nucleotides  were  removed  using  a  second 
commercial  kit  QIAquick™  Nucleotide  Removal  Kit  (Qiagen  Ltd.,  Dorking, 
Surrey,  UK).  After denaturing  by boiling for 10  min,  followed  by standing  on 
ice for 10  min,  the  labelled  probe was  incubated  with  the  membrane  in  the 
Rapid-Hyb buffer for 24 h.
Next,  the  membrane was washed  in  2X  SSC  (0.3  M  NaCI,  30  mM  sodium 
citrate,  pH  7.0)/0.1%  (w/v)  SDS) for 20  min  at  room  temperature.  This  was 
followed by washing with  1X SSC/0.1% (w/v) SDS for 15 min at 65°C. A third 
wash  using  0.1%  SSC/0.1%  (w/v)  SDS was  carried  out at 65°C for  15  min. 
The purpose of these post-hybridisation washes is to increase the stringency 
conditions  in  order to  remove  non-specific  binding  from  the  membrane,  yet 
allowing  the  stronger  affinity  of  the  probe  to  the  gene  of  interest  to  be 
unaffected. The membrane was placed in a radiographic cassette on top of a 
sheet of radiographic film (BioMax MR,  Eastman Kodak Co.,  Rochester, New 
York,  USA) and exposed for 3-4 days at -70°C. The film was developed and 
the  image  scanned  using  a  scanner  and  cropped  to  size  using  Adobe 
Photoshop  6.0  (Adobe  Systems  UK,  Uxbridge,  UK).  Staining  of  the  18S 
ribosomal RNA (rRNA) band was used to confirm integrity and equal loading 
of the  RNA.  In  all  Northern  blot  experiments  only  one  blot  (replicate)  was 
prepared.
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2.5  Spectrophotometric  and  electrochemical  studies  of bile  pigments 
and NO congeners
2.5.1  Spectrophotometric analysis of bile pigments and NO congeners
Stock solutions (10 mM) of the bile pigments, bilirubin and biliverdin, and NO 
congeners, AS (a NO’ liberator) and DeaNO (a NO donor), were dissolved in 
0.1  M (bile pigments) or 0.01  M  (NO congeners)  NaOH and diluted down to 
0.5 or 1   mM working solutions, respectively. The agents were prepared freshly 
on the day of use in opaque Eppendorfs and placed on ice until required. All 
spectra were recorded using a Helios a UV-visual spectrophotometer (Unicam 
Ltd.,  Cambridge,  UK).  The absorbance readings,  between  300 and  750 nm, 
were conducted at 37°C against a blank of DPBS  (pH  7.4)  containing 5  pM 
vehicle (0.1  M NaOH). Initial spectra of the bile pigments (final concentration 5 
pM in DPBS) alone were compared with absorption spectra in the presence of 
freshly  prepared  AS  or  DeaNO  over  time  (0-30  min)  and  across  a 
concentration range (0-300 pM). Changes in spectra were also recorded after 
exposure of bilirubin to 50 pM of decomposed AS or DeaNO,  i.e. the agents 
were preincubated in DPBS at 37°C for 1   h before the addition of bilirubin (5 
pM).  The  data  was  plotted  using  the  accompanying  Convert  application 
together with Microsoft Excel and GraphPad Prism 3.0 software.
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2.5.2  Detection of NO release from NO congeners**
Release  of  NO  from  AS,  DeaNO  and  DetaNO  was  measured 
amperometrically using a NO-sensitive electrode (ISO-NO Mark II) and sensor 
(ISO-NOP,  detection  limit  1   nM)  both  from  World  Precision  Instruments 
(Sarasota,  FL,  USA).  Calibration  of  the  electrode was  performed  daily  by 
measuring known amounts of NO in solution according to the manufacturer's 
instructions. This consisted of generating NO by cumulative additions (25-100 
pM) of potassium nitrite (KNO2) to an acidic solution (0.1  M  H2S04,  sulphuric 
acid)  containing  0.1  M  potassium  iodide  (Kl).  The  product  of  plateau  value 
minus peak height was plotted against the respective NO concentrations as a 
calibration  curve,  a  representative  plot  is  shown  in  Figure 2.4.  Experiments 
were  performed  in  a  nitric  oxide  chamber  (NOCHM,  World  Precision 
Instruments) maintained at 37°C.  The electrode was immersed in either 1   ml 
of complete  DMEM,  DPBS or rat plasma, followed  by addition  of the agents 
being  analysed,  and  NO  concentration  was  recorded  continuously  under 
constant stirring. The amount of NO released over time was expressed as the 
area under the curve (AUC) calculated after 15 min of readings (pM  x   sec).
**  All  NO  electrode  assays  were  kindly  performed  by  Sandip  K.  Bains,  Dept,  of  Surgical  Research, 
NPIMR.
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Figure 2.4 Representative calibration curve for nitric oxide release
2.6  Statistics Analysis
The statistical analyses employed in this Thesis included a one-way analysis 
of variance (ANOVA) combined with the  Bonferroni  post test to compare  all 
treated  values  to  one  another.  The  one way ANOVA compares  the  means 
from three or more  groups,  assuming that data  are  sampled from  Gaussian 
populations.  The aforementioned tests were applied to time course,  multiple 
concentrations and different treatments, data.  Linear regression analysis was 
used  to  plot  standard  curves  while  non-linear  regression  (one  phase 
exponential  decay)  was  employed  for  the  bilirubin  reaction  rate  graphs  in 
Chapter 6. The values were expressed as the means ± standard error of the 
mean  (S.E.M.)  and  differences  between  the  groups were  considered  to  be 
statistically significant at probability (P)  <  0.05.  All  analyses were  performed 
using  GraphPad  Prism  3.00  for Windows  (GraphPad  Software,  San  Diego, 
California, USA, www.graphpad.com).
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3  INDUCTION  OF  HAEM  OXYGENASE-1  BY  THE 
NITROXYL ANION RELEASER, ANGELI’S SALT
3.1  Introduction
First  identified  in  the  late  1960s  the  enzyme  system  HO  represents  the 
primary biological  route  of haem  catabolism  363-413  So far,  inducible  (HO-1, 
also referred to as HSP 32) and constitutive (HO-2 and HO-3) isoforms of the 
enzyme  have  been  discovered.  Two  isoforms  (HO-1  and  HO-2)  degrade 
haem to the final products CO,  bilirubin and ferrous iron (Fe2+ ) 364.  However, 
HO-1  has generated most interest due to its greater sensitivity to induction by 
a  wide  range  of  inducers  (e.g.  haem,  UV  irradiation,  heavy  metals  and 
pathological states such as atherosclerosis and inflammation) and its ability to 
mitigate vascular and cellular dysfunction 433  The basis for the cytoprotective 
actions  attributed  to  HO-1  stem from  compelling  evidence  showing  that CO 
and  bilirubin  act as  a  potent vasodilator and  antioxidant,  respectively 428  A 
common factor leading to the induction and overexpression of the HO-1  gene, 
and  thus  CO  and  bilirubin  formation,  is  an  increased  generation  of  ROS 
leading to oxidative stress 429  More recently,  a  number of publications  have 
highlighted  the  ability  of the  gaseous  molecule  NO  and  its  different  redox 
derivatives,  known  collectively  as  RNS,  to  induce  the  HO-1/bilirubin/CO 
pathway 372-373
Due  to  the  complex  chemistry  of  NO  and  its  ability to  exist  in  a  variety  of 
interrelated  redox-activated  forms  13,  investigations  are  now  required  to
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identify  the  NO  congeners  responsible  for stimulating  HO-1  induction.  The 
NO+  and  NO*,  respectively the one electron oxidation and reduction products 
of NO,  are  possible  candidates  as  both  of these  redox forms  can  invoke  a 
variety of biological  responses depending  upon their concentration,  location, 
the  presence  of thiols  and  the  composition  of the  cellular  milieu  29.  In  this 
chapter, experiments conducted in cardiac H9c2 cells to examine the effect of 
the  NO*  generator AS  on  HO-1  protein  and  mRNA  expression  as  well  as 
haem oxygenase activity will be described. A comparison of the extent of HO- 
1   induction will be made with known NO donors, i.e.  DeaNO and  DetaNO, to 
determine the  cellular response to  stress,  i.e.  nitrosative  stress,  inflicted  by 
NO and its congeners.
3.2  Objective
The aim of this chapter is to demonstrate that haem oxygenase activity and 
HO-1  protein  and  mRNA  expression  are  increased  in  the  cardiac  cell  line 
H9c2 in response to different forms of nitrosative stress, specifically from the 
NO* liberator AS.
3.3  Materials and Methods
3.3.1  Preparation of reagents
Stock solutions (50 mM) of the NO* generator AS and the NO donors (DeaNO 
and  DetaNO)  were  prepared  in  0.01  M  NaOH.  A 2  mg/ml  stock  solution  of 
actinomycin D was prepared in ethanol. All reagents were prepared in opaque 
Eppendorfs shortly before each experiment and placed on ice until use.
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3.3.2  Maintenance and treatment of cells
Rat  H9c2  cardiomyocytes  were  grown  to txmfluence  in  flasks  and  24  well 
plates as described in Section 2.2.2. The reagents (AS,  DeaNO and DetaNO) 
were  applied  to  cells  directly  or following  their decomposition  (see  Section
2.2.3 for methodology) in a specific vehicle (fresh complete DMEM or DPBS, 
modified with Ca2+ and Mg2+) for the durations and concentrations specified in 
each graph. In the case of actinomycin D it was applied to cells in  DMEM 30 
min before the addition of AS to the same media. After incubation, cells were 
collected for analysis of either haem oxygenase activity, Western blot of HO-1 
protein,  RT-PCR  or  Northern  blot  of  HO-1  mRNA  expression,  or  a 
combination of such assays, as described in Sections 2.3.4, 2.4.2, 2.4.4 and
2.4.5,  respectively. To determine the possible cytotoxic effects of AS,  DeaNO 
and  DetaNO  and  correlate  this  with  their  respective  effect  upon  haem 
oxygenase  activity and  HO-1  protein  expression  a  concentration  range  (0-2 
mM)  of  these  compounds  was  applied  to  cells  cultured  in  24  well  plates. 
Cytotoxicity  was  assessed  spectrophotometrically  via  the  cell  metabolism 
assay  (Section  2.2.4).  Negative  controls,  which  consisted  of vehicle  alone, 
were included in all experiments.
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3.4  Results
3.4.1  Concentration-dependent  effect  of  Angeli’s  salt  (AS)  on  haem 
oxygenase  activity,  HO-1  protein  and  mRNA expression  in  H9c2 
cardiomyocytes
In  order to establish  the effect of AS on haem oxygenase activity and  HO-1 
protein  and  gene  expression,  cardiomyocytes  were  treated  with  a 
concentration range (0 to 2 mM) of the NO' donor for 6 h in complete DMEM. 
As shown  in  Figure 3.1  A,  AS  (0-1  mM)  elicited  a  concentration-dependent 
increase  in  haem  oxygenase  activity  (254.8  ±  16.2  to  1062  ±  43.6  pmoles 
bilirubin/mg  protein/h;  P <  0.05) with a  slight decline  in activity at the  higher 
concentrations  (1.5-2  mM).  Western  blot  analysis  (Figure  3.1  B;  n  =  1) 
demonstrated  a  change  in  the  expression  of a  32  kDa  protein  band,  which 
corresponds to  HO-1  protein,  over the  same  concentration  range.  After 6  h 
exposure to various concentrations of AS,  the intensity of HO-1  mRNA gene 
expression levels also increased gradually with maximal levels visible at 2 mM 
AS (Figure 3.1  C; n = 1). This correlated with the results depicted in Figure 3.1 
B. The 18S rRNA band is also shown to confirm integrity and equal loading of 
the  RNA  of the  samples  on  the  gel,  while  hemin  (50  pM)  was  used  as  a 
positive control. We hypothesised that the mechanism by which AS mediates 
an increase in haem oxygenase activity occurs at the transcriptional level.  In 
fact, the use of the transcription inhibitor actinomycin  D completely abolished 
any increase in haem oxygenase activity and mRNA expression when it was 
combined with AS in the media (see Figure 3.3).
165INDUCTION OF HO-1
3.4  Results
3.4.1  Concentration-dependent  effect  of  Angeli’s  salt  (AS)  on  haem 
oxygenase  activity,  HO-1  protein  and  mRNA expression  in  H9c2 
cardiomyocytes
In order to  establish the effect of AS  on haem oxygenase activity and  HO-1 
protein  and  gene  expression,  cardiomyocytes  were  treated  with  a 
concentration range (0 to 2 mM) of the NO' donor for 6 h in complete DMEM. 
As shown  in  Figure  3.1  A,  AS  (0-1  mM)  elicited  a  concentration-dependent 
increase  in  haem  oxygenase  activity  (254.8  ±  16.2  to  1062  ±  43.6  pmoles 
bilirubin/mg  protein/h;  P <  0.05) with a slight decline  in activity at the higher 
concentrations  (1.5-2  mM).  Western  blot  analysis  (Figure  3.1  B;  n  -  1) 
demonstrated  a  change  in  the  expression  of a  32  kDa  protein  band,  which 
corresponds to  HO-1  protein,  over the  same  concentration  range.  After 6  h 
exposure to various concentrations of AS,  the intensity of HO-1  mRNA gene 
expression levels also increased gradually with maximal levels visible at 2 mM 
AS (Figure 3.1  C; n = 1). This correlated with the results depicted in Figure 3.1 
B. The 18S rRNA band is also shown to confirm integrity and equal loading of 
the  RNA  of the  samples  on  the  gel,  while  hemin  (50  pM)  was  used  as  a 
positive control. We hypothesised that the mechanism by which AS mediates 
an increase in haem oxygenase activity occurs at the transcriptional level.  In 
fact, the use of the transcription inhibitor actinomycin  D completely abolished 
any increase in haem oxygenase activity and mRNA expression when it was 
combined with AS in the media (see Figure 3.3).
165INDUCTION OF HO-1
B
1250:
%   2  1000
500
£  g  250
HO-1
0  0.25  0.5  0.75  1   1.5  2
AS [mM]
0  0.25  0.5  0.75
AS [mM]
1.5
HO-1
18S
0 + ve Con 0.25  0.5  0.75  1   2
AS [mM]
Figure  3.1  Concentration-dependent  effect  of  Angeli’s  salt  on  haem 
oxygenase  activity,  HO-1  protein  and  mRNA  expression  in 
H9c2 cardiomyocytes.
Cells  were  incubated  with  Angeli’s  salt  (AS,  0-2  mM)  in  fresh 
complete DMEM. After 6 h, cells were collected and analysed for: 
(A)  haem  oxygenase  activity;  (B)  HO-1  protein;  and  (C)  HO-1 
mRNA  expression,  as  described  in  Sections  2.3.4,  2.4.2  and
2.4.5,  respectively.  Control (0 mM AS)  represents cells exposed 
to  media  alone.  The  +ve  Con  in  panel  C was  generated  using 
hemin (50 pM). The  18S rRNA band is shown to confirm integrity 
and equal loading of RNA.  Blots (B and C) are representative of 
one  replicate.  Bars  represent  the  mean  ±  S.E.M.  of  n  =  6 
experiments. * P < 0.05 vs. 0 mM AS.
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3.4.2  Time-dependent  effect of Angeli’s  salt (AS)  on  haem  oxygenase 
activity and HO-1  protein expression in H9c2 cardiomyocytes
Having  established  that  AS  induces  haem  oxygenase  in  a  concentration 
dependent manner,  the  next step was to assess the extent of this induction 
over time.  To do this cardiomyocytes were exposed to  a fixed concentration 
(0.75 mM) of the  NO' generator over a 24 h period in order to evaluate any 
changes in haem oxygenase activity and HO-1  protein. Figure 3.2 A illustrates 
that AS achieved maximal induction of activity after 6 h (245.5 ± 52.9 (0 h) vs.
685.2  ±  29.1  (6  h)  pmoles  bilirubin/mg  protein/h;  P  <  0.05)  followed  by  a 
gradual decline in activity over the remaining duration (from 441.1  ± 46.6 (12 
h)  to  307.7  ±  13.8  (24  h)  pmoles  bilirubin/mg  protein/h;  P  <  0.05).  A 
corresponding pattern of HO-1  protein expression was observed over the 24 h 
period, with maximal intensity of the HO-1  protein band visible at 6 h followed 
by weaker intensity with increasing duration of exposure to AS (Figure 3.2 B; 
n = 1). Taken together, the data presented in Figures 3.1  and 3.2 demonstrate 
that AS  has the ability to  induce  haem  oxygenase  activity,  as well  as  HO-1 
protein and mRNA gene expression,  in a concentration- and time-dependent 
manner.
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Figure  3.2  Time-dependent  effect  of Angeli’s  salt  on  haem  oxygenase 
activity  and  HO-1  protein  expression  in  H9c2 
cardiomyocytes.
Following exposure to a fixed concentration (0.75 mM) of Angeli’s 
salt (AS) for various times  (0-24  h),  haem oxygenase activity (A) 
and  Western  blot assay (B) for  HO-1  protein  were  assessed  as 
described  in  Sections 2.3.4 and 2.4.2,  respectively.  Control (0 h) 
represents cells exposed to media alone. The Western blot panel 
is  representative  of one  experiment.  Bars  represent the  mean  ± 
S.E.M. of n = 6 experiments. * P < 0.05 vs. 0 h.
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Figure 3.3 Effect of Angeli’s salt and actinomycin D on haem oxygenase 
activity  and  HO-1  mRNA  expression  in  rat  H9c2 
cardiomyocytes.
Cells were exposed to Angeli’s salt (AS, 0.75 mM) in the absence 
(-)  or  presence  (+)  of  actinomycin  D  (0.5  or  1   |jg/ml)  in  fresh 
complete  DMEM.  In  the  latter  case  actinomycin  D  was 
preincubated  with  cells  for  30  min  and  AS  was  added  for  the 
remaining  duration.  After  6  h  haem  oxygenase  activity  (A)  and 
HO-1  mRNA  expression  (B)  were  determined  according  to 
Sections 2.3.4  and 2.4.4,  respectively.  Control  (CON) represents 
cells  exposed  to  media  alone.  The  PCR  image  (panel  B)  is 
representative  of  a  single  experiment  with  p-actin  serving  as  a 
loading  control.  Bars  represent  the  mean  ±  S.E.M.  of  n  =  4 
experiments. * P < 0.001 vs. CON. t  P < 0.001 vs. AS alone.
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Figure 3.4 Multiple additions of Angeli’s salt stimulates haem oxygenase 
activity in H9c2 cardiomyocytes.
Angeli’s salt (AS, 50 or 100 pM) was added to cells at 1   h intervals 
(**) over a period of 6 h. Haem oxygenase activity was determined 
according  to  Section  2.3.4.  Control  (CON)  represents  cells 
exposed to media alone.  Bars represent the mean ± S.E.M. of n - 
4 experiments. * P< 0.01 vs. control (CON).
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3.4.4  Effect  of  different  vehicles  on  the  haem  oxygenase  inducing 
potential of Angeli’s salt
Given  that AS  has  quite  a  short  half-life  (VA =  2.3  min),  it was  decided  to 
investigate  whether  the  agent  had  any  inducing  potential  upon  haem 
oxygenase after its capacity to liberate NO' had expired. To do this AS (0.75 
mM) was allowed to ‘decompose’ for 1   h at 37°C (see Section 2.2.3)  in two 
different vehicles,  complete  DMEM or DPBS.  A comparison was  also  made 
with freshly  prepared AS  in  both vehicles.  Following  a 6  h  exposure to AS, 
cells  were  collected  for  haem  oxygenase  activity  determination.  Figure  3.5 
shows  that  freshly  prepared  AS  had  a  greater  ability  to  induce  haem 
oxygenase  activity  in  both  vehicles  compared  with  the  decomposed  form. 
Fresh AS had the greatest influence on haem  oxygenase activity when cells 
were cultured in DMEM compared with DPBS (1132 ± 328.2 vs. 705.8 ± 133.5 
pmoles bilirubin/mg protein/h,  respectively; P < 0.05). When decomposed AS 
was applied to cells the level of haem oxygenase activity was significantly less 
(P >  0.05)  in  both vehicles.  A  possible  reason for the  higher level  of haem 
oxygenase activity observed when freshly prepared AS was added to cells in 
media  compared  with  DPBS  could  be  due  to  the  influence  of constituents 
within the media enhancing the inducing potential of AS. The fact that freshly 
prepared AS elicited a stronger induction suggests that the NO', derived from 
AS, is likely to promote the signalling cascade. This point is reinforced by the 
lower level of haem oxygenase activity observed when decomposed AS was 
incubated with both vehicles.
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Figure  3.5  Effect  of  Angeli’s  salt  decomposition  on  haem  oxygenase
activity elicited in different culture vehicles.
Angeli’s salt (AS, 0.75 mM) was applied to cardiomyocytes either 
directly  or  following  preincubation  (see  Section  2.2.3  for 
preparation procedures) in fresh complete  DMEM  (filled bars) or 
DPBS  (hatched bars).  Haem oxygenase activity was determined 
after 6 h treatment as described  in Section 2.3.4.  Control (CON) 
represents  cells  exposed  to  media  alone.  Bars  represent  the 
mean ± S.E.M. of n = 4 experiments. * P < 0.05 vs. CON. t  P < 
0.05 vs. directly applied AS.
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3.4.5  Potency of nitric oxide donors on  HO-1  induction and activity in 
H9c2 cardiomyocytes
It has been shown that NO can induce haem oxygenase activity in endothelial 
cells 373-423  To complement the work carried out so far two different types of 
NO donors were  used:  diethylamine  NONOate  (DeaNO),  which  has  a  short 
half-life  (t1 /4  =  2  min);  and  diethlyenetetraamine  NONOate  (DetaNO),  which 
has  a  long  half-life  (VA  =  20  h).  Stock  solutions  of  both  NO  donors  were 
prepared  according  to  Section  2.2.3.  Cardiomyocytes  were  treated  with  a 
concentration range (0-2 mM) of DetaNO for 6 and 18 h in DMEM to examine 
the change,  if any,  in  haem oxygenase activity and HO-1  protein expression. 
The same parameters were assessed using DeaNO (0-2 mM),  but this agent 
was applied to cells for just 6 h.
Following  a  6  h  exposure  to  DetaNO  (0-2  mM)  (Figure  3.6  A)  there was  a 
concentration-dependent increase  in  haem oxygenase activity, with  maximal 
activity attained at  1.5 mM  (P < 0.05). At 2 mM there was a slight decline in 
activity,  possibly due to cell toxicity at this concentration  (see data  in  Figure
3.9).  Western  blot  analysis  (Figure  3.6  B;  n =  1)  identified  a  protein  band 
corresponding  to  HO-1  at  0.25  to  2  mM  DetaNO,  the  intensity  of  which 
increased  with  increasing  concentration  of  the  drug.  An  18  h  incubation 
(Figure 3.7 A) with  DetaNO caused a more significant (P < 0.05) increase in 
haem oxygenase  activity compared with  a 6  h  exposure.  As  DetaNO has a 
long half-life it is often used to mimic physiological  NO release. The fact that 
activity levelled  off from  1   mM onwards indicates that high concentrations of 
the  drug  are  tolerable  over  the  duration  of  exposure.  After  18  h  a
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corresponding change in HO-1  protein expression was observed, with similar 
intensity of staining from 0.75 to 2 mM (Figure 3.7 B; n  = 1).
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Figure  3.6  Concentration-dependent  effect  of  DetaNO  on  haem 
oxygenase  activity and  HO-1  protein  expression  after 6  h 
treatment.
A concentration range of DetaNO (0-2 mM) was applied to cells 
in fresh complete  DMEM for 6 h.  Haem oxygenase activity (A) 
and  Western  blot (B)  assays were  performed  as described  in 
Sections 2.3.4 and 2.4.2,  respectively.  Control (0 mM DetaNO) 
represents  cells treated with fresh  DMEM  alone.  The Western 
blot panel  is representative of one experiment.  Bars represent 
the mean ± S.E.M. of n- 3-4 experiments. * P < 0.05 vs. 0 mM 
DetaNO.
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Figure  3.7  Concentration-dependent  effect  of  DetaNO  on  haem 
oxygenase activity and  HO-1  protein expression after 18 h 
treatment.
A concentration range of DetaNO (0-2 mM) was applied to cells 
in fresh complete DMEM for 18 h. Haem oxygenase activity (A) 
and  Western  blot (B) assays were  performed  as  described  in 
Sections 2.3.4 and 2.4.2,  respectively. Control (0 mM DetaNO) 
represents  cells treated with fresh  DMEM alone.  The Western 
blot panel  is  representative of one experiment.  Bars represent 
the mean ± S.E.M. of n   =  3-4 experiments. * P  < 0.05 vs. 0 mM 
DetaNO.
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When  DeaNO  (0-2  mM)  was  applied  to  cardiomyocytes  for 6  h  a  different 
pattern  of  haem  oxygenase  activity  was  observed  (see  Figure  3.8  A). 
Specifically,  maximal  activity  was  accomplished  at  0.5  mM  (1265  ±  622 
pmoles  bilirubin/mg  protein/h  compared  to  control  125.6  ±  21.5  pmoles 
bilirubin/mg protein/h; P < 0.05). At higher concentrations there was a gradual 
decline  in  haem  oxygenase activity  due to the  toxicity  of the  agent at such 
levels. This pattern of concentration effects was mimicked when  DeaNO was 
used to  induce  HO-1  protein  expression  (Figure 3.8  B;  n  =  1),  i.e.  maximal 
intensity at 0.5  mM followed  by a gradual decline to almost negligible levels 
with successive increases in concentration. The pattern of results produced by 
DeaNO are due to its fast acting potency and short half-life (t  14 = 2 min) which 
is similar to that for AS (VA = 2.3 min). In the case of DeaNO, it can be used to 
simulate  short  but  intense  bursts  of NO  release  rather like  that seen  under 
pathological conditions involving NO.
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Figure  3.8  Concentration-dependent  effect  of  DeaNO  on  haem
oxygenase activity and HO-1  protein expression.
A concentration range of DeaNO (0-2 mM) was applied to cells 
in fresh complete  DMEM for 6 h.  Haem oxygenase activity (A) 
and  Western  blot  (B)  assays were  performed  as  described  in 
Sections 2.3.4  and 2.4.2,  respectively.  Control  (0 mM  DeaNO) 
represents cells treated with fresh  DMEM  alone.  The Western 
blot panel  is  representative of one experiment.  Bars represent 
the mean ± S.E.M. of n = 3-4 experiments. * P < 0.05 vs. 0 mM 
DeaNO.
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3.4.6  Effects  of  nitric  oxide  (NO)  and  nitroxyl  anion  (NO )  on  cell 
metabolism
The  procedures  detailed  so  far  have  focused  on  the  modulation  of  haem 
oxygenase activity and  HO-1  protein expression  in  H9c2  cardiomyocytes  by 
NO’  (AS)  and  NO  (DeaNO  and  DetaNO).  The  potential  cytotoxic  effect  of 
these  compounds  was  tested  in  a  concentration  range  (0-2  mM)  using  the 
Alamar blue cell metabolism assay.  Following a 6 h  exposure to agents that 
liberate NO’ or donate NO and a subsequent 5 h incubation with the Alamar 
blue reagent, each agent had a different effect upon cell metabolism  (Figure
3.9).  When  AS  was  applied  to  cells,  cell  metabolism  was  maintained  at 
approximately  100%  across  the  concentration  range.  After  DetaNO  was 
applied,  there  was  an  overall  reduction  in  cell  metabolism  by  20%,  while 
DeaNO  promoted  a  significant  (40%;  P  <  0.05)  concentration-dependent 
reduction  in  cell  metabolism.  These  results  suggest  that  the  H9c2s  show 
different levels of tolerance to the agents chosen. Of the three, AS is the most 
acceptable followed by DetaNO with DeaNO being the least tolerable.
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Figure 3.9 Effect of NO and NO' on cell metabolism.
Cardiomyocytes were treated with similar concentrations (0-2 mM) 
of AS  (hatched  bars),  DetaNO  (filled  bars)  and  DeaNO  (empty 
bars) for 6 h in fresh complete media. Cell metabolism, which was 
determined  according  to  Section  2.2.4,  was  expressed  as  a 
percentage of the control (assigned  100%). Control  (0 mM  agent) 
represents  cells  treated  with  fresh  DMEM  alone.  Bars  represent 
the  mean  ±  S.E.M.  of n  =  6  experiments.  *  P <  0.05  vs.  0  mM 
agent.
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3.5  Discussion
For the first time this study demonstrates that a commercially available agent 
that liberates NO’, AS, can induce haem oxygenase activity, HO-1  protein and 
HO-1  mRNA  expression  in  cardiac  cells  in  a  time-  and 
concentration-dependent  manner.  Although  the  exact  mechanism  of  haem 
oxygenase induction  by NO' is  unknown,  it appears to involve transcriptional 
activation  of  the  HO-1  gene  because  increases  in  both  HO-1  mRNA 
expression and haem oxygenase activity were completely suppressed by the 
transcriptional  inhibitor  actinomycin  D.  It  is  also  plausible  that  other  NO 
intermediates, e.g. ONOO', may activate the transcription of the HO-1  gene as 
this powerful oxidant can be generated from NO' at physiological pH 41,58 and 
has been shown to  increase endothelial  HO-1  protein and  haem oxygenase 
activity in vitro 482-668  At this stage it is not known what transcription factor(s) 
are responsible for upregulating the expression of the HO-1  gene and protein 
in response to nitrosative reactions; however, Chapter 5 will explore this topic 
in more detail.
It  is  interesting  to  note  that  multiple  additions  of  low  (50  or  100  pM) 
concentrations of AS over a 6 h period was sufficient to induce a high level of 
haem oxygenase activity. This suggests that the short half-life of AS {W z = 2.3 
min) is a limiting factor in HO-1  protein induction and by simulating sustained 
NO' production, as would be the case under physiological/pathophysiological 
conditions,  it  is  possible  to  preserve  the  signalling  mechanisms  involved  in 
AS-mediated  haem  oxygenase  activation.  The  latter  observation  is  further 
supported by the experiments carried out in different vehicles, as the level of
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haem  oxygenase  activity  is  higher when  freshly  prepared  AS  was  applied 
directly to cells in  DMEM and  DPBS,  compared with decomposed AS  in the 
same  vehicles.  The  difference  in  the  activity  levels  between  DMEM,  which 
contains a variety of nutrients,  and DPBS, which comprises mainly water and 
Mg2 +  and Ca2 +  ions, also suggests that NO' can directly stimulate the enzyme 
system,  but the possibility that constituents of the media  may oxidise NO' to 
NO,  and  eventually  other  RNS,  thus  stimulating  haem  oxygenase  activity, 
cannot be excluded.
It is known that various cell types respond to nitrosative stress induced by NO 
via the activation of haem oxygenase 427,481,669.  Using  specific  NO releasing 
compounds, which release NO at different rates, a comparison was made with 
NO' in  terms  of the  degree  and  duration  of haem  oxygenase  induction  and 
toxicological  effects exhibited by the cardiomyocytes in response to different 
forms of nitrosative stress. The data reveal that DetaNO, which releases NO 
at a slow rate (VA = 20 h), was less effective than DeaNO, which releases NO 
at a faster rate (VA = 2 min), at stimulating an early increase in  HO-1  protein 
expression and haem oxygenase activity. When using DeaNO maximal haem 
oxygenase  activity was  obtained  with  a  concentration  of 0.5  mM  after 6  h 
which is rather similar to that observed with AS (0.75 mM). Chronic exposure 
of the cardiomyocytes to low fluxes of NO from DetaNO for a prolonged period 
of  time  was  manifested  by  the  preservation  of  HO-1  induction  and  haem 
oxygenase  activity  at  maximal  levels  over  the  duration  of  exposure.  In 
contrast,  exposure to a  high concentration of DeaNO (2  mM) for 6 h did not 
result in a marked increase in HO-1  protein and haem oxygenase activity, but
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an increase of cytotoxicity which was manifested  by a decline in the level of 
cell  metabolism.  The  data  from  the  NO  releasers  is  in  line  with  previous 
findings which showed that compared to treatment with slow NO releasers, a 
burst of NO considerably extends the half-life of HO-1  mRNA, suggesting that 
translation-independent mRNA stability could be an important mechanism by 
which cells sense NO challenge6 7 0
Notably,  the  present  data  would  indicate  that  NO*  is  less  harmful  than  NO 
since exposure of cells to AS, which has a similar half-life to DeaNO, did not 
result in any detectable cytotoxicity over a range of concentrations (0-2 mM). 
Although  the  current  findings  contrast  with  previous  studies  showing 
significant cytotoxic activity for NO* 352,  it must be  pointed  out that the  latter 
studies  employed  much  higher concentrations  of AS  (2-5  mM)  and  cellular 
damage was only aggravated when AS was combined with hydrogen peroxide 
57I n   agreement  with  previous  data  using  NO  donors,  the  NO'-mediated 
induction of HO-1  expression is transient and gradually disappears once the 
spontaneous generation of NO* ceases. These observations about NO* and its 
interaction  with  the  haem  oxygenase  pathway  may  have  important 
implications  in  the  design  of  agents  that  are  capable  of  amplifying  the 
induction  of  antinitrosative  systems  without  causing  a  major  threat  to  the 
cellular components.
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3.6  Conclusion
This  chapter  demonstrates  that  NO',  the  one  electron  reduction  product  of 
NO, stimulates cardiac HO-1  protein and mRNA expression as well as haem 
oxygenase  activity.  Decomposition  leads  to  a  loss  of  potency  towards 
inducing  haem  oxygenase  activity  suggesting  that  NO'  liberated  by  freshly 
prepared AS  promotes  HO-1  protein  induction.  This  upregulation  occurs via 
transcriptional  activation  as  actinomycin  D  completely  abolished  the 
responsiveness of the  HO-1  gene towards AS.  Although  it is not possible to 
say whether the concentrations of AS employed in these current experiments 
are  biologically  relevant  because  sensitive  methodologies  for  the 
measurement of NO' generated in vivo still need to be developed, Chapter 4 
provides information from in vitro experiments to support the notion that NO' is 
the chemical entity responsible for the induction of HO-1.
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4  DISSECTING  THE  CONTRIBUTION  OF  NITROXYL 
ANION  AND  NITRIC  OXIDE  TO  ANGELI’S  SALT- 
MEDIATED  INDUCTION  OF  HAEM  OXYGENASE 
ACTIVITY
4.1  Introduction
Following  the  discovery  that  NO  mediates  vasodilatation  a  number  of 
important biological functions have been purported for this gaseous molecule 
in the immune, nervous and reproductive systems59. In response to increased 
Ca2 +  or immunogenic stimuli  a  group of enzymes  known  as  NOSs catalyse 
the formation of NO from the amino acid L-arginine 78. The NO molecule can 
bind with sGC to promote the conversion of GTP to cGMP, the latter mediates 
the biological effects of NO 1 4 9   Recently a number of reports have suggested 
that NO'  is the  active  product of NOS  metabolism 43,671,  although this  issue 
remains controversial 45. At the same time interest in the biochemistry of NO' 
and its role in modulating specific biological reactions has expanded 25,46  Due 
to its unstable and  short lived  nature the fate of NO' within the cell  remains 
elusive.  However,  reaction  with  thiols,  molecular  oxygen  and  oxidants,  can 
generate other types of RNS and thus modulation of specific cellular targets 
30, 58,672  though the mechanism(s) behind these effects is still under scrutiny 
we can say that,  based upon the data in Chapter 3 NO' activates HO-1. The 
biochemical  mechanisms  leading to this  induction will  be  explored further in 
this chapter.
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4.2  Objective
This  chapter  aims  to  dissect the  contribution  of  NO'  and  NO  in  increasing 
haem  oxygenase  activity  and  HO-1  protein  expression  in  rat  H9c2 
cardiomyocytes following  their exposure to AS  and  DeaNO.  In  addition, the 
quantity  of  NO  released  by  the  latter  agents,  as  well  as  DetaNO,  will  be 
assessed in vehicle (DMEM or DPBS) using a sensitive NO electrode.
4.3  Materials and Methods
4.3.1  Preparation of reagents
Fifty milimolar (50 mM) stock solutions of the NO' liberator AS, the NO donors 
(DeaNO  and  DetaNO)  and  the  glutathione  synthesis  inhibitor  buthionine- 
sulfoximine  (BSO)  were  prepared  in  0.01  M  NaOH.  Nitrite  (NO2')  was 
prepared  as  a  50  mM  stock solution  in  dH20.  A  100  mM  stock  solution  of 
A/-acetylcysteine  (NAC)  was  prepared  with  5%  (v/v)  2  M  NaOH.  Stock 
solutions  (50  mM)  of  2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1- 
oxyl  3-oxide  (potassium  salt)  (C-PTIO)  and  hydroxocobalamin  (HCB)  were 
dissolved in ethanol and dH20, respectively. A 10 mM stock solution of copper 
sulphate (CuS04) was prepared with sterile PBS (10X). All of the agents were 
prepared fresh at the time of each experiment in opaque Eppendorfs, or a 15 
ml tube wrapped in foil for CuS04, and placed on ice until required.
4.3.2  Maintenance and treatment of cells
Cardiomyocytes were  grown to confluence  in flasks as described  in  Section
2.2.2.  The reagents (AS, DeaNO or DetaNO) were applied to cells directly or
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following their preincubation (see Section 2.2.3 for methodology) in a specific 
vehicle (fresh complete DMEM or DPBS, modified with Ca2 +  and Mg2+) for the 
times and concentrations specified in each graph. When AS was coincubated 
with  CuS04   or  NAC  the  agents  were  preincubated with  cells for  15  min  in 
vehicle (DPBS or DMEM) followed by DMEM for the remaining duration. In the 
case of BSO, the agent was applied to cells for 6 h in DMEM followed by AS 
for a further 6 h in fresh complete media. At the end of each experiment cells 
were  collected  for  analysis  of  haem  oxygenase  activity  or  HO-1  protein 
expression  as  described  in  Sections 2.3.4  and  2.4.2,  respectively.  Negative 
controls, which consisted of vehicle alone, were included in all experiments.
4.3.3  NO electrode experiments
The quantity of NO released by AS and the NO donors,  DeaNO and DetaNO, 
was examined in fresh complete DMEM or DPBS, final volume 1   ml,  using a 
NO-sensitive electrode under constant stirring at 37°C as described in Section
2.5.2.  Controls consisted of vehicle alone.
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4.4  Results
4.4.1  Modulation of the haem oxygenase inducing potential of Angeli’s 
salt (AS) by copper sulphate and a nitric oxide and nitroxyl anion 
scavenger
It has been shown that copper ions (Cu2+ ) can oxidise NO’ derived from AS to 
NO  62,63  Copper ions can also lead to the induction of haem oxygenase 673. 
Cardiomyocytes  were  exposed  to  various  concentrations  of  copper  sulfate 
(CUSO4,  10,  50,  100  or 200  pM)  in  DMEM  to  establish  its  effect on  haem 
oxygenase  activity  and  to  choose  an  optimal  concentration  for  further 
experiments.  Figure  4.1  illustrates  that  CuS04  produced  a  concentration- 
dependent  increase  in  haem  oxygenase  activity,  with  maximal  levels  being 
observed at 100 pM CuS04 (296.1  ± 36.1  (control) vs.  1627 ± 123.2 ( 1 0 0  pM) 
pmoles bilirubin/mg protein/h; P < 0.001). There was no significant increase in 
haem oxygenase activity if cells were incubated with  10  pM  CuS04 (486.1  ± 
38.58 pmoles bilirubin/mg protein/h; P > 0.05). Therefore,  10 pM CuS04 was 
chosen to examine  its effect on haem oxygenase activity in the presence or 
absence of AS.
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Figure  4.1  Concentration-dependent  effect  of  copper sulfate  on  haem 
oxygenase activity.
Cells were treated with copper sulfate (CuS04l  10, 50,  100 or 200 
pM)  in fresh complete DMEM for 6 h.  Experiments with Angeli’s 
salt (AS,  0.75 mM) are shown for comparison.  Haem oxygenase 
activity  was  determined  as  described  in  Section  2.3.4.  Control 
(CON)  represents  cells  treated  with  fresh  DMEM  alone.  Bars 
represent the mean ± S.E.M. of n = 4 experiments. * P < 0.05 vs. 
CON.
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In a second set of experiments (Figure 4.2 A) AS  (0.75 mM) was  incubated 
with or without CUSO4 (10 pM) in DMEM or DPBS for 15 min followed by 6 h 
in fresh  DMEM.  As  in the previous experiments,  incubation  of AS  in  DMEM 
gave  rise  to  a  greater  level  of  haem  oxygenase  induction  compared  with 
DPBS  (1260  ±  142.2  vs.  907.1  ±  78.46  pmoles  bilirubin/mg  protein/h, 
respectively). Once again, this particular experiment shows that AS on its own 
can promote haem oxygenase  induction  in both vehicles. When CuS04 was 
added  in combination  with  AS  there was a  potentiation  in  haem  oxygenase 
activity in both vehicles, the effect being more pronounced in DMEM  (1802 ±
179.2 pmoles  bilirubin/mg protein/h; P < 0.05). Western  blot analysis  (Figure
4.2 B; n =  1) of cells treated with a range of concentrations of CuS04 (1 0 , 50, 
100 or 200  pM) in the absence or presence of AS  (0.75  mM)  revealed that 
individually both agents were capable of eliciting an increase in  HO-1  protein 
expression  at  the  different  concentrations  examined.  In  combination  a 
synergistic interaction between the two agents brought about an augmentation 
in  the  intensity  of  HO-1  protein  expression  at  all  concentrations  of  CuS04 
used. These observations indicate that AS and CuS04 have the ability to act 
synergistically to promote an induction of haem oxygenase activity and HO-1 
protein expression in cardiomyocytes.
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Figure 4.2 Synergistic influence of copper sulphate and Angeli’s salt on
haem oxygenase activity and HO-1  protein expression.
Cardiomyocytes were treated with Angeli’s salt (AS,  0.75 mM) in 
the  absence  (-)  or  presence  (+)  of  10  pM  copper  sulphate 
(CuS04) in fresh complete DMEM (filled bars) or DPBS (hatched). 
Haem oxygenase activity (A) was determined after 6 h incubation 
according to Section 2.3.4. Cells were treated with CuS04 (10, 50, 
100  or 200  pM)  in  the  absence  (-)  or presence  (+)  of AS  (0.75 
mM)  in  fresh  DMEM.  After 6  h  a  Western  blot  assay for  HO-1 
protein (B) was performed  as described in  Section 2.4.2. Control 
(CON)  represents  cells  exposed  to  fresh  DMEM  alone.  The 
Western  blot  panel  is  representative  of  one  experiment.  Bars 
represent the mean ± S.E.M. of n = 4 experiments. * P < 0.05 vs. 
CON. %P< 0.05 vs. AS.
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To  support  the  hypothesis  that  NO'  induces  haem  oxygenase  activity  and 
HO-1  protein  expression,  a  set  of experiments  were  performed  to  test  the 
possibility  of  scavenging  NO,  which  could  be  derived  from  the  redox 
conversion  of  NO',  using  the  NO  scavengers  C-PTIO  and  HCB. 
Cardiomyocytes  were  challenged  with  AS  (0.75  mM)  in  the  absence  or 
presence of C-PTIO (25 pM) in fresh complete media. The latter concentration 
was  chosen  as  a  result  of a  preliminary  set of  experiments  (Figure  4.3 A) 
showing this concentration was the most suitable in terms of haem oxygenase 
induction and potential toxicity.  Exposure to AS promoted a 5.5-fold increase 
in  haem oxygenase activity compared with the control group  (100%)  (Figure
4.3  B), whereas C-PTIO had an insignificant (P > 0.05) effect. Combining both 
agents caused a significant (6-fold; P < 0.05) increase in activity similar to that 
produced by AS alone. Although C-PTIO is a known scavenger of NO6 9  it had 
no significant attenuating effect upon AS-induced haem oxygenase induction. 
This suggests that C-PTIO is unable to attenuate the effects of NO' and that 
any  NO  eventually  formed  does  not  contribute  to  AS-mediated  haem 
oxygenase  activation.  The  reason  for  the  significant  stimulation  of  haem 
oxygenase activity by CPTIO (25 and 50 pM) observed in Figure 4.3 A could 
be explained by the high sensitivity of the HO-1  enzyme to any external stimuli 
that creates  an  imbalance  in  the cellular redox state.  However,  it has  been 
noted that C-PTIO itself promotes a weak but measurable  increase in  HO-1 
mRNA expression 670 supporting the observations in Figure 4.3 A.
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Figure 4.3 Effect of carboxy-PTIO and Angeli’s salt on haem oxygenase 
activity.
Cells were treated with carboxy-PTIO (C-PTIO, 25, 50,  100 or 2 0 0  
pM)  in fresh  complete  DMEM  for  6  h.  The effect of Angeli’s salt 
(AS,  0.75  mM)  is  shown  for  comparison  (A).  A  0.75  mM 
concentration  of AS  was  applied  to  cells  in  the  absence  (-)  or 
presence (+) of C-PTIO (25 pM) (B) in fresh DMEM for 6 h. Haem 
oxygenase  activity  (assayed  as  described  in  Section  2.3.4) was 
expressed as a percentage of the control (CON),  i.e. cells treated 
with fresh DMEM alone.  Bars represent the mean ± S.E.M. of n = 
3-4 experiments. * P < 0.05 vs. CON. t  P K 0 05 vs. AS.
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When HCB (0.75 mM), a scavenger of both NO and NO' 69, was incubated in 
the  absence  or  presence  of  a  corresponding  concentration  of  AS,  striking 
changes in the  level  of haem oxygenase were observed  (Figure 4.4).  On  its 
own  AS  promoted  a  significant  increase  in  activity  compared  with  control 
(1358 ± 50.79 vs. 243.2 ± 36.4 pmoles bilirubin/mg protein/h, respectively; P < 
0.05) in contrast to  HCB which was similar to baseline. Coincubation of HCB 
with  AS  caused  a  significant  decrease  in  haem  oxygenase  activity  levels 
(597.4 ± 45.83 pmoles bilirubin/mg protein/h; P < 0.05).  Possible reasons for 
this observation include the ability of HCB to scavenge both NO and NO', also 
HCB  may  enhance  the  redox  conversion  of  NO'  to  NO  thus  enabling 
scavenging  to  occur  more  effectively  69  Taken  together  these  two  sets  of 
data, using CuS04 and  HCB,  add further weight towards the hypothesis that 
NO'  liberated  from  AS  induces  haem  oxygenase  in  cardiomyocytes  by  a 
mechanism that possibly involves redox conversion of NO" to NO.
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Figure  4.4  Attenuation  of  Angeli’s  salt-mediated  induction  of  haem
oxygenase activity by hydroxocobalamin.
Angeli’s salt (AS,  0.75 mM) was applied to cells in the absence 
(-)  or  presence  (+)  of  hydroxocobalamin  (HCB,  0.75  mM)  in 
fresh  complete  DMEM  for  6  h.  Haem  oxygenase  activity  was 
assayed  as  described  in  Section  2.3.4.  Control  (CON) 
represents cells treated with fresh  DMEM alone.  Bars represent 
the mean ± S.E.M. of n = 3-4 experiments. * P < 0.05 vs. CON. 
t  P < 0.05 vs. AS.
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4.4.2  Interaction  of  Angeli’s  salt  (AS)  with  thiols:  effect  on  haem 
oxygenase activity and HO-1  protein expression
It  has  been  shown  that  thiols,  in  particular  the  glutathione  precursor 
A/-acetylcysteine  (NAC),  have  the  potential  to  modulate  haem  oxygenase 
activity  in  different cell  types  under ‘stressful’  conditions  423-668  with  this  in 
mind,  cardiomyocytes  were  treated  with  AS  (0.75  mM)  in  the  absence  or 
presence of NAC (1  or 2 mM) in either fresh complete media or DPBS. After 6  
h cells were collected  and  analysed for haem  oxygenase  activity and  HO-1 
protein expression. The data shows that in DMEM AS alone increased haem 
oxygenase  activity  by  ~4-fold  with  respect  to  the  control  group  (100%); 
however, the addition of NAC (1  or 2 mM) significantly (P < 0.05) attenuates 
the upregulating potential of AS 3- and 3.5-fold,  respectively (Figure 4.5 A). A 
similar  pattern  of results  was  obtained  for AS  with  and  without  NAC  when 
DPBS was the vehicle (Figure 4.5 B). Of the two vehicles DMEM promoted a 
stronger (2-fold) enhancement of haem oxygenase activity in response to AS 
compared  with  a  similar  treatment  in  DPBS.  In  addition,  NAC  (2  mM) 
attenuated  AS-mediated  activity  more  effectively than  1   mM  NAC  in  media 
compared with a similar, but still significant (P < 0.05), scenario in DPBS.
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Figure 4.5 Attenuation of haem oxygenase activity following  interaction 
of Angeli’s salt with thiols.
Cells were exposed to Angeli’s salt (AS, 0.75 mM) in the absence 
(black bars) or presence (grey bars) of /V-acetylcysteine (NAC,  1  
or 2  mM)  either directly  in  DMEM  (A)  or after its  decomposition 
(see  Section 2.2.3 for preparation)  in  DPBS,  followed  by  DMEM 
(B). After 6  h haem oxygenase activity was assessed according to 
Section  2.3.4.  The  activity  was  expressed  as  a  percentage  of 
control  (CON)  (assigned  100%),  where  control  represents  cells 
treated  with  fresh  DMEM  or  DPBS  alone.  Bars  represent  the 
mean ± S.E.M.  of n = 4 experiments. * P < 0.05 vs. CON. t  P < 
0.05 vs. AS.
Media
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The ability of NAC to prevent the induction of HO-1  protein by AS is illustrated 
in Figure 4.6 (n =  1). When cardiomyocytes were incubated with AS (0.75,  1  
or 2  mM)  in  DMEM  a  strong  HO-1  protein  signal  was  observed  at  each 
concentration  used.  However,  when  equal  concentrations  of  NAC  and  AS 
were  coincubated  the  intensity  of  the  HO-1  bands  were  substantially 
decreased.  These  effects  upon  HO-1  protein were  due  to  the  interaction  of 
NAC with AS as NAC on its own was unable to induce HO-1. These three sets 
of data (Figure 4.5 and Figure 4.6) demonstrate that in this model exogenous 
thiols have the capacity to subvert the haem oxygenase inducing potential of 
NO' released from AS.
CON  NAC  AS 0.75 mM  AS 1   mM  AS 2 mM 
- NAC +  - NAC +  - NAC +
Figure 4.6 Attenuation of HO-1  protein expression following  interaction
of Angeli’s salt with thiols.
Cells were treated with Angeli’s salt (AS;  0.75,  1   or 2 mM) in the 
absence  (-)  or  presence  (+)  of  an  equal  concentration  of 
A/-acetylcysteine (NAC) for 6 h in fresh complete DMEM. Western 
blot  detection  of  HO-1  protein  was  performed  as  described  in 
Section 2.4.2. Control (CON) and NAC represent cells exposed to 
media or media containing 2 mM NAC, respectively. The Western 
blot panel is representative of one experiment.
The latter set of results  illustrate the crucial role thiols play in attenuating the 
activation  of haem  oxygenase  by AS.  To further illustrate the  importance of 
thiols in preserving the bioactivity and signal transducing properties of NO', an
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experiment  using  the  glutathione  synthesis  inhibitor  buthionine-sulfoximine 
(BSO) was performed. Following a 6 h preincubation with BSO (0.5 or 1  mM), 
which  was  a  sufficient  time  to  deplete  cellular glutathione  levels,  AS  (0.75 
mM)  was  applied  for  a  further  6  h  in  fresh  DMEM.  Measurement  of  haem 
oxygenase activity (Figure 4.7)  revealed that BSO on  its  own  did  not affect 
haem  oxygenase  activity,  unlike  AS  alone,  whereas  coincubation  with  AS 
significantly (P < 0.05) decreased the activation of haem oxygenase.
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Figure  4.7  Attenuation  of  Angeli’s  salt-mediated  induction  of  haem 
oxygenase  activity  by  the  glutathione  synthesis  inhibitor 
buthionine-sulfoximine.
Cells  were  exposed  to  the  glutathione  synthesis  inhibitor 
buthionine-sulfoximine  (BSO,  0.5  or  1   mM)  in  fresh  complete 
DMEM for 6  h.  Next, Angeli’s salt (AS,  0.75 mM) was added to 
the  BSO treated cells,  and on its own, for a further 6  h in fresh 
DMEM.  After  6   h  haem  oxygenase  activity  was  assessed 
according  to  Section  2.3.4.  Control  (CON)  represents  cells 
exposed to media alone, n = 4 experiments, * P < 0.05 vs. CON.
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4.4.3  Dissecting the NO redox forms responsible for Angeli’s salt (AS)- 
mediated induction of haem oxygenase-1
It  is  known  that  NO  can  readily  interconvert  between  its  different  redox- 
activated forms within  biological systems 13.  In subsection 3.4.4 it was noted 
that  the  haem  oxygenase  inducing  capacity  of AS  differs  according  to  its 
biological state,  i.e. freshly prepared or decomposed agent,  and surrounding 
environment (fresh  complete  DMEM  or  DPBS).  So far the  data  reveal  that 
combining  AS  with  HCB  and  thiols  leads to  an  attenuation  of AS-mediated 
induction of haem oxygenase activity, whereas C-PTIO and CUSO4 promotes 
an  increase.  To  further  probe  the  biochemistry  of  these  reactions 
measurements of NO release from equal concentrations (0.5 mM or 20 pM) of 
AS and two commonly used  NO releasing agents,  i.e.  DeaNO and  DetaNO, 
were  made  in  fresh  complete  DMEM  or  DPBS  using  a  Clark-type  NO 
electrode.
The  table  in  Figure  4.8  reveals  a  number of biochemical  details  about AS. 
Firstly, 0.5 mM of AS in DMEM generates much less NO (0.31  ± 0.01  pM x s) 
compared with  DeaNO (10.1  ± 0.78 pM x s, P < 0.05) but significantly more 
than  DetaNO  (0.03 ±  0.01  pM  x  s,  P <  0.05).  Secondly,  the amount of NO 
generated from AS in culture media (0.31  ± 0.0.1  pM x s) is significantly (P < 
0.05) higher than the quantity measured in DPBS (0.078 ± 0.01  pM x s), thus 
indicating that conversion of NO' to NO is indeed a feasible process within the 
cell  culture  environment.  Lastly,  a  concentration  of 20  pM  DeaNO  releases 
the same amount of NO over time as 0.5 mM AS in the cell culture medium
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(0.32 ± 0.01  pM  x  s and  0.31  ± 0.01  pM  x  s,  respectively). When these two 
concentrations, 0.5 mM AS and 20 pM DeaNO, were applied directly to cells 
in  culture  for  6  h  the  level  of  haem  oxygenase  activity  for  DeaNO  was 
comparable  to  control  levels  (300.7  ±  29.02  vs.  324.7  ±  49.7  pmoles 
bilirubin/mg  protein/h,  respectively),  whereas  AS  caused  a  significant  (P  < 
0.05)  increase  in  activity  (see  Figure  4.8).  Taken  together,  this  set  of data 
confirms  that  NO'  liberated  from  AS  can  directly  stimulate  the  haem 
oxygenase pathway and suggest that the extent and rate of NO' oxidation to 
NO  augments  the  contribution  of  NO  to  stimulating  the  haem  oxygenase 
pathway.
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Treatment  NO re|ease (AUC,  x sec)
_________________________ DPBS____________ DMEM
AS (0.5 mM)  0.078 ±0.1  0.31 ±0.01*
DeaNO (0.5 mM)  21.7 ± 0.65  10.1  ± 0.78n
DetaNO (0.5 mM)  0.079 ±0.02  0.03±0.01n
DeaNO (20 pM)  0.60 ±0.02  0.32 ±0.01*
$  500 (U   C
2 5  250
CON  AS  DeaNO
0.5 mM  20 pM
Figure 4.8 Direct involvement of Angeli’s salt-derived NO' in increasing 
haem oxygenase activity.
The Table inserted in this figure reports data on the amount of NO 
released  over  time  from  various  agents  measured 
amperometrically  using  a  NO-sensitive  electrode  (see  Section 
2.5.2).  Each  value  represents  the  mean  (±  S.E.M.)  of  4 
experiments performed independently. * P < 0.05 vs.  DPBS; f  P < 
0.05 vs.  AS.  The figure reports the effect of Angeli’s salt (AS,  0.5 
mM)  or  DeaNO  (20  pM)  on  H9c2  haem  oxygenase  activity  (see 
Section  2.3.4  for  method)  after  6  h  in  DMEM.  Control  (CON) 
represents  cells  treated  with  complete  DMEM  alone.  Each  bar 
represents  the  mean  (±  S.E.M.)  of  5-6  experiments  performed 
independently. * P < 0.05 vs. control (CON).
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4.4.4  Nitrite  (NO2)  liberated  from the  metabolism  of Angeli’s salt (AS) 
does not affect haem oxygenase activity
Ever since Angeli’s salt (AS,  Na2N203) was first identified in  1903 there have 
been  numerous  studies  into  its  chemistry,  reactivity  and  decomposition  in 
various  solutions  and  under  different  conditions  38,281,672.  Under  neutral  or 
mildly  alkaline  conditions  AS  rapidly  breaks  down  according  to  first-order 
kinetics  to  liberate  the  intermediates  nitrosyl  hydride  (HNO,  commonly 
referred  to  as  NO')  and  N02‘.  The  former  can  undergo  dimerization  and 
dehydration to form N20  as the final product 674. To eliminate the possibility of 
N02 '  having  an  effect  on  the  reactions  involving  AS  similar  concentrations 
(0.75 mM) of these agents were added to cells in  DMEM for 6 h.  Figure 4.9 
reveals  that  AS  promotes  a  significant  (P  <  0.05)  enhancement  of  haem 
oxygenase  activity  (1413  ±  60.41  (AS)  vs.  372.7  ±  49.22  (control)  pmoles 
bilirubin/mg  protein/h),  whereas  N02'  did  not  have  any  effect  upon  this 
parameter (P >  0.05).  Therefore,  this data suggests that NO' liberated from 
AS is the principal factor responsible for the results observed.
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Figure 4.9 Nitrite does not influence haem oxygenase activity.
Cells were treated with equal concentrations (0.75 mM) of Angeli’s 
salt  (AS)  and  nitrite  (NO2')  in  fresh  complete  DMEM.  After 6  h 
haem  oxygenase  activity  was  assessed  according  to  Section 
2.3.4. Control (CON) represents cells exposed to media alone, n = 
4 experiments, * P < 0.05 vs. CON.
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4.5  Discussion
Having  established  in  Chapter 3  that  NO'  liberated from AS  induces  haem 
oxygenase  activity,  HO-1  protein  and  gene  expression,  this  chapter further 
examined the chemistry of these responses. It is known that the composition 
of the cellular milieu and the surrounding environment can influence the type 
and  rate  of  NO  congener  formation  13.  Also,  oxidants,  e.g.  superoxide 
dismutase and copper ions, can bring about the oxidation of NO' to NO 48 6 2 > 6 3 . 
With  this  in  mind,  a  series  of  experiments  were  conducted  to  alter  the 
microenvironment towards the conversion of NO' to NO and also to examine 
the  influence  of  NO'  on  haem  oxygenase  activity  and  the  HO-1  protein. 
Incubation of a low (10 pM) concentration of CUSO4 in the presence of AS in 
different vehicles,  DMEM  and  DPBS,  elicited a synergistic increase  in  haem 
oxygenase activity  in  both vehicles,  particularly so  in  DMEM  (1802  +  179.2 
pmoles  bilirubin/mg  protein/h;  P  <  0.05).  The  possibility  that  CuS04  was 
exerting  an  influence  per se  was  excluded  as  the  activity  levels  remained 
similar to control in both vehicles using CuS04 alone. The synergistic capacity 
of both agents was repeated when increasing concentrations of CuS04 were 
combined with  a fixed concentration  of AS,  thus augmenting the intensity of 
HO-1  protein expression in cardiomyocytes.  However, at high concentrations 
(50-100  pM)  0uSO4 per se was  able to stimulate  haem  oxygenase activity. 
This set of data suggests that the effects of NO' appear to be independent of 
NO but can  be  amplified  by accelerating the rate of NO' oxidation to  NO.  In 
parallel  with  the  previous  results  showing  a  greater  degree  of  haem 
oxygenase activity in  DMEM  compared with  DPBS,  one cannot discount the
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possibility of media components exerting an influence.
The results from the latter experiment suggest that the oxidation of NO' to NO 
leads to an elevation in haem oxygenase activity. To fully verify the hypothesis 
that  AS-derived  NO'  induces  haem  oxygenase  activity  and  HO-1  gene 
expression  a  set  of  experiments  were  performed  to  test  the  feasibility  of 
scavenging the NO eventually generated from AS using the NO scavenger C- 
PTIO and HCB, a scavenger of both NO and NO' 69-675. Thus, in the presence 
of  a  NO  scavenger  NO'  should  represent  the  principal  mediator  of  haem 
oxygenase  induction.  When  the  cardiomyocytes  were  treated  with  AS  and 
C-PTIO  there  was  no  significant  increase  in  haem  oxygenase  activity 
compared with  that generated  by AS alone.  Possible  reasons for this  result 
could  be:  (a) the concentration of the agents applied,  AS  [mMJ  and  C-PTIO 
[pM], thus AS would subdue the scavenging capabilities of C-PTIO *[Note: we 
could not use concentrations of C-PTIO greater than 25 pM because toxicity 
would prevail]; (b) the C-PTIO is unable to attenuate the NO' derived from AS 
676; and (c) any NO that is formed does not contribute to AS-mediated haem 
oxygenase  activation.  When  HCB was used  as  a  NO/NO' scavenger in the 
presence of AS there was a significant reduction in  haem oxygenase activity 
compared with AS alone (1358 ± 50.79 vs. 597.4 ± 45.83 pmoles bilirubin/mg 
protein/h;  P <  0.05).  Recent publications suggest that HCB may mediate the 
oxidation  of  NO'  to  NO,  by  an  unknown  mechanism,  thus  facilitating  more 
effective scavenging, a similar reaction could account for the results observed 
with the cardiomyocytes 69-677-678  Taken together,  the  data  obtained with  C- 
PTIO and HCB substantiate the hypothesis that NO' induces haem oxygenase
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in cardiomyocytes, at the same time the data suggests a possible mechanism 
for this induction, i.e. redox conversion of NO' to NO.
In the context of HO-1  modulation by NO and NO-related species a number of 
reports  have  highlighted  the  protective capacity of the glutathione  precursor 
A/-acetylcysteine  (NAC)  423-668.  The  experiments  using  the  thiol  donor  NAC 
support the  notion that  NO' originating from AS  metabolism,  rather than  the 
agent itself, is the chemical entity responsible for the induction of HO-1  protein 
and  increased  haem  oxygenase  activity.  When  NAC  (1  or  2  mM)  was 
combined  with  a  fixed  concentration  of AS  (0.75  mM)  in  different vehicles, 
DMEM and  DPBS,  a considerable (3-3.5-fold)  reduction  in  haem  oxygenase 
activity  was  observed  using  both  vehicles,  while  coincubation  of  equal 
concentrations  of  the  two  agents,  in  DMEM,  significantly  attenuated  HO-1 
protein  expression.  These  results  indicate  that  NO'  can  directly  influence 
haem  oxygenase  activity  and  transcriptionally  activate  the  HO-1  gene  in 
addition to the notion that thiols exert a protective influence, possibly through 
the formation  of endogenous  R-SNO,  in different cell types  under ‘stressful’ 
conditions through their ability to scavenge harmful molecules 26,679. This idea 
is substantiated by the observation that BSO, a glutathione synthesis inhibitor, 
reduced  the  ability  of  AS  to  induce  haem  oxygenase  activity.  Thus, 
endogenous glutathione participates in the preservation of NO' bioactivity and 
signalling properties.
To dissect the contribution of NO' and NO towards the upregulation of haem 
oxygenase  activity  experiments  were  conducted  using  a  sensitive  NO 
electrode  and  the  agents AS,  DeaNO and  DetaNO.  A comparison  between
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AS and DeaNO, both of which have similar half-lives (t!4 = 2.3 min for AS and 
t1 /z = 2 min for DeaNO),  but release either NO' or NO,  respectively,  revealed 
that  in  DMEM,  0.5  mM  AS  generated  the  same  quantity  of  NO  as  20  pM 
DeaNO. However, only AS was capable of promoting a significant increase in 
haem  oxygenase  activity at these  concentrations.  The  low concentration  of 
NO release from AS in DPBS (0.078 ±0.1  pM  x  s), which is 4-fold less than 
that in  DMEM,  correlates with the results shown  in  Figure 3.5.  The very low 
concentration  of NO  released  by  DetaNO  in  DMEM  (-0.03  pM  x  s) can  be 
explained  by the long  half-life of this agent (V/2  = 20 h).  To complement the 
latter experiments the data  in  Figure 4.9 support the notion  that NO',  rather 
than  other  intermediates,  e.g.  NO2',  is  the  principal  factor  responsible  for 
activating the haem oxygenase pathway in this model.
4.6  Conclusion
The  aim  of  this  chapter  was  to  explore  the  chemistry  of  NO'-mediated 
induction of haem oxygenase activity and HO-1  protein expression. This study 
demonstrates that:  1.  NO' can directly influence haem oxygenase activity and 
HO-1  protein levels; 2.  this effect can be enhanced by increasing the rate of 
NO' oxidation to NO (or other RNS) or by media components; and 3. thiols are 
essential to convey the signalling  properties of NO'.  Collectively,  these data 
reveal that the  haem oxygenase  pathway is  not only a  highly sensitive and 
effective  stratagem for cellular defence against oxidative  challenge,  but can 
also be finely modulated by redox reactions involving nitrosative chemistry.
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5  INTERACTION  BETWEEN  NITROXYL  ANION  OR 
NITRIC  OXIDE  AND  HEMlN  AMPLIFIES  HAEM 
OXYGENASE-1  INDUCTION:  A  ROLE  FOR  THE 
TRANSCRIPTION FACTOR Nrf2
5.1  Introduction
Ferro-(Fe2+)protoporphyrin  IX  (or  haem)  plays  a  crucial  role  in  many 
mammalian functions  and  tissues 4 48  This  highly lipophilic and  hydrophobic 
tetrapyrrole participates as a cofactor in complex biological reactions and acts 
as  a  ligand  for  a  wide  range  of  haemoproteins,  e.g.  haemoglobin, 
cytochromes,  NOS  and  guanylate  cyclase  384.  Due to  its  low solubility and 
potential oxidative toxicity of the iron within haem mammals have developed a 
number  of  mechanisms  to  transport  and  contain  free  haem.  Examples  of 
these  include  the  formation  of  stable  complexes  between  free  haem  with 
proteins  such  as  albumin,  lipoproteins  and  haemopexin,  to  deliver  the 
tetrapyrrole to tissues and distribute it within cells 62°. The importance of haem 
and  in turn  iron  homeostasis  is illustrated  by the wide  range of pathological 
diseases  associated  with  uncontrolled  free  haem,  e.g.  sickle  cell  disease, 
renal failure, atherogenesis and the porphyrias 621.
The principal mechanism for the metabolism of free haem and containment of 
its  iron  molecule  is  via  the  enzyme  haem  oxygenase  and  the  iron  storage 
protein ferritin,  respectively 479-484  Basal  levels  of haem  are  metabolised  by 
the constitutive isoform of haem oxygenase (HO-2), while excessive amountsNITROXYLHAEM
of haem are dealt with by the inducible isoform, HO-1. Both isoforms give rise 
to  CO,  bilirubin  and  Fe2 +   as  the  end  products  of haem  metabolism.  Thus, 
haem derived  from  haemoproteins can  serve as  both  a  substrate for haem 
oxygenase and promote the induction of the HO-1  gene, which in turn leads to 
increased metabolism of haem 364. The cytoprotective characteristics of haem 
oxygenase,  in particular HO-1,  stems from the following observations:  1.  the 
HO-1 gene has stress response elements (StREs), which bear similarity to the 
recognition sequence for the oxidant sensitive transcription factor Nrf2, within 
its promoter region 465; 2. the products of haem metabolism, CO and bilirubin, 
have the ability to attenuate the adverse effects of oxidative reactions 48°; and 
3. NO has a very high affinity for haem and other haemoproteins, which in turn 
can promote HO-1  induction 617-630.
Oxidative stress was identified as one of the first mechanisms responsible for 
the induction  of HO-1  68°.  Recent evidence suggests that HO-1  can  also  be 
induced  following  exposure  to  elevated  levels  of  NO,  NO+   and  NO'  type 
agents  427481681.  Collectively,  these  observations  led  to  the  hypothesis  that 
HO-1  is  upregulated  in  the  presence  of  RNS  and  oxidative  type  insults  to 
attenuate such cellular stressors and maintain cellular function 373  However, a 
direct interaction between the substrate of haem oxygenase  (haem) and  NO 
in  stimulating  HO-1  induction  has  not  been  investigated.  This  chapter will 
describe experiments to examine how HO-1  expression is modulated by the 
prooxidant  haem  (delivered  as  hemin  (ferri-(Fe3+)protoporphyrin  IX)  its 
oxidised form) and inducers of nitrosative stress, e.g. the NO' liberator AS and 
the NO donor DeaNO.  To elucidate the signalling  pathway(s)  relating to the
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antinitrosative  capacity  of  HO-1,  the  -involvement  of  the  redox-sensitive 
transcription  factor  Nrf2  was  examined  in  parallel.  The  potential  biological 
implication of these findings will also be discussed.
5.2  Objective
The aim  of this chapter is to verify that induction  of HO-1  by the  combined 
effects  of  the  prooxidant  haem  and  different  types  of  RNS  is  an  intrinsic 
mechanism to alleviate redox imbalances caused by different types of cellular 
stress.  The  transcriptional  mechanism  leading  to  this  induction  will  also  be 
examined.
5.3  Materials and Methods
5.3.1  Preparation of reagents
Stock solutions of AS,  DeaNO,  NAC and  hemin were  prepared as described 
in Section 2.2.3. All of the agents were prepared fresh for each experiment in 
opaque Eppendorfs, or a 15 ml tube wrapped in foil for hemin, and placed on 
ice until required.
5.3.2  Maintenance and treatment of cells
Rat H9c2 cardiomyocytes were cultured in DMEM as previously described 681. 
The  agents  were  applied  to  cells directly,  or  following  their  preincubation
either alone  or  in combination  for 1   h  at  37°C,  in  vehicle  (DMEM),  at the
concentrations shown in each graph. Assessment of haem oxygenase activity, 
isolation  of  Nrf2, Western  blotting  of  HO-1  and  Nrf2,  RT-PCR,  or  cell
metabolism  assays  were  carried out  at  the  end  of  the  experiments  as
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described  in  Sections  2.3.4,  2.4.2,  2.4.4,  2.4.1  and  2.2.4,  respectively. 
Negative  controls,  which  consisted  of  vehicle  alone,  were  included  in  all 
experiments.
5.3.3  Oxygen tension experiments
Experiments in this chapter were carried out under normoxic (5% CO2,  PO2 = 
150 mmHg) or hypoxic (5%  C02  and 95%  N2,  PO2 = 2  mmHg) conditions at 
37°C.  For the  hypoxia  experiments cardiomyocytes were  incubated with the 
agents within an air tight chamber. A hypoxic environment was established by 
infusing the gas at a flow rate of 5  L/min for 2  h followed  by  1   L/min for the 
remaining duration of the experiment. Controls consisted of vehicle alone.
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5.4  Results
5.4.1  Synergism between Angeli’s salt {AS) and hemin increases haem 
oxygenase activity, HO-1 protein and mRNA expression
Figure 5.1  reports the effects of hemin, AS or a combination of both agents on 
haem oxygenase activity (A) and HO-1  protein expression (B; n =  1) in H9c2 
cells following direct application of the agents in complete media for 6 h. Akin 
to  previous  experiments  involving  this  mode  of  addition,  AS  promoted  a 
significant increase in haem oxygenase activity compared to control (797.8 ±
102.3  (AS)  vs.  202.9  ±  14.9  (control)  pmoles  bilirubin/mg  protein/h, 
respectively; P < 0.05); this observation was replicated vis-a-vis HO-1  protein 
expression.  Similarly,  hemin  (5-20  pM)  induced  a  concentration  dependent 
increase  in  haem  oxygenase  activity and  HO-1  protein  levels.  Of  particular 
interest  is  the  observation  that  simultaneous  addition  of  AS  and  hemin 
significantly elevates the measured parameters in  a synergistic manner (P <
0.05 vs. control or hemin alone). When the same experiments were repeated 
following a 1   h preincubation of the agents at 37°C in media before addition to 
cells, AS lost its ability to induce either haem oxygenase activity (260.7 ± 37.1 
(control) vs. 223.7 ±6.1  (AS) pmoles bilirubin/mg protein/h) (Figure 5.2 A) or 
HO-1  protein (Figure 5.2 B; n =  1). This response is similar to that witnessed 
in earlier experiments  involving decomposed AS.  However,  hemin  (5-20 pM) 
maintained  AS’s  ability to  promote  an  elevation  in  haem  oxygenase activity 
and intensity of HO-1  protein expression. Surprisingly, coincubation of AS with 
hemin (5-20  pM) resulted in augmented haem oxygenase activity (P < 0.05) 
and  HO-1  protein  expression  compared to control,  an effect similar to direct
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application  of  the  agents.  Thus,  the  presence  of  hemin  during  the 
preincubation step synergised with NO' ta induce HO-1.
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Figure 5.1  Interaction  between Angeli’s salt and  hemin amplifies  haem
oxygenase activity and HO-1  protein expression.
Cells were exposed directly to Angeli’s salt (AS,  0.75 mM) in the 
absence  (-)  or presence  (+)  of hemin  (5,  10  or 20  pM)  in fresh 
complete DMEM. After 6 h haem oxygenase activity (A) and HO-1 
protein  expression  (B)  were  determined  according  to  Sections 
2.3.4 and 2.4.2,  respectively.  Control  (open  bar)  represents cells 
exposed  to  fresh  DMEM  alone.  The  Western  blot  panel  is 
representative  of  one  experiment.  Bars  represent  the  mean  ± 
S.E.M. of n = 4 experiments. * P < 0.05 vs. Control, t  P < 0.05 vs. 
hemin alone.
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Figure 5.2 Formation of a haem-nitrosyl complex maintains the induction
of haem oxygenase activity and HO-1  protein expression.
Cells were exposed to Angeli’s salt (AS, 0.75 mM) in the absence 
(-)  or  presence  (+)  of  hemin  (5,  10  or  20  pM)  following  their 
preincubation for 1   h at 37°C beforehand in fresh complete DMEM. 
After  6  h  haem  oxygenase  activity  (A)  and  HO-1  protein 
expression  (B) were  determined  according  to  Sections 2.3.4  and 
2.4.2,  respectively. Control (open bar) represents cells exposed to 
fresh  DMEM  alone.  The  Western  blot  panel  is  representative  of 
one  experiment.  Bars  represent  the  mean  ±  S.E.M.  of  n  =  4 
experiments. * P < 0.05 vs. Control.
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The  results  of  RT-PCR  analysis  (Figure 5.3;  n =  1)  shows  that AS  has the 
ability  to  intensify  the  transcriptional  activation  of  HO-1  mRNA  in  a 
concentration  dependent  manner  in  the  presence  of  low  micromolar 
concentrations  of hemin,  compared with  either agent alone,  following  direct 
incubation with cells for 3 and 6 h.
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Figure 5.3 Interaction of Angeli’s salt and hemin intensifies HO-1  mRNA 
expression.
Cells were exposed  directly to Angeli’s salt (AS,  0.75  mM)  in  the 
absence  (-)  or  presence  (+)  of  hemin  (5,  10  or 20  pM)  in  fresh 
complete  DMEM.  After  3  and  6  h  HO-1  mRNA  expression  was 
determined  by  RT-PCR  using  rat  HO-1  primers  (see  Section 
2.4.4).  Control  (no  treatment)  represents  cells  exposed  to  fresh 
DMEM  alone.  The  PCR  image  is  representative  of  a  single 
experiment with p-actin serving as a loading control.
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The data  reported  in  Figure  5.4  reveals  that combining  1   mM  NAC with AS 
significantly attenuated the haem oxygenase inducing capacity of NO", (279.9 
±  5.1  vs.  863.2  ±  53.4  pmoles  bilirubin/mg  protein/h;  P  <  0.05),  thus 
supporting the previous observations in Chapter 4,  i.e. that thiols can prevent 
HO-1  induction  by nitrosative agents.  However,  the simultaneous addition of 
AS and NAC with increasing concentrations (5-20 pM) of hemin was unable to 
prevent an  increase  in  haem oxygenase activity which was significantly (P <
0.05) higher than cells treated with hemin  alone. These  results suggest that:
1. a strong and specific interaction between NO' and hemin elicits an induction 
of HO-1; 2.  hemin  stabilises the NO' groups,  possibly through formation  of a 
haem-nitrosyl  complex,  even in  presence of high thiol concentrations;  and 3. 
the affinity of NO' towards haem is stronger and much greater than its affinity 
for cysteine residues.
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Figure 5.4 Possible formation of a haem-nitrosyl complex maintains the 
induction  of  haem  oxygenase  activity  in  the  presence  of
Cells  were  exposed  directly  to  Angeli’s  salt  (AS,  0.75  mM)  or 
hemin  (5,  10  or  20  pM)  in  the  absence  (-)  or  presence  (+)  of 
A/-acetylcysteine (NAC,  1   mM). After 6 h haem oxygenase activity 
was  determined  according  to  Section  2.3.4.  Control  (open  bar) 
represents  cells  exposed  to  fresh  DMEM  alone.  Bars  represent 
the mean ± S.E.M. of n = 4 experiments. * P < 0.05 vs. Control. $ 
P < 0.05 vs. AS alone, t  P < 0.05 vs. hemin alone.
thiols.
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Previous data from  Chapters 3 and 4 suggested that N0‘ activates  HO-1  at 
the transcriptional level. This observation was reinforced by Western blot data 
for  the  redox-sensitive  transcription  factor  Nrf2.  Following  a  3  and  6  h 
exposure  to  the  NO'  generator AS,  there  was  a  significant  increase  in  the 
expression of Nrf2  in the  nuclear fraction (see  Figure 5.5 A;  n =  1),  but this 
response was eliminated completely by the addition of 1   mM  NAC.  Similarly, 
the  combination  of  AS  and  hemin  (5-20  pM)  greatly  intensified  Nrf2 
expression (Figure 5.5 B;  n =  1),  but NAC was unable to attenuate the latter 
response (data not shown) which is akin to the effect observed in Figure 5.4. 
Interestingly,  hemin  alone  did  not  induce  any  Nrf2  expression.  Possible 
explanations  for  these  observation  are  that  hemin  (a  prooxidant)  may  be 
activating  the  haem  oxygenase  pathway  via  a  route  that  is  sensitive  to 
oxidative stress,  e.g. the activator protein-1  (AP-1) transcription factors or the 
haem response element, whereas the haem-nitrosyl complex (a pronitrosant) 
may  mediate  enhancement  of  HO-1  protein  via  Nrf2  in  this  model. 
Collectively, these data suggest that Nrf2 activation is augmented in response 
to nitrosative stress and haem-nitrosyl complex formation.
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Figure 5.5  Modulation  in the expression of the transcription factor Nrf2
in response to Angeli’s salt, thiols and hemin.
Cells were treated directly with Angeli’s salt (AS, 0.75 mM) in the 
absence (-) or presence (+) of the thiol generator A/-acetylcysteine 
(NAC,  1   mM)  (A)  or  with  (AS,  0.75  mM)  in  the  absence  or 
presence of hemin (5,  10 or 20 pM) (B) in fresh complete DMEM. 
After 3 and 6 h  nuclear extracts were prepared and Western blot 
detection of Nrf2 protein was performed as described in Sections 
2.4.1  and  2.4.2,  respectively.  Control  (no  treatment)  represents 
cells  exposed  to  media  alone.  Each  Western  blot  panel  is 
representative of one experiment.
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As noted in Chapter 3, the NO releasing agent DeaNO led to a concentration 
dependent increase in haem oxygenase activity and HO-1  protein expression. 
To  examine  the  possibility  that  DeaNO  (0.5  mM)  could  also  complex  with 
hemin  (5-20  pM)  the  agents  were  preincubated,  either  alone  or  in 
combination,  for  1   h  at  37°C  in  media  prior to  their addition  to  cells  for a 
further  6  h.  Also,  a  set  of  cells  treated  with  DeaNO  directly  for  6  h  was 
included  for  comparison.  The  results  in  Figure  5.6  reveal  that  DeaNO 
promoted  a  significant  increase  in  haem  oxygenase  activity  when  applied 
directly  to  cells  (1287  ±  62.0  (DeaNO)  v.  260.7  ±  37.1  (control)  pmoles 
bilirubin/mg  protein/h;  P <  0.05).  In  analogy with  the AS  data,  decomposed 
DeaNO  was  unable  to  induce  haem  oxygenase  activity.  However,  the 
presence  of  various  concentrations  of  hemin  in  the  media  led  to  an 
augmented  increase  in  haem  oxygenase  activity  which  was  much  more 
substantial (P < 0.05) than hemin alone and almost comparable with the direct 
addition of DeaNO. Therefore,  both  NO' and NO have the capacity to directly 
synergise  with  hemin  to  promote  an  increase  in  cardiac  haem  oxygenase 
activity.
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Figure  5.6  Interaction  between  DeaNO  and  hemin  amplifies  haem 
oxygenase activity.
Cells  were  exposed  to  DeaNO  (0.5  mM)  in  the  absence  (-)  or 
presence  (+)  of  hemin  (5,  10  or  20  pM)  following  their 
preincubation  for  1   h  at  37°C  beforehand  in  fresh  complete 
DMEM.  The  effect  of directly  applied  DeaNO  (hatched  bar)  is 
shown  for comparison.  After 6  h  haem  oxygenase  activity was 
determined  according  to  Section  2.3.4.  Control  (open  bar) 
represents cells exposed to fresh  DMEM  alone.  Bars represent 
the mean ± S.E.M. of n = 4 experiments. * P < 0.05 vs. Control, 
t  P < 0.05 vs. hemin alone.
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Exposure of cells directly to AS (0.75 mM), hemin (5-20 pM) or a combination 
of both  agents caused  minimal toxicity over a 6  h  period,  see  Figure 5.7. A 
somewhat similar pattern was observed after a  1   h  preincubation of AS with 
hemin  (5  or  10  pM),  although  AS  plus  20  pM  hemin  resulted  in  a  25% 
decrease  in  cell  metabolism.  This  data  correlates  with  previous  findings 
showing  reduced  activation  of the  haem  oxygenase  system  in  response  to 
increased cytotoxicity 681.
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Figure 5.7 Effect of haem-nitrosyl interaction on cell metabolism.
Cardiomyocytes were treated for 6  h with Angeli’s salt (AS,  0.75 
mM) in the absence (-) or presence (+) of hemin  (5,  10 or 20 pM) 
either directly  (filled  bars)  or after the  agents were  preincubation 
(hatched  bars)  for  1   h  at  37°C  beforehand  in  fresh  complete 
DMEM.  Cell  metabolism,  which  was  determined  according  to 
Section  2.2.4,  was  expressed  as  a  percentage  of  the  control 
(assigned  100%).  Control (no treatment) represents cells exposed 
to fresh  DMEM alone.  Bars represent the mean ± S.E.M.  of n = 6 
experiments. * P < 0.05 vs. Control.
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The data presented so far in this chapter were obtained from cells incubated 
under normoxic  conditions.  A  series  of experiments  were  conducted  under 
hypoxic conditions,  which  is a very potent stimulus for the  haem  oxygenase 
pathway  in  different  cell  types  ^s-495-682-6 83  to  investigate  if  the  synergism 
observed  between  hemin  and  NO' could  be  maintained.  Hemin  (5  pM),  AS 
(0.75 mM) or a combination of both agents were preincubated in media for 1   h 
at 37°C  before  their addition  to  cells  under normoxic or  hypoxic  conditions. 
The results of a time-course analysis of haem oxygenase activity,  expressed 
as a percentage of the control group, following 0-18 h normoxia or hypoxia are 
shown in Figure 5.8 A and B, respectively.
The  control  (0  h)  values  (100.3  ±  7.8  pmoles  bilirubin/mg  protein/h)  for 
normoxia and  hypoxia were derived from the same set of flasks as they are 
equivalent  situations.  Similarly,  the  haem  oxygenase  activity  levels  did  not 
deviate significantly from 0 h control at the subsequent control time points (6, 
12 and  18 h)  analysed. Akin to  previous observations,  decomposed AS was 
unable  to  promote  a  significant  increase  in  haem  oxygenase  activity, 
therefore, a pattern similar to control was observed over 18 h at both oxygen 
tensions. Based on the absolute values of haem oxygenase activity measured 
in cells during hypoxia or normoxia no difference was observed in cells treated 
with  AS  alone for  all  the  time  points  considered.  In  the  presence  of hemin 
alone there was a significant (F < 0.05) increase in  haem oxygenase activity 
over  18  h  under both  hypoxic and  normoxic conditions.  However,  while the 
increase  in  haem  oxygenase  activity  was  sustained  during  normoxia,  in 
hypoxia the pattern consisted of an increase (6 h) followed by a plateau (12 h)
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followed  by  a  further  increase  at  18  h.  Comparison  of the  respective  time 
points of hemin  treatment revealed  a significant (P <  0.05)  difference at the 
corresponding time  points especially under hypoxic conditions. The basis for 
the  latter  observation  could  be  due  to  the  simultaneous  stimulation  of the 
haem  oxygenase  pathway  by  two  potent  stimuli,  i.e.  hemin  and  hypoxia. 
When  exposed  to  a  combination  of  AS  and  hemin  there  was  a  strong 
amplification  in  the  level  of haem oxygenase activity during the first  12  h  of 
hypoxia  and  normoxia,  but  no  inter  group  differences  in  haem  oxygenase 
activity at 6 and 12 h were noted, after which there was a respective decline to 
levels equal to or below the ones obtained with  hemin alone.  This decline in 
haem  oxygenase activity was  more pronounced  (P <  0.05) when  cells were 
exposed to AS and hemin for 18 h hypoxia compared with a similar scenario 
under normoxic conditions.  A possible  reason for this is that the capacity of 
the haem oxygenase enzyme was overwhelmed by a triad of events,  i.e. the 
combination of AS and hemin plus the low oxygen tension environment.
Although Western blot data has not been included with these observations our 
group has previously shown the ability of hypoxia and hemin to induce HO-1 
protein  expression  in  a  time-dependent  manner  compared  to  normoxia  6 47 
The aforementioned data, together with the previous Western blot data for AS 
presented  in this  and  preceding chapters of this Thesis strongly support the 
fact that an increase in haem oxygenase activity under hypoxic and normoxic 
conditions would  be  paralleled  by a corresponding  induction of HO-1  protein 
expression, thus precluding the need for further Western blot analysis. Taken 
together, these data reveal that the ability of hemin to complex with  NO' and
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promote  a  significant  augmentation  in  haem  oxygenase  activity  can  be 
maintained during conditions of high and low oxygen tension.
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Figure  5.8  Induction  of  haem  oxygenase  activity  by  a  haem-nitrosyl
interaction is maintained at different oxygen tensions.
Cells were exposed to Angeli’s salt (AS, 0.75 mM) in the absence 
(-) or presence (+) of hemin  (5  pM) following their preincubation 
for  1   h  at  37°C  in  fresh  complete  DMEM.  After 6,  12  or  18  h 
exposure  to  a  normoxic  (A)  or  hypoxic  (B)  environment  haem 
oxygenase  activity  was  determined  according  to  Section  2.3.4. 
The  activity  was  expressed  as  a  percentage  of  control  (0  h) 
(assigned  100%),  where  control  represents  cells  treated  with 
fresh DMEM alone.  Each symbol represent the mean ± S.E.M. of 
n = 4 experiments.  * P < 0.05 vs.  Control,  f  P < 0.05 vs.  hemin 
alone.
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Both NO and its congeners, e.g.  NO+  and NO’, are effective inducers of HO-1 
in vascular and cardiac cell types 427,481,681. The data presented in this chapter 
demonstrates that a combination of hemin (the oxidised (Fe3+) form of haem) 
and the nitroxyl generator (AS) or NO donor (DeaNO) significantly increased 
haem oxygenase activity and enhanced HO-1  protein and mRNA expression. 
These effects were more pronounced than those observed when either agent 
was applied to cells alone.  Furthermore,  preincubation of AS or DeaNO with 
hemin  for  1   h  in  media  at  37°C  before  their addition  to  cells  preserved  the 
biological  potency  of  both  the  former  compounds  to  activate  the  HO-1 
pathway.  This  suggests  a  direct  interaction  between  haem  and  NO'  or  NO 
leads to an amplification of HO-1  induction. The formation of a haem-nitrosyl 
complex  by  NO'  is  a  feasible  outcome  given  its  affinity for  Fe3+   complexes 
68,684.  The  data  also  shows  that  NO  (originating  from  DeaNO)  can  form  a 
similar complex which  is unusual given the greater affinity of this species for 
Fe2 +  centres  19,67,183  although Juckett et al.  observed  a similar affinity when 
using  DeaNO  in endothelial cells 617.  Furthermore,  the  stability of the haem- 
nitrosyl complex, which can avidly bind with serum proteins such as albumin 
685,  is  enhanced  as  the  latter protein  is  present at  high  levels  in the  media 
used  in these  experiments.  Interestingly,  the addition of NAC to the  medium 
was only capable of moderately attenuating the induction of haem oxygenase 
activity  and  HO-1  protein  by  AS  plus  hemin,  despite  the  fact  that  data  in 
Chapter 4 and from  previous groups 423,668 indicated that NAC can suppress 
HO-1  mediated induction by NO* or NO. Thus, the strong affinity of the haem-
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nitrosyl complex can serve as a potent inducer of the HO-1 system to combat 
different  types  of  nitrosative  stress  even  in  the  presence  of  high 
concentrations of thiols.
The actinomycin  D data from  Chapter 3 suggests that induction  of HO-1  by 
NO' or NO occurs at the transcriptional level. Chen and Maines have reported 
that HO-1  mRNA expression is upregulation by different NO congeners via the 
activation of MAPKs, e.g. ERK and p38, but the SAPK/JNK pathway and AP-1 
transcription factor levels were unchanged 686. The possibility that other redox- 
sensitive transcription  factors  participate  in  the  induction  of HO-1  by  NO' or 
NO-related  species  has  not  been  examined.  For  the  first  time  the  current 
study shows that protein expression of the redox-sensitive transcription factor 
Nrf2 is significantly increased within the nuclear fraction of cells in response to 
NO' stimulation, but this effect if completely eliminated by the addition of NAC. 
In  contrast,  a  fixed  concentration  of  AS  and  increasing  concentrations  of 
hemin  promotes  a  gradual  enhancement  in  intensity  of  Nrf2  expression. 
Taken  together,  the  observations  so  far  indicate  that  Nrf2  can  serve  as  a 
sensitive gauge of the extent of nitrosative stress, which in turn leads to HO-1 
induction, and these responses are strongly regulated by thiols.
The  ability  of  Nrf2  to  exert these  effects  upon  HO-1  is  feasible  due  to  the 
presence of a series of StREs,  which resemble the recognition sequence for 
Nrf2, within the promoter region of the HO-1  gene 465  Normally Nrf2 lies in an 
inactive state within  the  cytosol  via  binding with  its chaperone  Keapl  666.  In 
response to electrophilic agents,  or compounds that modify cysteine residues 
687, the link between Nrf2 and Keapl  is broken, thus allowing  Nrf2 to migrate
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into the nucleus where it can activate phase II detoxifying enzymes and stress 
inducible genes including HO-1  466  The fact that Keapl  contains many highly 
reactive sulphydryl  groups 687,  and  NO’ and  NO posses  a  strong  affinity for 
such  groups  636,  it  is  feasible  that activation  of the  Nrf2/HO-1  sequence  by 
haem-nitrosyl  complexes  occurs  through  S-nitrosation  6 88  Further  work  is 
required  to  clearly  elucidate  the  mechanism(s)  behind  this  chemical 
modification of the HO-1  gene.
As  formation  of  a  haem-nitrosyl  complex  can  not  only  amplify  the  HO-1 
pathway  during  normoxic,  but  also  hypoxic  conditions,  suggests  that 
interaction between  haem and  NO’,  or NO-related species,  could serve as a 
potent signalling  mechanism to augment the cytoprotective aspects of haem 
oxygenase  during  situations  of  reduced  oxygen  tension.  A  number  of 
pathological  conditions,  e.g.  sickle  cell  anaemia  or  haemorrhagic  and 
subarachnoid  shocks,  are  characterised  by  increased  haemolysis,  thus 
increasing free haem  availability,  as well as localised  hypoxia,  both  of which 
serve  as  potent  inducers  of the  HO-1  pathway  365-647-689  in  addition,  these 
pathologies  may  be  associated  with  excessive  NO  formation  as  well  as 
significant vascular dysfunction 354-690  Therefore,  further expansion upon the 
findings in this chapter could serve as a potential therapeutic intervention in a 
wide range of diseases.
5.6  Conclusion
It is well documented that haem can serve as  both  a stimulus  and substrate 
for the induction of HO-1  364  More recently, the gaseous molecule NO and its
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reduction  product  NO'  have joined  the  long  list  of  potential  HO-1  inducers 
373.681  j ^ j S Chapter details how haem and NO'/NO can synergistically promote 
enhanced haem oxygenase activity, HO-1  protein and mRNA expression. The 
potency of the haem-nitrosyl complex to increase haem oxygenase activity is 
quite strong as thiols are unable to diminish this response. The data suggests 
that augmented HO-1  gene expression occurs in response to activation of the 
redox-sensitive  transcription  factor  Nrf2.  Collectively,  these  observations 
support  the  notion  that  amplification  of the  HO-1  pathway  is  an  important 
defence  stratagem  towards  the  twin  dilemmas  of  oxidative  and  nitrosative 
stress.
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6  PROTECTION  AGAINST NITROSATIVE STRESS  BY 
BILE PIGMENTS
6.1  Introduction
Oxidative  catabolism  of haem  by the  microsomal  enzyme  haem  oxygenase 
releases  the central  iron  molecule of the tetrapyrrole  and  produces  CO and 
biliverdin.  The  biliverdin  is  subsequently  reduced  by  the  serine/threonine 
kinase biliverdin reductase to bilirubin within the cytosol 446. Collectively, these 
two reaction are known as the haem oxygenase pathway and this represents 
the  primary  mechanism  by  which  mammals  generate  bilirubin  411.  The 
traditional perception that the bile pigments, biliverdin and bilirubin, were toxic 
waste products  derived from the known prooxidant haem was challenged by 
compelling  evidence  revealing  their  antioxidant  potential,  particularly  by 
bilirubin,  and  their  ability  to  modulate  cell  signalling  pathways  385-525. 
Furthermore, a number of publications have highlighted a correlation between 
plasma  levels  of  bilirubin  and  the  incidence  of  CAD,  i.e.  increased  serum 
bilirubin is associated with a reduced risk of cardiovascular morbidity and vice 
versa 543-546-547.  Although  low  serum  bilirubin  is  not  necessarily  a  causative 
factor for CAD development it can occur due to increased oxidative activity 543 
or via parental history of cardiovascular disease 549, thus making the individual 
more prone to CAD and serving as a potential predictive risk marker for this 
ailment.
The process of haem catabolism,  particularly by the inducible isoform HO-1,
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can be augmented by agents that cause oxidative injury 457. In addition, recent 
evidence  suggests  that  HO-1  activity  is  markedly  increased  by  NO  and  its 
different redox subtypes,  thus highlighting the potential of HO-1  to attenuate 
nitrosative  stress  636  As  HO-1  is  induced  by  oxidative  and  nitrosative  type 
stressors and  bilirubin  and  biliverdin  decrease the degree of oxidative  injury 
385, the premise that these bile pigments could exert a comparable effect upon 
NO and its congeners is an enticing prospect. To investigate this hypothesis 
biliverdin  and  bilirubin  were  reacted  with  the  NO'  liberator AS  and  the  NO 
donor  DeaNO  under  in  vitro  conditions  and  the  stability  of  bilirubin  was 
quantified  spectrophotometrically.  In  addition,  the  antinitrosative  potential  of 
bilirubin was examined in plasma using a NO microsensor.
6.2  Objective
The aim of the study investigated in this chapter is to verify that bilirubin and 
biliverdin  can  interact  with  NO'  and  NO,  thus  highlighting  the  potential 
antinitrosative capacity of bile pigments.
6.3  Materials and Methods
6.3.1  Preparation of reagents
The  bile  pigments  (bilirubin  and  biliverdin)  and  RNS  (AS  and  DeaNO) were 
prepared as 10 mM stock solutions in 0.1  M (bile pigments) or 0.01  M (AS and 
DeaNO)  NaOH  and  diluted  down  to  0.5  mM  or  1   mM  working  solutions, 
respectively.  All  the  agents  were  prepared  fresh  at  the  time  of  each 
experiment in opaque Eppendorfs and placed on ice until required.
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6.3.2  Spectrophotometric studies
All  spectra  were  recorded  using  a  UV-visual  spectrophotometer  (Helios  a, 
Unicam  Ltd.,  Cambridge,  UK)  according  to  Section  2.5.1.  The  absorbance 
readings between 300 and 750  nm were conducted  at 37°C against a blank 
containing vehicle (DPBS,  pH 7.4) and an equal concentration of buffer (0.01 
M  NaOH). To assess the effect of NO* or NO,  increasing concentrations (IQ- 
300  pM)  of  AS  or  DeaNO  were  added  to  DPBS  containing  bilirubin  or 
biliverdin  (5  pM  final  concentration)  and  absorption spectra  recorded after 5 
min. Changes in the spectra of the bile pigments over time (30 min) were also 
determined after their reaction with different concentrations (10 and 50 pM) of 
AS or DeaNO.  In each experiment the bile pigment was added to the DPBS 
first, mixed gently by inversion, followed by either AS or DeaNO, remixed and 
read.  The  latter  sequence  was  reversed  only  when  AS  or  DeaNO  were 
allowed to decompose in vehicle for 1   h at 37°C, i.e. bilirubin was added after 
1   h. The experimental data and kinetics of these reactions was recorded onto 
a disk and plotted using the accompanying Convert package,  Microsoft Excel 
and  GraphPad  Prism  3.0  software.  Negative  controls  were  included  in  all 
experiments.
6.3.3  Nitric oxide (NO) electrode experiments
The quantity of NO released by the NO donor DeaNO (5 pM) in the presence 
or absence of bilirubin (50 pM) was recorded continuously in a solution (final 
volume 1   ml) consisting of 50% (v/v) rat plasma,  50% (v/v) DPBS (Control) or 
a  combination  of  the  two,  using  a  NO-sensitive  electrode  under  constant
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stirring  at 37°C  as  described  in  Section  2.5.2.  The  rate of  NO  release was 
expressed  as  the  area  under  the  curve  (AUC)  calculated  after  15  min  of 
reading (pM x s). Controls consisted of vehicle alone.
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6.4  Results
6.4.1  Bilirubin  and  biliverdin  interact  with  nitric  oxide  (NO)-related 
species over time
Figure 6.1  and 6.2  reveal that bilirubin  (5  pM)  has the capacity to react with 
variable concentrations (10 and 50 pM) of AS or DeaNO, a source of NO' and 
NO, respectively, over a 30 min duration.  In the case of 10 pM AS (see Figure
6.1 A), bilirubin led to a steady decline in absorbance from a maximum of 0.36 
to  0.15  in  the  445-450  nm  region.  Concurrently,  a  second  peak  began  to 
appear in  the  315-320  nm  region.  Addition  of AS  (50  pM)  (Figure  6.1  B) 
promoted  a  rapid  consumption  of  bilirubin,  e.g.  after 5  min  the  absorbance 
maximum  was  0.15  compared  with  0.28  in  the  presence  of  10  pM  AS.  In 
parallel,  the  absorbance  peak  in  the  315-320  nm  region  became  more 
pronounced over time.
When 10 pM DeaNO (Figure 6.2 A) was reacted with bilirubin the absorbance 
pattern was somewhat similar to that obtained with the same concentration of 
AS,  but  there  was  little  evidence  of  a  second  peak  developing.  In  the 
presence  of  50  pM  DeaNO  (Figure  6.2  B)  the  loss  of  bilirubin  was  more 
gradual;  however,  there  was  a  change  in  the  absorbance  pattern  between 
315-320  nm  which  is  akin  to  that  observed  with  10  pM  AS.  Figure  6.3 
illustrates  that  biliverdin  (5  pM)  does  not  react  as  rapidly  with  50  pM  AS 
(Figure 6.2 A) or DeaNO (Figure 6.3 B) as bilirubin does over 30 min.  In both 
cases the characteristic double  peaks of biliverdin  are  observed  at 410  and 
650 nm. However, the appearance of a third peak in the 315-320 nm region of 
the AS graph suggests that an as yet uncharacterised entity is formed.
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Figure 6.1  Effect of nitroxyl (NO ) on bilirubin absorption spectra.
Absorption spectra of bilirubin (5 pM) were recorded at different 
time points (0-30 min) after interaction with Angeli’s salt (AS) at 10 
pM (A) or 50 pM (B) in DPBS (pH 7.4, 37°C) as described in 
Section 2.5.1.
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Figure 6.2 Effect of nitric oxide (NO) on bilirubin absorption spectra.
Absorption  spectra  of bilirubin  (5  pM)  were  recorded  at different 
time points (0-30 min) after interaction with DeaNO at 10 pM (A) or 
50 pM (B) in DPBS (pH 7.4, 37°C) as described in Section 2.5.1.
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Figure  6.3  Effect  of  nitroxyl  (NO )  and  nitric  oxide  (NO)  on  biliverdin 
absorption spectra.
Absorption spectra of biliverdin (5 pM) were recorded at different 
time  points  (0-30  min)  after  interaction  with  50  pM  AS  (A)  or 
DeaNO (B) in DPBS (pH 7.4, 37°C) as described in Section 2.5.1.
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6.4.2  Bilirubin  and  biliverdin  attenuate  nitrosative  agents  in  a 
concentration-dependent manner
The  antinitrosative  capacity  of  bilirubin  is  quite  strong  as  5  pM  of the  bile 
pigment is sufficient to attenuate up to 300 pM of AS (Figure 6.4 A) or DeaNO 
(Figure  6.4  B).  Increasing  concentrations  (10-300  pM)  of AS  promoted  the 
loss  of  bilirubin  over  5  min.  As  observed  in  the  time-dependent  graphs  a 
second peak became more defined in the 315-320 nm region in parallel with a 
decline in the  absorbance  maxima  in the 445-450  nm  zone.  In  contrast,  the 
change  in  absorbance  spectra  observed  with  DeaNO  (10-300  pM)  was 
gradual over 5 min and there was little evidence of a second peak developing. 
The basis for these diverse results could relate to a stronger affinity between 
NO' and bilirubin, thus leading to a more rapid consumption of the latter. The 
ability of AS  and  DeaNO to consume bilirubin  is lost when  both agents have 
undergone decomposition (i.e. they have lost their biological potency) via a 1  
h  preincubation  in  vehicle  (see  Figure  6.5).  This  suggests  that  a  direct 
interaction  occurs  between  the  NO  congeners  and  bilirubin  leading  to 
degradation of the latter.
The pattern  of results  obtained with  biliverdin  in the  presence  of 10-300  pM 
AS or DeaNO (Figure 6.6 A and  Figure 6.6 B,  respectively)  is similar to that 
with 50  pM of both agents after 30 min.  Again the double peak fingerprint of 
biliverdin  is  maintained,  while  the  third  peak  produced  by  AS  within  the 
315-320 nm region becomes more distinct.
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Figure 6.4 Nitroxyl (NO ) and nitric oxide (NO) promote a concentration-
dependent change in bilirubin absorption spectra.
Changes  in  the  absorption  spectra  of bilirubin  (BR,  5  pM)  were 
detected  5  min  after  reaction  with  increasing  concentrations 
(10-300  pM) of Angeli’s salt (AS) (A) or DeaNO (B) in DPBS (pH
7.4,  37°C) as described in Section 2.5.1.
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Figure 6.5 Direct interaction between NO congeners and bilirubin.
Changes  in  the  absorption  spectra  of bilirubin  (BR,  5  pM)  were 
detected 5 min after reaction with a fixed concentration (50 pM) of 
Angeli’s  salt  (AS)  (A)  or  DeaNO  (B)  either  directly  (Dir)  or 
following  a  1   h  preincubation  (PI)  in  DPBS  (pH  7.4,  37°C)  as 
described in Section 2.5.1.
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Figure 6.6 Nitroxyl (NO ) and nitric oxide (NO) promote a concentration-
dependent change in biliverdin absorption spectra.
Changes  in  the  absorption  spectra  of biliverdin  (BV,  5  pM) were 
detected  5  min  after  reaction  with  increasing  concentrations 
(10-300  pM) of Angeli’s salt (AS) (A) or DeaNO (B) in DPBS (pH
7.4,  37°C) as described in Section 2.5.1.
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6.4.3  Kinetics of bilirubin interaction with nitrosants
A  standard  curve  of  bilirubin  (1-20  pM)  in  DPBS  was  plotted  using  the 
maximal  absorbance  reading  at 440  nm for each  concentration  (see  Figure 
6.7). The extinction coefficient (s440 = 64,000 M'1  cm’1 ) was derived from the 
slope of the  latter plot.  Using the s440 value of the  bilirubin  standard  curve 
and the absorbance maxima (i.e. A440 nm) of the time course (Figure 6.1  and 
Figure  6.2)  and  concentration  (Figure  6.4)  data  for  AS  and  DeaNO  rate 
graphs were plotted according to Equation 6.1 to illustrate the concentration of 
bilirubin remaining during a 30 min analysis.
Following its interaction with AS (Figure 6 .8  A) a 10 pM concentration caused 
a  gradual  decline  in  the  rate  of bilirubin  consumption  over the course  of 30 
min. In contrast, 50 pM AS caused a rapid and near complete consumption of 
bilirubin  within  the  first  1 0  min,  while  the  rate  remained  unchanged  for the 
remaining 20 min. These observations correspond with  most of the half-lives 
of AS  {V/2 = 2.3  min),  and therefore its biological  potency,  being  exhausted. 
The  reaction  rate  for  both  10  and  50  pM  DeaNO  (Figure  6 .8   B)  caused  a 
gradual decrease in bilirubin concentration over 30 min. Despite having similar 
half-lives (AS t!4 = 2.3 min;  DeaNO VA = 2 min) these results reflect the rapid 
decomposition of AS and instability of its product NO’ compared with the NO 
donor DeaNO.
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Figure 6.7 Standard curve of bilirubin in DPBS.
Bilirubin  (BR)  from  stock  solutions  was  added  at  a  final 
concentration  of  1,  5,  10  or 20  |jM  to  DPBS  (pH  7.4,  37°C)  as 
described  in  Section 2.5.1.  Absorbance values were  read  at 440 
nm and plotted against the respective BR concentration. Solid line 
indicates the standard curve line.  The dashed lines represent the 
95% confidence interval.
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The rate of bilirubin disappearance was also plotted using the A440 nm of the 
concentration  (10-300  pM)  graphs for AS and  DeaNO,  Figure 6.4 A and  B, 
respectively.  Figure 6.9 illustrates that in the presence of a fixed concentration 
of bilirubin and increasing concentrations of DeaNO the rate of change in the 
absorbance spectra was uniform over 30 min.  However, the reaction between 
bilirubin  and  AS  had  reached  completion  by  100  pM  AS  and  remained 
constant  thereafter.  Collectively,  the  data  in  Figure  6 .8   and  Figure  6.9 
demonstrate that bilirubin  has the capacity to combine with different types of 
RNS  for various  durations  and  at  numerous  concentrations.  The  pattern  of 
these reactions suggest that bilirubin is consumed more rapidly by NO' rather 
than NO type species.
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Figure  6.8  Rate  of disappearance  of  bilirubin  over time  after  reaction 
with Angeli’s salt and DeaNO.
Absorption  spectra  of bilirubin  (5  pM) were  recorded  at different 
time points (0-30 min) after interaction with Angeli’s salt (AS, 10 or 
50 pM) (A) or DeaNO (10 or 50 pM) (B) in DPBS (pH 7.4,  37°C) 
as described in Section 2.5.1. The concentration of BR at different 
time  points was  measured from  Figure 6.7  using  e440  =  64,000 
M'1  cm'1.
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Figure  6.9  Rate  of  disappearance  of  bilirubin  after  reaction  with
increasing concentrations of Angeli’s salt and DeaNO.
The  change  in  absorption  spectra  of  bilirubin  (5  pM)  were 
detected  5  min  after  reaction  with  increasing  concentrations 
(10-300 pM) of Angeli’s salt (AS) (open boxes) or DeaNO (filled 
boxes)  in  DPBS  (pH  7.4,  37°C)  as  described  in  Section  2.5.1. 
The  concentration  of BR was  measured from  Figure 6.7  using 
e440 = 64,000 M'1  cm'1.
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Having established that bilirubin is capable of reacting with different types of 
nitrosants  in  DPBS,  we  wondered  whether  the  same  could  occur  in  a 
physiological  solution.  To  test for a  physiological  role  for the  antinitrosative 
capacity of bilirubin,  rat plasma with or without bilirubin (50 pM) was exposed 
to  DeaNO  (5  pM)  for  15  min  and  the  concentration  of  NO  release  was 
quantified in both cases using a NO-electrode. Figure 6.10 A shows that in the 
presence  of  DeaNO  a  50%  (v/v)  mixture  of  plasma  and  DPBS  releases  a 
much greater concentration of NO compared with a similar mixture that also 
contains  bilirubin.  Plotting  the  area  under  the  curve  (AUC)  of  each  trace 
(Figure  6.10  B)  clearly  demonstrates  that  bilirubin  significantly  (F  <  0.05) 
attenuates the rate of NO release from DeaNO in plasma. This data suggests 
that bilirubin  has  the  potential to exert a  protective  influence  in  vivo against 
pathologies characterised by increased NO release.
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Figure 6.10 Bilirubin attenuates NO release from DeaNO.
A NO electrode was immersed in  1   ml of a solution consisting of 
50%  (v/v)  rat  plasma  and  50%  (v/v)  DPBS  (Control)  or  in 
plasma/DPBS  solution  containing  bilirubin  (BR,  50  pM  final 
concentration).  The  NO  releasing  agent,  DeaNO  (5  pM  final 
concentration),  was  then  added  to  the  chamber  and  the  NO 
concentration  continuously  monitored  under constant  stirring  at 
37°C as described  in  Section 2.5.2 (A).  The  rate of NO release 
was  expressed  as  the  area  under the  curve  (AUC)  calculated 
after 15 min of reading (pM x s) (B).  Bars represent the mean ± 
S.E.M  of three  independent experiments.  * P <  0.05 vs.  control 
(CON).
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6.5  Discussion
The haem of senescent erythrocytes represents the primary source of linear 
tetrapyrroles  (LTPs)  or  bile  pigments  (biliverdin  and  bilirubin)  in  mammals. 
This reaction  is catalysed  by two enzymes:  1.  microsomal  haem oxygenase 
(HO,  EC 1.14.99.3) which oxidises haem to biliverdin with CO and Fe2 +  as by 
products;  and  2.  cytosolic  biliverdin  reductase  (BVR,  EC  1.3.1.24)  which 
metabolises  biliverdin  to  bilirubin  364  The  intermediate  biliverdin  is  water 
soluble,  while  bilirubin  is  insoluble.  Within  the  liver  bilirubin  is  made  water 
soluble via the glucuronyl transferase system and excreted  in the bile 568  In 
birds,  amphibians  and  reptiles  the  reactions  involving  BVR  and  liver 
metabolism  do  not  occur,  rather  biliverdin  is  excreted  directly  411.  Why 
mammals should expend energy in the generation of a toxic product bilirubin, 
from a know prooxidant haem, puzzled scientists for many years 382. However, 
during the last few decades a number of reports have highlighted the potential 
usefulness  of  the  LTPs,  particularly  bilirubin,  as  potential  antioxidants  385, 
immunomodulators  525,  a  safeguard  against  different  models  of  ischaemic 
reperfusion  injury 430 553(   hypoxic conditions 386 647i  as well  as an  indicator of 
CAD development 543.
For the first time the results presented in this chapter describes a potentially 
novel function for the  LTPs  biliverdin  and  bilirubin  as they could function as 
antinitrosative agents. In the presence of a fixed concentration of bilirubin and 
varied  concentrations  of AS,  a  source  of  NO',  or  DeaNO,  a  source  of  NO, 
there  was  a  time-  and  concentration-dependent  loss  of  bilirubin.  This 
attenuation  of  different  forms  of  nitrosative  stress  (a  type  of  cellular threat
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which  is  analogous  to  the  ability  of  ROS  to  cause  oxidative  stress)  3 3 8  
demonstrates the robust cytoprotective capacity of bilirubin.  Even though AS 
and DeaNO have similar half-lives (t!4 = 2.3 and 2 min,  respectively) the rate 
of change  in  the  bilirubin  absorbance  spectra was  more  pronounced  in  the 
presence of AS than DeaNO. A possible reason for this is due to a faster rate 
of  interaction  between  bilirubin  and  AS.  In  both  cases  the  NO  congeners 
promoted the degradation of bilirubin through a direct interaction with the bile 
pigment as there was little,  if any change,  in the maximal absorption spectra 
of bilirubin in the presence of decomposed AS and DeaNO. The change in the 
absorption  pattern  of biliverdin  in the presence of AS or DeaNO was not as 
dramatic  compared  with  the  bilirubin  traces,  suggesting  biliverdin  is  not  as 
strong an antinitrosative agent as bilirubin.
A common  feature  in  the  traces with  AS,  particularly so  in  the  presence  of 
bilirubin,  was  the  appearance  of  a  peak  between  315-320  nm.  The 
absorbance  intensity of this  peak became  more  pronounced  with  increasing 
time and concentration of exposure to AS.  Due to technical  limitations it was 
not possible to identify and characterise the species originating from this peak; 
one  could  speculate  that  it  has  arisen  due  to  AS  forming  a  ‘nitrosated’ 
complex with  bilirubin  and  biliverdin.  Further work using  more  sophisticated 
techniques,  e.g.  electron  spin  (paramagnetic)  resonance  (ESR,  EPR) 
spectroscopy, could help to elucidate the exact nature of the latter nitrosated 
complex  68  Although  it  has  not  been  included  in  this  chapter,  a  set  of 
experiments  using  the  NO+   donor S-nitroso-N-acetylpenicillamine  (SNAP)  in 
the presence of bilirubin revealed a second peak, which became more intense
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with increasing concentration and duration of exposure, within the 315-320 nm 
region.  Parallel with the latter changes the intensity of the bilirubin absorption 
peak declined (unpublished data, not shown). Together, these results illustrate 
the ability of bilirubin to exert an antinitrosative influence against a variety of 
NO  congeners.  Furthermore,  the  data  measuring  NO  release  from  plasma 
using  a  NO  electrode  highlight  the  potential  of  bilirubin  as  a  physiological 
scavenger of RNS in vivo. These observations concur with those presented by 
Kaur et ai. 656 with regards the ability of bile pigments to attenuate nitrosative 
stress caused by different types of RNS.
6.6  Conclusion
Collectively, these results reveal a potential new physiological role for the bile 
pigments,  particularly bilirubin, as a means to assuage the adverse effects of 
nitrosative  stress.  The  results  observed  would  only  become  relevant  in 
situations  where  NO  is  in  excess  and  the  potential  scavenging  capacity  of 
other targets, e.g. thiols in the form of GSH 691692)  are saturated as Kaur and 
colleagues  demonstrated  decreased  bilirubin  degradation  by  RNS  in  the 
presence  of  NAC  656.  As  the  level  of  NO  and  activation  of  the  haem 
oxygenase  pathway  to  release  bile  pigments  are  intimately  linked  373,  in 
situations where NO is limited GSH levels would not be diminished and thus 
HO-1  would  not  be  activated.  Any  endogenous  bilirubin  generated  by  the 
haem  oxygenase  pathway  would  not  necessarily  be  a  threat  to  NO  in 
situations where the bioavailability of the latter is limited, e.g. due to oxidative 
stress. Rather, HO-1-derived bilirubin would exert a protective influence where 
NO  is  limited  due  to  the  fact  that  bilirubin  can  attenuate  oxidative  stress
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386,529,533,535  Qjven  ancj jts congeners have been implicated in a wide
range  of  pathological  conditions  25,  and  in  view  of  the  fact  that  an 
‘uncontrolled’  increased  production  of NO redox forms  can  strongly  activate 
the  haem  oxygenase  system  leading  to  enhanced  bilirubin  production,  the 
findings presented in this chapter merit further exploration both in in vitro and 
in vivo models to confirm the antinitrosative properties of bile pigments.
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7  EFFECT  OF  GLYCERYL  TRINITRATE  ON  HAEM 
OXYGENASE  ACTIVITY  AND  HO-1  PROTEIN  IN 
CARDIOMYOCYTES
7.1  Introduction
Glyceryl  trinitrate  (nitroglycerin;  GTN  (MW 227.09),  Figure  7.1)  is  a  potent 
organic nitrate vasodilator that has been used clinically for the past 125 years 
to treat a number of cardiovascular complications, e.g. angina pectoris,  acute 
and chronic episodes of myocardial infarction and congestive heart failure 6 9 3
CH, -  O -  NO,
I
CH -  O -  NO,
I
CH, -  O -  NO, 
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CH, -  O -  NO,  CH, -  O -  NO,
I  I
C H -O -N O ,  CH-OH
I  I
CH, -  OH  CH, - O - NO,
1,2-Glyceryl Oinitrate  1,3-Glyceryl Dinitrate
Figure 7.1  Chemical  structure  of glyceryl trinitrate and  its  metabolites,
1,2-glyceryl dinitrate and 1,3-glyceryl dinitrate.
Adapted from 693.
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Given  its  long  term  therapeutic  use,  facile  delivery,  variable  formulations 
(tablet,  spray  and  patches)  and  routes  of administration  (buccal,  sublingual 
and transdermal) *[Note: oral administration is not feasible due to inactivation 
via rapid first-pass metabolism] the  precise mechanism(s) of GTN  action still 
remains  unresolved  and  controversial  693-694.  a  major  drawback  of  GTN 
therapy is the development of nitrate tolerance, i.e. loss of clinical efficacy due 
to  its  continuous  administration  192.  Nitrate  tolerance  is  a  complex 
phenomenon possibly involving specific vascular and biochemical responses. 
The  subject  is  currently  of  much  debate  and  still  unresolved;  however,  it 
appears  that  both  aspects  of  GTN,  i.e.  its  mode  of  action  and  nitrate 
tolerance, are interlinked 693.
From a mere pharmacological point of view, GTN is considered a prodrug as it 
requires  cellular  metabolism  to  yield  1,2-glyceryl  dinitrate  (1,2-GDN),  1,3- 
glyceryl  dinitrate  (1,3-GDN)  (see  Figure  7.1  for structures),  inorganic  nitrite 
(N02‘) and NO (or a NO congener e.g. R-SNO) in variable amounts and ratios 
695  In  general,  the  therapeutic  effects  of  GTN  are  mediated  by  its 
biotransformation  to  NO,  the  active  metabolite,  which  in  turn  activates  the 
enzyme sGC,  leading to smooth  muscle relaxation 4,693  Two pathways have 
been  proposed  for the  latter  reaction:  1.  clearance-based  metabolism  or a 
detoxification pathway which produces N02 ' that has no direct cardiovascular 
effect;  and  2.  mechanism-based  biotransformation  that  requires  a  chemical 
mechanism to produce an activator of sGC, e.g.  NO.  In addition to N02, both 
pathways  generate  the  active  metabolites  1,2-GDN  and  1,3-GDN,  although
1,2-GDN  predominates  in  vivo  192-345-693.  So  far the factor(s)  responsible for
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the metabolic denitration and reduction of GTN to NO has not been identified; 
however,  it  is  known  that  the  reaction  takes  place  within  microsomal 
membranes, is enhanced by reducing equivalents, e.g. thiols, and is catalysed 
by nonenzymatic and enzymatic processes8.
Nonenzymatic  production  of NO  by reduced  intracellular thiols was  the first 
proposed mechanism of GTN biotransformation, and oxidation or depletion of 
thiols  was  associated  with  tolerance  3 4   These  theories  have  since  been 
contradicted and thiols have been suggested as cofactors 696, despite the fact 
that thiol containing  drugs (e.g.  N-acetylcysteine) can  enhance the effects of 
GTN  in  the  absence  of  tolerance  6 93  or  overcome  tolerance  346  Four 
enzymatic  pathways  have  been  proposed  for  GTN  biotransformation:  1. 
glutathione-S-transferase  (GST);  2.  microsomal  CYP-450  or  the  CYP-450 
reductase  system;  3.  an  unidentified  membrane-bound  pathway;  and  4. 
mitochondrial aldehyde dehydrogenase (mtALDH) which metabolises GTN to
1,2-GDN and NO2' 345-695.  In all these examples, the role of these enzymes in 
GTN  metabolism  and  nitrate tolerance  is  ambiguous.  Of note  is  the  crucial 
role of thiols,  either as cofactors or part of an enzyme (except in CYP-450s), 
for the interaction and metabolism of GTN and activation of sGC 694, although 
this (thiol) induction is weak compared with NO 697.
So far, the present Thesis has investigated the potential of NO'/NO releasing 
agents  (AS,  DeaNO  and  DetaNO)  to  activate  HO-1  and  dissected  the 
biochemistry associated with these reactions in vitro.  However,  these agents 
are not clinically used  unlike GTN,  a pharmacological agent that exhibits  NO 
bioactivity.  Since  NO  derived  from  NO  releasing  compounds  is  capable  of
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interacting with  the  HO-1  pathway,  one aspect of this subject that might be 
clinically  relevant  is  to  examine  the  effects  of  GTN  on  haem  oxygenase 
activity  and  HO-1  protein  expression  in  cardiomyocytes.  Although  the 
concentration  of  GTN  administered  in  these  experiments  was  greater than 
clinically  observed,  i.e.  0.5  pM  345,  the  purpose  of this  chapter was  not  to 
make a comparison with a clinical scenario, rather to examine if GTN has the 
ability to modulate the haem oxygenase pathway.  Indeed, changes in cardiac 
haem oxygenase activity and HO-1  protein were noted in this model following 
administration  of  GTN  and  were  in  agreement  with  data  reported  by 
Minamiyama  et  al.  in  rat  hearts  exposed  to  GTN  698  The  findings  will  be 
discussed with regards their potential implications in the mechanism required 
to alleviate vascular dysfunction.
7.2  Objective
The  intention  of  this  chapter  is  to  explore  a  possible  link  between  a 
NO-generating  compound  that  is  used  for  the  treatment  of  vascular 
dysfunction (GTN) and its ability to induce haem oxygenase activity and HO-1 
protein  expression,  and  briefly  discuss  the  possible  clinical  implications  of 
these findings.
7.3  Materials and Methods
7.3.1  Preparation of reagents
Ampoules  of  glyceryl  trinitrate  (GTN,  Nitrocine®,  1   mg/ml,  4  mM)  were 
provided  free  gratis  by  Schwarz  Pharma  Ltd  (Chesham,  Bucks.,  England). 
Stock  solutions  of  A/-acetylcysteine  (NAC,  100  mM)  and  hydroxocobalamin
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(HCB,  50  mM)  were  dissolved  in  5%  (v/v)  NaOH  (2  M)  and  dH20, 
respectively.  The  latter  reagents  were  prepared  fresh  at  the  time  of  each 
experiment in opaque Eppendorfs and placed on ice until required.
7.3.2  Maintenance and treatment of cells
Rat H9c2 cardiomyocytes were cultivated  in  DMEM  as previously described 
647. The agents were applied to cells directly either alone or in combination in 
DMEM  at  the  concentrations  shown  in  each  graph.  Assays  for  haem 
oxygenase  activity  and  determination  of  HO-1  protein  expression  were 
performed  as  described  in  Sections  2.3.4  and  2.4.2,  respectively.  Negative 
controls, which consisted of vehicle alone, were included in all experiments.
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7.4  Results
7.4.1  Concentration-dependent  effect  of  glyceryl  trinitrate  (GTN)  on 
haem  oxygenase  activity  and  HO-1  protein  expression  in  H9c2 
cells
To  confirm  a  biochemical  link  between  GTN  and  the  haem  oxygenase 
pathway,  cardiomyocytes were exposed to increasing concentrations  (0.25-1 
mM) of the organic nitrate in complete DMEM. After 6 h incubation cells were 
collected  and  assayed  for  haem  oxygenase  activity  and  HO-1  protein 
expression. As illustrated in Figure 7.2 A GTN promoted an increase in haem 
oxygenase  activity  up  to  0.5  mM  relative  to  control  (566.4  ±  17.9  (0.5  mM 
GTN)  vs.  234.7  ±  12.4  (control)  pmoles  bilirubin/mg  protein/h;  P  <  0.05) 
followed  by  a  decline  to  near  baseline  at  subsequent  concentrations.  A 
corresponding pattern in the expression of HO-1  protein was found using the 
same concentrations of GTN (Figure 7.2 B; n = 1).
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Figure  7.2  Concentration-dependent  induction  of  haem  oxygenase
activity and HO-1 protein expression by glyceryl trinitrate.
Cells were treated directly with  glyceryl trinitrate  (GTN,  0,  0.25, 
0.5,  0.75  or  1   mM)  in  fresh  complete  DMEM.  After 6  h  haem 
oxygenase  activity  (A)  and  HO-1  protein  expression  (B)  were 
determined  according to Sections 2.3.4 and 2.4.2,  respectively. 
Control  (open  bar)  represents  cells  exposed  to  fresh  DMEM 
alone.  The  Western  blot  panel  is  representative  of  one 
experiment.  Bars  represent  the  mean  ±  S.E.M.  of  n  =  4 
experiments. * P < 0.05 vs. Control.
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7.4.2  Time-dependent  effect  of  glyceryl  trinitrate  (GTN)  on  haem 
oxygenase activity and HO-1  protein expression in H9c2 cells
Since 0.5  mM  GTN  promoted  the maximal level of haem oxygenase activity 
and  HO-1  protein  induction,  this  concentration  was  chosen  to  assess  the 
effect  of  GTN  on  haem  oxygenase  activity  and  HO-1  protein  over  a  24  h 
period.  Figure  7.3  A shows  that GTN  caused  a  time-dependent increase  in 
haem  oxygenase activity with  maximal  levels attained  at 6  h  (459.9 ± 35.22 
pmoles bilirubin/mg protein/h; P < 0.05) and a gradual decrease in activity at 
successive  time  points  (from  396.6  ±  30.92  (12  h)  to  322.4  ±  55.85  (24  h) 
pmoles  bilirubin/mg  protein/h;  P  >  0.05).  The  expression  of  HO-1  protein 
(Figure 7.3 B; n = 1) correlated with the activity data, i.e. strongest intensity at 
6  h  followed  by  weaker,  but  rather  similar,  intensities  for  the  remaining 
duration of exposure to GTN. Collectively, the results in Figure 7.2 and Figure
7.3  reveal  that  GTN  has  the  capacity  to  promote  an  increase  in  haem 
oxygenase activity and HO-1  protein expression at various concentrations and 
time points.
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Figure  7.3  Time-dependent  induction  of  haem  oxygenase  activity  and
HO-1  protein expression by glyceryl trinitrate.
Cells  were treated  directly with  glyceryl  trinitrate  (GTN,  0.5mM) 
for 6,  12,  18 or 24  h  in fresh complete  DMEM.  After 6  h  haem 
oxygenase  activity  (A)  and  HO-1  protein  expression  (B)  were 
determined  according  to  Sections 2.3.4  and  2.4.2,  respectively. 
Control  (open  bar)  represents  cells  exposed  to  fresh  DMEM 
alone.  The  Western  blot  panel  is  representative  of  one 
experiment.  Bars  represent  the  mean  ±  S.E.M.  of  /?   =  4 
experiments. * P < 0.05 vs. Control.
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7.4.3  Interaction of glyceryl trinitrate (GTN) with thiols and a nitric oxide 
(NO) scavenger
Previous  reports  have  highlighted the ability of thiols and  NO scavengers to 
attenuate  the  activation  of  the  haem  oxygenase  pathway,  by  NO  and  its 
congeners,  in various cell types 668681. Therefore, the potential of using such 
agents to  modulate the  induction of haem oxygenase activity in  response to 
GTN  was  investigated.  Following  exposure  of  cardiomyocytes  to  a  fixed 
concentration  (0.5  mM)  of  GTN  in  the  presence  or  absence  of  the  NO 
scavenger HCB (0.5 mM) there was a significant (P < 0.05) increase in haem 
oxygenase activity (Figure 7.4 A).  Of note,  is the observation that GTN  plus 
HCB enhanced haem oxygenase activity compared with GTN alone (665.0 ± 
46.98  (GTN  plus  HCB)  vs.  510.5 ± 24.96  (GTN  alone)  pmoles  bilirubin/mg 
protein/h,  respectively;  P <  0.05).  As expected,  HCB  alone  did  not promote 
any  significant  change  in  haem  oxygenase  activity.  When  similar 
concentrations  (0.5  mM)  of  GTN  and  the  glutathione  precursor  NAC  were 
coincubated there was  no  reduction  in the level  of haem  oxygenase activity 
compared  with  GTN  alone  (Figure  7.4  B),  i.e.  both  scenarios  promoted  a 
significant  (P  <  0.05),  but  similar,  degree  of  haem  oxygenase  induction, 
whereas NAC alone did not enhance haem oxygenase activity.
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Figure 7.4 Induction of haem oxygenase activity by glyceryl trinitrate is 
not attenuated in the presence of a nitric oxide scavenger or 
thiols.
Cells were exposed directly to glyceryl trinitrate (GTN, 0.5 mM) in 
the  absence  (-)  or  presence  (+)  of  an  equal  concentration  of 
hydroxocobalamin  (HCB)  (A)  or  A/-acetylcysteine  (NAC)  (B)  in 
complete  DMEM.  After  6  h  haem  oxygenase  activity  was 
determined  according  to  Section  2.3.4.  Control  (open  bar) 
represents  cells  exposed  to  fresh  DMEM  alone.  Bars  represent 
the mean ± S.E.M. of n = 4 experiments. * P < 0.05 vs. Control.
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7.4.4  Effect of nitrate (NO3 ) on haem oxygenase activity
As its name suggests GTN has NO3' as part of its chemical structure, in fact it 
has  three  NO3*  molecules.  To  investigate  the  contribution  of  N03'  to  GTN- 
mediated  activation  of  the  haem  oxygenase  pathway  an  experiment  was 
conducted  using  GTN  (0.5  mM)  and  N03  (1.5  mM,  as there are three  N03' 
molecules  per  GTN).  Following  a  6  h  incubation  with  cells  the  haem 
oxygenase activity assay (see Figure 7.5) revealed that N03' did not influence 
the  latter  parameter  (P  >  0.05),  but  gave  a  reading  comparable  to  control 
(293.4 ± 31.14 (control) vs. 284.8 ± 3.82 (N03 ‘) pmoles bilirubin/mg protein/h). 
In the presence of GTN there was a significant increase in haem oxygenase 
activity  compared  to  control  (573.8  ±  20.76  vs.  293.4  ±  31.14  pmoles 
bilirubin/mg  protein/h,  respectively;  P <  0.05).  Therefore,  it  is  GTN  and  not 
N03' that activates the haem oxygenase pathway.
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Figure 7.5 Nitrate does not influence haem oxygenase activity.
Cells  were  exposed  directly  to  glyceryl  trinitrate  (GTN,  0.5  mM) 
and  nitrate  (N O 3 ',  1.5  mM)  in  complete  DMEM.  After 6  h  haem 
oxygenase  activity  was  determined  according  to  Section  2.3.4. 
Control (open bar) represents cells exposed to fresh DMEM alone. 
Bars represent the mean ± S.E.M. of n = 4 experiments. * P < 0.05 
vs. Control.
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7.5  Discussion
To  date  no  studies  have  measured  the  parameters  of  haem  oxygenase 
activity  and  HO-1  protein  expression  following  exposure  of  cells  to  GTN. 
Herein,  the  clinically  used  organic  nitrate  GTN  enhanced  haem  oxygenase 
activity and  HO-1  protein expression  in a concentration- and time-dependent 
manner in  cardiac cells.  Previous  experimental evidence suggests that GTN 
mediates  its  pharmacological  effect,  vasorelaxation  of  vascular  smooth 
muscle  cells,  via  enzymatic  or  nonenzymatic  biotransformation  within  the 
microsomal membrane to specifically yield NO and 1,2-GDN, while loss of this 
activity may account for tolerance 8 695. Therefore, GTN-derived NO enhances 
haem  oxygenase  activity  and  HO-1  protein  expression,  an  observation 
observed  in  other  cells  types  using  different  sources  of  NO  374i67°  in  this 
model cells exposed to high concentrations of GTN (0.75 and 1   mM) or a fixed 
concentration (0.5 mM) for prolonged durations (12,  18 or 24 h) both led to an 
attenuation in the measured parameters. A possible reason for this is that the 
cells  became  tolerant  to  the  effects  of  GTN  under  these  conditions  696  A 
number  of  theories  have  been  advanced  for  this  phenomenon  including 
decreased  formation  of  NO  from  GTN,  depletion  of  intracellular  thiols  and 
altered  sGC  activation,  enhanced  phosphodiesterase activity and  production 
of vascular O2' 697.
Data from  Chapter 4,  as well  as from  previous  groups,  have highlighted the 
ability of thiols,  particularly NAC,  to  attenuate  haem oxygenase  induction  by 
NO,  its  congeners  or other factors  4 82'668-6" - 700  However,  the  results  in  this 
chapter suggest that NAC is  unable to allay an increase in haem oxygenase
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activity  caused  by  GTN.  A  possible  reason  for  this  is  that  NAC  may  be 
promoting  the  biotransformation  of  GTN  in  this  model.  In  Chapter  4  HCB 
attenuated NO’-mediated induction of haem oxygenase activity. The inhibitory 
aspects of HCB can also be mediated against NO and its redox congeners in 
various cell types  49 452.668.678.7oi  Howeveri  jn this  mode|  HCB was  unab|e to
attenuate  haem  oxygenase  activity,  in  fact,  it  enhanced  GTN-mediated 
activation. A recent publication by Chambers et al.  suggests that B vitamins, 
e.g.  vitamin  Bi2 a   or  HCB,  may  increase  the  availability  of  NO  through 
reduction  of  free  plasma  homocysteine  (Hyc),  thus  enhancing  vascular 
endothelial function  702 and haem oxygenase activity in the current scenario. 
Using endothelial cells Sawle and coworkers noted that Hyc attenuated haem 
oxygenase  activity  induced  by  the  NO  donor  SNP  679  Thus,  HCB  may  be 
thwarting the negative impact of Hyc towards the endogenous cytoprotectant 
HO-1 which enhances the potency of GTN. Although the potential of the GTN 
metabolites  1,2-GDN  and  1,3-GDN  to  induce  haem  oxygenase  activity was 
not investigated  the  data  reveals  that  N03‘  does  not  influence  the  effect of 
GTN.
7.6  Conclusion
The aim of this chapter was  to examine a  possible direct link between  GTN 
and  the  haem  oxygenase  pathway.  The  data  reveals  this  hypothesis  to  be 
true,  although  the  mechanism  by which  this is  achieved  is  not entirely clear 
and  differs  with  respect  to  the  current  knowledge  of  NO  donors  and  HO-1 
induction.  Given that GTN  mediates blood vessel  relaxation via bioactivation 
to NO, and the latter can upregulate the HO-1  gene, which in turn releases the
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vasoactive gas CO and  antioxidant bilirubin, the current results suggest that 
the products of the haem oxygenase pathway may enhance the vasodilatory 
capacity  of GTN.  The  lengthy  (over  125 years)  clinical  use  of GTN  for the 
treatment of certain  cardiovascular disorders and the inability to fully explain 
its  mechanism(s)  of  action  makes  scientists  wonder  whether  additional 
biochemical  pathways  may  be  involved.  The  data  presented  in  this  Thesis 
merits further investigation in vivo. It is plausible to suggest that the beneficial 
actions of NO-derived GTN  may ultimately involve the generation of a stable 
signalling factor (i.e. CO) and a potent antioxidant (i.e. bilirubin), both required 
to restore the function of impaired vascular activities.
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8  GENERAL DISCUSSION
8.1  Background to current work
I
Each day a myriad of important biological and chemical reactions take place 
within our cells,  tissues and organ systems to sustain  life.  At the same time 
potentially  toxic  waste  products  are  generated;  among  these  are  the 
prosthetic  haem  moiety(ies)  of denatured  haemoproteins,  e.g.  haemoglobin 
and  cytochromes.  Due  to  the  potential  toxicity  of  uncomplexed  ‘free’  haem 
and its central  iron  atom  mammals  have developed highly sophisticated and 
regulatory  processes  to  catabolise,  compartmentalise  and  recycle  these 
molecules 361. The most effective means of haem catabolism,  also known as 
the haem oxygenase pathway,  occurs in two steps:  1 .  oxidative cleavage of 
haem’s  tetrapyrrole  ring  by  the  rate-limiting  enzyme  microsomal  haem 
oxygenase which generates biliverdin concomitant with the release of CO and 
Fe2+; and 2. reduction of biliverdin to bilirubin by the cytosolic serine/threonine 
kinase,  biliverdin  reductase 364-446.  The  resulting  Fe2 +   is  sequestered  by the 
parallel induction of the iron storage protein ferritin, thus both proteins (haem 
oxygenase  and  ferritin)  act  in  unison  to  prevent  iron  toxicities  and  maintain 
iron homeostasis 484-485-703i  while CO is expired via the lungs  582 and bilirubin 
is made water soluble via glucuronidation in the liver and excreted in the bile
510
The existence of the haem oxygenase system was first reported by Tenhunen 
and colleagues  in the late  1960s  363,413  Since then three distinct isoforms of 
the enzyme haem oxygenase have been identified in mammals: the inducibleGENERAL DISCUSSION
isoform haem oxygenase-1,  HO-1  (also known as HSP-32) 415; a constitutive 
isoform,  HO-2  436;  and  a weak haem  metaboliser,  HO-3 418.  Of these,  HO-1 
and  HO-2  have  been  fully characterised  and  shown  to  exhibit a  number of 
differences, principally, HO-1  is extremely sensitive to a wide variety of stress- 
inducing stimuli to which  HO-2 is refractory 371.  Therefore,  HO-1,  rather than 
HO-2,  is the  most studied  of the two  isoforms.  A unique feature of haem  is 
that it serves as both a substrate and inducer of HO-1, thus, for two decades 
the perception of the haem oxygenase pathway was purely as an  important, 
but unassuming,  means to degrade and control intracellular haem levels 382. 
However, from the late 1980s this opinion was profoundly changed, and is still 
being challenged, with the accumulation of convincing evidence showing that 
induction  of the  ubiquitous  and  redox-sensitive  protein  HO-1  decreases the 
cellular haem (prooxidant) level and elevates the production of bilirubin, which 
exhibits potent antioxidant characteristics 385 529.  Furthermore, CO may exert a 
positive influence in vasorelaxation 377, neurotransmission  506 and inhibition of 
platelet  aggregation  594,  in  a  manner  similar  to  the  gaseous  molecule  NO 
504,704,705  jn  addition,  iron  released  from  HO-1  regulates  several  genes 
including:  ferritin;  transferrin  (an  iron  binding  protein);  NOS;  and  HO-1  itself
368,384
The  discovery  that  enhanced  cfe  novo  synthesis  of  HO-1  could  occur  in 
response  to  an  extensive  array  of chemically  and  structurally  diverse  non- 
haem  agents,  many  of which  have the  ability to alter the  intracellular redox 
state, led to a deeper interest into the mechanisms controlling HO-1  induction 
381,431,432  As  a  resu|t)  HO-1  soon  gained  the  reputation  as  an  effective
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endogenous cytoprotectant towards oxidative stress,  especially in  conditions 
whereby other cellular antioxidants,  e.g:  glutathione,  become  exhausted 426. 
This led to the notion that induction of HO-1, concomitant with the release of 
bilirubin and CO, could be exploited as a means to thwart the adverse effects 
associated  with  pathologies  arising  from  an  oxidative  source  in  the 
cardiovascular  428-430'480i  immune  706  and  neurological  372-483-554  systems. 
However,  HO-1  may  also  exert  a  prooxidant  influence  depending  upon  the 
cellular redox potential and the metabolic fate of iron 486-707.
The concept that unabated production of ROS leads to tissue oxidative stress 
resulting  in  the  development  of  a  variety  of  pathologies  is  now  universally 
accepted 708.  Similarly,  compelling evidence exists to support the notion that 
activation of the HO-1/bilirubin/CO pathway is an effective means to thwart the 
adverse effects associated with  oxidative stress  370-386-470  More recently,  the 
gaseous  molecule  NO and  its  redox congeners,  known  collectively as  RNS, 
have  been  implicated  in  another  form  of  cellular  damage  identified  as 
nitrosative  stress  338 709.  Recent  data  has  shown  an  enhancement of  HO-1 
protein,  mRNA  and  haem  oxygenase  activity  in  response  to  NO  and  other 
RNS  374-427 481-669-681.  |n  |jght of these observations it has  been  proposed that 
the haem oxygenase system is an effective stratagem to combat the adverse 
effects associated with nitrosative stress 373>636
Since the discovery that NO mediates the vasodilatory actions of EDRF 7 this 
diatomic  gaseous  molecule  has  been  implicated  in  a  diverse  range  of 
physiological  and  pathophysiological  processes  within  the  vascular  209, 
immune 305,  neurological710 and reproductive  320-323-330 systems.  More recent
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research  has broadened to take account of the diverse chemistry of the NO 
group,  in  particular oxidation  (loss of an  electron) and  reduction  (gain of an 
electron) type reactions, to  generate the  NO+  and  NO' 1325-29-58i  respectively 
(Equation 8.1).
NO+  <   - e-  NO  + e  >  NO-
Equation 8.1  Redox reactions of nitric oxide
Understanding  how these  and  other  N O   related  redox  products,  e.g.  N O 3 ', 
N O 2 ',  R -S N O ,  O N O O '  and  nitrosyl  metal  complexes,  are formed  enables  a 
better  appreciation  of  how  N O   biochemistry  relates  to  its  biological  effects 
13,29  Using  R - S N O   and the redox products derived from it, i.e. oxidised thiols 
(S S R ),  sulfenic acid  ( S O H ) ,  sulfinic acid  (S O 2 H )  and sulfonic acid (SOsH), as 
an  example,  the  importance  of  associating  N O   chemistry  to  its  biological 
outcome is illustrated in Figure 8.1.
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Reversible Irreversible
Figure 8.1 Relationship between NO chemistry and its biological effects.
Adapted from 711.
In the above diagram there is an inverse correlation  between signalling and 
toxicity with respect to the redox subtype produced as a result of successive 
rounds of oxidation. Of significance is the reversible nature of R-SNO-related 
signalling  process,  whereas  production  of  stronger  acids,  i.e.  SO2H  and 
SO3H, leads to cellular damage due to irreversible toxicity.
Although there is still much debate about the final product of NOS oxidation of 
L-arginine,  i.e.  is it NO or NO* 4345671, the chemical biology of the latter has 
assumed greater importance.  Despite its short lived nature (i.e. milliseconds) 
studies  have  shown  that  under certain  conditions  NO*  can  be  generated  in 
vitro and in vivo 25,46  Furthermore, studies of the biological, toxicological and 
pharmacological  aspects  of  NO  and  NO*  in  these  situations  reveal  distinct 
features in each case 61.  For example, high concentrations of NO* reacts with 
O2  to  generate  potent  oxidising  species  capable  of  damaging  DNA  352353
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whereas NO does not induce these changes under similar conditions, instead 
it acts  in  a  scavenging  capacity towards  ROS  57,58.  Due  to  its  electrophilic 
nature 351 NO* can modify the function of haemoproteins 672 and cellular thiols 
M;  however,  NO only reacts with thiols after RNS formation 712.  In  addition, 
NO* can  induce  HO-1  681,  mediate  vasodilation  713  and  regulate  the  NMDA 
receptor58
In  models  of  reperfusion  injury  the  time  of  exposure  to  either  species 
produces  contrasting  outcomes.  Addition  of  NO  or  NO*  at  the  time  of 
reperfusion endows protection against injury 714 or augments infarct area and 
tissue  damage  53,  respectively.  Interestingly,  exposure  to  NO*  before 
ischaemia endowed greater protection against subsequent reperfusion  injury 
compared with  NO  donors  46  In  vivo experiments  in  healthy  and  unhealthy 
dogs  revealed  that  NO*  enhanced  left  ventricular  contractility  (i.e.  it  is 
positively  inotropic)  and  lowered  cardiac preload  and  diastolic pressure,  via 
increasing  the  release  of  calcitonin  gene-related  peptide  (CGRP),  without 
altering heart rate. All these aspects of NO* contrast with the effects observed 
with NO in the same model  54  These examples illustrate that the orthogonal 
(i.e. of the same origin but not overlapping) aspects of the redox siblings NO* 
and  NO  with  regards  their  pharmacological,  physiological  and  biological 
effects is highly condition dependent61.
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8.2  Hypothesis and objectives
As  noted  earlier,  the  haem  oxygenase  pathway  is  extremely  sensitive  to 
activation  by  NO-mediated  redox signalling  in  addition  to  being  an  effective 
means to thwart cellular stress arising from RNS. Due to the complexity of this 
induction  it  is  not  known  if it  is  NO,  NO+   or  NO' that elicits  this  response. 
Therefore, the hypothesis of this Thesis was as follows:
Increased  haem  oxygenase activity and  induction  of HO-1  protein  and 
gene expression  in  response to  reactive  nitrogen  species,  particularly 
NO', attenuates nitrosative stress in cardiac cells.
To verify this theory a number of objectives were set:
(i)  Establish  that  Angeli's  salt  (AS),  a  NO'  generator,  activates  the 
haem oxygenase pathway.
(ii)  Dissect the mechanism of AS-mediated HO-1 induction.
(iii)  Investigate the  mechanism and  identify possible  molecular targets 
which  lead  to  increased  haem  oxygenase  activity  and  HO-1 
expression in response to cellular stress.
(iv)  Utilise bilirubin, an end product of the haem oxygenase pathway, as 
an effective means to counteract nitrosative stress.
(v)  Examine  the  potential  of  a  clinically  used  NO  donor,  GTN,  to 
promote activation of the haem oxygenase pathway.
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The data presented in Chapter 3 illustrated the novel finding that Angeli’s salt 
(AS) was  able to  promote  an  increase  in  cardiac  haem  oxygenase  activity, 
HO-1  protein  and  gene  expression  both  in  a  time-  and  concentration- 
dependent  manner.  This  induction  occurs  at  the  transcriptional  level  as 
actinomycin D completely eliminated AS-mediated activation of HO-1  mRNA. 
Furthermore,  the  results  related  to  the  transcription  factor  Nrf2  (detailed  in 
Chapter 5)  suggest that the  latter is  a  potential  transcriptional  target in  the 
response of HO-1  towards RNS.  Even though AS  has a short half-life (U4 =
2.3  min)  sustained  stimulation  of the  haem  oxygenase  pathway  by  multiple 
additions of micromolar concentrations of AS, a scenario likely to occur during 
prolonged  NO" production  under physiological/pathological  conditions,  led to 
levels of haem oxygenase activity comparable to a bolus dose of this agent. 
This suggests a potential clinical technique to maintain continuous stimulation 
of the haem oxygenase pathway by AS,  or other types of nitrosative agents, 
without causing adverse toxicity.
In  addition,  only  freshly  prepared  AS  had  the  ability  to  enhance  haem 
oxygenase activity,  either in DMEM or Dulbecco’s phosphate buffered saline 
(DPBS),  while  ‘decomposed’  AS  (see  Section  2.2.3 for preparation)  had  no 
inducing  potential.  Although  DMEM  promoted  a  greater degree  of induction 
compared  with  DPBS  one  cannot  exclude  the  possibility  of  the  media 
constituents  promoting  the formation  of other  RNS,  thus  augmenting  haem 
oxygenase activity levels.  Comparison between AS and a fast (DeaNO)  and 
slow  (DetaNO)  acting  NO  donor  revealed  that  DeaNO  (t%  =  2  min) 
upregulated haem oxygenase activity and induced HO-1  protein in a manner
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similar to that seen with AS, although AS was the most tolerable of the three 
agents examined via the Alamar blue assay.
Having verified that NO' derived from AS can directly stimulate an increase in 
haem oxygenase activity and induce HO-1  expression the intention of Chapter 
4 was to explore the mechanism behind these responses. Akin to the diverse 
biology and complex chemistry of NO its reduction  product,  NO', has its own 
unique biochemistry s9-58'61-352. The latter aspect of NO' was examined further 
in the context of AS-mediated HO-1  induction using a number of in vitro tools, 
including:  1. promotion of NO' oxidation to NO; 2. scavengers of NO and NO';
3.  modulation of thiol groups; and 4. measurement of NO release from AS and 
the  NO  donors  DeaNO  and  DetaNO.  The  incentive  for these  experiments 
stemmed from data suggesting that transition metals, e.g. Cu2 +  and Fe3+, can 
promote the oxidative conversion of NO' to NO both in vitro and in vivo 53,63, 
while intracellular thiols,  potential targets for NO and  NO',  can  influence the 
magnitude  of  these  redox  interconversions  13-30-47  in  this  system  copper 
sulphate  (CuS04) was employed to  oxidise NO' to  NO and thus assess the 
contribution of these congeners towards the modulation  of haem oxygenase 
activity and HO-1  protein expression. The data revealed that coadministration 
of AS  and  CuS04  led  to  an  enhancement of haem  oxygenase  activity  and 
HO-1  protein  expression.  However,  one  cannot  exclude  the  possibility that 
generation of other RNS by media constituents amplified this oxidation.
To  eliminate  the  contribution  of  NO  derived  from  the  metabolism  of  AS 
towards  the  measured  parameters,  the  NO  trapping  agent  carboxy-PTIO 
(C-PITO, 25 pM) and NO'/NO scavenger hydroxocobalamin (HCB, 0.75 mM)
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were coincubated with cells.  Inclusion of HCB in the medium with AS resulted 
in a  significant attenuation  of haem  oxygenase  activation,  but  C-PTIO  was 
unable to  promote  a  similar  response.  The  inability  of C-PTIO  to  attenuate 
haem  oxygenase  activity  suggests  that  AS-derived  NO',  rather  than  NO, 
contributes  towards  HO-1  induction.  This  observation  was  strengthened  by 
comparing the effect of AS and DeaNO as these agents, respectively release 
either NO' or NO species at physiological pH and have very similar half-lives 
(AS iVz = 2.3 min and DeaNO V /2  = 2 min). Experiments using a sensitive NO 
electrode, which can discriminate between NO' and NO species, revealed that 
in  DMEM,  containing  comparable  concentrations  (0.5  mM)  of  both  agents, 
almost  33-fold  less  NO  was  released  from  AS  compared  with  DeaNO. 
However,  DeaNO (20 pM) releases the same equivalents of NO (0.31  ± 0.01 
pM x sec) as 0.5 mM AS. When 20 pM DeaNO and 0.5 mM AS were applied 
to cells, only AS promoted the greatest degree of haem oxygenase induction. 
Additional  experiments  into AS  metabolism  revealed  that it  is  NO'  liberated 
from  AS,  rather  than  nitrite  (NO2'),  the  product  of  NO'  protonation, 
dimerization,  and dehydration, which  is responsible for the observed results. 
Collectively, the above data suggests that NO', rather than NO, liberated from 
the metabolism of AS,  is the principal factor responsible for increasing haem 
oxygenase  activity  and  HO-1  transcription  in  this  model.  However,  this 
balance can be shifted towards NO when the extent and rate of oxidation of 
NO' to NO is significantly increased.
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It is known that thiols participate in the modulation of HO-1  expression by NO 
and NO-related species possibly through the formation of endogenous R-SNO 
42 3 ,6 6 8 ,6 7 9   |n  ^   stuc|y  glutathione  precursor  A/-acetylcysteine  (NAC), 
promoted  a  significant  reduction  in  the  AS-mediated  induction  of  haem 
oxygenase activity and  HO-1  protein  expression  in  both  DMEM  and  DPBS. 
This  indicates  that  redox  activation  of  thiols  groups  by  NO'  is  a  plausible 
mechanism for the transcriptional  activation  of the  HO-1  gene.  This  idea  is 
reinforced by experiments using the glutathione synthesis inhibitor buthionine 
sulfoximine (BSO), which decreased the strength of haem oxygenase activity 
elicited by AS. The results from thiol modulation, along with the data related to 
actinomycin  D from  Chapter 3,  indicate that thiols,  in  particular glutathione, 
which represents the largest pool of intracellular thiols, contribute towards the 
preservation of NO' bioactivity and signalling properties for the transcriptional 
activation  of inducible  genes,  e.g.  HO-1  31.  The  importance  of thiols  in  the 
regulation  of the  haem  oxygenase  pathway  is  emphasised  by the  fact that 
they,  most  notably  in  the  form  of  GSH,  represent  the  first  barrier  against 
cellular stress while their depletion activates the second  line of cell  defence
_  _  u n   < 1   343,426,692,715,716 enzymes, e.g. HU-i
The  relationship  between  intracellular  thiols  and  the  haem  oxygenase 
pathway was further illustrated by the lack of HO-1  induction in the presence 
of  NAC,  i.e.  the  latter  provides  more  GSH,  thus  diverting  NO'  away  from 
critical  thiol  groups  within  transcription  molecules,  e.g.  Nrf2.  Although  the 
experiments combining AS with BSO,  a known  depletor of GSH and inducer 
of  HO-1  mRNA  expression  426,  were  expected  to  reveal  enhanced  haem
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oxygenase activity this was not the case. An explanation for this finding could 
be that BSO is blocking glutathione production but not necessarily thiol groups 
which  are constitutive components of the signal transduction  molecule  Nrf2. 
To further probe the  basis for these  observations  it would  be  necessary to 
employ  a  specific  thiol  blocker,  e.g.  N-ethylmaleimide  (NEM)  or  mercuric 
chloride  (HgCI2 ).  However,  as  both  these  agents  are  toxic to  cells  we  can 
speculate that targets other than Nrf2 may be involved in HO-1  amplification.
The principal function  of the haem  oxygenase  pathway is to  metabolise the 
prooxidant haem (ferro-(Fe2+ )protoporphyrin  IX) to bilirubin,  CO and  Fe2 +  364. 
Using  the  information  obtained  from  Chapters  3  and  4  it  was  decided  to 
examine the responsiveness of the haem oxygenase system to simultaneous 
exposure  to  oxidative  (hemin,  the  oxidised  (Fe3+)  form  of  haem)  and 
nitrosative  (AS  or DeaNO) stress  in  rat cardiomyocytes.  Also,  the signalling 
pathways  leading  to  transcriptional  activation  of  the  HO-1  gene  was 
investigated in parallel. Akin to previously documented reports, the data from 
Chapter 5 shows that addition of hemin (5-20 pM), AS (0.75 mM) or DeaNO 
(0.5 mM) directly to cells promoted an  increase in  haem oxygenase activity, 
HO-1  protein and  mRNA expression 374,681.  Furthermore,  the intensity of the 
latter parameters were strongly enhanced when hemin was coincubated with 
AS  or  DeaNO.  Of  note,  is  the  observation  that  the  synergistic  capacity  of 
hemin  and  the  nitrosants  (AS  or  DeaNO)  to  activate  the  haem  oxygenase 
pathway  is  maintained  following  exposure  of  cells  to  agents  that  were 
preincubated  for  1   h  at  37°C  in  complete  DMEM  beforehand,  whereas 
decomposed AS or DeaNO on their own were ineffective.  Although  NO" and
283GENERAL DISCUSSION
NO have differing degrees of affinity for haem  19-67-185-684 the novelty of these 
findings is that an interaction is taking place between hemin and  NO' or NO 
and  the  resulting  haem-nitrosyl  complex  is  sufficiently  potent  to  cause  an 
amplification  of  the  haem  oxygenase  pathway  response,  even  under 
conditions of reduced oxygen tension (hypoxia).
Moreover, the presence of hemin during the preincubation step maintains the 
biological  potency  of  AS  towards  increasing  haem  oxygenase  activity  and 
HO-1  protein  expression  compared  with  previous  assays  in  Chapters  3  
(Figure 3.5)  and  4  (Figure 4.2  and  Figure 4.5) where  decomposition  of this 
agent  was  involved.  As  formation  of  a  stable  haem-nitrosyl  complex  is 
enhanced  by  serum  proteins,  e.g.  albumin,  which  can  bind  haem  685,  this 
detail  must  be  considered  in  this  model  as  the  DMEM  contains  a  high 
concentration  (10%)  of  serum  proteins,  i.e.  FBS.  Recent  experiments 
involving preincubation of AS (20, 50 or 100 pM) with hemin  (1  pM) for 1  h at 
37°C  in  a  low  (0.5%)  FBS  environment revealed  that the  haem  oxygenase 
inducing capacity of the haem-nitrosyl complex was maintained in  H9c2 and 
Girardi,  a  human  cardiac  cell  line,  cells  (unpublished  preliminary  data,  not 
shown).  Taken  together,  this  data  illustrates  the  potential  of  utilising  low 
micromolar concentrations of both an oxidant (hemin) and a nitrosant (AS) in 
a  clinical  scenario  to  promote  increased  production  of  the  endogenous 
cytoprotectant HO-1.  More experiments are now required to characterise the 
eventual  haem-nitrosyl  complex  responsible  for  this  amplification 
phenomenon.
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Further evidence  of the  potency and  strength  of the  haem-nitrosyl  complex 
was shown  by the inability of high thiol concentrations,  provided  by NAC,  to 
prevent the synergistic effect of AS and  hemin on  haem oxygenase activity, 
even though  previous examples showed an attenuation of NO'/NO-mediated 
activation  of  the  haem  oxygenase  pathway  by  NAC  423668-681.  The 
acknowledged  function  of haem  as  a  substrate for  haem  oxygenase  and  a 
molecular switch  promoting  the  induction  of the  HO-1  gene  in  response  to 
redox signalling involving RNS suggests the potential of the active products of 
haem  metabolism,  particularly  bilirubin  and  CO,  as  a  means  to  counteract 
nitrosative stress 354636.  This concept has been investigated  by Foresti et al. 
using  aortic endothelial  cells exposed  to  hemin  and various  NO  donors  374 
The  authors  noted  enhanced  HO-1  protein  and  haem  oxygenase  activity 
following increased haem uptake concomitant with an elevation in intracellular 
bilirubin production, while Clark et al. documented a similar effect with bilirubin 
production using bovine vascular smooth muscle cells in a model of oxidative 
stress 533. Collectively, these observations suggest the haem-nitrosyl complex 
provokes  a  similar  response  with  the  ultimate  aim  of  neutralizing  the 
prooxidant (haem) and pronitrosative (NOVNO) environment. The participation 
of HO-2  in this  response was  not investigated;  however,  this  merits further 
examination  as this  isoform  has  been  linked with  regulating the  intracellular 
balance of NO 452 and can protect against oxidative stress, via production of 
bilirubin 483,554
Given that AS and other agents promote the activation of HO-1  mRNA at the 
transcriptional level457,681 the signalling pathways involved in this process are
285GENERAL DISCUSSION
subject to intense investigation. One important mechanism for the regulation
of  cytoprotective  genes  such  as  HO-1  is  governed  by  the  MAPK  signal
transduction  pathway  457'460  The  best  characterised  MAPK subfamilies  are
ERK,  p38  and  JNK,  each  of which  are  regulated  by  different  extracellular
stimuli, namely, growth and proliferation (ERK) and cellular stress signals (p38
and JNK)  458.  The  extracellular stimuli,  e.g.  cytokines,  growth  factors,  ROS
and  RNS,  initiate  a  sequential  phosphorylation  cascade  which  enables  the
MAPK subfamilies to target downstream substrates,  i.e.  transcription factors
such as NF-kB,  HIF, AP-1  and -2, that upregulate the HO-1  gene via binding
to  their respective  regulatory elements  within  the  5’-UTR  of HO-1  457-460.  a
number of reports have documented a close association between activation of
the  MAPKs  (ERK,  JNK and  p38) followed  by  upregulation  of  HO-1  protein,
mRNA or its  products  bilirubin  and  CO  in  different models of cellular stress 
462,463,467,469,470.473  |n  case  Q f  ancj  ^aem  oxygenase  pathway,
Chen  and  Maines  suggested  that  ERK  and  p38  may  be  potential  targets 
leading  to  upregulation  of  HO-1  by  NO  686.  Furthermore,  activation  of  the 
MAPKs  has  been forwarded  as  a  mechanism  by  which  RNS  mediate  their 
signalling effects717-718
For the first  time  this  report  suggests  a  link  between  NO'-mediated  redox 
signalling  leading  to  enhanced  haem  oxygenase  activity  and  increased 
expression  of the  redox-sensitive transcription factor Nrf2 within the  nuclear 
fraction of cells.  In the presence of AS the normally inactive cytosolic protein 
Nrf2 is released from its molecular chaperone Keapl  666 and  migrates to the 
nucleus where it binds to the antioxidant-responsive element (ARE) within the
286GENERAL DISCUSSION
HO-1  gene 465. Although the latter response was completely eliminated in the 
presence  of  the  thiol  donor  NAC,  coincubation  of  AS,  hemin  and  NAC 
maintains the stimulation of Nrf2,  in parallel with increased haem oxygenase 
activity. This suggests:  1. a greater affinity between AS and haem compared 
with  thiols;  2.  the  participation  of  Nrf2  in  the  response  to  nitrosative  and 
oxidative  stimuli  via  the  transcription  of  the  HO-1  gene  465,719;  and  3. 
regulation  by  thiol  modification  of  the  sulphydryl  groups  within  Keapl  is 
mediated by nitrosants 687.
Although Chapter 5 did not explore the mechanisms leading to the chemical 
modification  of  the  HO-1  gene,  a  recent  article  by  Balogun  et  al.  using 
curcumin, a potent plant derived polyphenolic inducer of HO-1  in vascular and 
neuronal cells, observed enhanced haem oxygenase activity and HO-1  gene 
expression  occurs  via  the  Nrf2/ARE  and  MAPK  pathway  in  renal  epithelial 
cells.  However,  this  induction was  lost when two  enhancer regions  (E1  and 
E2),  that contain  at least three AREs  and  lie  upstream  of the  transcription- 
initiation site of the HO-1 gene, were deleted, thus implicating a crucial role for 
Nrf2 in transcription of the HO-1  gene by electrophilic agents 7 2 °.  Furthermore, 
Alam et al. noted that haem can cause a stabilisation of the Nrf2 protein thus 
enhancing  the  tatter’s  stimulation  of  the  HO-1  gene  719  In  addition  to  its 
activation  of  HO-1,  Nrf2  regulates  the  expression  of  a  number  of 
cyto protective  genes,  e.g.  glutathione  S-transferases  (GSTs), 
NAD(P)H:quinone  oxidoreductase  (NQ01),  y-glutamylcysteine  synthase  721 
and thioredoxin 722.  Individually and collectively, these enzymes and proteins 
mitigate the  adverse  effects  of cytotoxic agents,  thus  illustrating  the  central
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role  played  by  Nrf2  in  the  transcriptional  regulation  of defensive  genes,  as 
deficiency of Nrf2  increases susceptibility to carcinogenesis  723 and oxidant- 
mediated cell injury  466  In summary,  this work suggests that amplification of 
the  HO-1  pathway  by  the  combined  effect  of  two  potent  signalling 
mechanisms (the prooxidant haem and pronitrosants NO'/NO) is an effective 
endogenous  cytoprotectant,  and  may  have  an  application  in  pathological 
illnesses characterised by disrupted haem metabolism,  increased NO release 
and localised  hypoxia,  e.g.  sickle cell disease,  intravascular haemolysis and 
haemorrhagic and subarachnoid shock 354.
The  most  important  mammalian  bile  pigments  (or  LTPs)  are  biliverdin  and 
bilirubin.  In  humans  the  primary  route  of  bile  pigment  formation  is  via  the 
oxidative  cleavage  of the  haem  tetrapyrrole  ring  at the  a  position  by  haem 
oxygenase which  generates  biliverdin  followed  by  reduction  of the  latter to 
bilirubin via cytosolic biliverdin reductase 364.  The negative perception  of bile 
pigments,  especially  bilirubin,  has  been  known  for  over  a  century  523. 
However,  this  view  changed  with  the  conclusive  demonstration  that  bile 
pigments, specifically bilirubin, are potent antioxidants against oxidative stress 
and high serum levels of bilirubin are associated with reduced susceptibility to 
development  of  cardiovascular  complications  385525529543546.  Knowing  that 
HO-1  responds  to  nitrosative  stimuli  and  bile  pigments  are  capable  of 
attenuating  oxidative  stress  Chapter  6  explored  the  possibility  of  utilising 
bilirubin and biliverdin as a means to counteract nitrosative stress originating 
from NO' (AS) and NO (DeaNO) species.
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Although AS and  DeaNO have rather similar half-lives  (VA = 2.3 and 2  min, 
respectively) the data revealed that AS,  a source of NO', consumed  bilirubin 
(5  pM)  to  a  greater  extent,  in  both  a  time-  and  concentration-dependent 
manner,  compared with the NO donor DeaNO.  Concomitant with the decline 
of the bilirubin peak at 440 nm the appearance of an as yet uncharacterised 
peak  in  the  315-320  nm  region  became  more  pronounced  with  increasing 
exposure to AS,  more  so  than with  DeaNO.  In  the  presence  of biliverdin  a 
somewhat similar pattern of results was observed,  but to a far lesser extent 
than  with  bilirubin.  Interestingly,  incubation  of  AS  or  DeaNO  that  had 
undergone a  1  h preincubation before the addition of bilirubin was ineffective 
at reacting with the latter.  Of note,  is the observation that high plasma levels 
of  bilirubin  can  attenuate  nitrosative  stress,  originating  from  DeaNO,  thus 
illustrating  the  protective  influence  of  bilirubin  in  in  vivo  situations 
characterised  by  excessive  NO  release.  Recently,  Western  blot  analysis  of 
nitrotyrosine (NT), a marker of nitrosation, using human serum albumin (HSA) 
treated with AS (10-300 pM) revealed a concentration-dependent increase in 
NT  levels;  however,  combining  HSA  with  bilirubin  resulted  in  a  significant 
attenuation  of NT expression, thus  reinforcing the antinitrosative potential of 
bilirubin  (unpublished  preliminary  data,  not  shown)  and  adds  to  earlier 
observations  that bilirubin  protects  HSA and  both  can  act  against oxidative 
damage  526-530-532534.  Overall  these  results  suggest  that  bile  pigments, 
particularly bilirubin, can react directly with AS and DeaNO to combat different 
types of RNS and the rate of these reactions is more rapid in the presence of 
NO'.  Work is  still  ongoing  within  the  department  to  investigate  these  novel
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features of bilirubin.
In the final chapter the haem oxygenase inducing potential of a clinically used 
NO donor, GTN, was examined. The data revealed that GTN could enhance 
haem  oxygenase  activity  and  HO-1  protein  expression  in  a  time-  and 
concentration-dependent  manner.  However,  overloading  the  capacity  of the 
HO-1  enzyme  led  to  ‘tolerance’,  a  complex  phenomenon  experienced  by 
patients following prolonged exposure to nitrates such as GTN 8.  Examination 
of the mechanism by which GTN promotes upregulation of haem oxygenase 
activity  suggests  that  thiols  (in  the  form  of  NAC)  could  enhance  GTN 
biotransformation, a theory which has been suggested in other models where 
GTN was  used 345,  while  reduction of plasma  homocysteine  (Hyc)  levels  by 
HCB may increase the availability of NO 679-702.  The fact that both  NAC and 
HCB,  respectively led to sustained and increased levels of haem oxygenase 
activity,  is  in  sharp  contrast to the  results  obtained  when  both  agents were 
incubated with AS (see Chapter'4). Together, these observations merit further 
investigation  into  the  mechanism  of  GTN-mediated  activation  of the  haem 
oxygenase pathway.
8.3  Conclusions and future direction
Although  many  elegant  studies  have  highlighted  the  ability  of  the  haem 
oxygenase  enzymes  (HO-1  and  HO-2)  and  their  products,  to  attenuate 
oxidative  stress,  only  a  few  studies  have  shown  an  association  between 
induction of HO-1  and nitrosative stress 423 427481482-669'724.  Due to the diverse 
chemistry of the NO group, which can exist as different redox subtypes 13, the
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exact  nature  of  this  induction,  the  molecular  targets,  as  well  as  the 
mechanism(s) behind it have not been probed. This Thesis has:  1 . described 
the  potential  of  AS,  a  NO'  generator,  to  activate  the  haem  oxygenase 
pathway;  2 .  explored  the  biochemistry  and  identified  a  possible  molecular 
mechanism responsible for this response; 3. identified the potential of bilirubin 
to  counteract  nitrosative  stress;  and  4.  established  a  link  between  a 
pharmacological  NO donor and  the  haem  oxygenase  pathway.  Collectively, 
these  findings  strengthen  the  association  between  two  very  important 
physiological systems,  1 . haem oxygenase; and 2 . nitric oxide, and reinforces 
the hypothesis that the haem oxygenase pathway exists as a means to thwart 
the adverse effects induced by excessive NO production and RNS 373-452'636
The  data  reveals  that  NO'  liberated  from  AS  can  directly  stimulate  HO-1 
induction  via  modulation  of  critical  thiol  targets  within  the  redox-sensitive 
transcription  factor  Nrf2.  The  latter  mechanism  of  transcription  factor 
activation is analogous to studies in E.coli of the redox-sensitive transcription 
factors OxyR  and SoxR  32-725'726  These regulatory proteins are activated by 
reversible oxidation or nitrosylation at critical thiol and transition metal centres, 
respectively  727*729.  Although  similar  mammalian  homologues  to  OxyR  and 
SoxR have not yet been identified the results in Chapter 5 support a direct link 
between  Nrf2 and  HO-1  gene expression and  imply a  mechanism  by which 
cells sense nitrosative stress 465-466  Recent publications by Buckley et al.  730 
and Alam and coworkers 719 involving NO,  Nrf2 and haem reaffirm the ability 
of  haem  and  AS  to  synergistically  stimulate  HO-1  via  Nrf2.  These 
observations,  together  with  sustained  stimulation  of  the  haem  oxygenase
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pathway  through  repeated  exposure  to  low  doses  of  AS  (see  Figure  3 .4 , 
Chapter 3) merits further investigation as a potential therapeutic application.
Not only  can  HO-1  serve  as  a  sensitive  redox-activator towards  nitrosative 
stimuli,  but one of its products of haem metabolism,  bilirubin, can effectively 
neutralise nitrosative stress akin to its potent antioxidant capacity 386  Further 
studies are required to examine the chemical and biological  reactions taking 
place  between  bilirubin  and  different  RNS.  The  novel  finding  that  GTN 
activates the haem oxygenase pathway could be pursued further with a view 
to  generating  a  pharmacological  NO'/NO  donor  which  can  be  used  for 
prolonged periods without the development of tolerance. Although it was not 
the  intention  of this Thesis to  look at the  role  of CO,  recent data from  this 
laboratory suggests that transition metal carbonyls, which exhibit the ability to 
function as carbon monoxide-releasing molecules (CO-RMs) and elicit distinct 
pharmacological  activities  in  biological  systems  615,  exert a  cardioprotective 
influence  in  in  vitro,  ex  vivo  and  in  vivo  models  of cardiac  dysfunction  640 
Work is ongoing within the department looking  into the chemistry of bilirubin 
and the synthesis of more efficacious CO-RMs with a view to harnessing the 
cytoprotective  effect  of  these  haem  metabolism  products  towards  different 
types of cellular stress and vascular dysfunction.  Lastly, the chemistry of N0‘ 
/NO in vivo is quite complex, and not always reflected by the findings under in 
vitro experimental conditions; however, the results presented herein provide a 
deeper understanding of how HO-1  interacts with and responds to nitrosative 
stimuli. Additional work is now required to examine the reaction of HO-1  and 
its products to different types of RNS in vivo.
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In  this  Thesis  rat  cardiomyocytes  exposed  to  different  types  of  RNS  were 
used  as  an  in  vitro  model  to  illustrate  the  protective  capacity  of the  haem 
oxygenase pathway. The data in this Thesis confirm the hypothesis that HO-1 
is a sensitive sensor to different types of nitrosative stress at different oxygen 
tensions,  i.e.  normoxia and hypoxia,  and this effect is  possibly  mediated via 
the antinitrosative effect of bilirubin 373. As the human myocardium contains all 
three isoforms of NOS (eNOS, iNOS and nNOS) 245 and the fact that HO-1  is 
upregulated  in  vascular tissues  and  the  cardiovascular  system  exposed  to 
RNS 636, these findings have implications for cardiovascular disease and give 
a further insight into how cardiac muscle responds to nitrosative stress.  Like 
all  cells  types,  cardiomyocytes  are  constantly  exposed  to  RNS  which  can 
mediate cytostatic (low NO) or cytotoxicity (high NO) effects via the activation 
of signal  transduction  pathways  17-332-641'642.  These  dichotomous  aspects  of 
NO  can  be  explained  by  its  complex  interactions  with  ROS  and  the 
maintenance  of a  redox equilibrium  by antioxidants such  as GSH,  catalase, 
SOD and a-tocopherol14-642-731. Physiological and pathological factors such as 
age, exercise and hypertrophy (increase in cell size) can disturb this balance 
leading  to  activation  of  a  second  line  of  defence,  i.e.  HO-1.  Although 
hypertrophy is  considered  an  adaptive  mechanism,  over a  prolonged  period 
sustained  haemodynamic changes  (e.g.  hypertension,  aortic  or  mitral  valve 
regurgitation) can lead to detrimental outcomes such as cardiac dysfunction, 
necrosis  and  apoptosis  642-643.  Both  NO  and  HO-1  have the  ability to  exert 
antiapoptotic  and  antiproliferative  effects  412732733i  as  a  result  data  has 
accumulated  to  illustrate  the  beneficial  potential  of  these  molecules  in  a
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number of cardiac pathologies,  e.g.  atherosclerosis,  cardiomyopathies,  heart 
failure,  IR  injury  and  myocardial  infarction  171-181-430'499-615-642-647-731-734  j^ e 
observation  in Chapter 5 that NO',  in the presence of haem,  acts as a very 
potent inducer of HO-1  has a  potential clinical application  as  Paolocci  et al. 
demonstrated that NO' on its own  could exert positive inotropic (contractility 
enhancing),  lusitropic (enhances relaxation) and selective venodilator effects 
in  failing  hearts  54,735.  Therefore,  in  heart  failure  administration  of  a 
pharmaceutical  nitroxylhaem  complex  could  possibly  provide  enhanced 
therapeutic advantages via the beneficial aspects of both HO-1  and NO' 736
From  its  humble  beginnings  as  a  single  function  enzyme,  i.e.  haem 
metabolism,  haem oxygenase,  and in particular HO-1,  has grown to assume 
an important position in the league table of crucial endogenous enzymes as a 
result of the myriad of functions in which its products bilirubin, CO and  Fe2+, 
participate.  Similarly,  NO'  and  NO  have  developed  into  multifaceted  redox 
siblings with their own distinct biology and chemistry.  However, there is still a 
great  deal  to  be  learned  about  the  regulatory  mechanisms  of  HO-1,  the 
chemical biology of NO' and NO, and how these molecules interact, so as to 
understand the physiological function of both systems in the pathogenesis of 
vascular disease.
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